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JUSTIFICACIÓN DE LA TESIS DOCTORAL 
 
Las lectinas de tipo C juegan un papel importante como receptores de reconocimiento 
de los carbohidratos derivados de patógenos  por el sistema inmunológico. Varios 
receptores de lectinas de tipo C se han caracterizado previamente, tales como DC-
SIGN, L-SIGN, SIGN-R1, Langerina, Siglecs, LSECtin, Mincle, DCIR, DCAR, BDCA-2, 
DCAL-1, MICL, Dectin-1, DNGR-1/CLEC9A, MR, DEC-205, MMR, MBL. El receptor 
DC-SIGN fue inicialmente identificado en el año 2000 por Geijtenbeek y cols. como el 
factor de la unión del VIH-1, que capturaba la envoltura viral y facilitaba la infección. 
Durante años, se llevaron a cabo múltiples estudios para caracterizar el papel biológico 
de DC-SIGN. 
 
Se ha demostrado que DC-SIGN juega un papel en la respuesta del sistema 
inmunológico, sin embargo, la importancia biológica de sus funciones no se ha 
aclarado todavía. DC-SIGN juega un papel substancial en la inmunidad a través del 
reconocimiento de glicoproteínas propias, como la molécula de adhesión intercelular 2 
(ICAM-2) y ICAM-3. Mediante la unión con ICAM-2, DC-SIGN funciona como 
receptor de adhesión celular que regula la migración de las DCs. La interacción de DC-
SIGN con la ICAM-3 tiene un impacto en la agrupación de las células DC-T, en la 
proliferación inducida por las DCs de las células T en reposo, en la detección de los 
complejos de péptido-MHC por las células T y en la estabilización del contacto celular 
de las células DC-T, lo que permite la participación eficiente de los receptores de las 
células T (TCR). La segunda función de DC-SIGN es su papel como un receptor para 
patógenos. DC-SIGN reconoce las glicoproteínas que contienen un número 
relativamente alto de los N-carbohidratos presentes en la superficie de diferentes 
patógenos: VIH-1, virus del Ébola, citomegalovirus, virus de la Hepatitis C, virus del 
Dengue, Helicobacter pylori, Klebsiella pneumoniae, Mycobacterium tuberculosis, Candida 
albicans, Leishmania, Schistosoma mansoni.  
 
Justificación de la Tesis Doctoral 
 
i 
 
Se ha sugerido que DC-SIGN puede mejorar la entrada viral y la infección directa en el 
proceso referido como infección en cis, así como también puede capturar y transmitir 
las partículas virales a células susceptibles en el proceso denominado como infección 
en trans.  
 
El objetivo de nuestro estudio fue estandarizar y evaluar el modelo celular de la 
infección mediada por DC-SIGN por el virus. Queríamos evaluar la consistencia del 
modelo de infección utilizando diferentes líneas celulares que expresan el receptor DC-
SIGN, así como estandarizar el nivel de expresión de DC-SIGN y el título infeccioso de 
los retrovirus recombinantes para los ensayos de infección. También hemos  
pretendido establecer las mejores condiciones para los ensayos de infección en cis y en 
trans mediadas por DC-SIGN. 
 
Los ensayos in vitro presentados por diferentes grupos sugerían que DC-SIGN 
participa en la difusión del virus en los primeros momentos de la infección, por lo 
tanto, en los últimos años se diseñaron diferentes estrategias antivirales basados en 
compuestos de carbohidratos para bloquear la interacción del VIH-1 y Ébola virus con 
DC-SIGN. En presente estudio hemos evaluado la utilidad del nuestro modelo de 
infección mediada por DC-SIGN como una plataforma de monitorización de las 
estrategias antivirales destinadas frente DC-SIGN, incluyendo: las estructuras 
glicodendríticas, los dendrones tetravalentes, los compuestos basados en dendrímeros, 
los glicofullerenos y las glicodendrinanoparticulas.  
 
Por otra parte, hemos tratado de estudiar la implicación del receptor DC-SIGN en la 
patogénesis del virus de Ébola. Se ha descrito que el grupo de filovirus del Ébola 
comprende cinco subtipos: Zaire, Sudán, Reston, Costa de Marfil, Bundibugyo, entre 
los cuales la cepa del Ébola Zaire muestra la tasa de mortalidad más alta (50-90%), 
mientras que la del Ébola Reston nunca ha sido asociada con la enfermedad humana. 
El fenómeno de las diferencias en la patogénesis del EBOZ y EBOR no ha sido 
completamente aclarado todavía. Se ha especulado que las glicoproteínas de la 
envuelta de las dos cepas pueden ser responsables de estas diferencias en la 
Justificación de la Tesis Doctoral 
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patogénesis. Sin embargo, estas especulaciones no han sido confirmados aún en un 
modelo in vivo. Por esta razón, en nuestro estudio hemos tratado de analizar las 
diferencias en la infección en trans mediada por DC-SIGN por las dos cepas del virus 
de Ébola: la cepa patógena Zaire y la cepa no patógena para los humanos Reston. 
 
Por último, hemos investigado la implicación del receptor DC-SIGN en la patogénesis 
del VIH-1. El VIH es responsable de la causa del síndrome de inmunodeficiencia 
adquirida (SIDA) caracterizado por un fallo progresivo del sistema inmunitario que 
resulta en infecciones oportunistas y tumores. La mayoría de los pacientes infectados 
por el VIH-1 muestran una alta carga viral en plasma y la pérdida de células T CD4+ a 
lo largo del curso de la infección por VIH-1 en caso de ausencia de la terapia 
antirretroviral. Gran parte de los pacientes no tratados desarrollan la 
inmunodeficiencia del sistema inmunológico y mueren a causa de las complicaciones 
relacionadas con el SIDA en un tiempo aproximado de 10 años tras haberse infectado. 
Sin embargo, un porcentaje muy pequeño de individuos no tratados permanecen 
clínicamente y/o inmunológicamente estables durante años. Por este motivo también 
hemos analizado el proceso de la infección en trans en diferentes cepas del VIH-1 y su 
correlación con el control virológico. 
 
 
 
 
 
 
 
 
 
 
 
 
Justificación de la Tesis Doctoral 
 
i 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction    
 
2 
 
 
 
  
Introduction 
3 
 
I. INTRODUCTION 
 
1. Immune system: innate and adaptive immunity 
 
All living organisms have evolved many different strategies to defeat pathogen infec-
tion (Hoffmann et al., 1999). The mammalian immune system is composed of two types 
of immunity that are used to protect the host from infections: innate and adaptive im-
munity (Medzhitov and Janeway, 1999). 
 
The innate immune system is the first line of host defense against pathogens. It is im-
mediate and genetically programmed to detect features of invading microbes. The ma-
jor components of the innate immunity include epithelial barriers (skin, mucosal epi-
thelia of gastrointestinal, respiratory and reproductive tracks), soluble molecules (anti-
microbial peptides, complement, cytokines, natural antibodies), innate immune cells 
and pattern-recognition receptors (PRRs) (Ip et al., 2009). Innate immune cells include 
macrophages, neutrophils, natural killer cells (NKs), dendritic cells (DCs). Macrophag-
es are phagocytic cells in lymphoid and non-lymphoid tissues. They are believed to be 
involved in tissue homeostasis through the clearance of apoptotic cells and the produc-
tion of growth factors. Macrophages are well equipped with a wide range of PRRs that 
make them efficient at phagocytosis as well as at production of inflammatory cytokines 
(Gordon, 2002). Neutrophils are produced in a great number from stem cells in bone 
marrow and circulate in blood for a few hours. Microorganisms generate substances 
that guide neutrophils towards the microbe, which are taken up by neutrophils in the 
process of phagocytosis and exposed to high concentration of bactericidal substances in 
the phagocytic vacuole. Neutrophils are fully equipped with granules that contain pro-
teins lethal for microbes, but which also cause a tissue damage (Borregaard, 2010). 
Natural Killer cells are defined as large granular cytotoxic lymphocytes, which differ-
entiate in the bone marrow, lymph nodes, spleen, tonsils and thymus and further enter 
blood circulation. NK cells provide a rapid response to viral infection as well as to tu-
mor formation. These cells detect pathogen antigens presented on the infected cell sur-
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face and release cytokines causing cell lysis and apoptosis (Vivier et al., 2011). NK cells 
play also a role in the adaptive immunity by formulation of antigen-specific immuno-
logical memory fundamental for the second contact with the same antigen (Arina et al., 
2007). DCs are heterogeneous population, which is differentiated in lineage, pheno-
type, location, growth factor requirements and functions. DCs express a wide reper-
toire of PRRs. Upon pathogen invasion, PRRs send signals to DCs, which result in 
phenotypic and functional transformation called “DC activation” to become immuno-
genic antigen-presenting cells (APCs) (Mellman et al., 1998; Reis e Sousa, 2006). Pro-
inflammatory mediators are the first molecules to be released after stimulation of in-
nate immunity cells. The major pro-inflammatory cytokines produced by stimulated 
macrophages are: tumor necrosis factor (TNF), interleukin 6 (IL-6) and interleukin 1 
(IL-1). They stimulate the acute phase of immune response, such as triggering phago-
cytosis by neutrophils and opsonization, activating complement, decreasing bacterial 
and viral replication, increasing antigen processing, promoting adaptive immune re-
sponse. Persistent production of those cytokines is often the reason of systemic in-
flammatory conditions (Crozat et al., 2009). Type I interferon is essential in antiviral 
immunity and it plays role in inhibition of viral replication, activation of NKs and mac-
rophages, enhancement of class I MHC molecules expression, Th1 polarization and dif-
ferentiation of DCs (Le Bon et al., 2003). 
 
Adaptive immunity is responsible for the elimination of pathogens in the late phase of 
infection and the generation of immunological memory. The acquired immune re-
sponse is highly specific, since it is developed by clonal selection from repertoire of 
lymphocytes bearing antigen-specific receptors that are not encoded in the germ line 
but are generated de novo in each organism (Akira et al., 2006). The innate phase of im-
mune response in vertebrates is rapidly supplemented by an adaptive response, which 
is characterized by the activities of pathogen-specific B and T cells. The key role in 
translating innate information into adaptive immunity plays the members of the den-
dritic cell family (Reis e Sousa, 2001). 
 
Introduction 
5 
 
In most tissues, DCs are present in immature state, which is characterized by different 
features allowing them to capture antigens and take up particles or microbes by phag-
ocytosis (Inaba et al., 1993). Immature DCs can form large pinocytic vescicles, which 
function in the process of macropinocytosis of extracellular liquids and solutes 
(Sallusto et al., 1995). DCs can also express receptors that mediate adsorptive endocy-
tosis, including C-type lectin receptors and Toll-like receptors (TLRs). Maturation of 
DCs is crucial for the initiation of immunity (Fig. 1). Maturation of DCs might be trig-
gered by different factors including microbial and inflammatory products. Upon acti-
vation, DCs migrate to the lymphoid tissues (spleen and lymph nodes), where they can 
complete their maturation process and attract T and B cells by releasing chemokines. 
DCs activate and expand T-helper cells, which induce B cell growth and antibody pro-
duction (Kitajima et al., 1996). DCs are efficient stimulators of both B and T lympho-
cytes. B cells are the precursors of antibody secreting cells and can directly recognize 
native antigen via their B-cell receptors (BCRs). T lymphocytes need the antigen pro-
cessing and presentation by APCs for their activation (Banchereau and Steinman, 
1998).  
 
The T-cell receptors (TCRs) recognize fragments of antigen bound to the molecules of 
major histocompatibility complex (MHC) on the surface of APCs. This recognition de-
livers the first activating signal to T cells (signal 1). Activated by pathogens DCs ex-
press a variety of co-stimulatory molecules, which engage receptors on T cells and 
transmit signals that are important for T cell proliferation and survival (signal 2). The 
best known co-stimulatory molecules are CD80 and CD86, which trigger CD28 on T 
cells. Activated DCs produce also mediators that act on T cells to promote their differ-
entiation into effector cells (signal 3) (Joffre et al., 2009). There are two types of MHC 
peptide-binding proteins: MHC class I and MHC class II. Intracellular antigens are cut 
into pieces in the cytosol of APCs and then bound to MHC class I molecules that drives 
cytotoxic T cell (CTLs), which might directly kill a target cell. Extracellular antigens 
that entered the endocytic pathway of the APCs are processed and presented by MHC 
class II molecules that stimulate T-helper cells, playing thus role in the immune regula-
tion (Banchereau and Steinman, 1998).  
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Figure 1. DCs as immunological sensors translating perceived information into efficient adaptive immune 
response. Modified from Palucka et al. (Palucka and Banchereau, 2002). 
 
 
2. Pattern recognition receptors and the innate immunity 
 
The innate immune system senses the presence of infection through the recognition of 
conserved microbial pathogen-associated molecular patterns (PAMPs) by germ-line 
encoded PRRs (Janeway, 1989). Innate immune receptors trigger a variety of responses 
that depend on the receptor and cell type. Innate receptors might mediate internaliza-
tion of microbes by phagocytic cells. They might activate antimicrobial killing mecha-
nisms through the production of reactive nitrogen and oxygen. Innate receptors might 
also stimulate production of inflammatory cytokines that recruit and activate other 
immune cells and signal the development of adaptive immunity. The proper activation 
of innate immune response and cooperation between innate receptors play a crucial 
role in regulating and shaping of immune response for invading pathogens. The innate 
immunity must be tightly regulated since too little response leaves host susceptible to 
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the infection and too much response may lead to lethal systemic inflammation or auto-
immunity (Underhill, 2003). Microbial pathogens are recognized through multiple, dis-
tinct PRRs that can be categorized into three classes: secreted, cytosolic and transmem-
brane receptors. Secreted PRRs, which include colectins, ficolins, pentraxins, bind to 
microbial cell surfaces, activate classical and lectin pathways of the complement sys-
tem, and opsonize pathogens for phagocytosis by macrophages and neutrophils. The 
cytosolic PRRs include the nucleotide oligomerization domain NOD-like receptors 
(NLR) and the retinoic acid inducible gene I RIG-like receptors (RLR). The transmem-
brane PRRs include the Toll-like receptors (TLRs) and members of the C-type lectin 
family (Iwasaki and Medzhitov, 2010).  
 
 
2. 1. C-type lectin receptors and DC-SIGN 
 
C-type lectins are PRRs involved in the recognition of pathogen-derived carbohydrates 
by immune system. Several different C-type lectin receptors have been characterized, 
such as DC-SIGN, L-SIGN, SIGN-R1, Langerin, Siglecs, LSECtin, Mincle, DCIR, DCAR, 
BDCA-2, DCAL-1, MICL, Dectin-1, DNGR-1/CLEC9A, MR, DEC-205, MMR, MBL. 
 
Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN) receptor was dis-
covered by Geijtenbeek et al. in 2000 by investigating the binding of intercellular adhe-
sion molecules to DCs and finding that DCs bound the intracellular adhesion mole-
cule-3 (ICAM-3) with very high affinity (Geijtenbeek et al., 2000c). ICAM-3 belongs to 
the immunoglobulin superfamily (de Fougerolles et al., 1994) and it is expressed most-
ly in resting T lymphocytes (de Fougerolles and Springer, 1992). ICAM-3 plays a role in 
the initial adhesion between T lymphocytes and APC and further formation of a func-
tional immunological synapse (Montoya et al., 2002). It was originally described that 
DCs-expressed β-integrin, leukocyte function associated molecule-1 (LFA-1), was the 
major ligand for ICAM-3 on T lymphocytes. However, antibodies against LFA-1 failed 
to abolish T cell-DC clustering, while anti-ICAM-3 antibodies fully abrogated this in-
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teraction. Therefore, anti-DC hybridoma supernatants were widely screened to en-
counter a new DC-expressed molecule with the ability to inhibit ICAM-3 binding. A 
new C-type lectin was cloned and designated as DC-specific ICAM-3 grabbing non-
integrin (DC-SIGN) (Geijtenbeek et al., 2000c). The sequence of DC-SIGN was then 
found to be identical to a C-type lectin capable of binding HIV envelope glycoprotein 
gp120 that was cloned in 1992 (Curtis et al., 1992). Subsequent investigation of the 
group who discovered DC-SIGN showed that this lectin could bind HIV gp120 and 
retain infectious virus for up to several days. DC-SIGN-bound HIV viral particles 
could transmit infection to other cells expressing proper HIV receptors and coreceptors 
in the process described as trans-infection (Geijtenbeek et al., 2000b). Similarly to the 
ligand binding by other C-type lectins, DC-SIGN adhesion to ICAM-3 or HIV can be 
abrogated by mannose and calcium-chelating agents (Geijtenbeek et al., 2000b; 
Geijtenbeek et al., 2000c). Over years, consecutive studies were implemented to charac-
terize the biological role of DC-SIGN. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Tetrameric structure of DC-SIGN. Modified from Wu et al. (Wu and KewalRamani, 2006). 
 
 
 
DC-SIGN is a type II transmembrane C-type lectin that contains a carbohydrate recog-
nition domain (CRD), an extracellular stalk composed of seven complete and one par-
tial tandem repeat, a transmembrane domain and a short cytoplasmic N-terminal do-
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main with several intracellular sorting motifs (Fig. 2) (Geijtenbeek et al., 2000c). The 
neck domain of DC-SIGN, which consists of seven complete and one partial tandem 
repeat, is required for oligomerization and regulate carbohydrate specificity. The neck 
domain is followed by a transmembrane region. A cytoplasmic tail of DC-SIGN con-
tains internalization motifs, such as the di-leucine motif (LL), tri-acidic clusters motif 
(EEE) and an incomplete immunoreceptor tyrosine-based motif (ITAM) (van Kooyk 
and Geijtenbeek, 2003). 
 
The CRD of DC-SIGN is a globular structure, which consists of 12 β-strands, 2 α-
helices and 3 disulphide bridges. These elements form a loop on the outer surface of 
the protein that builds a part of 2 Ca2+ -binding sites. One of these Ca2+ -binding sites is 
essential for the conformation of the CRD and the second Ca2+ -binding site is funda-
mental for direct coordination of the carbohydrate structures (van Kooyk and 
Geijtenbeek, 2003). Four amino acids (Glu347, Asn349, Glu354, Asn365) interact with 
Ca2+ at this site and provide recognition of specific carbohydrate structures. Mutation 
of these amino acid positions leads to the loss of ligand binding (Geijtenbeek et al., 
2002b).  
 
DC-SIGN carbohydrate recognition 
Mannose residues Fucose residues 
Man α1→2 α-L-fucose  
Man α1→3 Lex - Galβ1→4[GlcNAcα1→3]Fuc 
Man α1→4 Ley - Fucα1→2[Galβ1→4GlcNAc α1→3]Fuc 
Man α1→6 Lea - Galβ1→3[GlcNAcα1→4]Fuc 
Man α1→3[Man α1→6]Man Leb- Fucα1→2 [Galβ1→3[GlcNAc α1→4] Fuc 
Man α1→3[Man α1→3[Man α1→6] Man α1→6] Man   
GlcNAc β1→2Man α1→3 [GlcNAcβ1→2Man α1→6] Man   
Man9-GlcNAc2   
Man5-GlcNAc2   
methyl α-mannoside   
N-acetylmannosamine   
 
Table 1. Carbohydrate profiling of DC-SIGN recognition. 
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The CRD of DC-SIGN shows high affinity for mannose and fucose residues (Table 1) 
(Feinberg et al., 2001; Guo et al., 2004; Mitchell et al., 2001) and it has been demonstrat-
ed that DC-SIGN binds with much higher affinity for the fucose-containing carbohy-
drates than for mannose-containing carbohydrates (Appelmelk et al., 2003; Geijtenbeek 
and van Kooyk, 2003; Mitchell et al., 2001). DC-SIGN binds also to Lewis blood groups 
antigens (Lex, Ley, Lea, Leb), which contain fucose residues in different anomeric linkag-
es. Moreover, it has been shown that DC-SIGN interacts with glucose, methyl α-
glucoside, GlcNAc, 2-deoxyglucose, however with much weaker affinity than it inter-
acts with mannose or fucose (Mitchell et al., 2001). 
 
Glycans cover the surface of all mammalian cells. They are added to the protein or li-
pid backbones during glycosylation process. During the biosynthesis of the glycans, 
these molecules are transported from the ER to the Golgi. Glycosylation is mediated by 
cell machinery, which involve glycosyltranferases (catalyze the transfer of the sugar 
from a nucleotide sugar donor or a lipid sugar to a substrate) and glycosidases (cata-
lyze hydrolysis of glycosidic bonds in glycan structures). Genes that are responsible for 
encoding for the glycosylation process represent >1% of the total genome and there are 
more than 100 glycosyltranferases and glycosidases described so far (Ohtsubo and 
Marth, 2006). The glycosylation might give different structural variations to a protein, 
which results in thousands of variations of potential glycan structures. Within mam-
malian cell, 3 types of glycosylation have been identified, such as O-linked glycosyla-
tion, N-linked glycosylation and glycosaminoglycosylation. N-linked glycans are at-
tached to the nitrogen of asparagine and O-linked glycans are attached to the hydroxy 
oxygen of serine, threonine, tyrosine, hydroxylysine, or hydroxyproline side-chains. 
 
O-linked glycosylation (Fig. 3) takes place in a later phase during protein folding 
(Drickamer, 2006). Biosynthesis of the O-linked oligosaccharide begins with transfer of 
N-acetyl-galactosamine (GalNAc) from UDP-N-acetyl-galactosamine to hydroxyl 
group of a serine or threonine residue in the protein. This reaction is catalyzed by a 
GalNAc transferase, which is localized to the ER or the cis-Golgi network. Following 
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the transfer of the protein to the trans-Golgi vescicles, a galactose residue is added to 
the N-acetyl-galactosamine by a specific 
trans-Golgi galactosyltransferase. In most 
vertebrate cells biosynthesis of O-linked 
oligosaccharides is completed by addi-
tion of two negatively charged N-
acetylneuraminic acid (sialic acid) resi-
dues in trans-Golgi apparatus or trans-
Golgi network (Lodish, 2000). 
 
 
 
 
 
 
 
Biosynthesis of N-linked oligosaccharides begins in the rough ER with the addition 
of a large oligosaccharide precursor. This oligosaccharide precursor is linked by pyro-
phosphoryl residue to dolichol, a long-chain (75-95 carbon atoms) polyisoprenoid lipid, 
which is inserted in the ER membrane and acts as a carrier for the oligosaccharide. The 
dolichol pyrophosphoryl oligosaccharide is formed on the ER membrane in a complex 
set of reactions that are catalyzed by enzymes attached to the cytosolic and luminal 
faces of the ER membrane. The final dolichol pyrophosphoryl oligosaccharide is ori-
ented in the way that the oligosaccharide faces the ER lumen. The structure of this pre-
cursor is conserved in plants, animals and single-cell eukaryotes and it contains the ol-
igosaccharide chain of 3 glucoses, 9 mannoses and 2 N-acetylglucosamines. Five resi-
dues of this 14-sugar precursor (core) are conserved in all N-linked oligosaccharides. 
The entire precursor is transferred from the dolichol carrier to asparagine present in tri-
peptide sequence asparagine-X-serine/threonine (where X can by any amino acid ex-
cept proline) in the reaction catalyzed by oligosaccharyltransferase. Immediately after, 
the oligosaccharide is transferred to a nascent polypeptide, 3 glucoses are removed 
Figure 3. O-linked oligosaccharide structures. aa-
any amino acid, GalNAc-N-acetylgalactosamine, 
Glc-glucose, SA-sialic acid, Ser-serine, Thr-
threonine. Modified from Lodish et al. (Lodish, 
2000). 
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from the chain and the protein is exported from the ER. The 3 glucose residues appear 
to act as a signal peptide, informing that the oligosaccharide is complete and ready to 
be transferred to a protein. The protein is then transported to the Golgi apparatus, 
where further removal of mannose residues occurs, that leads to the core structure that 
contains 3 mannose and 2 N-acetylglucosamine residues (Fig. 4). Different enzymes 
localized in the cis-, medial- and trans-Golgi cisternae catalyze these reactions as a pro-
tein moves through Golgi complex. Galactosyltransferases are localized in trans-Golgi, 
sialyltransferases are localized in the trans-Golgi and trans-Golgi network and manno-
sidases are localized in trans-Golgi (Lodish, 2000). 
 
 
 
 
Figure 4. Biosynthetic pathway for the generation of N-linked glycosylation. Processing of N-linked gly-
cans occurs in the ER and Golgi apparatus. Glucose trimming in the ER results in high mannose glycans, 
which are available for further processing and trimming by glycosidase and mannosidases to yield high-
mannose, hybrid and complex glycan structures. Modified from Lodish et al. (Lodish, 2000). 
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Differences in the processing of oligosaccharides within the ER and Golgi result in the 
variations of N-linked oligosaccharides structures. In some cases, the first reactions of 
removal of glucose residues may not occur, thus the relevant part of N-linked oligosac-
charide is not accessible to the enzymes catalyzing these reactions. The resulted glyco-
protein contains thus high-mannose oligosaccharide (Fig. 5C). In most mammalian 
cells, high-mannose oligosaccharide is further modified by mannosidases. The addition 
of various monosaccharide residues to oligosaccharide chain results in gaining com-
plexity in terms of residues type, modification and branching, which are called C-
glycans (Fig. 5A, 5B). C-glycans are different in size, electric charge and are performing 
different biological functions (Lodish, 2000). 
 
 
A            B           C 
                        
 
Figure 5. N-linked high mannose structures. A. Tri-antennary complex-type N-glycan. B. Hybrid-type N-
glycan. C. High-mannose-type N-glycan. Asn-asparagine, Fuc-fucose, Gal-galactose, GlcNAc-N-
acetylglucosamine, Man-mannose, SA-sialic acid, Ser-serine, Thr-threonine, X-any amino acid except pro-
line. Modified from Lodish et al. (Lodish, 2000). 
 
 
 
It has been shown that DC-SIGN plays a role in the immune system response, how-
ever the biological importance of its functions have not been clarified yet. The initially 
described binding of DC-SIGN to ICAM-3 was identified to be important for the initial 
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DC-T cells interactions (Starling et al., 1995). The intercommunication of T cells with 
DCs is antigen-dependent and allows scanning of the peptide – MHC class II complex-
repertoire by TCRs. This cooperation requires the formation of a specialized immuno-
logical synapse that is generated by the recruitment of specific adhesion receptors, 
which strengthen DC-T cell contact (Dustin and Chan, 2000; Grakoui et al., 1999; 
Monks et al., 1998). The initial DC-T cell interaction stabilizes DC-T cell membrane con-
tact, enabling efficient TCR engagement. The transient character of this communication 
allows DCs to interact with a large number of T cells until reaching the productive TCR 
involvement (Geijtenbeek and van Kooyk, 2003). DC-SIGN regulates also DC migra-
tion from blood into tissues for continuous surveillance of immune system. Precursors 
and immature DCs migrate to peripheral tissues to replenish resident DCs or in a re-
sponse to inflammatory signals. The way out from blood into tissues is mediated by 
multiple processes, such as leukocyte rolling, rapid activation of leukocytes, adhesion 
to endothelial ligands and diapedesis (Vestweber and Blanks, 1999). ICAM-2 is an en-
dothelial ligand, constitutively expressed on the endothelium of blood, lymphatic and 
vascular cells. DC-SIGN mediates binding and rolling of DC-SIGN+ cells along ICAM-2 
expressing surfaces. DC-SIGN therefore is involved in the adhesion of DCs to endothe-
lium and further trans-endothelial migration (Geijtenbeek et al., 2000a). DC-SIGN 
plays also the role of antigen receptor. Binding of soluble ligands by DC-SIGN induces 
rapid internalization of this receptor from cell surface and further targeting to late en-
dosomes, where antigens are processed and presented by MHC class II molecules 
(Engering et al., 2002). It has been also indicated that engagement of DC-SIGN on DCs 
results in the activation of signal transduction pathways, which can cause wide modu-
lation of immune responses, mostly when co-activated with Toll-like receptors 
(Gringhuis et al., 2007). DC-SIGN may thus induce of tolerance by immature DCs after 
recognition of glycosylated self-antigens for homeostatic control (Geijtenbeek et al., 
2004). 
 
The second function of DC-SIGN is its role as a receptor for pathogens. DC-SIGN 
recognizes the glycoproteins expressed on the surface of different pathogens that con-
tains a relatively large number of N-linked carbohydrates (HIV, Ebola virus, Cytomeg-
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alovirus, Hepatitis C virus, Dengue virus, Helicobacter pylori, Klebsiella pneumoniae, My-
cobacterium tuberculosis, Candida albicans, Leishmania, Schistosoma mansoni) (Alvarez et 
al., 2002; Appelmelk et al., 2003; Cambi et al., 2003; Colmenares et al., 2002; Curtis et al., 
1992; Geijtenbeek et al., 2002b; Geijtenbeek et al., 2003; Halary et al., 2002; Maeda et al., 
2003; Navarro-Sanchez et al., 2003; Pohlmann et al., 2003; van Die et al., 2003; van 
Kooyk and Geijtenbeek, 2003). It has been suggested that DC-SIGN can enhance viral 
uptake for direct infection in the process referred as cis-infection, as well as it can inter-
nalize viral particles into cell and storage in non-lysosomal compartments for subse-
quent transfer to susceptible cells in the process called as trans-infection (Alvarez et al., 
2002; Geijtenbeek et al., 2000b; Lee et al., 2001). DC-SIGN-bound viral particles were 
speculated to enter the cell, but escape from degradation by internalization into non-
lysosomal organelles and after migration to the lymphoid tissues, recycle back to the 
cell surface transmitting the infection to susceptible cells (van Kooyk and Geijtenbeek, 
2003).  
 
However, all of predicted functions of DC-SIGN are mostly based on multiple in vitro 
studies. To clarify the hypothesized physiological functions of DC-SIGN in coexistence 
with other lectins the proper in vivo model should be set up. It has been shown that 
human DC-SIGN family consists only of two receptors: DC-SIGN and L-SIGN, where-
as the mice have 8 DC-SIGN homologs (Park et al., 2001; Powlesland et al., 2006). The 
sequence analysis of those homologs and human DC-SIGN indicated that DC-SIGN 
receptor family suffered considerable diversification, which might be the result of evo-
lution pressure from exposure to different species-specific pathogens. As a result, there 
is not one member of mice DC-SIGN receptor family capable of performing the same 
functions as human DC-SIGN. The studies concerning glycan binding showed that the 
members of mice DC-SIGN family differ substantially in the glycan recognition from 
the pattern recognized by human DC-SIGN (Park et al., 2001; Powlesland et al., 2006; 
Takahara et al., 2012). It has been also shown that there are differences in the DC-
SIGN-activated cytokine responses and in the signaling pathways activated down-
stream of ligand binding by DC-SIGN in mice and human (Gringhuis et al., 2009; Kato 
and Kojima, 2010; Ohtani et al., 2012; Srivastava et al., 2009; Tanne et al., 2009; Wieland 
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et al., 2007). Additionally, the receptor distribution pattern might be also responsible 
for divergence between human DC-SIGN and mice receptor SIGNR. The receptor 
SIGNR1 is expressed on marginal zone macrophages (Geijtenbeek et al., 2002a), 
SIGNR3 is expressed on a fraction of DCs and/or macrophages in lymph nodes, spleen 
and dermis (Nagaoka et al., 2010). The most similar pattern of expression to DC-SIGN 
reveals SIGNR5, however this receptor does not mediate internalization and differ sig-
nificantly in glycan binding pattern as compared to DC-SIGN (Powlesland et al., 2006). 
 
To overcome the problem of wide variability between human DC-SIGN and mice 
SIGNR, a transgene encoding for human DC-SIGN was introduced in C57/B16 mice 
(hSIGN) (Schaefer et al., 2008). Human receptor DC-SIGN was expressed on hSIGN 
mice under the control of minimal promoter CD11, which allows reproducing a part of 
the expression pattern of human DC-SIGN. In the study of challenging of hSIGN mice 
with Mycobacterium tuberculosis the results showed that hSIGN mice infected with this 
pathogen survived longer as compared with wild-type mice, which might results from 
DC-SIGN functions in limiting the tissue-damaging inflammatory responses (Schaefer 
et al., 2008). Nevertheless hSIGN model displays also other C-type-mice specific lectins 
together with human DC-SIGN, which might contribute to the host response for the 
mannosylated glycans on Mycobacterium tuberculosis. Therefore it was suggested that 
SIGNR receptors showing mannose specificity should be knocked out in future mice 
models to address DC-SIGN function in vivo (Garcia-Vallejo and van Kooyk, 2013). It 
has been also demonstrated that Rhesus macaque DC-SIGN has a high homology with 
human DC-SIGN performing therefore similar functions of trans-receptor in HIV-1 in-
fection. The primate homologue to DC-SIGN is abundantly expressed in mucosal and 
lymphoid tissues, which might suggest its involvement in sexual transmission 
(Baribaud et al., 2001; Geijtenbeek et al., 2001; Schwartz et al., 2002; Yu Kimata et al., 
2002). These facts indicate that primate model may be suitable for further dissecting the 
role of DC-SIGN in the transmission and pathogenesis of HIV-1. However, the difficul-
ty of handling primate models and availability of proper installation for this kind of 
studies encourage continuing the development of new in vivo models for future DC-
SIGN investigation. Therefore, although appropriate in vivo models will be crucial for 
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understanding of the physiological role of DC-SIGN, in the meantime, in vitro studies 
on this aspect should be encouraged since it is the most relevant source of information 
so far. 
 
3. Ebola virus and DC-SIGN 
 
Ebola virus, together with Marburg virus, belongs to the family of Filoviridae. Ebola vi-
rus was first recognized during two major disease outbreaks, which occurred almost 
simultaneously in Zaire and Sudan in 1976 (Johnson et al., 1977). At that time over 500 
cases were reported, with the mortality rate of 88% in Zaire and of 53% in Sudan. Alt-
hough the emergence of both strains (EBOZ and EBOS) took place simultaneously, 
both strains varied significantly taking into account criteria such as sequence analysis 
and serology. In 1989, a new strain of Ebola virus was isolated from monkeys being 
held in quarantine in Reston after their transportation from Philippines (Jahrling et al., 
1990). The Ebola Reston (EBOR) strain is less virulent in humans than EBOZ and EBOS. 
The EBOR reappeared in monkeys in Italy in 1992 and in Texas in 1996 (Sanchez et al., 
2001). The second outbreak of EBOZ occurred in Zaire in 1995. In 1994 the fourth strain 
of Ebola virus was described in Ivory Coast (Lozano et al., 1995). This strain was fatal 
for humans as well as for monkeys. A large outbreak of EBOS reoccurred in Uganda in 
2000-2001 (CDC, 2001). A fifth species of Ebola virus was confirmed in an outbreak that 
took place in 2007 in Bundibugyo in Uganda (Alsop, 2007). 
 
The infection with Ebola virus starts with incubation period of 4-16 days, which often 
is marked by fever, chills, headache, anorexia, myalgia. These signs are soon followed 
by nausea, vomiting, sore throat, abdominal pain, and diarrhea. In general when first 
examined, patients are ill, dehydrated, apathetic, disoriented. Within several days oth-
er symptoms appear, such as a characteristic maculopapular rash, mucous membrane 
hemorrhages, and gastrointestinal bleeding. Shock in patients develops shortly before 
death, often 6-16 days after onsets of illness (Jahrling, 2003). Although the development 
of preventive vaccine for Ebola virus in primates has been described, there is no ap-
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proved specific Ebola virus therapy for humans available. The highly effective vaccina-
tion strategy in non-human primates was based on an immunization with a single 
plasmid encoding Zaire-strain virion glycoprotein that generated a substantial virus-
specific antibody response and conferred protective immunity in guinea pigs (Sullivan 
et al., 2000). 
 
Ebola virus is an enveloped, non-segmented, negative-strand RNA virus. The viral par-
ticles are typically 790-970 nm long and consistently 80 nm in diameter (Geisbert and 
Jahrling, 1995). The Ebola virus genome consists of 7 genes, which direct the synthesis 
of 8 proteins.  
 
 
 
 
Figure 6. Organization of Ebola virus genome. 
 
 
Transcriptional editing of the fourth gene, glycoprotein, leads to the expression of 2 
products: a 676-residue trans-
membrane-linked glycoprotein 
GP and a 364-residue secreted 
glycoprotein sGP. The tran-
scriptional editing of glycopro-
tein gene is due to the overlap-
ping of transcription stop site 
with transcription start site of 
the downstream VP30 gene 
(Sanchez et al., 1996).  
 
 
Figure 7. Ebola virus particle. 
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After entry of Ebola virus into the host cell cytoplasm, the RNA is transcribed to gener-
ate a polyadenylated, subgenomic mRNA. The genome shows the following gene or-
der: 3’ leader, nucleoprotein (NP), virion protein 35 (VP35), virion protein 40 (VP40), 
glycoprotein (GP/sGP), virion protein 30 (VP30), virion protein 24 (VP24), polymerase 
protein (L), 5’ leader (Fig. 6). The transcription and translation lead to the synthesis of 7 
structural polypeptides. Four of produced proteins, NP, VP30, VP35 and L, are associ-
ated with the viral RNA in ribonucleoprotein complex. Three structural proteins, 
GP1/2, VP24, VP40 are membrane associated. VP24 and VP40 are located in the inner 
site of the membrane (Fig. 7). The NP, VP35 and L proteins are essential for virus tran-
scription and replication. VP40 functions as the matrix protein. Additionally, one non-
structural, secreted glycoprotein (sGP) is expressed (Feldmann and Kiley, 1999). 
 
 
3. 1. Ebola virus glycoproteins 
 
Ebola virus glycoproteins are encoded by the fourth gene of RNA genome. The prima-
ry structure of the editing site is composed of 7 uridine residues in the genomic se-
quence. Transcriptional editing is performed by the viral RNA-dependent RNA poly-
merase (L protein). Unedited viral mRNA (about 70-80% of GP-specific mRNA) give 
rise to the primary product of the forth gene, the secreted, non-structural glycoprotein 
(sGP). In about 20-25% of GP-specific transcripts, the addition of single adenosine resi-
due at editing site shifts the ORF to -1, which results in the production of transmem-
brane GP (Cook and Lee, 2013; Sanchez et al., 1996) (Fig. 8). It has been observed that 
the shift of ORF to -2 might also occur that results in the expression of third nonstruc-
tural small secreted protein (Volchkova et al., 1998) (Fig. 8). There are solid evidences 
that viral envelope glycoproteins of Ebola viruses are modulators of host antiviral de-
fenses (Cook and Lee, 2013). The GP gene product, which is responsible for viral entry, 
is synthesized in only about 20-25% of transcripts (Cook and Lee, 2013; Sanchez et al., 
1996).  
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Figure 8. Processing of EBOV glycoproteins. Modified from Cook et al. (Cook and Lee, 2013). 
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The rest of synthesized products are free glycoproteins that act mostly to mislead hu-
moral immune responses. The Ebola-infected cells release into person´s sera secreted 
glycoprotein sGP and shed GP (Dolnik et al., 2004; Sanchez et al., 1998). Both secreted 
glycoproteins might compete with virion-attached GP in the antibody-binding as it 
was shown that most of the antibodies derived from EBOV survivors or macaques 
were directed against sGP rather than the virion-attached GP (Druar et al., 2005; Ito et 
al., 2001; Maruyama et al., 1999). 
 
Transcriptional editing based on the insertion of one adenosine residue at editing site 
of the glycoprotein gene results in the synthesis of transmembrane glycoprotein GP. 
The precursor of Ebola virus glycoprotein (preGP) undergoes a complex of processing 
events in ER and Golgi that result in the production of mature GP. After the removal of 
the signal peptide, preGP is N-glycosylated and oligomerized in ER. ER processing is 
followed by acetylation in pre-Golgi compartment, O-glycosylation and maturation of 
N-glycans in Golgi apparatus (Feldmann et al., 1991). preGP is then cleaved proteolyti-
cally into large amino-terminal GP1 (~130 kDa) and smaller carboxy-terminal GP2 (~24 
kDa) subunits in the trans-Golgi network by the furin, enzyme belonging to the subtil-
izin-like protein convertase family. The furin cleavage motif is highly conserved 
among all filovirus transmembrane glycoprotein sequences and it consists of R-X-K/R-
R motif (Volchkov et al., 1998). Mature envelope glycoprotein (150-170 kDa) is an-
chored in the membrane by a carboxy-terminal hydrophobic domain of GP2. Ebola vi-
rus glycoproteins form a trimeric conformation on the viral surface that is composed of 
3 covalently attached monomers adopting a chalice-like shape. Each monomer contains 
two disulphide-linked subunits, GP1 and GP2. GP trimerization is mediated by multi-
ple GP1-GP2 and GP2-GP2 contacts. Three GP1 ectodomains form together a bowl-like 
structure encircled by helices of three GP2 subunits (Lee et al., 2008). GP1 is responsi-
ble for the cell-surface attachment. GP1 is composed of a single domain that can be 
subdivided into: base, head and the glycan cap regions (Fig. 9). The base subdomain is 
composed of two sets of β-sheets, which form a semicircular surface that fix the inter-
nal fusion loop with a helix of GP2 through the hydrophobic interactions. The base re-
gion contains Cys53 that form an intermolecular disulphide bridge to Cys609 of the 
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GP2 subunit (Jeffers et al., 2002). The head subdomain is located between the base and 
the glycan cap regions. The head region contains two intramolecular disulphide bonds 
that stabilize the structure of GP1. The glycan cap subdomain contains 4 predicted N-
glycosylation sites and is fully exposed 
on the outer surface of the chalice (Lee 
et al., 2008). GP2 is responsible for fu-
sion of viral and host cell membranes 
since it contains a fusion peptide motif 
at residues 528-539. GP2 consists also 
of the internal fusion loop, the immu-
nosuppressive motif at residues 584-
600, the heptad regions: HR1, HR2, a 
transmembrane domain at position 
651-670 and a cytoplasmic domain at 
residues 671-676 (Fig. 9). 
 
 
 
 
 
 
The middle region of GP1/GP2 is extremely hydrophobic and contains a bulk of N- and 
O-linked glycans that account for more than one-third of the molecular mass of the ma-
ture protein (Geyer et al., 1992). Most of N-glycans are located in the mucin-like do-
main and the glycan cap of GP1. The approximate number of total oligosaccharides on 
the full-length GP is estimated to be 19 (17 on the mucin-like region). Among all at-
tached oligosaccharides, Ebola virus glycoprotein contains 11 high-mannose N-
glycosylation sites. The dense clustering of glycans generates an unfavorable condition 
for the interaction with neutralizing antibodies. The most critical regions responsible 
for Ebola virus entry such as the receptor-binding site are hidden under layers of gly-
cans and no neutralizing antibodies were identified targeting this site (Wilson et al., 
2000). Thus, although the major role of GP1 is receptor binding, it acts also in the pro-
Figure 9. The structure of domains that form GP of 
Ebola virus. Modified from Lee et al. and Sanchez et al. 
(Lee et al., 2008; Sanchez et al., 1998). 
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tection of the virion from immune response through extensive glycosylation. GP2 plays 
a role in assembly of trimer structure, positioning of GP1 for receptor binding and host 
cell entry (Sanchez et al., 2001). 
 
The secreted glycoprotein of EBOZ is a 365 aa in length and shares the amino-terminal 
295 aa with the transmembrane glycoprotein GP (Fig. 10). 
 
 
 
 
Figure 10. Diagrammatic representation of glycoprotein (GP) and secreted glycoprotein (sGP) of Ebola 
virus strain Zaire. The N-terminal 295 nt region identical in GP and sGP is shown in blue. The C termini 
with unique sequences in GP and sGP are shown in grey. The furin cleavage site for GP0 (uncleaved form 
of GP), the fusion peptide, the heptad region and the transmembrane anchor are shown on the graphics. 
Additionally, the cysteine residues (S) and the predicted N-glycosylation sites (blue stars) are shown in 
both GP and sGP. Modified from Sanchez et al. (Sanchez et al., 1998). 
 
 
Pre-sGP undergoes several co- and post-translational processing events, such as signal 
peptide cleavage, glycosylation, oligomerization and proteolytic cleavage (Volchkova 
et al., 1998). Post-translational cleavage by furin in the Golgi compartments results in 
cleavage into sGP (50-70 kDa) and a small peptide termed ∆-peptide (Volchkova et al., 
1999). Due to the lack of a transmembrane domain, sGP is secreted efficiently from in-
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fected cells. sGP forms disulphide bonds between cysteines at the both ends of this 
molecule, which results in dimer formation. sGP might interact with the immune sys-
tem at the cellular and humoral level. sGP plays a role in depletion of the immune 
cells. sGP binds to neutrophils and inhibits their activation, which results in the in-
flammatory instead of immune response. At the humoral immunity level, sGP pre-
vents from acting of high-affinity antibodies on virion (Sanchez et al., 1996). By-
product of sGP processing, ∆-peptide varies in length between 40-48 aa (10-14 kDa). 
 
The small secreted glycoprotein (28 kDa) resembles a natural carboxy-terminal trun-
cated variant of sGP. It lacks three carboxy-terminal cysteines, which are responsible 
for the dimerization of sGP. ssGP is therefore secreted in a monomeric form (Volchkov 
et al., 1995). 
 
3. 2. Ebola virus receptors 
 
Ebola virus cell entry is mediated by the interaction of a GP1 subunit with the recep-
tors expressed on host cell. A number of molecules have been proposed as the main 
cellular entry receptors for Ebola virus. It has been identified that a glycophosphatidyl-
inositol-linked protein, a folate receptor α (FRα), serves as a co-factor in Ebola virus 
cell entry. FRα is highly conserved in mammalian cells and it is expressed in the epi-
thelial and parenchymal cells of a number of organs, but not in liver or endothelial cells 
(Chan et al., 2001). It has been demonstrated that endosomal membrane protein Nie-
mann-Pick C1 (NPC1) encoding an endolysosomal cholesterol transporter plays an es-
sential function in Ebola virus entry (Carette et al., 2011; Cote et al., 2011). It was shown 
that cells lacking NPC1 revealed resistance to infection by Ebola and Marburg enve-
lope glycoprotein pseudotyped viruses (Carette et al., 2011). In vitro studies demon-
strated that treatment of cells with molecules targeting NPC1 potently inhibited viral 
infection by Ebola GP-pseudotyped viruses (Cote et al., 2011). Binding of Ebola virus 
GP to different cellular lectins has been also shown to augment virus infection. Lectins 
might play a role through the concentration of viral particles on the cell surface and 
Introduction 
25 
 
therefore increasing the cell entry and infection level (Alvarez et al., 2002). Essential 
lectins enhance Ebola virus entry, such as DC-SIGN, L-SIGN (Alvarez et al., 2002), 
MBL (Ji et al., 2005), a human macrophage galactose (hMGL), N-acetylgalactosamine-
specific C-type lectin (Takada et al., 2004), the liver-specific asialoglycoprotein receptor 
(ASGP-R) (Becker et al., 1995) and LSECtin (Gramberg et al., 2005). The members of 
tyro3 protease kinase family (Shimojima et al., 2006) and integrin β1 (Takada et al., 
2000) play also the role in facilitating Ebola cell entry.  
 
Ebola viruses can lead to the productive infection in a number of systems, such as hu-
man, simian and bat (Anonymous, 1978; Bowen et al., 1978; Fisher-Hoch et al., 1992). 
Wool-Lewis et al. has studied the cellular tropism of Ebola virus by using MLV parti-
cles pseudotyped with Ebola Zaire glycoprotein.  It was shown that Ebola GP-
pseudotyped particles displayed a very broad host range of receptors being able to in-
fect different cell lines from various species and tissues, including 293T, HeLa, Vero, 
BSC-1, Cos-7, NIH 3T3, MDBK, BAEC, PK-15, BHK, CHO, Qt6, CEF, TEF, U87, MDCK, 
Tb 1 Lu and Pt K1. Remarkably, they discovered that human and murine lymphoid cell 
lines were resistant to Ebola GP-pseudoparticles infection suggesting that lymphoid 
lineage cells lack the functional Ebola virus receptors (Wool-Lewis and Bates, 1998; 
Yang et al., 1998). In the natural course of Ebola virus infection, hepatocytes, DCs, 
monocytes and macrophages are the preferred target cells of filoviruses and the infec-
tion of these cells is important for hemorrhagic manifestations and immune disorders 
(Davis et al., 1997).  
 
3. 3. DC-SIGN-mediated Ebola virus infection 
 
The potential role of DC-SIGN in Ebola virus infection has been studied in the cellular 
model based on non-permissive for Ebola virus infection T-lymphocyte-derived Jurkat 
cells. This study demonstrated that the expression of DC-SIGN molecule on the surface 
of non-susceptible cells has allowed Ebola GP-pseudotyped retrovirus cell entry 
(Alvarez et al., 2002). DC-SIGN is not the main receptor for Ebola virus and many dif-
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ferent cell lines lacking DC-SIGN has been earlier described as a target of viral infec-
tion (Wool-Lewis and Bates, 1998; Yang et al., 1998). It has been shown that the expres-
sion of DC-SIGN increases the level of the infection with Ebola virus in susceptible 
cells. Moreover, DC-SIGN acts as a trans-receptor since Ebola particles might be cap-
tured by DC-SIGN-expressing monocyte-derived DCs to be further transmitted to re-
cipient cells (Alvarez et al., 2002). Although all predicted in vitro DC-SIGN functions 
have not been confirmed in in vivo studies, DC-SIGN was predicted to participate in 
the dissemination of the virus at the first moments of the infection. Therefore, over the 
years many different antiviral strategies based on carbohydrate compounds targeting 
DC-SIGN were used to block Ebola virus-DC-SIGN interaction. 
 
 
4. Human Immunodeficiency Virus (HIV) and DC-SIGN  
 
4. 1. The discovery of HIV 
 
AIDS was first described as a new clinical syndrome in 1981 when the first five clinical 
cases of AIDS were published in the Morbidity and Mortality Weekly report and subse-
quently in the New England Journal of Medicine. These reports described an epidemic of 
Pneumocystis carinii pneumonia (PCP) combined in most cases with oral rush and 
chronic ulcerating perianal herpes infection in previously healthy homosexual men 
(Gottlieb et al., 1981; Masur et al., 1981). The first evidence of the AIDS agent was 
shown by the group of Luc Montagnier and Françoise Barré-Sinoussi, who isolated a 
retrovirus from a lymph node of patient with persistent generalized lymphadenopathy 
showing AIDS symptoms and named it lymphadenopathy-associated virus (LAV) 
(Barresinoussi et al., 1983). In early 1984, the group of Robert Gallo isolated the lym-
photropic retrovirus from the peripheral blood mononuclear cells (PBMCs) of patient 
with AIDS syndrome and named it HTLV-III (Gallo et al., 1984). At the same time, the 
group of Levy isolated also the retrovirus infecting CD4+ T cells from patients with 
AIDS symptoms as well as from asymptomatic patients from the risk groups in San 
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Francisco and named it ARV (AIDS-associated retrovirus). Finding the ARV in asymp-
tomatic individuals indicated for the first time the healthy carrier for the AIDS agent 
(Levy et al., 1984). A short time later, it was shown that all three virus variants (LAV, 
HTLV-III, ARV) corresponded to the same infectious agent that was renamed in 1986 
by The International Committee on Taxonomy of Viruses to human immunodefi-
ciency virus type I (HIV-1). In 2008 the French group of Luc Montagnier and 
Françoise Barré-Sinoussi received the Nobel Prize in Medicine for the discovery of 
HIV-1. 
 
4. 2. The structure of HIV  
 
HIV-1 particle is 100-120 nm in diameter, with heterogeneous morphological shape 
(Kuznetsov et al., 2003). Each viral particle is surrounded by lipoprotein membrane 
with integrated glycoprotein complexes. The glycoprotein complex is composed of 
trimers of an external glycoprotein gp120 and a transmembrane spanning protein 
gp41. The number of viral spikes was initially described as 72 (Chan et al., 1997), how-
ever electron microscopy studies showed that by the time the virus particle is released 
from the cell only 7-14 spikes appear to be present on the virion surface (Chertova et 
al., 2002; Layne et al., 1992). The spikes are arranged on the virion surface as tripod-like 
structures in the varied number reflected by the reduction in envelope formation rather 
than envelope shedding (Chertova et al., 2002). The diameter of each spike is about 14 
nm and its high is 9-10 nm. Infectious particles contain the three gag proteins: matrix 
(MA, p17), capsid (CA, p24) and nucleocapsid (NC, p7) (Gomez and Hope, 2005). MA 
forms the inner shell in the viral particle below the viral membrane, CA forms the ca-
nonical core enclosing the viral genomic RNA and NC interacts with the viral RNA in-
side the capsid (Fig. 11). The genomic RNA is a dimer, held together by sequences near 
its 5’ ends of both subunits (Bender and Davidson, 1976). The viral proteins are gener-
ated by the viral protease (PR), which processes the HIV-1 p55 gag precursor polypro-
tein into p17, p24, p2, p7, p1 and p6 (Fig. 12). Inside the CA are two identical RNA 
strands in close contact with the viral RNA-dependent DNA polymerase (reverse tran-
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scriptase, RT) and NC proteins (p6 and p9). The inner part of the viral membrane is 
surrounded by a myristylated p17 core protein (MA) (Gelderblom et al., 1988).  
 
 
 
 
 
Figure 11. Structure of HIV particle. Modified from Hoffmann et al. (Hoffmann and Rockstroh, 2010). 
 
 
 
The genomic size of HIV is about 9 kb, with three open reading frames (ORF) coding 
for several viral proteins. The structural scheme of a retroviral genome is: 5’LTR – gag 
– pol – env – LTR3’ (Fig. 12). The long terminal repeat (LTR) regions represent the ter-
minal parts of the viral genome, which are connected to the host cellular DNA after 
integration and do not encode for viral proteins. The gag genes code for nucleocapsid, 
capsid and core proteins. The env genes encode envelope glycoproteins. The pol genes 
code for viral enzymes (Wong-Staal, 1991). The primary transcript of HIV is full-length 
viral mRNA, which is translated into the polymerase (pol) and group-antigen (gag) pro-
teins. The pol precursor is autocleaved by its PR region into viral enzymes: RT, PR and 
integrase (IN). The proteolytic cleavage of gag precursor gives rise to p24, p17, p9, p6, 
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p2 and p1. The env precursor gp160 is cleaved by endoprotease furin into superficial 
gp120 and transmembrane gp41 (Gomez and Hope, 2005). 
 
 
 
Figure 12. The organization of HIV-1 genome. Modified from Coffin (Coffin et al., 1997). 
 
 
 
4. 3. The structure of HIV envelope 
 
The HIV envelope glycoprotein is a type I membrane spanning protein that is synthe-
sized and processed to its mature form by the host cell machinery (McKeating and 
Willey, 1989). The env protein gives rise to surface (SU) and transmembrane (TM) enve-
lope glycoproteins that are derived from a common precursor. The nascent env poly-
peptide binds to a signal recognition particle through its amino-terminal leader seg-
ment and becomes associated with the membrane of the ER. Further translation ex-
trudes most of the envelope polypeptide through the membrane into the lumen of ER, 
Introduction    
 
30 
 
where the process of oligomerization takes place. After cleavage of the leader se-
quence, env is transported by vesicular traffic through the Golgi apparatus to the plas-
ma membrane. During the transport through Golgi apparatus, the env protein is glyco-
sylated during N-glycosylation and O-glycosylation process. Env is then cleaved in 
Golgi by a cellular protease, furin, to yield mature SU gp120 and TM gp41 glycopro-
teins. SU and TM remain attached to each other by non-covalent interactions (Coffin et 
al., 1997). The glycosylation process of HIV envelope is required for proper folding and 
conformational stability of the envelope glycoprotein (Fenouillet et al., 1994). The gly-
cosylation mainly involves the attachment of N-linked high-mannose-type oligosac-
charides to the protein backbone to the asparagine in Asn-X-Thr or Asn-X-Ser motifs, 
where X is any aa apart from proline. The number and distribution of N-linked glyco-
sylation sites varies widely between different HIV isolates, being in the range of ap-
proximately 18-32 PNGS in gp120 accounting for about 50% of the total molecular 
weight. As the glycoprotein is transported through the Golgi, accessible glycan moie-
ties are trimmed and modified by various cellular enzymes resulting in the generation 
of complex-type oligosaccharides. The gp120-gp41 complexes, which remain associated 
through non-covalent interactions between the gp41 ectodomain and discontinuous 
structures composed of NH2- and COOH-terminal gp120 sequences, are initially ex-
pressed at the surface of infected cells. During the process of HIV budding, the gp120-
gp41 complexes are then incorporated into the virus envelope and displayed on the 
viral surface as viral spikes (Wyatt and Sodroski, 1998). gp120 is composed of five con-
stant regions (C1-C5) and five variable regions (V1-V5) (Starcich et al., 1986). Intramo-
lecular disulfide bonds in the gp120 glycoprotein result in the incorporation of the first 
four variable regions into large, loop-like structure (Leonard et al., 1990). gp120 core is 
composed of 25 β-strands, 5 α-helices and 10 loop segments folded into a heart-shaped 
globular structure with dimensions of 5 x 5 x 2.5 nm. The core is formed of inner and 
outer domains that are linked together by a four-stranded sheet called bridging sheet. 
The inner domain is more conserved than outer domain and is largely devoid of gly-
cans (Kwong et al., 1998). The inner domain of gp120 faces the trimer axis, whereas the 
outer domain is mostly exposed on the surface of env oligomer. The outer domain is 
largely covered by glycans resulting in lower overall immunogenicity of this domain 
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(Wyatt et al., 1998). The bridging sheet links the inner and outer domain. The primary 
HIV-specific receptor is CD4, a 58 kDa monomeric glycoprotein, which is expressed on 
the surface of T lymphocytes, monocytes, dendritic cells, and brain microglia (Deng et 
al., 1996). The binding site for CD4 on the ligated gp120 structure is formed by the in-
terface between the inner domain, bridging sheet and outer domain. Most of the CD4 
contact residues are situated on the outer domain of the ligand-covered gp120 and 
form a continuous binding region (Kwong et al., 1998). The majority of gp120 confor-
mational shifts resulting from CD4 binding are located in the portion of gp120 that in-
teracts with gp41. These conformational changes are necessary to lock the coreceptor-
binding site (CoRBs) into a fixed conformation resulting in the initiation of the first 
steps in fusion process (Wyatt and Sodroski, 1998). The region that is important for the 
interaction with the β-chemokine receptor CCR5 has been mapped to the residues in 
the bridging sheet located close to the V3 stem. V3 loop plays a major role in determin-
ing the coreceptor usage of virus strain. Moreover, certain single amino acid changes 
within V3 loop can alter cell tropism of HIV-1 (Takeuchi et al., 1991). The isolates using 
CCR5 coreceptor are named R5-tropic viruses, isolates using CXCR4 coreceptor are 
named X4-tropic viruses and the isolates able to use both coreceptors are called dual-
tropic (DM) (Berger, 1997). The HIV-1 clinical isolates of primary infection use general-
ly the CCR5 coreceptor for its entry (Feng et al., 1996). It has been proven that a single 
viral particle most often establishes infection (80% of heterosexual transmissions), 
which results in very homogeneous virus population at the beginning of the infection. 
After time, viral population diversifies, accumulating mutations to evade HIV-specific 
immune responses (Abrahams et al., 2009; Keele et al., 2008). The CoRBs is not present 
on the gp120 until CD4 binding occurs (Rizzuto and Sodroski, 2000). The CoRBs is one 
of the most conserved surfaces on the gp120 core, even more conserved than the CD4 
binding site (CD4Bs) (Rizzuto et al., 1998). The CoRBs is located close to the trimer axis 
and faces the target cell surface after CD4 ligation to gp120. The rearrangements in 
gp120 involve a movement of the V1-V2 stem away from the underlying CoRBs, while 
V3 loop may move towards this binding site. Binding of the coreceptor to gp120 leads 
to further conformational changes resulting in the gp41 activation into its fusion-active 
state. gp41 exists in a metastable non-coiled-coil conformation when associated with 
Introduction    
 
32 
 
gp120. After coreceptor binding, the envelope glycoprotein complex undergoes con-
formational changes, which lead to the insertion of gp41 fusion peptide into the mem-
brane of the target cell and the formation of a pre-hairpin intermediate, where gp41 
protein is both a viral and a cell membrane protein. The pre-hairpin intermediate is fol-
lowed by a formation of a gp41 coiled-coil structure, which further leads to the apposi-
tion of membranes and to the fusion (Wyatt et al., 1995). 
 
The exposure of the primate immunodeficiency virus envelope glycoproteins on the 
surface of virions or infected cells makes them the major target of neutralizing antibod-
ies (NAbs). NAbs responses against HIV-1 infection in vivo is generally limited (Wyatt 
and Sodroski, 1998). Structures on the viral envelope glycoproteins that are conserved 
among diverse viral strains are generally poorly exposed to humoral immune system. 
The conserved gp120 surfaces involved in binding to gp41, CD4 and chemokine recep-
tors, exhibit problems with respect to the elicitation or sensitivity to NAbs. The moie-
ties involved in binding to CD4 or coreceptors are buried in the interior of functional 
spikes, flanked by variable regions exhibiting high glycosylation pattern (Wyatt et al., 
1993). Because most carbohydrates moieties may appear as “self” to the immune sys-
tems, this concentrated glycosylation may reduce the potential of a large portion of the 
gp120 surface to serve as an immunogenic target. The efficacy of the humoral immune 
response in limiting the spread of virus in vivo is compromised by the relative re-
sistance of primary virus isolates to neutralization and the temporal pattern with 
which NAbs are generated (Wyatt and Sodroski, 1998). The non-covalent nature of the 
association between gp120 and gp41 contributes to the lability of the functional enve-
lope trimer. During natural infection, disassembled envelope glycoproteins elicit most 
of the Abs directed to these viral components (Wang et al., 1986). In general, the cog-
nate Abs cannot bind the assembled, functional envelope spikes to exhibit neutralizing 
activity. Thus, although Abs are detected in the sera of HIV-1-infected individuals by 
2-3 weeks after infection, they lack the ability to inhibit virus infection. By the time that 
NAbs are efficiently elicited, HIV-1 infection is established in the host. Several weeks 
after infection, NAbs can be detected in sera of HIV-1-infected individuals, however, 
they often exhibit little or no activity against other strains. Later in the course of infec-
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tion, Abs capable of neutralizing wider range of HIV-1 isolates may appear, however 
they are mostly active against early infection virus variants (Wyatt and Sodroski, 1998). 
 
It has been shown that hypervariable loops of HIV-1 envelope tend to be shorter and to 
carry fewer PNGS in viruses from early infection as compared with their chronic coun-
terparts (Chohan et al., 2005; Frost et al., 2005). Larger loops mask epitopes recognized 
by NAbs, thus it is hypothesized that during the time of infection they are acquired 
under immune pressure. Increased length of VLs may also reduce CD4 receptor and 
CCR5 coreceptor access (Sagar et al., 2009). Changes in glycosylation pattern play a key 
role in chronic infection, which may results in immune escape. Although the reduced 
loops lengths and number of PNGS are characteristic for early viruses, some specific 
PNGS in outer domain has been shown to be lost in the course of chronic infection. It 
has been shown that glycans at positions N188, N362, N462, N392, N397, N356 play a 
role in facilitating of transmission in early infection, and their loss contributes to im-
mune escape in chronic infection (Gnanakaran et al., 2011).  
 
The dense layer of the glycans have an important role in viral transmission through 
interactions with lectins, particularly the C-type lectin DC-SIGN (de Witte et al., 2008). 
It has been shown that some glycan changes confer to the increased binding to DC-
SIGN. DC-SIGN can facilitate viral infection in trans and in cis, especially when CD4 
and coreceptors levels are limited. The presence of an additional glycan (N158) at the 
N-terminal base of the V2 loop of SHIVSF162 gp120 compared to the parental strain 
was responsible for the increasing binding to DC-SIGN (Lue et al., 2002). It has been 
also shown that R5 viruses emerging during end-stage AIDS disease displayed re-
duced ability to use DC-SIGN. R5 end-stage viruses lacked PNGS in the gp120 V2 
(N160) and V4 (N406) as compared with early infection viruses. N160 was shown to be 
responsible for more efficient use of DC-SIGN for binding and trans-infection. The 
competition assay reveled that strains containing N160 were selected for trans-
infection, whereas strains lacking N160 were selected for direct cell infection (Borggren 
et al., 2008). Hong et al. demonstrated also that elimination of PNGS by mutagenesis at 
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positions N293Q, N382Q, N388Q and N328Q exhibited a significant decrease in bind-
ing to DC-SIGN as compared with wild type JR strain (Hong et al., 2007).  
 
 
 
 
Figure 13. Natural course of HIV-1 infection. Modified from Hoffmann et al. (Hoffmann and Rockstroh, 
2010). 
 
 
 
4. 4. The natural course of HIV infection 
 
Shortly after HIV exposure, the acute retroviral syndrome is observed in some patients. 
This syndrome is defined by unspecific and variable “flu-like” symptoms that make 
the diagnosis of HIV-1 more difficult (Schacker et al., 1996; Vanhems et al., 1999). The 
acute infection phase was characterized in details by Fiebieg et al. showing the pres-
ence of specific HIV markers in each phase of the acute period (Fiebig et al., 2003). Af-
ter acute phase, the period of several years of asymptomatic chronic infection takes 
place in most of the people. Followed asymptomatic phase of HIV-1 infection, the 
AIDS-defining illness occurs at a median of 8-10 years after infection (Phillips, 1992). 
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Without antiretroviral therapy (ARV) this phase eventually leads to the death of pa-
tients after a variable period of time (Fig. 13). 
 
 
4. 5. Mechanisms of durable HIV control in the absence of antiretroviral 
treatment: HIV-1 controllers 
 
Most of HIV-1-infected patients show high plasma viral load and the loss of CD4+ T 
cells along the course of HIV-1 infection in case of absence of ART (Lassen et al., 2009). 
The majority of antiretroviral-untreated individuals eventually develops immunodefi-
ciency of immune system and dies from AIDS-related complications in approximately 
10-year time after becoming infected. However, a very small percentage of untreated 
individuals remain clinically and/or immunologically stable for years (Cao et al., 1995; 
Munoz et al., 1995). The term of “long-term non-progressors (LTNP)” was used in case 
of people that were able to maintain normal CD4+ T cell counts for prolonged periods 
(>10 years). According to virological criteria, some of the individuals (less than 1% of 
infected population) called “elite controllers (EC)” are able to maintain viral loads un-
detectable (<50 copies HIV RNA/ml) (Deeks and Walker, 2007). According to the Inter-
national HIV Controller Consortium there are three main criteria for enrolment a pa-
tient as EC: 1) being HIV antibody positive as determined by serologic tests, 2) being 
under no antiretroviral therapy in the last 12 month period, 3) having done at least 3 
plasma HIV RNA determinations spanning at least 12 last months that resulted in be-
ing below the limit of detection. The International HIV Controller Consortium defined 
the second group of HIV controllers called viremic controllers (VC). Individuals who 
belong to VC group have to accomplish 3 following criteria: 1) maintain RNA levels 
below 2000 copies of viral RNA per ml, 2) not receive antiretroviral therapy for 1 year 
or longer, 3) episodes of viremia are acceptable as long as they represent the minority 
of all available determinations (www.eliteconrollers.org).  
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The factors associated with HIV control in vivo have not been fully defined yet, in part 
due to the fact that HIV controllers form a very heterogeneous population (Lefrere et 
al., 1997). Individuals destined to become HIV controllers seem to have less sympto-
matic primary infections as compared with those destined to remain viremic (Madec et 
al., 2005a), which suggest that complex virus and host interactions leading to pro-
longed control of viral replication play already an important role during the earliest 
phases of HIV disease (Altfeld et al., 2006). It has been shown that neither the route of 
HIV acquisition is associated with the likelihood of controlling HIV infection (Madec et 
al., 2005b), neither the gender of infected person (Deeks and Walker, 2007; Sterling et 
al., 1999) nor the race, geographical location, viral subtype (Deeks and Walker, 2007). It 
has been speculated about the potential role of virus factors or host genetics as an ele-
ments associated with virological control.  
 
There is some evidence that pathogenicity of HIV isolates can differ, which was shown 
in a group of individuals infected through blood transfusion from a common donor 
harbouring a virus containing deletion in the nef gene and who maintained low vire-
mia for years (Deacon et al., 1995). Over the time, many of these individuals eventually 
have progressed to AIDS (Churchill et al., 2006), which showed that viral attenuation 
through the nef gene did not lead to life-long control of HIV infection in vivo. Different 
small studies or case reports argued that mutations or deletions within the HIV func-
tional and accessory genes (rev, tat, vif, vpr and vpu) can lead to virus control and/or 
immunologic non-progression (Alexander et al., 2000; Hassaine et al., 2000; Kirchhoff 
et al., 1995; Lum et al., 2003; Wang et al., 1996; Yamada and Iwamoto, 2000). Neverthe-
less, there are difficulties in the interpretation of these studies since they were based on 
a very low number of infected individuals. The frequency of infectious units per mil-
lion of resting CD4+ T cells has been estimated as a value of 0.02, which is 1.5 log lower 
than the value observed during suppressive ART. In some studies virus from HIV con-
trollers showed normal replication kinetics in vitro and lacked any genetic insertions or 
deletions, providing the evidence of rather host and not virus factors being responsible 
for viral control (Blankson et al., 2007). However, other studies have revealed that HIV 
envelopes derived from EC demonstrated reduced entry fitness (Casado et al., 2013; 
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Lassen et al., 2009; Miura et al., 2009). Envelopes from EC interacted with cellular re-
ceptors CD4 and CCR5 inefficiently as compared to those from individuals with de-
tectable viral loads. Envelope clones derived from EC required higher levels of recep-
tor and coreceptor for efficient entry. This work has also demonstrated that the HIV 
envelope clones EC-derived revealed delay in fusion kinetics as compared with acute 
and chronic envelope clones (average T1/2 of 92.1 min versus T1/2 of 67.5 min for acute 
infection clones and T1/2 of 58.3 min for chronic infection clones). The HIV clones de-
rived from EC also completed reverse transcription process slower (T1/2 =8.89 hours) 
than acute infection clones (T1/2 =7.74 hours) and chronic infection clones (T1/2 =7.95 
hours) (Lassen et al., 2009). However, lower envelope fitness is likely not sufficient to 
mediate absolute viral suppression. The envelope sequence diversity of plasma virus 
obtained from HIV controllers showed low genetic diversity, which might suggest lim-
ited viral replication and evolution during the course of the infections. The lack of en-
velope diversification has raised the suggestion that HIV envelopes in EC may be 
closely related in genotype and phenotype to the founder virus establishing infection 
(Bailey et al., 2006a; Casado et al., 2013; Lassen et al., 2009). 
 
The most consistent factor responsible for virological control is a vigorous cellular re-
sponse. After the acute phase of HIV infection there is an increase in HIV-specific CD8+ 
T cells, which are able to kill HIV-infected cells. It has been shown that the function of 
HIV-specific CD8+ T cells is clearly higher in controllers as compared with non-
controllers including their ability to proliferate after encounter with HIV antigens, the 
ability to produce the cytolytic protein perforin (Migueles et al., 2002) and the ability to 
produce multiple cytokines such as: interferon-γ, MIP-1β, TNF-α and IL-2 (Betts et al., 
2006; Zimmerli et al., 2005). The virus-specific cytotoxic T cell response plays the cru-
cial role in the control of HIV/SIV infection (Goulder and Watkins, 2004). HLA mole-
cules detect and present infectious agent peptides to T cells. There is a high level of 
variability between individuals and populations in both HLA classes (HLA class I: A, 
B, C and HLA class II: DR, DQ, DP) (Hughes and Yeager, 1998; Parham and Ohta, 
1996). Different HLA alleles specify the molecules of infectious agents to be presented 
on the cell surface, therefore various HIV-1 peptide motifs might be presented influ-
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encing in this way the differences in the kinetics of HIV-1 infection in diverse individu-
als (Barber et al., 1995; Gao et al., 2001; Moore et al., 2002). The presence of several dif-
ferent HLA alleles have been described to be associated with effective HIV control, 
such as HLA-B57, HLA-B5801, HLA-B27, HLA-B14, HLA-A32 (Gao et al., 2001; Geczy 
et al., 2000; Hendel et al., 1999; Kaslow et al., 1996; Keet et al., 1999; Magierowska et al., 
1999; McNeil et al., 1996; Saah et al., 1998). HLA-B57 allele was consistently shown to 
be associated with a delay onset to AIDS (Carrington and O'Brien, 2003; O'Brien et al., 
2001). HLA-B57 presents the HIV epitope TW10 (TSTLQEQIGW) that corresponds to 
gag residues 240-249. It has been demonstrated that TW10 epitope within p24 gag re-
veals high conservation between different HIV-1 strains and TW10 escape mutations 
reduce significantly viral replicative capacity (Martinez-Picado et al., 2006). The pres-
ence of allele variants HLA-B5701 and HLA-B27 were found strongly enriched among 
European and North American cohorts of HIV controllers as compared to non-
controllers (Bailey et al., 2006b; Lambotte et al., 2005). The incidence of HLA-B5703 al-
leles was also found enriched among African populations who were able to maintain 
low viral loads (Kiepiela et al., 2007). Nevertheless, some other HLA allele variants 
have been associated with rapid progression to AIDS, including HLA-B35, HLA-A23, 
HLA-B37, HLA-B49, which seemed to fail at stimulation of cytotoxic T-cell recognition 
(Carrington et al., 1999; Chen et al., 1997; Gao et al., 2001; Kaslow et al., 1996; Saah et 
al., 1998). The potential impact of reduced host cell susceptibility to HIV infection has 
been also studied by verifying the presence of a 32 base pair deletion in LTNP patients. 
A Δ32 deletion in the coreceptor gene CCR5 is strongly associated with the resistance 
to HIV infection, however this deletion was described not to be specifically associated 
with the HIV controllers (Lambotte et al., 2005). In addition, it was also described that 
individuals, who maintain low viral load in the absence of therapy often lack high-titer 
neutralizing antibodies (Bailey et al., 2006a; Deeks et al., 2006). 
 
Most recently it has been also shown that some patients might keep viral control after 
treatment interruption. These individuals were called as “secondary controllers” (Van 
Gulck et al., 2012) or “post-treatment controllers” (PTC) (Saez-Cirion et al., 2013). The 
majority of these patients were treated already in the acute phase of infection, therefore 
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it cannot be excluded that some of these patients could actually evolved to become EC 
or VC (Vanham et al., 2014). PTC individuals were shown distinct to EC in the mean-
ing of host genetics, including HLA allele profile and cellular response. PTCs revealed 
a higher viral load and a lower CD4+ T cell count as compared to EC. Moreover, PTC 
patients demonstrated lower immune activation including lower CD8+ T cell HIV-
specific inhibitory activity as compared to EC. Additionally, some of PTC-derived vi-
ruses cultivated from CD4+ T cells revealed delayed kinetics or low fitness. Although 
PTCs are a heterogeneous population, the most consistent factor associated with this 
group so far has been a very low proviral reservoir. Nevertheless, the characteristics of 
PTC patients has been based on very small cohorts of individuals, therefore the phe-
nomenon of post-treatment virological control requires further investigation (Lewin 
and Rouzioux, 2011; Saez-Cirion et al., 2013; Van Gulck et al., 2012; Vanham et al., 
2014). 
 
 
4. 6. Signaling through DC-SIGN 
 
DC-SIGN contains several different motifs in its cytoplasmic tail, which allow for the 
induction of intracellular signaling pathways. It has been indicated that engagement of 
DC-SIGN on DCs results in the activation of signal transduction pathways, which can 
cause a wide modulation of immune response, mostly when co-activated with Toll-like 
receptors (Gringhuis et al., 2007). It has been suggested that DC-SIGN signaling after 
binding to HIV leads to modifications of NF-kB activity and the production of immu-
nosuppressive cytokines. The engagement of DC-SIGN by HIV activates Raf-1-
dependent signaling, which results in the phosphorylation of p65 subunit of NF-kB 
p65-p50 dimer. The phosphorylation of serine 276 of the p65 subunit induces acetyla-
tion of lysines in p65, which outcomes in prolonged transcriptional activity of NF-kB 
and prolonged nuclear retention. Increased activity of NF-kB causes the enhanced 
transcription rate from IL-10 gene. IL-10 inhibits Th-1 response and decreases capaci-
ties of antigen presentation by DCs. The phosphorylation of serine in the p65 subunit 
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of NF-kB allows also the recruitment of the transcription-elongation factor pETF-b to 
the HIV promoter that phosphorylates RNA polymerase II at serine 2. This phosphory-
lation increases processivity of the RNA polymerase II, allowing therefore the synthesis 
of full-length HIV transcripts in DCs (Fig. 14) (Svajger et al., 2010; Tsegaye and 
Pohlmann, 2010) 
 
 
  
 
 
Figure 14. DC-SIGN signaling upon HIV binding promotes DCs infection and production of immunosup-
pressive cytokines. Modified from Tsegaye et al. (Tsegaye and Pohlmann, 2010). 
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4. 7. Mechanisms of DC-mediated HIV transmission 
 
The sexual transmission has been shown as a primary route of HIV-1 infection nowa-
days. Several different cells, including DCs and Langerhans cells, have been demon-
strated to be present at the mucosal surface during HIV sexual transmission. Different 
C-type lectins expressed on these cells may play a role in HIV-1 attachment and further 
virus dissemination (de Witte et al., 2007; Wu and KewalRamani, 2006).  Langerin is a 
lectin expressed exclusively on Langerhans cells, which induces the formation of 
Birbeck granules that play significant role in antigen processing (Hunger et al., 2004; 
Valladeau et al., 2000). De Witte et al. showed that infection of T cells was significantly 
inhibited by Langerhans cells as compared with DCs. Moreover, they demonstrated 
that Raji-Langerin cells could efficiently bind HIV-1 particles, however they could not 
transfer HIV-1 viruses to T cells.  The results obtained in their study proved that 
Langerin plays a role as a scavenger receptor rather than as trans-receptor for HIV-1 
dissemination. Langerin acts in capturing of HIV-1 particles and further internalization 
into Birbeck granules for virus degradation (de Witte et al., 2007). In contrary, DCs are 
thought to facilitate viral dissemination through HIV-1 capture at mucosal site and 
transmission to secondary lymphoid tissues (Haase, 2005, 2010; Pope et al., 1994; 
Shattock and Rosenberg, 2012; Steinman et al., 2003). The DC-mediated HIV infection 
can occur through several distinct processes taking place concurrently, including trans-
infection through infectious synapse, trans-infection through exosomes or cis-infection 
following de novo production of viral particles in DCs (Fig. 15) (Wu and KewalRamani, 
2006).  
 
The efficient CD4+ T cell infection through infectious synapse in the process of HIV 
trans-infection requires cell-to-cell contact (Tsunetsugu-Yokota et al., 1997). It has been 
shown that HIV particles and HIV receptors (including DC-SIGN attachment mole-
cules) are concentrated at the zone of infectious synapse (McDonald et al., 2003). Infec-
tious synapse is therefore responsible for most of rapid and efficient virus transfer be-
tween DCs and CD4+ T cells. HIV trans-infection might also occur through exosomes. 
HIV particles captured by immature DCs might be rapidly internalized into endosomal 
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multivescicular bodies (endocytic bodies enriched in transmembrane proteins, such as 
tetraspanins). Some of endocytosed HIV particles are released into extracellular milieu 
associated with endocytic vesicles, which are known as exosomes (Thery et al., 2002; 
Wiley and Gummuluru, 2006). Those exosomes might subsequently fuse with target 
cell membrane and deliver infectious virus. The remaining HIV particles in mul-
tivescicular bodies in DCs might enter lysosomal pathway and be further degraded 
(Wiley and Gummuluru, 2006). 
 
 
 
 
Figure 15. Mechanisms of DC-mediated HIV transmission. 1) HIV infection resulting from cis-infection of 
DCs, production de novo of viral particles and transmission of HIV to CD4+ T cells; 2) HIV transmission 
through infectious synapse between DCs and CD4+ T cell; 3) HIV transmission by an exocytic pathway. 
Modified from Wu et al. (Wu and KewalRamani, 2006). 
 
 
HIV transmission might also occur through HIV infection in cis. It has been reported 
that immature DCs can retain infectious virus up to 6 days after exposure to HIV 
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(Trumpfheller et al., 2003). However, it was also suggested that most of incoming vi-
ruses are degraded in DCs within 24 hours (Turville et al., 2004). Therefore, after 24 
hours, the virus that is transmitted is thought to be the de novo produced virus. The 
first phase (within 24 hours of exposure to HIV) involves trafficking of captured viral 
particles from the endolysosomal pathway to the DC-T-cell infectious synapse. In the 
second phase (24-72 hours after exposure to HIV) the virus is replicating de novo in DCs 
providing production of progeny virus able to infect CD4+ T cells (Wu and 
KewalRamani, 2006). HIV-infected DCs function as viral reservoirs during their migra-
tion to the lymphoid organs, helping in spreading of the viral infection. In addition, 
DC-bound viruses can be internalized and processed for MHC presentation. DC-SIGN 
engagement triggers also signal transduction that modulates TLR-dependent cytokine 
production (Fig. 16) (Tsegaye and Pohlmann, 2010). 
 
 
 
Figure 16. Mechanisms of DC-mediated HIV transmission. 4) DC-SIGN-bound viruses are internalized, 
processed and presented by MHC molecules; 5) Binding of pathogens to DC-SIGN involve signal trans-
duction and production of cytokines to attract other cells of immune response. Modified from Wu et al. 
and Tsegay et al. (Tsegaye and Pohlmann, 2010; Wu and KewalRamani, 2006). 
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It has been shown that some genetic polymorphisms within DC-SIGN gene might be 
associated with promoting of HIV-1 capture and transmission to T cells. The study of 
Martin et al. identified single-nucleotide polymorphisms (SNP) in the DC-SIGN pro-
moter that was linked to higher susceptibility to parental infection. Patients with the 
promoter variant p-336C were more vulnerable than individuals with p-336T DC-SIGN 
variant for parental acquisition of HIV-1 infection but not for a mucosal route (Martin 
et al., 2004). Subsequently, Boily-Larouche et al. have studied the association between 
the major haplotypes of DC-SIGN and the risk of mother-to-child transmission (MTCT) 
among Zimbabwe infants. They found out that the infants carrying H4 and H6 haplo-
types of DC-SIGN were under increased risk of intra-uterine HIV-1 infection while the 
haplotype 2 was described to be related less likely to intra-uterine transmission. Fur-
ther study of SNP revealed that several variants of DC-SIGN promoter (p-336C and p-
201A) and exon 4 (198Q and 242V) have been associated with increased risk of HIV-1 
infection during pregnancy (Boily-Larouche et al., 2012). The variant of DC-SIGN pro-
moter p-336C was identified in both study as a polymorphism associated with in-
creased risk for parental HIV-1 acquisition.  
 
Given that unprotected sexual intercourse is the most common global mode of HIV-1 
transmission (Royce, 1997), many different interventions have been proposed for slow-
ing the spread of HIV-1 infection worldwide.  It has been shown that male circumci-
sion reduces the risk of HIV-1 infection. Randomized, controlled trials in Africa have 
demonstrated that circumcision could reduce the acquisition of HIV-1 in men by ~60% 
(Auvert et al., 2005; Bailey et al., 2007; Gray et al., 2007). During sexual intercourse, the 
foreskin in uncircumcised men is often retracted over the shaft exposing thus the inner 
mucosa to genital secretions of sexual partner, which very often contain high levels of 
HIV particles (Butler et al., 2008). It has been shown that favorable moistened envi-
ronment is generated in the subpreputial penile in uncircumcised med after sexual in-
tercourse while in circumcised men this environment is quite dry. Moreover, the fore-
skin was demonstrated to be vulnerable to tissue damage and inflammatory conditions 
during intercourse (Gray et al., 2007). Hirbod et al. studied the localization of different 
HIV-1 target cells and the expression of C-type lectins in the foreskin tissue in a group 
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of young Kenyan men at high risk of HIV exposure. This study revealed the presence 
of intraepithelial Langerhans cells, CD11c+ mononuclear phagocytes and DCs as well 
as the expression of Langerin, DC-SIGN and MR on these cells. It was suggested that 
male circumcision decrease the number of HIV-1 target cells with proper virus recep-
tors and results therefore in better resistance to HIV-1 particles penetration (Hirbod et 
al., 2010). 
 
The development of HIV-1 preventive strategies at mucosal site as a first line of contact 
with pathogens is the prior subject of interest. The attempts to develop an efficient vac-
cine against chronic viruses have failed so far, mainly due to the immunological escape 
mechanisms of these viruses or the lack of conserved epitopes of viruses involved in 
acute infections (Letvin, 2006). Along the time of HIV epidemic a broad range of antivi-
ral drugs become available for the treatment of virus infections. However, the appear-
ance of long-term side effects, emergence of viral resistance under drug pressure very 
often weakens therapy, making drugs useless and harmful in the long run (Balzarini, 
2007). Condom use and behavioral interventions have been only partially successful in 
slowing the spread of HIV-1 infection worldwide. There is an urgent need for addi-
tional interventions to prevent new infections, such as the development of female-
controlled topical formulations of anti HIV-1 compounds that could be used as a gel, 
cream, suppository before sexual intercourse (Elias and Coggins, 1996). Ideally, topical 
microbicides should be inexpensive, easy to use, colorless, stable under low pH condi-
tions, tasteless, non-irritating to genital mucosal tissue, stable at higher temperatures, 
compatible with latex, acceptable to all sexual partners. The main role however should 
be to inactivate a variety of sexually transmitted microbes within genital secretions 
and/or block relevant HIV-1 receptors on initial target cells (Kawamura et al., 2000).  
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II. CHAPTER 1:  
A model of viral infection mediated by DC-SIGN  
 
 
1. OBJECTIVES 
 
Standardize and evaluate a cellular model of viral infection mediated by DC-SIGN: (a) 
consistency of the infection model using different cell lines expressing the DC-SIGN 
receptor, (b) standardization of the DC-SIGN expression level and the infective titre of 
recombinant retroviruses for infection assays and (c) establish the proper conditions for 
the DC-SIGN mediated cis-infection and trans-infection assays. 
 
 
2. MATERIAL AND METHODS 
 
2. 1. Plasmids 
 
pNL4-3.Luc.R-E- is an envelope-defective HIV-1 genome that contains firefly luciferase 
gene inserted into the pNL4-3 nef gene as a reporter gene. pNL4-3.Luc.R-E- consists of 
two frameshifts (5′ Env and Vpr aa 26), which render this clone Env- and Vpr-. pNL4-
3.Luc.R-E- is competent for a single round of replication and it requires co-transfection 
with envelope expression vector to produce infectious particles (Connor et al., 1995). 
pNL4-3.Luc.R-E contains: gag (790-2292), pol (2085-5096), rev (5969-8643), tat (5830-
8414), env (6221-8785), vpu (6061-6306), vif (5041-5619), nef/luc (8787-9407), vpr (5559-
5849), 5´LTR (1-634), 3´LTR (9076-9709). 
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p1012-Ebola GP is a vector containing the full sequence of Ebola envelope glycoprotein 
strain Zaire Mayinga or Ebola 
strain Reston under the expres-
sion of CMV promoter. p1012-
Ebola GP contains following 
genes: human CMV immediate-
early promoter (1-675), Ebola virus 
glycoprotein (1074-3479), polyad-
enylation signal (3561-3756), kan-
amycin resistance gene (5083-
5885). 
 
 
 
 
pcDNA3.1/V5-His TOPO TA-HIV-1 env is an expression plasmid containing: human 
CMV immediate-early promoter (209-863), T7 promoter/priming binding site (863-882), 
MCS (902-1019), TOPO cloning site (953-954), HIV-1 envelope gene (1020-3551), V5 
epitope (3552-3593), polyhistidine tag 
(3603-3620), BGH reverse priming site 
(3660-3643), BGH polyadenylation 
signal (3642-3856), f1 origin of repli-
cation (3919-4332), SV40 promoter 
and origin (4397-4722), neomycin re-
sistance gene (4758-5552), SV40 poly-
adenylation signal (5571-5809), pUC 
origin (6914-6241), ampicillin re-
sistance gene (7059-7919). 
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pNGLV-3-VSV contains the gene of complete glycoprotein of Vesicular Stomatitis vi-
rus (VSV-G) envelope under the ex-
pression of CMV promoter. pNGLV-3-
VSV includes: human CMV immediate-
early promoter (1-675), intron A (676-
1067), VSV glycoprotein (1071-2606), 
rabbit β-globin polyadenylation site 
(2691-2886), ori replication origin (3068-
3603), kanamycin resistance (4213-
5015). 
 
 
 
2. 2. Cell lines used in this study 
 
Human Embryonic Kidney 293 cell line (HEK 293T) is derived from human embryon-
ic kidney cells. HEK was generated in the early 70s by the transformation of human 
embryonic kidney cultures with adenovirus 5 DNA in the laboratory of Alex van der 
Eb in Leiden (The Netherlands). The human embryonic kidney cells were obtained 
from a healthy aborted fetus and transformed subsequently with adenovirus by Frank 
Graham (Graham et al., 1977). E1A adenovirus gene is expressed in these cells and par-
ticipates in trans-activation of some viral promoters, allowing these cells to produce 
very high levels of protein. The widespread use of this cell line is due to its extreme 
transfectability by various techniques, including calcium phosphate method, achieving 
efficiencies approaching 100%. An important variant of this cell line is the 293T cell 
line, which contains additionally the SV40 Large T-antigen that allows for episomal 
replication of transfected plasmids containing the SV40 origin of replication. This ena-
bles amplification of transfected plasmids and extended temporal expression of the de-
sired gene products. 
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Human cervical epithelial carcinoma cell line (HeLa) was the first human cell line, 
which functioned successfully in vitro, providing therefore great achievement for scien-
tific research (Rahbari et al., 2009). HeLa cells were derived from cervical cancer cells 
taken from Henrietta Lacks shortly before she died of her cancer in 1951 and propagat-
ed by George Otto Gey (Watts, 2010). At the beginning the cells were donated by Gey 
to any scientists that requested them and later they were commercialized. HeLa cells 
contain human papillomavirus 18 (HPV18) that was integrated to its genome by hori-
zontal gene transfer. HeLa cell line is widely used in cancer research, AIDS research, 
gene mapping, studies of the effects of radiation and toxic substances (Silberman, 
2010). 
 
Human astroglioma cell line (U87) is an epithelial cell line obtained from human as-
troglioma cells (Ponten and Macintyre, 1968). 
 
U87-CD4-CXCR4 – Parental U87 cells were stably transduced with the 
MV7neo-T4 retroviral vector and selected for the resistance to G418 antibiotic. 
Cells were subsequently transduced with pBABE-puro-CXCR4 and selected for 
the resistance to puromycin antibiotic. Human CD4 and CXCR4 expression is 
directed by the MV7 vector and pBABE vector, both driven by MLV LTR pro-
moter. U87-CD4-CXCR4 is suitable for the infection experiments with HIV and 
SIV pseudotyped viruses (Bjorndal et al., 1997). 
 
U87-CD4-CCR5 - Parental U87 cells were stably transduced with the MV7neo-
T4 retroviral vector and selected for the resistance to G418 antibiotic. Cells were 
subsequently transduced with pBABE-puro-CCR5 and selected for the re-
sistance to puromycin antibiotic. Human CD4 and CCR5 expression is directed 
by the MV7 vector and pBABE vector, both driven by MLV LTR promoter. U87-
CD4-CCR5 is suitable for the infection experiments with HIV and SIV pseudo-
typed viruses (Bjorndal et al., 1997). 
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Human T cell leukemia cell line (Jurkat) is immortalized line of T lymphocytes, which 
was established in the late 1970s from the peripheral blood of a 14 year old boy suffer-
ing from T cell leukemia (Schneider et al., 1977). Jurkat cells express CD4 on its surface 
and after induction might secrete interferon-γ. Jurkat cell line is widely used in the 
studies of acute T cell leukemia, T cell signalling, expression of various chemokine re-
ceptors that permit virus cell entry, determination of differential susceptibility of can-
cer to drugs and radiation (Weiss et al., 1984). 
 
Jurkat DC-SIGN-GFP is a “home-prepared” cell line that was transduced with 
recombinant retrovirus construction (pNGVL-VSV-G – encoding the sequence 
of VSV envelope, pNGVL-MLV-gag-pol – codifying the proteins of capsid and 
matrix of MLV, LZR-DC-SIGN-CITE-GFP – encoding the sequence of DC-
SIGN) to express protein DC-SIGN on its surface. The expression of DC-SIGN 
was quantified by direct measure of fluorescence by FACS. 
 
Human B lymphocyte Burkitt´s lymphoma cell line (Raji) is the first continuous hu-
man cell line from hematopoietic origin that is categorized as lymphoblast-like 
(Karpova et al., 2005). Raji cells were established by R. J. V. Pulvertaft in 1963 from a 
Burkitt´s lymphoma of the left maxilla of an 11-year-old black male (Pulvertaft, 1964). 
This cell line is EBNA positive and produces unusual strain of Epstein-Barr virus, 
which can transform blood lymphocytes and induce early antigens in Raji cells. The 
Raji cells are partially resistant to poliovirus and Vesicular Stomatitis virus. Raji cells 
are widely used for: studying hematopoietic malignancies, transfection or detection of 
immune complex (Epstein and Barr, 1965; Ohsugi et al., 1980). 
 
Raji cell line is Epstein Barr Virus–positive Burkitt´s lymphoma line obtained 
from the ATCC (Wu et al., 2004). 
 
Raji DC-SIGN+ cell line is derived from Raji cells, an EBV-positive Burkitt´s 
lymphoma cells. Parental Raji cells were transduced with the MLV vector MX-
DC-SIGN and sorted by FACS as a population for high levels of DC-SIGN ex-
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pression. The MX-DC-SIGN vector encodes no drug-selectable marker gene 
(Wu et al., 2004). 
 
2. 3. Production of recombinant viruses 
 
Recombinant viruses were produced in 293 T cells. The viral construction was pseudo-
typed with virus envelope (Ebola virus envelope glycoprotein, HIV-1 envelope glyco-
protein, VSV envelope glycoprotein) and expressed luciferase as a reporter of the infec-
tion (Yang et al., 1999). The recombinant pseudoviruses are composed of expression 
plasmid with the sequence of desired pathogen envelope and of pNL4-3.LUC.R-E- (ob-
tained through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH: pNL4-3.Luc.R–E– from Dr. Nathaniel Landau) (Connor et al., 
1995). 
  
 
 
 
 
 
 
 
Fiure 17. pNL4-3.LUC.R-E- vector structure (NIH AIDS Research and Reference Reagent Program, Divi-
sion of AIDS, NIAID). 
 
 
 
pNL4-3.LUC.R-E- (Fig. 17) is a backbone plasmid containing whole HIV-1 genome 
with two frameshifts at 5’envelope gene and at aa26 of vpr gene (both mutations render 
this clone env- and vpr-). Additionally, the firefly luciferase gene is inserted into 
pNL4.3 nef gene. For the production of viral particles it is necessary to co-transfect with 
an env+ expression plasmid (driven by intermediate-early CMV promoter). Pseudopar-
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ticles are able to infect but due to the absence of complete genome are unable to pro-
duce infectious progeny. Produced pseudoparticles are capable of 1 cycle of infection 
and 1 round of viral genes expression but unable to propagate a spreading infection. 
Due to those mutations, the HIV genome cannot be retrotranscribed in subsequent cy-
cles of replication. 
 
 
 
Figure 18. Production of recombinant viruses. 
 
 
One day (18-24 h) before transfection, 5 x 106 293T were seeded onto 10 cm plates. Cells 
were cultured in DMEM medium supplemented with 10% heat-inactivated FBS, 25 mg 
Gentamycin, 2 mM L-glutamine. Few minutes before transfection, the medium on 
transfection plates was changed to 9 ml DMEM and chloroquine was added to 25 µM 
final concentration. Transfection reaction with all reagents at room temperature (RT) 
was prepared in 15 ml tubes: 183 µl of 2M CaCl2, virus envelope (500 ng of Ebola virus 
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envelope, 9 µg of HIV-1 envelope, 6 µg of VSV envelope), 21 µg of pNL4-3 luc and 
1350 µl of H2O. Next, 1.5 ml of 2xHBS (Hepes Buffer Saline) pH 7.00 was added quickly 
to the tubes and bubbled for 30 sec. HBS/DNA solution was dropped gently onto me-
dium. After 8 h of incubation at 37º C with 5% CO2, medium on transfection plates was 
changed to 10 ml DMEM and once again one day after transfection to 7 ml DMEM. 
Transfection supernatants were harvested after 48 h, centrifuged at 1200 rpm for 10 
min at RT to remove cell debris, and stored frozen at -80° C (Fig. 18). 
 
2. 4. Infection in cis assay with Ebola GP-pseudotyped retroviruses 
 
Infection in cis was performed on Jurkat cells expressing receptor DC-SIGN (Fig. 19). 
Since Ebola virus does not infect T-lymphocytes, its entry to Jurkat cells is absolutely 
dependent on the interaction with DC-SIGN. Jurkat DC-SIGN+ (2.5–5 x 105) were chal-
lenged with 5000-10000 TCID of recombinant viruses. After 48 h of incubation, cells 
were washed twice with PBS and lysed with 100 µl of 1x Lysis Buffer (Promega) for 
luciferase assay. Control experiment of infection in cis was performed with VSV-G 
(DC-SIGN independent) pseudoviruses in the same conditions. 
 
 
 
Figure 19. Infection in cis with recombinant Ebola GP-pseudotyped retroviruses in cellular model Jurkat 
DC-SIGN+. 
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2. 5. Infection in trans assay with Ebola GP-pseudotyped retroviruses 
 
Jurkat DC-SIGN+ cells (2.5-5 x 105) were challenged with 5000-10000 TCID of recombi-
nant viruses and incubated for 2 h at RT with rotation. After 2 h, cells were centrifuged 
at 1000 rpm for 5 min and washed twice with 1 ml of PBS supplemented with 0.5% 
BSA and 1mM CaCl2. Jurkat DC-SIGN + were resuspended in 500 µl of RPMI medium 
and co-cultivated with adherent HeLa cells (105 cells/ well) on 24-well plate (Fig. 20). 
After 48 h, the supernatant was removed and monolayer of HeLa was washed twice 
with 1 ml of PBS and lysed with 100 µl of 1x Lysis Buffer (Promega) for luciferase as-
say. As a control, trans-infection experiment with DC-SIGN independent VSV-G pseu-
doviruses was performed. 
 
 
 
 
 
 
Figure 20. Infection in trans with recombinant Ebola GP-pseudotyped retroviruses. Jurkat DC-SIGN+/ 
Jurkat are challenged with recombinant viruses and further co-cultivated with susceptible HeLa cells. 
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2. 6. Infection in trans assay with HIV-1 GP-pseudotyped retroviruses 
 
Infection in trans was performed on Jurkat DC-SIGN+ or Raji DC-SIGN+ (5 x 105), which 
can capture and transmit HIV-1 virus to susceptible cells. Cells were pulsing with HIV-
1 pseudoviruses for 3 h at 37º C. After 3 h, cells were centrifuged at 1000 rpm for 5 min 
and washed twice with 1 ml of PBS (supplemented with 0.5% BSA and 1mM CaCl2) to 
remove unspecifically bound viruses. Next, Jurkat/ Raji DC-SIGN+ were co-cultivated 
with susceptible U87-R5/X4 cells (Fig. 21). After 48 h, the supernatant was removed 
and monolayer of U87-R5/X4 was washed twice with 1 ml of PBS and lysed with 100 µl 
of 1x Lysis Buffer (Promega) for luciferase assay. 
 
 
 
 
 
Figure 21. Infection in trans with recombinant HIV-1 GP-pseudotyped retroviruses, which are captured by 
Raji DC-SIGN+/Jurkat DC-SIGN+ and further transmitted to U87-CD4-CCR5/CXCR4 cells. 
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3. RESULTS 
 
3. 1. DC-SIGN model validation 
 
3. 1. 1. Impact of DC-SIGN expression level on the trans-infection ratio 
 
The impact of the DC-SIGN expression level on the trans-infection ratio was verified in 
the trans-infection experiment, in which cells expressing different level of DC-SIGN 
were challenged with 10000 TCID of recombinant viruses pseudotyped with HIV-1 en-
velope 13-6. The experiment was performed in triplicate using 100%, 75%, 50%, 25%, 
10%, 5%, 1% and 0% Jurkat DC-SIGN+ cells. The results obtained in this experiment 
clearly showed that he cellular infection model based on DC-SIGN is very straightfor-
ward and the infection depends exclusively on the presence of DC-SIGN on the cell 
surface. This infection model showed that trans-infection ratio was doses-dependent on 
the expression level of DC-SIGN (Fig. 22).  
 
 
 
Figure 22. Trans-infection experiment with HIV-1 GP-pseudotyped retroviruses in the cellular model 
Jurkat DC-SIGN+/ U87-CD4-CCR5 showing the dependency of trans-infection phenomenon on DC-SIGN 
expression level. The symbols on the graph represent mean with SEM error bars of 3 independent experi-
ments. 
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The ratio obtained in case of all tested lower DC-SIGN expression levels was statistical-
ly significant as compared to the cellular population that expressed 100% of DC-SIGN 
(75% p=0.0352, 50% p=0.0266, 25% p=0.0042, 10% p=0.0010, 5% p=0.0009, 1% p=0.0007) 
(Fig. 22). Given that the infection in the cellular model based on Jurkat DC-SIGN+ is not 
dependent on any other variable, it can be useful in the studies of the entry as well as 
the entry inhibition by antiviral strategies targeting this receptor. 
 
3. 1. 2. Impact of virus titer on trans-infection studies 
 
The impact of the virus titer on the trans-infection ratio was verified in the experiment 
of trans-infection, where cells were challenged with different titers (range: 100–25000 
TCID) of recombinant retroviruses pseudotyped with 6 HIV-1 envelopes: 8-13, 13-6, 15-
7, 20-1, 37-2 and 40-2. In case of most of the envelopes used in the experiment, the no-
table variation in the ratio was seen when using titers below 5000 TCID. The recombi-
nant virus titers above 5000 TCID did not show any statistically significant influence on 
the trans-infection ratio thus 5000-10000 TCID was chosen as an optimal for further ex-
periments (Fig. 23).  
 
 
 
Figure 23. Trans-infection experiment with 6 HIV-1 GP-pseudotyped viruses in the cellular model Jurkat 
DC-SIGN+/U87-CD4-CCR5. The trans-infection ratio was defined for the range of virus titers: 100-25000 
TCID. The symbols on the graph represent mean with SEM error bars of 3-12 independent experiments. 
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3. 2. Model of the infection in cis 
 
The infection in cis model is based on cells expressing receptor DC-SIGN on its surface. 
The experiment of cis-infection was performed by challenging control cells and cells 
expressing DC-SIGN with recombinant Ebola retroviruses. This infection system is 
very efficient since infection in vitro of cells, distinguished only in the expression of 
DC-SIGN, by Ebola virus is absolutely dependent on the presence of receptor DC-
SIGN on cell surface (Fig. 24). Cells, which do not express DC-SIGN, were used as a 
negative control of infectivity. VSV-G pseudotyped retrovirus was used as a control 
virus for infection experiment based on the interaction with DC-SIGN. VSV is an en-
veloped, non-segmented, negative-strand RNA virus that belongs to the family of 
Rhabdoviruses (Matlin et al., 1982). Although VSV express 2 highly N-glycosylated 
structures on its surface, it fails to interact with DC-SIGN, what indicates some speci-
ficity in DC-SIGN binding (Kwon et al., 2002). 
 
 
 
Figure 24. Cis-infection with the recombinant Ebola GP (red) and VSV-G (blue) pseudotyped viruses in the 
cellular model Jurkat DC-SIGN+ cells/ Jurkat control cells. The bars represent mean with SEM error bars of 
3 independent experiments. 
 
 
3. 3. Model of the infection in trans 
 
During trans-infection process more complex events take place, such as internalization 
and presentation of the viral particles to susceptible cells. The trans-infection experi-
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ment was performed on DC-SIGN+ cells, which bind and transfer viral particles. Cells 
expressing DC-SIGN+ were incubated with recombinant pseudoviruses for 2 h, washed 
and co-cultivated with adherent susceptible cells. The trans-infection assay was per-
formed by, either: 1) challenging DC-SIGN+ cells with recombinant Ebola retroviruses 
and further infection of HeLa cells, or 2) challenging DC-SIGN+ cells with recombinant 
HIV-1 retroviruses and infection of U87-CD4-CCR5/ U87-CD4-CXCR4 cells. Both re-
combinant retroviruses use DC-SIGN receptor for capturing and transferring its parti-
cles to susceptible cells expressing all receptors necessary for efficient infection. Cells 
that do not express DC-SIGN were used as a negative control of transmitted trans-
infection. VSV-G-pseudotyped recombinant retroviruses are DC-SIGN-independent 
and can infect control cells and DC-SIGN+ cells (Fig. 25). 
 
 
 
Figure 25. Trans- infection with the recombinant Ebola GP (red) and VSV-G (blue) pseudotyped viruses, 
which are captured by Jurkat DC-SIGN+ cells or Jurkat control cells for further transmission to susceptible 
HeLa cells. The bars represent mean with SEM error bars of 3 independent experiments. 
 
 
3. 4. Comparison of two infection models based on Raji DC-SIGN+/Raji cells 
and Jurkat DC-SIGN+/Jurkat cells 
 
The trans-infection process was studied in two different cellular models to verify the 
efficiency of DC-SIGN usage by recombinant viruses when using Jurkat DC-SIGN+ and 
Raji DC-SIGN+ cells in comparison to control cells. The assay was performed by using 
HIV-1 recombinant retroviruses pseudotyped with 4 different HIV-1 envelopes (Fig. 
Chapter 1: Results/Discussion 
63 
 
26). The level of DC-SIGN usage by both cell lines showed similar tendency when us-
ing certain HIV-1 envelopes. The level of DC-SIGN-mediated infection by Raji DC-
SIGN+ was generally slightly higher than the level mediated by Jurkat DC-SIGN+ cells. 
Nevertheless, both cellular models clearly showed the importance of DC-SIGN recep-
tor in capturing and transmitting viral particles to susceptible cells as compared with 
control cells that did not express DC-SIGN on its surface. 
 
 
 
Figure 26. Trans-infection experiment using two cellular models: 1) Jurkat DC-SIGN+/Jurkat cells (pink) 
and 2) Raji DC-SIGN+/Raji cells (blue) for transmission to U87-CD4-CCR5/CXCR4 cells of recombinant 
viruses pseudotyped with 4 HIV-1 envelopes: 2-1, 3-1, 9-6, 10-4. The bars represent mean with SEM error 
bars of 3-7 independent experiments. 
 
 
 
4. DISCUSSION 
 
It has been previously shown that DC-SIGN in vitro plays multiple functions in differ-
ent aspects of immune system as well as it can mediate efficient virus infection, both in 
cis and in trans of cells expressing appropriate entry receptors (Alvarez et al., 2002; 
Geijtenbeek et al., 2000b; Lee et al., 2001). The expression of DC-SIGN receptor might 
enable the direct infection by some viruses, such as Ebola, of cells previously non-
permissive for those viruses.  
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The DC-SIGN trans-infection model was validated by studying the impact of DC-SIGN 
expression level and the titer of recombinant pseudoviruses. It was clearly shown that 
the trans-infection ratio in Jurkat DC-SIGN+/Jurkat cellular model depends exclusively 
on the presence of DC-SIGN on the cell surface (Fig. 22). Since it is the only variable 
having impact on the infection in this cellular system, it can be considered as a useful 
model to study viral entry and to test antiviral strategies targeting DC-SIGN. The im-
pact of the virus titer on the trans-infection ratio was also verified and revealed no sig-
nificant differences between 5000 and higher TCID in case of most HIV-1 envelopes 
used in the experiment. When using low virus titers, the notable variations in the trans-
infection ratio were observed therefore the titer 5000-10000 TCID was chosen as an op-
timal for further infection experiments (Fig. 23). 
 
The model of infection in cis based on Jurkat DC-SIGN+/Jurkat cells clearly showed de-
pendence of the Ebola virus cell entry on DC-SIGN presence (ratio 2567.8) (Fig. 24). The 
cis-infection of both cell lines by DC-SIGN independent VSV-G-pseudotyped retrovi-
ruses was at very similar level (ratio 0.96) (Fig. 24). The model of trans-infection con-
firmed the results obtained in the cis-infection experiment, revealing higher transmis-
sion of Ebola infection to susceptible cells by Jurkat DC-SIGN+ as compared with nega-
tive cells (ratio 870.4) (Fig. 25). The trans-infection obtained with VSV-G-pseudotyped 
viruses was comparable between both cell lines (Fig. 25). The trans-infection model 
was also verified in the cellular model of Raji DC-SIGN+ and Raji control cells. 
Raji is a B-cell line that has been extensively used in DC-SIGN trans-infection 
experiments (Chung et al., 2010; Geijtenbeek et al., 2000b; Trumpfheller et al., 
2003). The results obtained in the experiment of trans-infection with 4 recombi-
nant retroviruses pseudotyped with 4 different HIV-1 envelopes supported the 
consistency of the presented model showing the high usage of DC-SIGN recep-
tor by viral particles in the transmission of the infection (Fig. 26). 
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5. CONCLUSIONS 
 
The infection model based on cell lines expressing DC-SIGN is a consistent plat-
form to study direct viral entry (Ebola virus) and the trans-infection phenome-
non (Ebola virus and HIV) since the infection events depend almost exclusively 
on DC-SIGN-viral interaction. 
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III. CHAPTER 2:  
A screening platform of antiviral strategies targeting DC-SIGN 
 
 
1. OBJECTIVES 
 
Study the utility of the DC-SIGN infection model as a screening platform of antiviral 
strategies targeting DC-SIGN. Analyze the potential antiviral effect of synthetic de-
signed compounds: glycodendritic structures, tetravalent dendrons, dendrimers-based 
compounds, glycofullerenes and glycodendrinanoparticles. 
 
 
2. MATERIAL AND METHODS 
 
2. 1. Plasmids: p1012-Ebola GP, pNGLV-3-VSV, pNL4-3.Luc.R-E- (See Chaper I. 2. 1.) 
 
2. 2. Glycodendritic structures 
 
Glycodendritic structures were kindly provided by Dr. Javier Rojo from Glycosystems 
Laboratory, Instituto de Investigaciones Químicas (CSIC; Seville, Spain). Compound 
RR114 and compound RR115 are two new glycodendritic structures based on carbohy-
drate moiety, a pseudo-1,2-mannobioside, presenting high enzymatic stability and 
good affinity for DC-SIGN (Reina et al., 2007). This ligand was conjugated to the scaf-
folds based on the pentaerythritol and bis-pentaerythritol presenting 4 and 6 terminal 
alkyne groups. The attachment of the ligands to the multivalent scaffold was per-
formed by the coupling reaction, which results in the synthesis of compound RR114 
containing 4 copies of pseudo-1,2-mannobiosides (Fig. 27B) and compound RR115 con-
taining 6 copies of pseudo-1,2-mannobiosides (Fig. 27A). 
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Figure 27. A. Structure of compound RR115. B. Structure of compound RR114. 
 
 
2. 3. Tetravalent dendrons 
 
Tetravalent dendrons were kindly provided by Dr. Anna Bernardi from Università de-
gli Studi di Milano (Milan, Italy). Compound 12 and compound 14 are tetravalent den-
drons (compound 12 is tetravalent pseudo-diMannose, compound 14 is tetravalent 
pseudo-triMannose) (Fig. 28 and Fig. 29). These tetravalent compounds are based on a 
scaffold composed of 2, 2´-bis (hydroxymethyl) propionic acid that was used for 
presentation of multiple copies of selected ligands (Fig. 29). The ligands in the produc-
tion of compounds 12 and 14 (Fig. 28) were attached by applying chemistry presented 
in the figure 29. 
 
A.      B. 
                       
 
Figure 28. Ligands presented on tetravalent dendrons: A. compound 12 and B. compound 14. 
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Figure 29. Synthesis of compounds: 12 and 14. 
 
 
2. 4. Dendrimer-based compounds 
 
Dendrimer-based compounds were kindly provided by Dr. Anna Bernardi from Uni-
versità degli Studi di Milano (Milan, Italy). Compound G3(pseudodi)32 and compound 
G3(pseudotri)32 are 3rd Generation Boltorn type (Fig. 30) dendrimer-based compounds. 
The preparation of a Boltorn-type polyester dendrimers in a monodisperse manner 
was approached by using a strategy based on the anhydride 1 as a building block 
monomer and pentaerythriol as a central core. The set of reactions used in the produc-
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tion of compounds G3(pseudodi)32 and G3(pseudotri)32 is presented in the figure 30 
(Luczkowiak et al., 2011). 
 
 
 
 
 
Figure 30. Synthesis of G3(pseudodi)32 and G3(pseudotri)32. 
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2. 5. Glycofullerenes 
 
Glycofullerenes were kindly provided by Dr. Nazario Martín, Universidad Com-
plutense (Madrid, Spain). Fullerenes are molecules composed of carbon in the form of 
a hollow sphere resembling “the balls used in association football”. Fullerene C60 is a 
truncated icosahedron made of 20 hexagons and 12 pentagons with a carbon atom at 
the verticals of each polygon and a bond along each polygon edge. The van der Waals 
diameter of a C60 molecule is about 1.1 nm with the nucleus diameter of 0.71 nm (Qiao 
et al., 2007). Fullerenes can be considered as very attractive spherical scaffolds for a 
multivalent presentation of carbohydrates in a globular shape. Many synthetic meth-
ods for functionalization of fullerenes have been well established during past decades. 
Nowadays, fullerene hexa-bingle adducts can be obtained in a very straightforward 
approach in good yields. This strategy permits the introduction of substituents in the 
positions corresponding to octahedral vertexes resulting in the complete coverage by 
ligands showing a globular presentation. 
 
Glycofullerenes (sugar balls) are soluble in water due to the presence of non-protected 
carbohydrates that surround completely the fullerene molecule. Additionally, these 
compounds show good stability and low toxicity, which confirm the appropriate fea-
tures to be used in cellular assays. Glycofullerene 3 with 12 copies of mannoses was 
prepared using a straightforward strategy based on click chemistry conjugation of sug-
ars onto a hexa-bingle adduct fullerene (Fig. 31A). Since DC-SIGN is not able to recog-
nize galactose, a fullerene with 12 copies of galactoses (glycofullerene 4) has been pre-
pared as negative control for experiment involving DC-SIGN as a target molecule (Fig. 
31B). 
 
Glycofullerenes 1 and 2 bearing 36 copies of mannoses have been prepared based on a 
convergent strategy using a small glycodendron 6 or 10 and the hexa-bingle adduct 5 
(Fig. 32 and Fig. 33). Glycodendron 6 used for the synthesis of glycofullerene 1 present-
ing a short linker at the focal position has been previously prepared by using a func-
tionalized mannose with an azido group providing a building block to create highly 
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multivalent species. The glycofullerene 1 with 36 mannoses was prepared by conjuga-
tion of the glycodendron 6 with the hexa-bingle 5 (Fig. 33). The glycofullerene 2 was 
synthesized using the same strategy. This compound contains a larger spacer between 
the carbohydrate ligands and the fullerene scaffold (conjugation of the glycodendron 
10 with the hexa-bingle 5). The introduction of a larger spacer provided increase in the 
flexibility of the carbohydrate ligands on the fullerene surface allowing a better acces-
sibility and availability of ligands for the receptor recognition (Fig. 33) (Luczkowiak et 
al., 2013). 
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Figure 31. Structure of: A. glycofullerene 3 presenting 12 mannoses, B. glycofullerene 4 presenting 12 ga-
lactoses. 
 
 
 
Figure 32. Synthesis of glycodendron 10. 
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Figure 33. Synthesis of glycofullerenes: 1 and 2. 
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2. 6. Glycodendrinanoparticles 
 
Glycodendrinanoparticles were kindly provided by Dr. Benjamin G. Davis from Uni-
versity of Oxford (Oxford, The United Kingdom). The glycodendrinanoparticles are 
based on the structure obtained from bacteriophage Qbeta. The monomeric proteins of 
Qbeta are of about 30 nm in diameter and of a 14 kDa molecular weight. Monomers 
Qbeta were conjugated together to form a 180-copy multivalent scaffold resembling 
“virus-like” particle (Fig. 34). The assembly of entities with higher dimensions might 
provide the mimic displayed in target pathogens. A non-natural amino-acid tag was 
selectively introduced to a protein scaffold Qbeta for further attachment of the selected 
glycodendrons, appropriately functionalized, at the focal position. Moieties of α-D-
mannoses were then introduced onto the dendritic scaffolds prepared by Cu(I)-
catalysed modification of the Huisgen cycloaddition to serve as relevant ligands for the 
DC-SIGN recognition (Ribeiro-Viana et al., 2012) (Fig. 35). 
 
                               
 
 
 
Figure 34. Schematic representation of virus-like glycodendrinanoparticles assembly. Glycodendrons are 
created through multivalent assembly and then attached to multiple tags, each in a monomer protein. 
 
 
 
Compound Qbeta (MW = 2538900) did not contain any carbohydrate moiety attached 
to the scaffold and was therefore used as a control compound of this virus-like scaffold 
in the cis-infection experiment. Compound Qbeta-(Mann3)180 (MW = 2738880) contained 
monomeric protein virus-like particle 
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540 mannose residues conjugated to the Qbeta scaffold. Compound Qbeta-(Mann9)180 
(MW = 3220020) displayed 1620 mannose residues attached to the Qbeta scaffold. 
 
 
 
 
 
Figure 35. Synthesis of polyvalent virus-like glycodendrinanoparticles using a tag-and-modify strategy. 
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2. 7. Isolation of Peripheral Blood Mononuclear Cells (PBMCs) and genera-
tion of monocyte-derived Dendritic Cells (DCs) 
 
PBMCs were isolated from buffy coats from healthy donors (Hospital 12 de Octubre, 
Madrid, Spain) by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density-gradient cen-
trifugation. Following the centrifugation of 40 ml of whole blood samples on Ficoll-
Paque at 1800 rpm for 40 min, the cells from interface were collected and washed 3 
times with PBS at 1200 rpm for 10 min at RT. PBMCs were then resuspended in RPMI 
medium (supplemented with 10% heat-inactivated FBS, 25 mg Gentamycin, 2 mM L-
glutamine) at concentration 2 x 106 cells per cm2 and placed onto 24-well plate for 1 h at 
37º C with 5% CO2. The adherent monolayer of monocytes were then washed twice 
with PBS and resuspended in RPMI medium supplemented with cytokines GM-CSF 
(200 ng/ml) (MACS, Miltenyi Biotec) and IL-4 (10 ng/ml) (MACS, Miltenyi Biotec). For 
the proper differentiation of immature monocyte-derived DCs, cells were incubated at 
37º C with 5% CO2 for 7 days and subsequently activated with cytokines on a day 2 
and 5. 
 
 
2. 8. Inhibition of the infection in cis of immature monocyte-derived DCs by 
DC-SIGN targeting compounds 
 
Immature DCs (2 x 104 cells) were incubated at RT for 20 min with the carbohydrate-
based compounds and then challenged with 5000 TCID of EBOV-GP recombinant 
pseudoviruses. After 48 h of incubation, cells were washed twice with PBS and lysed 
for luciferase assay. As a control, experiment of inhibition of infection of EBOV-GP was 
performed in the presence of monoclonal antibody anti-DC-SIGN (R&D Systems) and 
mannan at concentration of 25 µg/ml. 
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Figure 36. Infection in trans with recombinant Ebola GP-pseudotyped retroviruses in cellular model Jurkat 
DC-SIGN+/ HeLa cells. Jurkat DC-SIGN+ and Jurkat control cells were pre-incubated with compounds tar-
geting DC-SIGN, challenged with recombinant viruses and after intensive washing co-cultivated with sus-
ceptible HeLa cells. 
 
 
 
2. 9. Inhibition of the infection in trans of Ebola pseudoparticles by DC-
SIGN targeting compounds 
 
Jurkat DC-SIGN+ cells (2.5-5 x 105) were pre-incubated for 20 min at RT with carbohy-
drate compounds. Then, the cells were challenged with 5000-10000 TCID of recombi-
nant viruses and incubated for 2 h at RT with rotation. After 2 h, cells were centrifuged 
at 1000 rpm for 5 min and washed twice with 1 ml of PBS supplemented with 0.5% 
BSA and 1mM CaCl2. Jurkat DC-SIGN + were resuspended in 500 µl of RPMI medium 
and co-cultivated with adherent HeLa cells (105 cells/ well) on 24-well plate. After 48 h, 
the supernatant was removed and monolayer of HeLa was washed twice with 1 ml of 
PBS and lysed with 100 µl of 1x Lysis Buffer (Promega) for luciferase assay (Fig. 36). As 
a control, trans-infection experiment with DC-SIGN independent VSV-G pseudovirus-
es was performed.  
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 3. RESULTS 
 
DC-SIGN molecule is not the only receptor responsible for the entrance and binding of 
Ebola and HIV-1 envelopes. Although DC-SIGN is not the main receptor in case of 
both Ebola and HIV-1 viruses, it plays a significant role in the cell entrance and/or 
trans-infection process of these two infectious agents. Therefore, DC-SIGN can function 
as a good model of studying the first steps of pathogenesis of those viruses and screen-
ing the antiviral strategies based on DC-SIGN targeting compounds for vaccination 
and treatment purposes. The antiviral activity of carbohydrate compounds was tested 
using pseudotyped viral particles presenting Ebola virus glycoproteins. The possibility 
of blocking DC-SIGN receptor was examined in the experiments of cis-infection and 
trans-infection in the presence of carbohydrate-based compounds at different final con-
centrations. All compounds were checked at least in 3 independent experiments. Dur-
ing the infection in cis experiment, Jurkat DC-SIGN+ were challenged with recombinant 
retroviruses in the presence or absence of compounds. In the trans-infection experiment 
Jurkat DC-SIGN+ were incubated with recombinant pseudoviruses for 2 h in the pres-
ence or absence of carbohydrate-based compounds, washed and co-cultivated with ad-
herent HeLa cells. 
 
The results of blocking DC-SIGN receptor by different compounds were shown as a 
function of concentration. The 50% of inhibition of the infection was calculated with 
the 95% confidence intervals. As a control, infection with VSV-G pseudotyped retrovi-
ruses was performed in the same conditions. 
 
3. 1. Glycodendritic structures 
 
The results obtained in the infection in cis experiment did not show any difference in 
the potency of those compounds in blocking of EBOV GP pseudotyped particles. The 
IC50 were of the same order of magnitude. The IC50 of compound RR114 was 3.6 µM 
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(95%CI=1.2–10.9 µM) (Fig. 37A). The IC50 for compound RR115 was 2.8 µM 
(95%CI=670.6 nM–12.1 µM) (Fig. 37B). 
 
A.      B. 
            
 
Figure 37. Inhibition of cis-infection by pseudotyped Ebola viruses of Jurkat DC-SIGN+ cells using: A. 
Compound RR114, B. Compound RR115 
 
 
 
Although both compounds showed similar efficiency in the infection in cis, in the ex-
periment of infection in trans compound RR115 was more potent than compound 
RR114. The IC50 for compound RR114 was 52.4 µM (24.4–112.6 µM) (Fig. 38A). The 
highest concentration of compound RR114 used in the experiment (100 µM) was able 
to block infection in the median percentage of 40% (range of 23-85%).The IC50 obtained 
for compound RR115 was 7 µM (4.6–10.7 µM) (Fig. 38B). 
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Figure 38. Inhibition of trans-infection by pseudotyped Ebola viruses of Jurkat DC-SIGN+ cells using: A. 
Compound RR114, B. Compound RR115. 
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3. 2. Tetravalent dendrons 
 
The results obtained in the cis infection experiment revealed that the tetravalent sys-
tems presenting four copies of pseudomannotrioside (compound 14) showed a potency 
of 1 order of magnitude higher than the tetravalent systems presenting four copies of 
linear pseudomannobiosides (compound 12). The IC50 of compound 14 was 106.5 nM 
(95%CI=24.07–470.9 nM) and the IC50 of compound 12 was 1.4 µM (95%CI =404.2 nM–
5.166 µM) (Fig. 39). 
 
 
A.       B. 
           
 
 
Figure 39. Inhibition of cis-infection by pseudotyped Ebola viruses of Jurkat DC-SIGN+ cells using: A. 
Compound 12, B. Compound 14. 
 
 
 
The results obtained in the trans-infection experiment were similar to the results of the 
infection in cis. The tetravalent dendron 14 with 4 copies of pseudomannotrioside 
showed an IC50 of 203 nM (95%CI=73.84–562.5 nM) (Fig. 40B). The tetravalent dendron 
12 with 4 copies of pseudomannobioside was 1 order of magnitude less potent with an 
IC50 of 1.22 µM (95%CI=475.5 nM–3.17 µM) (Fig. 40A). 
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A.         B. 
      
 
Figure 40. Inhibition of trans-infection by pseudotyped Ebola viruses of Jurkat DC-SIGN+ cells using: A. 
Compound 12, B. Compound 14. 
 
 
3. 3. Dendrimer-based compounds 
 
Dendrimer-based compounds are multivalent systems presenting an average of 30-32 
glycomimetic ligands. In case of multivalent systems bearing 30-32 pseudomannotrio-
side (G3(pseudotri)32) or 30-32 pseudomannobiosides (G3(pseudo-di)32) no difference 
was found in their potency of inhibition of EBOV GP pseudotyped particles cell entry. 
The IC50 value of compound G3(pseudotri)32 was 17.12 nM (95% CI=5.946 nM–49.30 
nM) and the IC50 value of compound G3(pseudodi)32 was 27.21 nM (95% CI =16.53 nM–
44.78 nM) (Fig. 41). 
 
A.      B. 
              
Figure 41. Inhibition of cis-infection by pseudotyped Ebola viruses of Jurkat DC-SIGN+ cells using: A. 
Compound G3(pseudodi)32, B. Compound G3(pseudotri)32. 
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The results obtained in the trans-infection experiment were similar to the results of the 
infection in cis. The IC50 values of 32-valent systems were of the same order of magni-
tude. The IC50 of multivalent pseudomannobioside was 62 nM (95%CI=43.53 nM–89.1 
nM) (Fig. 42A). The IC50 of multivalent pseudomannotrioside was 31.51 nM 
(95%CI=13.89 nM–71.48 nM) (Fig. 42B). 
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Figure 42. Inhibition of trans-infection by pseudotyped Ebola viruses of Jurkat DC-SIGN+ cells using: A. 
Compound G3(pseudodi)32, B. Compound G3(pseudotri)32. 
 
 
 
 
 
Figure 43. Inhibition of infection by pseudotyped Ebola virus infection of Jurkat DC-SIGN+ cells using 
mannosylated glycofullerenes 1, 2, 3 and negative control galactosyl glycofullerene 4. 
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3. 4. Glycofullerenes 
 
The results obtained in the infection in cis experiment revealed the dependence of the 
inhibition effect on mannoses (Fig. 43). Galactosyl fullerene 4, as expected, was not able 
to inhibit the infection process mediated by DC-SIGN. The comparison of the fullerene 
1 (presenting 36 mannoses) and fullerene 3 (displaying 12 mannoses) showed an im-
portant decrease of activity with the increase of valency. Glycofullerene 3 with 12 
mannoses showed the IC50 of 2 µM (95%CI=859.8 nM–3 µM). The IC50 for the fullerene 
1 was 68 µM (34 fold less active than fullerene presenting 12 mannoses). The introduc-
tion of a longer spacer in glycofullerene 2 had a very important effect on recovering the 
activity of this compound with the IC50 of 286.4 nM (more than 200 fold increase in 
comparison with glycofullerene 1 presenting the same valency). 
 
3. 5. Glycodendrinanoparticles 
 
Compound Qbeta was used in the experiment as a control of the impact of this new 
type of structures on the results in the infection in cis. The highest concentration of 
compound Qbeta (25 nM) used in the experiment could block infection in ~30-40%. The 
same concentration (25 nM) of compound Qbeta-(Man3)180 could block infection in 50-
60%. The concentration of 25 nM of compound Qbeta-(Man9)180 could efficiently block 
infection in ~90-100%. The values presented on the graphs correspond to means of 6 
experiments with error bars representing standard errors of the mean (Fig 44). The 
IC50s were estimated using GraphPad Prism v4.0 with a 95% CI (7.7 nM–24.3 nM for 
Qβ-(Man3)180 and 404.2 pM–4.1 nM for Qβ-(Man9)180) and settings for normalize dose-
response curves (Fig. 45). 
 
The inhibitory effect of glycodendrinanoparticles were then studied in the direct infec-
tion of DCs, which were generated from isolated human peripheral blood mononuclear 
cells (PBMCs) and displayed multiple C-type lectins. Compounds Qbeta and Qbeta-
(Man9)180 were tested at concentrations of 25 nM, 5 nM and 1 nM. The values presented 
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on the graph corresponded to the mean of 2 experiments with range shown above each 
bar. As a control, inhibition of infection of EBOV-GP pseudovirus was verified in the 
presence of antibody anti-DC-SIGN and mannan at concentration of 25 µg/ml. Com-
pound Qbeta-(Man9)180 displayed potent activity, inhibiting infection by >80% at 5 nM 
and >95% at 25 nM (estimated IC50 ~ 2 nM) (Fig. 46). 
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Figure 44. Results of infection in cis experiment using compounds: Qbeta, Qbeta-(Man3)180, Qbeta-(Man9)180. 
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Figure 45. Cis-infection by pseudotyped Ebola viruses of Jurkat DC-SIGN+ cells using: A. Compound 
Qbeta-(Man3)180, B. Compound Qbeta-(Man9)180. 
 
 
Chapter 2: Results/Discussion 
87 
 
 
 
 
Figure 46. Infection of primary DCs by EBOZ pseudotyped viruses. 
 
 
 
4. DISCUSSION 
 
Although in vitro DC-SIGN models are not sufficient for understanding the physiologi-
cal role of DC-SIGN, the cellular model based on DC-SIGN+ cells might function as a 
useful model of antiviral screening platform of compounds targeting this receptor. DC-
SIGN recognizes mannosylated and fucosylated oligosaccharides presented in a multi-
valent manner on the surface of several pathogens. Therefore, the preparation of mul-
tivalent carbohydrate systems is necessary for the efficient interaction with this recep-
tor as well as for the effective competition with the natural ligands. However, there is 
not sufficient information about the adequate orientation of the ligands thus many dif-
ferent strategies of the synthesis has been tested so far, such as: gold-nanoparticles (de 
La Fuente et al., 2001), polymers (Roy, 1996), liposomes (Stewart and Boggs, 1993), 
dendrimers (de La Fuente et al., 2001; Imberty et al., 2008), multivalent glycoconjugates 
(Luczkowiak et al., 2013; Luczkowiak et al., 2011; Ribeiro-Viana et al., 2012; Rojo and 
Delgado, 2004). Multivalent carbohydrate systems based on dendrimers or dendritic 
polymers have been shown to be promising candidates as antiviral agents. These den-
drimers are able to form stable complexes with cell receptors or viral structures, which 
results in disruption of infection process by abolishing virus-cell interaction. A multi-
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valent scaffold based on Boltorn polymer functionalized with monosaccharide man-
nose has been shown to inhibit DC-SIGN-mediated Ebola virus infection at nanomolar 
concentrations (IC50=337 nM). However, these glycodendritic structures are recognized 
and degraded by mannosyl glycosylases thus the synthesis strategy should be per-
formed by usage of mimic carbohydrates that are not recognized by hydrolytic en-
zymes (Rojo and Delgado, 2004). The carbohydrate mimics, such as pseudomannobi-
oside, demonstrated higher antiviral activity than mannose in the inhibition of HIV-1 
infection. This new carbohydrate-based compounds were considered as proper candi-
dates for further clinical use since they were more stable against enzymatic degrada-
tion (Reina et al., 2007; Sattin et al., 2010). 
 
In the CARMUSYS programme interdisciplinary group of scientists (biologist, virolo-
gists, synthetic chemists, computational chemists, biochemists, immunologists) aimed 
at designing and synthesizing carbohydrate multivalent systems to be used as inhibi-
tors for pathogen attachment and penetration into target cells that present the receptor 
DC-SIGN. In this collaboration we have planned to use these multivalent systems as 
tools to get information about the molecular basis of the recognition process between 
pathogen glycoproteins and DC-SIGN with the aim to rationalize the design and syn-
thesis of new drugs. The development of compounds with strong affinity for the recep-
tor DC-SIGN is a topic of remarkable interest due to the role of this lectin in pathogen 
infection processes. DC-SIGN is a tetravalent calcium-dependent lectin, expressed on 
DCs, that specifically recognizes highly glycosylated structures present at the surface 
of several pathogens such as viruses, bacteria, yeast and parasites (Geijtenbeek et al., 
2000c). DC-SIGN recognizes mannosylated and fucosylated oligosaccharides presented 
in multivalent manner. Therefore, the multivalent carbohydrate systems are required 
to interact in an efficient manner with this receptor and compete with the natural lig-
ands (Lasala et al., 2003; Luczkowiak et al., 2011; Rojo and Delgado, 2004). The main 
carbohydrate ligand recognized by DC-SIGN is the high mannose glycan, 
(Man)9,(GlcNAc)2, a branched oligosaccharide displayed in multiple copies on several 
pathogen glycoproteins (gp120, GP1). Thus, the structural analogues of Man9 would 
compete with binding of virus glycoprotein to DC-SIGN. It has been reported that the 
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pseudo-dimannoside, mimicking the natural disaccharide Manα1-2Man, binds to DC-
SIGN and exhibits anti-infective activity in an Ebola pseudovirus infection model 
(Reina et al., 2007). The additional results showed that 2-C-substituted branched D-
mannose analogues bind to DC-SIGN with higher affinity than mannose (Mitchell et 
al., 2007). Multivalent oligomannosides, which display complex oligomannose den-
drons in high density, were also described to block DC-SIGN receptor (Wang et al., 
2008). The gold nanoparticles presenting various linear and branched mannosyl oligo-
saccharides (Manno-GNPs) might behave as potent inhibitors of HIV-1 trans-infection 
at the cellular level (Martinez-Avila et al., 2009). It has been demonstrated that multiva-
lent carbohydrate systems based on dendrimers and dendritic polymers are promising 
candidates as antiviral drugs. Dendrimers are able to form stable complexes with re-
ceptors or viral structures at the cell surface, which results in disruption of the virus-
cell interaction during the process of the virus infection. The functionalization with 
negatively charged molecules of dendrimers based on polyamidoamine (PAMAM) 
support generation of polyanion structures that are able to interact with viral envelope 
glycoproteins, preventing therefore the binding of viruses such as HIV-1 or herpes 
simplex virus (HSV) (Bourne et al., 2000; Witvrouw et al., 2000). Glycodendrimers, pre-
senting at their surface numerous moieties of carbohydrates, were described as excel-
lent tools to address carbohydrate-protein interactions. Hyperbranched glycodendritic 
polymers were shown to block the binding of pathogen glycoproteins to DC-SIGN. 
Glycodendritic structures, based on Boltorn polymer of second and third generations, 
are easy to prepare, non-toxic, soluble in physiological conditions and able to block the 
cell receptor DC-SIGN (Rojo and Delgado, 2004). The commercially available hyper-
branched BoltornH30 (Perstrop Speciality Chemicals), that was modified to present 32 
mannose units linked through succinyl spacer (BH30sucMan), was shown to inhibit 
DC-SIGN-mediated Ebola GP-pseudotyped retroviruses during Jurkat DC-SIGN+ cells 
infection in cis and in trans with the IC50 of 0.3 µM (Lasala et al., 2003). Combining den-
dritic platforms with glycomimetic compounds to obtain novel DC-SIGN antagonists 
could provide stronger binding affinity to block DC-SIGN and inhibit the HIV infec-
tion process. The pseudo-trisaccharide mimic of the linear mannotriose Manα1-2 
Manα1-6 Manα produced by replacing the central mannose units with a carbocyclic 
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diol, could inhibit HIV infection of CD4+ T lymphocytes at low micromolar concentra-
tion. This tetravalent construct presenting 4 copies of the pseudo-trimannoside on Bol-
torn-type dendron at 50 µM concentration reduced the trans-infection of CD4+ T lym-
phocytes by over 90% (Sattin et al., 2010). 
 
The results obtained in the experiments performed within this thesis, could contribute 
in a very fast and effective way in the first studies of antiviral screening based on dif-
ferent strategies: tetravalent dendrons, dendrimer-based compounds, glycofullerenes 
and glycodendrinanoparticles. Tetravalent dendrons and dendrimers-based com-
pounds are the combination of new pseudomannoside carbohydrate mimic and the 
potency of multivalent presentation. The importance of the valency was evaluated by 
the presentation of the same pseudosaccharide ligands on the tetravalent system pre-
senting 4 copies of the ligand and on the multivalent scaffolds displaying 30-32 of se-
lected ligands (Luczkowiak et al., 2011). The synthesis of glycofullerenes provided the 
achievement of even higher valency (36 mannoses). These compounds were synthe-
sized by combining glycodendrons with a hexakisadduct [60] fullerene allowing thus 
globular presentation of carbohydrates (Luczkowiak et al., 2013). Nevertheless, the 
highest valency constructs were gained in case of glycodendrinanoparticles. This de-
sign was based on the multivalent assembly of protein monomers (glycodendripro-
teins) carrying polyvalent glycan motifs (glycodendrons). In this way these constructs 
displayed many glycans in a precise manner and created well-defined single entities of 
up to 32 nm in diameter (Ribeiro-Viana et al., 2012). 
 
4. 1. Tetravalent systems 
 
The tetravalent systems presenting four copies of pseudomannobiosides (compound 
12) or pseudomannotrioside (compound 14) were tested in vitro in the experiments of 
cis- and trans-infection as antiviral compounds. The results obtained in the experiments 
showed inhibition of the infection by blocking of DC-SIGN receptor. In the infection in 
cis experiment, the tetravalent pseudomannotrioside was more than 10 times more ac-
tive than tetravalent pseudomannobioside (the IC50 of 106 nM vs 1.4 µM) (Fig. 39). The 
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results obtained in the trans-infection experiment confirmed previously obtained re-
sults in the cis-infection assay. The tetravalent dendron 14 showed an IC50 of 203 nM 
and the tetravalent dendron 12 was 1 order of magnitude less potent with an IC50 of 
1.22 µM (Fig. 40). Our results confirmed that these systems could be considered as a 
very potent inhibitors to be tested in further experiments as ligands for multivalent 
presentation (Luczkowiak et al., 2011). 
 
 
4. 2. Dendrimer-based compounds 
 
The synthesis of multivalent systems was based on the commercially available third 
generation of a Boltorn dendritic polymer that serves as a very convenient platform for 
a multivalent presentation of carbohydrates (Arce et al., 2003). These polydisperse 
dendritic polymers bear 30-32 copies of selected ligands. In the case of pseudodimulti-
valent and pseudotrimultivalent systems, no significant differences were found as a 
function of the pseudosaccharide presented. The IC50 values obtained for the multiva-
lent systems were around 20 nM (17.12 nM for G3(pseudotri)32 and 27.21 nM for 
G3(pseudodi)32), which shows that their inhibitory potency is between 1 to 2 orders of 
magnitude higher than that of corresponding tetravalent systems (Fig. 41). Similar re-
sults were gained in the trans-infection experiment. The IC50 of 32-valent system bear-
ing pseudomannobioside was 62 nM and bearing pseudomannotrioside was 31.5 nM 
(Fig. 42). In the same way like in cis-infection assay, in the trans-infection relatively 
small differences were observed between the two selected monovalent ligands pre-
sented in the multivalent scaffold. Both multivalent systems G3(pseudosugar)32 
showed very strong inhibition effect in the low nanomolecular range in both assays. 
The results acquired in performed experiments confirmed pseudoglycosylated multi-
valent systems as very promising antiviral drugs with strong DC-SIGN blocking activi-
ties (Luczkowiak et al., 2011). 
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4. 3. Glycofullerenes 
 
The mannosylated fullerenes containing several copies of carbohydrates in a globular 
presentation are water-soluble and show a low cytotoxicity of several cell lines. Our 
experiments have demonstrated for the first time the potential biological function of 
glycodendrofullerenes in preventing viral infection. The fullerene displaying 12 man-
noses showed a low micromolar IC50 in the infection model using Ebola glycoprotein-
pseudotyped viruses. The increase of valency in glycofullerene 1 from 12 to 36 man-
noses induced a negative effect, probably due to steric congestion of sugars at the sur-
face of the fullerene. This result has highlighted the importance to combine an ade-
quate scaffold to achieve the multivalency (the spherical fullerene) with the right lig-
and accessibility and flexibility. The introduction of a longer spacer in glycofullerene 
displaying 36 mannoses had a very important effect on its antiviral functions. Longer 
spacer enabled recovering the activity of this compound and showed potent DC-SIGN 
blocking effect with the IC50 of 286.4 nM (Fig. 43). The valency of the compound is an 
important factor to obtain good affinities in a carbohydrate-lectin interaction but as it 
has been shown in these experiments that it is not the only factor to be taken into ac-
count. Nevertheless, we can consider fullerenes as very attractive scaffolds for a globu-
lar multivalent presentation of sugars (Luczkowiak et al., 2013). 
4. 4. Glycodendrinanoparticles 
 
The main problem in the preparation of synthetic carbohydrate systems that are able to 
prevent DC-SIGN-mediated infection is reaching adequate size and multivalency while 
maintaining control of shape and structure (Sanchez-Navarro and Rojo, 2010). These 
features are very important in effective mimic of natural systems such as viruses or 
bacteria. It has been previously shown that ligand valences above 32 have not had a 
full control (Greatrex et al., 2009; Lasala et al., 2003). Glycodendrinanoparticles were 
prepared under the control design for highly polyvalent proteins that displayed sugar 
moieties in polyvalent manner (structure Qbeta). Therefore the inhibitory properties of 
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each mannoside monomer were considerably more potent when displayed on Qbeta 
(Qb) structures as compared with monosaccharide presentation (~250-fold when dis-
played on Qb(Man3)180 and ~860- fold when on Qb(Man9)180). These well-defined poly-
valent glycoproteins presented on their surface up to 1620 copies of glycan, a consider-
ably higher valency than has never been obtained before using a fully controlled strat-
egy. The efficiency of this system was gained by the effect of a high number of dis-
played ligands as well as proper size and geometry. It has been reported that no ho-
mogeneous polyvalent systems that can generate such a large surface area have been 
described before. The constructs tested in our experiments were composed of nested 
glycan polyvalency, which allows the display of many varying polyvalent combina-
tions, playing therefore different biological functions. Glycodendrinanoparticles are 
therefore not ‘balls of sugar’ but homogenous constructs exhibiting different polyva-
lent glycans. Thus it might be suggested that the most relevant features can be the to-
pology of glycan presentation, its relation to the inter-domain distances in the DC-
SIGN tetramer (Tabarani et al., 2009) and the constructs organization on cell surface (de 
Bakker et al., 2007) rather than just average glycan-to-glycan distance (Tabarani et al., 
2009). The results obtained in performed experiments showed a potent antiviral activi-
ty of glycodendrinanoparticles in the Ebola DC-SIGN-mediated infection model. The 
glycodendrinanoparticles presenting 1620 glycan moieties showed antiviral activity in 
the picomolar to low nanomolar to range (Fig. 44-46). These results revealed the effi-
ciency of these systems to interact with DC-SIGN and to compete with pathogens dur-
ing their entry into target cells. However, the functions of these glycodendrinanoparti-
cles in vivo remain to be tested. The high activity, high surface area and morphology of 
these new glycoconjugates provides them as promising candidates for the develop-
ment of new antiviral agents (Ribeiro-Viana et al., 2012). 
 
5. CONCLUSIONS 
 
1) The DC-SIGN infection model is a useful model of an antiviral screening platform to 
test carbohydrates strategies targeting DC-SIGN. 
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2) The inhibition of DC-SIGN-mediated infection by carbohydrate-based compounds 
depends strongly on the multivalency of glycan presentation. 
 
3) The most potent antiviral activity was obtained by glycodendrinanoparticles show-
ing an effective antiviral activity in the picomolar to low nanomolar concentration 
range. Multivalency depends on the presentation of 1620 glycan moieties generating a 
large surface of interaction (30 nm in diameter). 
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IV. CHAPTER 3:  
DC-SIGN in EBOLA virus pathogenesis: DC-SIGN-mediated trans-infection 
in pathogenic and non-pathogenic strains of Ebola virus 
 
 
1. OBJECTIVES 
 
Evaluate DC-SIGN-mediated trans-infection by the pathogenic and non-pathogenic 
Zaire and Reston strains of Ebola virus. 
 
 
2. MATERIAL AND METHODS 
 
2. 1. Plasmids: p1012-Ebola Zaire GP, p1012-Ebola Reston GP, pNL4-3.Luc.R-E- (see 
Chapter I: 2.1.) 
 
2. 2. Isolation of PBMCs and generation of monocyte-derived DCs (see Chapter 
II: 2.6.) 
 
2. 3. Infection in cis of immature monocyte-derived DCs 
 
Immature DCs (2 x 104 cells) were challenged with 5000 TCID of recombinant viruses 
pseudotyped with: a) EBOZ or b) EBOR envelope glycoproteins. After 48 h of incuba-
tion, cells were washed twice with PBS and lysed for luciferase assay. As a control, ex-
periment of inhibition of infection of EBOV-GP was performed in the presence of mon-
oclonal antibody anti-DC-SIGN (R&D Systems) and mannan at concentration of 25 
µg/ml. 
 
2. 4. Infection in trans assay with Ebola GP-pseudotyped retroviruses (see 
Chapter I: 2.5) 
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2. 5. Statistical analysis 
 
2. 5. 1. The t Student test 
 
The t Student test compares the means of two groups. It is used to determine if two sets 
of data are significantly different from each other. It is most commonly applied when 
the statistic test follows a normal distribution. 
 
2. 5. 2. The two-tailed test 
 
The two-tailed test is a statistical test used in inference, in which a given statistical hy-
pothesis, H0 (the null hypothesis), will be rejected when the value of the test statistic is 
either sufficiently small or sufficiently large. The statistical results of the two-tailed test 
were calculated by GraphPad Prism 4. The two-tailed test assumes that samples follow 
a Gaussian bell-shaped distribution. If the values of the test statistic fell into tail of its 
sampling distribution, the null hypothesis would be rejected. The p value of the two-
tailed test was calculated. 
 
3. RESULTS 
 
3. 1. Analysis of the sequences of envelope glycoproteins of EBOZ and EBOR 
 
The glycoproteins of Ebola viruses are considered to be the major determinants in virus 
pathogenesis, responsible for the binding of virus to the cell receptors and virus entry 
into the cell cytoplasm (Feldmann et al., 1993). Ebola virus glycoproteins are highly 
glycosylated by both N-linked and O-linked carbohydrates, which contributes to 30-
50% of their total molecular weight (Geyer et al., 1992). The Ebola group of filoviruses 
comprises five subtypes: Zaire, Sudan, Reston, Cote dÍvoire, Bundibugyo, among 
which Ebola Zaire strain shows the highest mortality rate (50-90%), whereas Ebola 
Reston has never been associated with human disease (Usami et al., 2011). The main 
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envelope gene product, secreted glycoprotein (sGP), is slightly longer in Ebola virus 
strain Reston (368 aa) than sGP of Ebola virus strain Zaire (365 aa), however both con-
tain 6 N-linked glycans. The second glycoprotein product resulting from transcription-
al editing of the glycoprotein ORF, transmembrane GP, is similar in length in both 
strains (Ebola Zaire = 677 aa and Ebola Reston = 678 aa). The transmembrane glycopro-
tein contains 11 N-linked glycans in both strains, located mostly in the mucin-like do-
main and the glycan cap. Although the sequences of those regions show relatively low 
level of similarity (23.7% of pairwise identity in mucin-like domain, 52.3% of pairwise 
identity in the glycan cap), the number of N-linked glycans is quite conserved in both 
Ebola strains (Lee et al., 2008). The mucin-like domain is a region of 151 aa containing 5 
N-glycans in Ebola Zaire (N317, N333, N346, N386, N436) and 4 N-linked glycans in 
Ebola Reston (N317, N318, N339, N420). The N-glycosylation pattern in the glycan cap 
is conserved in both strains. The glycan cap is 86 aa long and contains 4 N-linked gly-
cans (EBOZ: N228, N238, N257, N268; EBOR: N229, N239, N258, N269) in both Ebola 
strains. The shift of one aa in the PNGS position results from the length of signal pep-
tide of GP since in EBOR is 34 aa long and in EBOZ is 33 aa long. N-linked glycosyla-
tion sites for Ebola Zaire and Reston were predicted by the NetNGlyc (Gupta et al., 
2004). 
 
3. 2. DC-SIGN-mediated trans-infection of EBOZ and EBOR in the cellular 
system Jurkat DC-SIGN+/Jurkat 
 
Recombinant retroviruses pseudotyped with envelope glycoproteins of Ebola Zaire 
and Ebola Reston were produced by transfection of 293T by using standard Calcium 
Chloride protocol. The trans-infection experiment with retroviral particles pseudo-
typed with EBOZ or EBOR GP was performed to study the differences in DC-SIGN-
mediated infection by both strains. Infection in trans was performed on Jurkat DC-
SIGN+, which could capture and transmit Ebola virus to susceptible cells. As a control, 
Jurkat cells which did not express DC-SIGN on its surface were used. The ratio be-
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tween trans-infection Jurkat DC-SIGN+ and Jurkat cells for Ebola Zaire and Ebola 
Reston glycoprotein was calculated as an average from 9 independent experiments. 
 
 
 
Figure 47. Trans-infection with EBOZ (red) and EBOR (blue) in Jurkat DC-SIGN+/Jurkat system. The bars 
represent mean with SEM error bars of 9 independent experiments. The statistical analysis was performed 
by two-tailed Student t test. 
 
 
 
The statistical significance of differences between the ratios of EBOZ and EBOR pseu-
doparticles obtained in 9 independent experiments of trans-infection was analyzed by 
Student t test. The two-tailed p value was calculated by GraphPad Prism V4. The dif-
ference in the mean ratio in the trans-infection experiment between EBOZ and EBOR 
was statistically significant (p=0.0034) (Fig. 47). Additionally, the mean (35.97 vs 99.64), 
95% CI of mean (28.97-42.97 vs 57.56-141.7), SEM (3.035 vs 18.25), SD (9.106 vs 54.74) 
were calculated by using GraphPad Prism V4. 
 
3. 3. DC-SIGN-mediated cis-infection of primary DCs by EBOZ and EBOR  
 
Dendritic cells used in the infection experiment were generated from isolated human 
peripheral blood mononuclear cells (PBMCs) and displayed multiple C-type lectins 
providing a route for infection of pseudotyped Ebola retroviruses. The difference in 
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using DC-SIGN receptor by EBOZ and EBOR pseudoviruses was verified in direct in-
fection assay of immature DCs cells. The infection levels were adjusted by the results of 
direct infection with the same amount of recombinant Ebola Zaire and Reston pseudo-
viruses of HeLa cells. As a control, immature DCs were pre-incubated with the mono-
clonal antibody anti-DC-SIGN and then challenged with recombinant EBOZ and EBOR 
pseudoviruses. 
 
 
Figure 48. DC-SIGN-mediated cis-infection of primary DCs by EBOZ (red) and EBOR (blue). The inhibi-
tion of the infection with monoclonal antibody anti-DC-SIGN was performed for both, EBOZ (pink) and 
EBOR (light blue). The bars represent mean with SEM error bars of 3 independent experiments. The statis-
tical analysis was performed by two-tailed Student t test. 
 
 
 
The statistical significance of differences between the infection levels of Ebola Zaire 
and Ebola Reston pseudoparticles in immature DCs obtained in 3 independent exper-
iments of infection in cis was analyzed by Student t test. The two-tailed p value was 
calculated by GraphPad Prism V4. The difference in the mean infection level in the cis-
infection experiments between Ebola strain Zaire and Ebola strain Reston was not sta-
tistically significant (p=0.5479) (Fig. 48). Moreover, the mean (5696.53 vs 13219.67), SEM 
(2738.13 vs 11144.68), SD (4742.58 vs 19303.15) were calculated by using GraphPad 
Prism V4. 
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3. 4. DC-SIGN-mediated trans-infection of EBOZ and EBOR in the cellular 
system: primary DCs/HeLa cells 
 
The relevance of the differences in DC-SIGN receptor involvement in the trans-
infection process in immune system was verified by using immature DCs. Immature 
DCs were incubated with recombinant EBOZ and EBOR and after intensive washing, 
they were co-cultured with susceptible HeLa cells. The infection levels were adjusted 
by the results of direct infection with the same amount of recombinant EBOZ and 
EBOR viruses of HeLa cells. The ratio between DCs-mediated trans-infection for EBOZ 
and EBOR glycoprotein was calculated as an average from 3 independent experiments. 
As a control, immature DCs were pre-incubated with the monoclonal antibody anti-
DC-SIGN and then challenged with recombinant EBOZ and EBOR. The statistical sig-
nificance of differences between the transmitted infection by Ebola Zaire and Ebola 
Reston pseudoparticles to susceptible HeLa cells obtained in 3 independent experi-
ments of trans-infection was analyzed by Student t test. The two-tailed p value was cal-
culated by GraphPad Prism V4. The difference in the mean of  transmitted infection in 
the trans-infection experiments between Ebola strain Zaire and Ebola strain Reston was 
statistically significant (p=0.0084) (Fig. 49). In addition, the mean (24426.67 vs 38781.88), 
SEM (533.67 vs 2921.65), SD (924.35 vs 50606.45) were calculated by using GraphPad 
Prism V4. 
 
 
4. DISCUSSION 
 
Ebola viruses cause a severe, often fatal disease consisting in a highly lethal hemor-
rhagic fever syndrome (Peters et al., 1996). Ebola virus strain Zaire is the virus variant 
with the highest mortality rate being in the range 50-90%. In contrast to the Zaire 
strain, Ebola virus strain Reston does not cause a disease in humans despite a number 
of documented infections during animal epizootics (Barrette et al., 2009; Miranda et al., 
1999). The molecular basis for this difference in their pathogenesis remains unclear. 
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Figure 49. DC-SIGN-mediated trans-infection of EBOZ (red) and EBOR (blue) in the cellular system: pri-
mary DCs/HeLa cells. The inhibition of the trans-infection with monoclonal antibody anti-DC-SIGN was 
performed for both, EBOZ (pink) and EBOR (light blue). The bars represent mean with SEM error bars of 3 
independent experiments. The statistical analysis was performed by two-tailed Student t test.  
 
 
 
It has been speculated about the important role of viral glycoprotein in this phenome-
non. This hypothesis was raised after a number of in vitro studies, which analyzed the 
possible role of immunosuppressive motifs (Becker, 1995; Volchkov et al., 1992; 
Yaddanapudi et al., 2006), efficiency of cleavage by furin (Neumann et al., 2002; 
Neumann et al., 2007) or cytotoxicity (Alazard-Dany et al., 2006; Volchkov et al., 2001; 
Yang et al., 2000). However, there is no confirmed evidence for these speculations in 
vivo. The sequence analysis of Ebola Zaire and Reston envelope glycoproteins revealed 
similarity in overall length and PNGS number of envelope gene products, however, 
important divergence was seen in the sequence of mucin-like domain and glycan-cap. 
Glycan-cap subdomain contains 4 predicted PNGS in both strains (EBOZ: N228, N238, 
N257, N268; EBOR: N229, N239, N258, N269). This region does not form any mono-
mer-monomer contacts within the trimeric GP but is fully exposed on the outer side of 
the glycoprotein (Lee et al., 2008). Although the PNGS number in this region is con-
served in both strains, the sequence similarity is relatively low (52.3% of pairwise iden-
tity). Mucin-like domain is the high molecular mass region of about 75 kDA, where 
Chapter 3: Discussion   
 
104 
 
most of PNGS are concentrated. The crystal structure presented by Lee et al. demon-
strated that the mucin-like domain is associated with the side of each monomer of gly-
coprotein trimer and may function in building up the walls of the chalice. The mucin-
like domain of Ebola Zaire contains 5 PNGS (N317, N333, N346, N386, N436) and of 
Ebola Reston has 4 PNGS (N317, N333, N346, N386, N436). The sequence similarity is 
very low as comparing both strains showing 23.7% of pairwise identity. The mucin-like 
domain and glycan-cap are located together as an external domain playing the role in 
the immune evasion (Lee et al., 2008). The main envelope gene product, secreted gly-
coprotein (sGP), of both Ebola strains is of similar length (slightly longer in case of 
EBOR 368 aa vs 365 aa of EBOZ) and contains the same number of PNGS. The second 
glycoprotein product resulting from transcriptional editing of the glycoprotein ORF, 
transmembrane GP, is very similar in length in both strains (EBOZ: 677 aa, EBOR: 678 
aa) and have 11 N-linked glycans in both strains, located mostly in the mucin-like do-
main and the glycan cap (Fig. 50). 
 
 
 
Figure 50. Structure of Ebola virus glycoprotein. A. Ebola Zaire GP. B. Ebola Reston GP. Predicted N-
linked glycans are represented by red Y-shaped symbols. SP – signal peptide, HR – heptad repeat, TM – 
transmembrane domain. Modified from Cook et al. (Cook and Lee, 2013). 
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Yang et al. identified the Ebola virus glycoprotein as the main viral determinant of Ebo-
la virus pathogenicity (Yang et al., 2000). It has been shown that the process of transfec-
tion of retrovirus producer cells with GP of Ebola virus had a considerable effect on 
alteration of the cells phenotype. After 24 hours cells were rounded and detached, and 
by the time of 2-4 days post-transfection the cell death was observable. In this study, 
they mapped the region of GP responsible for cytotoxic effect by using deletion muta-
tions and checking the functional activity of created mutants. It has been then discov-
ered that GP proteins with internal deletion in serine-threonine-rich mucin-like domain 
did not cause morphological changes of cells or cellular cytotoxicity. The effect of wild-
type and mutant GP on endothelial cells was then studied by the comparison of the 
outcome elicited by adenovirus vectors encoding wild-type GP (ADV-GP) or mucin-
region-deleted GP (ADV-GPΔmuc). They observed that endothelial cells infected with 
ADV-GP exhibited altered cell morphology with cells rounding and detachment after 
12-16 h, whereas cells transfected with ADV-GPΔmuc were unchanged. Therefore, 
they suggested the mucin-like domain as being responsible for the GP cytotoxicity to 
endothelial cells in vitro since the deletion of this region abrogated its toxic effect with-
out affecting the cell surface expression. Further, they studied the contribution of other 
viral genes to the cytotoxicity of Ebola virus, however, none of genes studied showed 
cytotoxic activity. It was also shown that cytotoxic effect required the intracellular syn-
thesis and/or transport of GP gene product to the cell surface since it was blocked by 
an inhibitor of protein synthesis and the exposure to extracellular sGP protein fused 
downstream with mucin-like domain of GP had no effect on cell morphology or viabil-
ity. Subsequently, they tried to analyze the effect of GP on endothelial cells in blood 
vessels by using adenovirus vectors to infect porcine or human saphenous vein ex-
plants. It has been demonstrated that ADV-GP, unlike ADV-GPΔmuc, increased the 
permeability of cells of both models resulting from damage and loss of endothelial 
cells. To identify the potential relevance of GP in vivo, Yang et al. examined also the ef-
fects of Ebola Zaire and Reston GP expression in vascular cells of nonhuman primates 
and in men. They showed that ADV-GP Zaire caused endothelial damage in both hu-
man and monkey vessels explants, while ADV-GP Reston demonstrated this effect on-
ly in nonhuman primate model. Moreover, they confirmed the crucial role of mucin-
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like domain of Zaire strain in the cytotoxic effect by inserting this region into an analo-
gous region of another viral envelope (MLV) and observing more cell rounding and 
detachment as compared with a wild-type envelope. The trials of inserting of Ebola 
Zaire mucin-like domain into Reston GP yielded a protein that was not expressed on 
the cell surface thus the determination of the effect of this domain on the cytotoxicity 
could not be studied in this model (Yang et al., 2000). 
 
Nevertheless, the study of Groseth et al. about the contribution of Ebola virus glycopro-
tein for virulence in vivo, did not confirm the data obtained when using adenovirus 
vectors. The approach to understand the role of GP in pathogenesis was performed in 
the model of Ebola virus chimeras, where the glycoproteins of these two strains were 
exchanged and examined in the full-length clone system (recombinant REBOV, recom-
binant REBOV expressing ZEBOV GP, recombinant ZEBOV and recombinant ZEBOV 
expressing REBOV GP). The study indicated that exchange of the GP ORF is well toler-
ated in terms of basic viral functions including entry, replication and budding enabling 
the successful growth in vitro. Although no significant differences could be identified 
between the parental and wild-type viruses, the 2-3 log differences were observed be-
tween REBOV-based viruses as compared with ZEBOV-based viruses. The chimeric 
envelopes were examined in the IFNAR-/- model (severe combined immunodeficiency 
(SCID) and STAT1 knock-out (STAT-/-) mouse model), the only rodent model that reca-
pitulate difference in virulence between ZEBOV and REBOV in humans (Bray, 2001). 
The infection with rREBOV did not exhibit lethal disease while infection with rZEBOV 
showed uniform lethality with animals displaying decrease in activity, weight loss, ruf-
fled fur and hunched posture. This mice model revealed information about significant 
changes in the ability of the chimeric rZEBOV-RGP to reduce lethality and prolong the 
time to death as compared with rZEBOV. However, REBOV and REBOV-ZGP-infected 
IFNAR-/- mice did not cause any signs of disease. The introduction of Ebola Zaire GP to 
full-length Ebola Reston led to a slight decrease in the virulence of this envelope chi-
mera, which indicated that GP alone is not a sufficient determinant of EBOV virulence 
in this model. Despite the observed differences in the mortality caused by infection 
with ZEBOV and ZEBOV-RGP, no important changes in viral load in any or-
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gans/tissues were observed. Comparison of the pathology from REBOV-based or 
ZEBOV-based recombinant viruses showed continuously higher levels of inflammation 
and necrosis in case of animals infected with ZEBOV or ZEBOV-RGP, as compared to 
REBOV and REBOV-ZGP. The findings of their work could possibly reflect fundamen-
tal difference between ZEBOV and REBOV in their in vivo growth and spread in this 
model. The data obtained in this study clearly supported the conclusion that while GP 
is a relevant element of filovirus pathology, alone is not sufficient for Ebola virulence 
(Groseth et al., 2012). 
 
Binding of Ebola virus GP to different cellular lectins has been shown to augment virus 
infection. Although DC-SIGN is not the main receptor for Ebola cell entry, it has been 
demonstrated that the presence of DC-SIGN on non-permissive cells enable the virus 
entry. In case of Ebola virus, DC-SIGN receptor acts as a cell entry receptor as well as 
trans-infection receptor responsible for binding of viral particles and further transmis-
sion to susceptible cells (Alvarez et al., 2002). 
 
In our study, we have used recombinant particles expressing two Ebola virus envelope 
glycoproteins (Ebola Reston and Ebola Zaire) to evaluate the role of DC-SIGN in the 
cell entry and dissemination mediated by both Ebola variants. The DC-SIGN-mediated 
infection was verified in the experiments of trans-infection Jurkat DC-SIGN+/Jurkat, cis-
infection of primary DCs and trans-infection DCs/HeLa cells. 
 
The first experiment of the trans-infection in cellular model Jurkat DC-SIGN+/Jurkat 
showed the significant differences in the mean ratio of the trans-infection experiments 
between Ebola Zaire and Ebola Reston (p=0.0034). The mean ratio of EBOR was about 
three times higher than the ratio of EBOZ (35.97 vs 99.64) (Fig. 43). The relevance of the 
differences in DC-SIGN receptor usage in the trans-infection process was then verified 
by using immature DCs. These cells were incubated with EBOZ/EBOR and after inten-
sive washing they were co-cultured with susceptible HeLa cells. The results obtained 
in the experiment based on human immune cells (DCs) have confirmed the results of 
trans-infection in cell line system. The difference between the transmitted infection by 
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Ebola Zaire and Ebola Reston pseudoparticles to susceptible HeLa cells was statistical-
ly significant (p=0.0084) (Fig. 45). Both of performed experiments demonstrated statis-
tical significance of higher EBOR DC-SIGN-mediated trans-infection as compared with 
EBOZ. Despite significant differences in DC-SIGN usage by EBOZ/EBOR in the trans-
infection experiment, the direct infection of immature DCs did not give any significant 
result (Fig. 44). 
 
Our results found the association between the Ebola Reston and a higher trans-
infection ratio mediated by DC-SIGN. This finding might raise a hypothesis that alt-
hough DC-SIGN receptor participates effectively in the cell entrance, in vivo it could 
play apparently more important role in the proper immune system activation. DC-
SIGN may be responsible for virus capture, destruction and further presentation of its 
antigens to cells causing effective immunological control. DC-SIGN therefore, although 
able to capture effectively Ebola virus particles, might serve more as a host defence fac-
tor rather than pathogen escape receptor. Therefore the higher level of DC-SIGN-
mediated entry of Ebola Reston might suggest that overall DC-SIGN might be more 
implicated in antiviral responses. The results obtained in performed experiments 
somehow resemble the results from the Schaefer et al. study, in which mice expressing 
human DC-SIGN survived longer than wild-type mice after infection with Mycobacte-
rium tuberculosis, suggesting the role of DC-SIGN in the proper immune system activa-
tion by the antigen presentation and limiting of tissue-damaging inflammatory re-
sponses (Schaefer et al., 2008). 
 
 
5. CONCLUSIONS 
 
Despite the role of DC-SIGN in Ebola virus entry and potential initial dissemination, 
we found significantly higher DC-SIGN trans-infection by the non-pathogenic Ebola 
Reston strain. This finding could indicate that in Ebola virus infection DC-SIGN is in-
volved in a more efficient immune control. 
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V. CHAPTER 4:  
DC-SIGN in HIV-1 pathogenesis: Implication of DC-SIGN-mediated trans-
infection in HIV-1 virological control 
 
 
1. OBJECTIVES 
 
Evaluate the implication of DC-SIGN trans-infection in HIV-1 virological control 
through the study of a group of clinical isolates of virological controllers and non-
controllers.  
 
 
2. MATERIAL AND METHODS 
 
2. 1. Patients and samples  
 
All biological samples included in this thesis were obtained from patients from La Un-
idad VIH-1 del Hospital Universitario 12 de Octubre de Madrid under active follow-up 
by Dr. Rafael Rubio and Dr. Federico Pulido and from the Hospital La Paz, Madrid, 
Spain. Each sample was accessed upon informed consent under an internal review 
board approved protocol and were then stored in the Biobank of Laboratory of Micro-
biology. Some HIV-1 envelopes from HIV-1 controllers and patients with chronic HIV-
1 infection included in this thesis were kindly provided by Cecilio Lopez Galindez 
(Centro Nacional de Microbiología, Madrid, Spain) and by Miguel Thomson (Centro 
Nacional de Microbiología, Madrid, Spain). 
 
2. 2. Plasmids: pcDNA3.1/V5-His TOPO TA-HIV-1 env, pNL4-3.Luc.R-E- (See 
Chapter I. 2. 1) 
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2. 3. Isolation of whole blood DNA (QIAamp DNA Mini Kit, Qiagen) 
 
Isolation of whole blood DNA was performed by using of QIAamp DNA Mini Kit (Qi-
agen). Proteinase K (Qiagen) in volume of 40 µl was pipetted into the bottom of a 1.5 
ml microcentrifuge tube. The 400 µl of sample was added to the tube followed by 400 
µl of Buffer AL. The sample was mixed by pulse-vortexing for 15 sec and incubated at 
56º C for 10 min. After incubation, the tubes were centrifuged briefly to remove drops 
from the inside of the lid. Next, 400 µl of ethanol (96-100%) was added to the sample 
and mixed again by pulse-vortexing for 15 sec. After mixing, the microcentrifuge tubes 
were centrifuged briefly. The mixture was carefully applied to the QIAamp Spin Col-
umn (in a 2 ml collection tube) without wetting the rim, the cap was closed and the 
columns were centrifuged at 6000 g (8000 rpm) for 1 min. The QIAamp Spin Column 
was placed in a clean 2 ml collection tube and the filtrate was discarded. Then 500 µl of 
Buffer AW1 was added and the tubes were centrifuged at 6000 g (8000 rpm) for 1 min. 
The QIAamp Spin Column was again placed in a clean 2 ml collection tube and the fil-
trate was discarded. The 500 µl of Buffer AW2 was added and the tubes were centri-
fuged at full speed (20000 g; 14000 rpm) for 3 min. The QIAamp Spin Column was 
again placed in a new 2 ml collection tube and the filtrate was discarded. Next, the 
tubes were centrifuged at 20000 g (14000rpm) for 1 min. The QIAamp Spin Column 
was placed in a clean 1.5 ml microcentrifuge tube and the collection tube containing 
the filtrate was discarded. Then, 100 µl of Buffer AE or distilled water was added. The 
tubes were incubated at RT for 5 min and centrifuged at 6000 g (8000 rpm) for 1 min. 
 
2. 4. Purification of viral RNA (QIAamp RNA Mini Kit, Qiagen) 
 
Purification of viral RNA was performed by using of QIAamp RNA Mini Kit (Qiagen). 
Buffer AVL containing carrier RNA was pipetted in a volume of 560 µl into the bottom 
of a 1.5 ml microcentrifuge tube. The 140 µl of plasma sample was added to the Buffer 
AVL-carrier RNA and mixed by pulse-vortexing for 15 sec. The sample was incubated 
at RT for 10 min to lyse completely viral particles. After incubation, the tubes were cen-
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trifuged briefly to remove drops from the inside of the lid. Next, 560 µl of ethanol (96-
100%) was added to the sample and mixed by pulse-vortexing for 15 sec. After mixing, 
the microcentrifuge tubes were again centrifuged briefly. The 630 µl of the solution 
was carefully applied to the QIAamp Mini Spin Column (in a 2 ml collection tube) 
without wetting the rim, the cap was closed and the columns were centrifuged at 6000 
g (8000 rpm) for 1 min. The QIAamp Mini Spin Column was placed in a clean 2 ml col-
lection tube and the filtrate was discarded. Then, the rest of the solution was applied to 
the column and centrifuged at 6000 g (8000 rpm) for 1 min. The 500 µl of Buffer AW1 
was added to the tubes, the caps were closed and the microcentrifuge tubes were cen-
trifuged at 6000 g (8000 rpm) for 1 min. The QIAamp Mini Spin Column was again 
placed in a clean 2 ml collection tube and the filtrate was discarded. The 500 µl of Buff-
er AW2 was added and the tubes were centrifuged at full speed (20000 g; 14000 rpm) 
for 3 min. The QIAamp Mini Spin Column was again placed in a new 2 ml collection 
tube and the filtrate was discarded. Next, the tubes were centrifuged at 20000 g 
(14000rpm) for 1 min to eliminate residual AW2 Buffer. The QIAamp Mini Spin Col-
umn was placed in a clean 1.5 ml microcentrifuge tube and the collection tube contain-
ing the filtrate was discarded. Then, 40 µl of Buffer AVE was added. The tubes were 
incubated at room temperature for 5 min and centrifuged at 6000 g (8000 rpm) for 1 
min. 
 
2. 5. Synthesis of HIV-1 cDNA 
 
The viral cDNA was synthesized by using SuperScriptIII System (Invitrogen). Each 
sample was synthesized by using envelope-specific outer reverse primer OAS. 
 
OAS:  5´ TTGCTACTTGTGATTGCTCCATGT 3´ 
 
Each cDNA reaction was performed in a final volume of 40 µl using 500 ng – 1 µg of 
total RNA for reaction. The following components: 2 pmol of gene-specific OAS pri-
mer, 10 mM of each dNTPs, 500 ng – 1 µg of total RNA in a total volume of 26 µl were 
added to a nuclease-free microcentrifuge tube, heated at 65º C for 10 min and then in-
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cubated on ice for 2 min. Next, the 14 µl of reaction mixture containing 1X First-Strand 
Buffer, 5 mM DTT, 80 units of RNaseOUTTM Recombinant RNase Inhibitor, 400 units of 
SuperScriptIII was added into each reaction tube. The reaction mixture was mixed by 
pipetting gently up and down. RT-PCR cycle for the generating cDNA was: 25° C for 
10 min, followed by incubation at 50° C for 40 min and inactivation at 70° C for 15 min. 
The synthesized cDNA was then used as a template for the amplification by PCR. 
 
2. 6. Amplification of HIV-1 envelope sequences by PCR 
 
The envelope sequence of HIV-1 was amplified by using Expand High Fidelity PCR 
System (Roche) in Thermo Cycler 2720 (Applied Biosystems). Each sample was ampli-
fied by nested PCR using a set of outer primers OS/OAS and a set of inner primers 
IS/IAS. 
 
OS:   5´ TAGAGCCCTGGAAGCATCCAGGAAG 3´ 
 
OAS:   5´ TTGCTACTTGTGATTGCTCCATGT 3´ 
 
IS:   5´ GATCAAGCTTTAGGCATCTCCTATGGCAGGAAGAAG 3´ 
HindIII restriction site 
 
IAS:   5´ AGCTGGATCCGTCTCGAGATACTGCTCCCACCC 3´ 
BamHI restriction site 
 
Each first-round PCR reaction was performed in a final volume of 50 µl using 750 ng – 
1 µg of total cellular DNA or 7.5 µl of cDNA for reaction. Reactions were performed as 
follows: 1X Expand High Fidelity Buffer (with 15 mM MgCl2), 0.25 mM MgCl2, 0.2 mM 
dNTP, 0.5 µM of each primer and 1 unit of Expand High Fidelity Polymerase (Roche). 
PCR cycle for the first-round PCR was: 94° C for 3 min as initial denaturation, followed 
by 94° C for 15 sec, 50° C for 30 sec and 72° C for 5 min. After 10 cycles, the step of ex-
tension was modified by adding 5 sec to each subsequent cycle (5 min + 5 sec/cycle). 
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The PCR reaction was run for 20 more cycles followed by final extension at 72° C for 10 
min. For the second-round PCR, the amplification was performed in a final volume of 
50 µl using 3-5 µl of first-round PCR product. The conditions of second-round PCR 
were as follows: 1X Expand High Fidelity Buffer (with 15 mM MgCl2), 0.25 mM MgCl2, 
0.2 mM dNTP, 0.5 µM of each primer and 1 unit of Expand High Fidelity Polymerase 
(Roche). The second-round PCR cycle was: 3 min at 94° C followed by 15 sec at 94° C, 
30 sec at 60° C, 2.5 min at 72° C. After 10 cycles, the step of extension was modified by 
adding 5 sec to each subsequent cycle (5 min + 5 sec/cycle). The PCR reaction was run 
for 20 cycles followed by final extension at 72° C for 10 min. PCR amplicons were visu-
alized on a 0.8% agarose gel stained with ethidium bromide. The second-round PCR 
using primers IS/IAS results in a product of approximately 2.8-3 kb. 
 
 
2. 7. Cloning of HIV-1 envelopes into pcDNA3.1/V5-His TOPO by ligation 
and transformation of competent bacteria TOP10-F (Invitrogen) 
 
Each HIV-1 envelope obtained by nested PCR was cloned into pcDNA3.1/V5-His 
TOPO (Invitrogen). The cloning reaction was as follows: 2 µl of PCR product, 1 µl of 
Salt Solution, 2 µl of H2O, 1 µl of TOPO vector. The reaction was mixed gently and in-
cubated at RT (22-23º C) for 30 min. Next, the ligation reaction was added into a tube 
with competent bacteria cells and mixed gently. The transformation reaction was incu-
bated on ice for 30 min. Next, the heat-shock was performed on competent bacteria 
cells for 30 sec at 42º C without shaking. After heat-shock, the tubes were immediately 
transferred on ice. Following 10 min of incubation on ice, 250 µl of RT SOC medium 
was added into the tubes. The tubes were capped and incubated for 1 h at 37º C with 
shaking 200-250 rpm. Next, the tubes were centrifuged at 1000 rpm for 5 min and half 
of medium was removed. The rest of each transformation was resuspended, spread on 
the selective plates (LB+) and incubated up-side-down overnight at 37º C. The next day, 
the plate was analyzed, the colonies were picked up and cultured for further isolation 
of plasmid DNA. 
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2. 8. Isolation of plasmid DNA (QIAprep Spin MiniPrep Kit, Qiagen) 
 
One day before isolation, 3 ml of LB (supplemented with proper antibiotic) were inocu-
lated with 30 µl of bacteria carrying desired plasmid or 1 single colony picked from LB+ 
agar plates and cultured overnight with shaking (250 rpm) at 37º C. The following day, 
the bacteria culture was pelleted by centrifugation at 6500 rpm for 10 min at RT and the 
isolation of plasmid DNA was performed by using QIAprep Spin MiniPrep Kit (Qiagen). 
The pelleted bacteria were resuspended in 250 µl of Buffer P1 and transferred into mi-
crocentrifuge tubes. Next, 250 µl of Buffer P2 was added and tubes were mixed thor-
oughly by inverting 6 times until the solution become clear. After 5 min of incubation, 
350 µl of Buffer N3 was added and the tubes were mixed immediately thoroughly by 
inverting 6 times. The tubes were centrifuged for 10 min at 13000 rpm. Then, the su-
pernatant after centrifugation was applied into QIAprep spin column by pipetting. The 
columns were centrifuged for 1 min at 13000 rpm and the flow-through was discarded. 
Next, 0.5 ml of Buffer PB was added, the columns were centrifuged for 1 min at 13000 
rpm and the flow-through was discarded. Then, QIAprep spin columns were washed 
by centrifugation for 1 min at 13000 rpm with 0.75 ml of Buffer PE. The flow-through 
was discarded and the columns were centrifuged for an additional 1 min to remove 
residual wash buffer. The QIAprep spin column were placed into a clean 1.5 ml micro-
centrifuge tubes. To elute DNA, 50 µl of Buffer EB was added into column, incubated 
for 5 min and centrifuged for 1 min at 13000 rpm. 
 
2. 9. Isolation of plasmid DNA (PureLink HiPure Plasmid Filter MaxiPrep, 
Invitrogen) 
 
One day before isolation, 150 ml of LB (supplemented with proper antibiotic) were in-
oculated with 75-150 µl of bacteria carrying desired plasmid and cultured overnight 
with shaking (250 rpm) at 37º C. The next day, the bacteria culture was harvested by 
centrifugation at 4000 rpm for 30 min at 4º C and the plasmid DNA was isolated by us-
ing PureLink HiPure Plasmid Filter MaxiPrep (Invitrogen). The supernatant was removed 
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and harvested bacteria were resuspended in 10 ml of Resuspension Buffer (R3) with 
RNase A. Next, 10 ml of Lysis Buffer (L7) was added and bottles were mixed gently by 
inverting until the lysate mixture was homogeneous. After 5 min of incubation, 10 ml 
of Precipitation Buffer (N3) was added and the bottles were mixed again by inverting. 
Immediately after this step, the precipitated lysate was transferred into equilibrated 
(with 30 ml of Equilibrating Bufer EQ1) HiPure Filter Maxi Column. The lysate was let 
to run through the filter by gravity flow until the flow stops or becomes very slow (<1 
drop per 10 sec). The flow-through was discarded and the HiPure Filter Maxi Column 
was additionally washed with 10 ml of Wash Buffer (W8) to increase final DNA yield. 
Immediately after the HiPure Filter Maxi Column has stopped dripping, the Filtration 
Cartridge from the column was removed. The column was then washed with 50 ml of 
Wash Buffer (W8) allowing the solution to flow by gravity flow. The flow-through was 
discarded and the column was placed into new 50 ml tube. The DNA was eluted by 15 
ml of Elution Buffer (E4). The solution was let to drain by gravity flow. The HiPure Fil-
ter Maxi Column was discarded and the flow-through was precipitated by adding 10.5 
ml of isopropanol and centrifugation at 12000 g for 45 min at 4º C. After centrifugation, 
the supernatant was carefully discarded and 5 ml of cold 70% ethanol was added. The 
tubes were again centrifuged at 12000 g for 30 min at 4º C. The supernatant was then 
removed and the pellet was let to air-dry for 10 min. The DNA pellet was resuspended 
in 300 µl of TE Buffer (TE) and the DNA concentration was subsequently measured. 
The purified DNA was stored at -20º C. 
 
2. 10. Screening of cloned envelopes by restriction digestion 
 
After isolation of plasmid DNA, the cloning efficiency and the orientation of the insert 
(cloning into pcDNA3.1/V5-His TOPO is bi-directional) were verified by restriction di-
gestion. The reaction mix of total volume 20 µl was composed of: 500 ng of DNA, 1X of 
Restriction Buffer, 1X of BSA, 1U of BamHI. The reaction was then incubated for 2 h at 
37º C and visualized on a 0.8% agarose gel stained with ethidium bromide to check the 
orientation of the HIV-1 envelope cloned into pcDNA3.1/V5-His TOPO. 
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2. 11. Sequencing of HIV-1 envelopes 
 
PCR-sequencing reaction was performed by using of ABI PRISM BigDye Terminator 
v3.1 Cycle Sequencing (Applied Biosystems). The PCR products were first purified with 
2 µl of the ExoI/SAP-IT (2 µl of the ExoI/SAP-IT per 5 µl of PCR product) by incubation 
at 37º C for 15 min. After PCR clean-up treatment, ExoI/SAP-IT was inactivated by 
heating at 80º C for 15 min. ExoI/SAP-IT (USB) is composed of two hydrolytic enzymes, 
Exonuclease I and Shrimp Alkaline Phosphatase. Exonuclease I degrades residual sin-
gle-stranded primers and single-stranded DNA produced by PCR. The Shrimp Alka-
line Phosphatase hydrolyses remaining dNTPs from PCR mixture, which would inter-
fere with sequencing reaction. 
 
For the each well of 96-well plate the reaction mix of final volume 10 µl was prepared 
as follows: 1 µl of the reaction mix BigDye, 1 µl of primer at the concentration of 4 µM, 
2 µl of BigDye Reaction buffer and DNA (30–90 ng of HIV-1 envelope PCR product or 
200-500 ng of plasmid pcDNA3.1/V5-His TOPO-HIV-1 envelope). Each sequencing re-
action was amplified in the termocycler 2720 (Applied Biosystems). The PCR cycle was: 
initial denaturation of 1 min at 96º C, denaturation of 10 sec at 96º C, annealing of 5 sec 
at 50º C and extension of 4 min at 60º C. The cycle was repeated 25 times and the PCR 
product was left to cool at 4º C. 
 
Primers used for sequencing of HIV-1 envelopes: 
 
• gp120: 
AV304  5’ ACATGTGGAAAAATGACATGGT 3’ (HxB2: 6501-6522) 
 
AV305  5’ GAGTGGGGTTAATTTTACACATGG 3’ (HxB2: 6572-6595) 
 
AV306  5’ TGTCAGCACAGTACAATGTACACA 3’ (HxB2: 6937-6960) 
 
AV307  5’ TCTTCTTCTGCTAGACTGCCAT 3’ (HxB2: 6999-7020) 
 
AV308  5’ TCCTCAGGAGGGGACCCAGAAATT 3’ (HxB2: 7304-7327) 
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AV309  5’ CARTAGAAAAATTCYCCTCYACA 3’ (HxB2: 7346-7368) 
 
AV313  5’ TCCYTCATATYTCCTCCTCCAGGTC 3’ (HxB2: 7620-7644) 
 
 
• gp41: 
 
AV322  5’ AAGCAATGTATGCCCCTCC 3’ (HxB2: 7509-7527) 
 
AV323  5’ CTGCTCCYAAGAACCCAA 3’ (HxB2: 7771-7790) 
 
AV324  5’ GGCAAAGAGAAGAGTGGT 3’ (HxB2: 7714-7731) 
 
AV326  5’ TTGGGGYTGCTCTGGAAAAC 3’ (HxB2: 7999-8018) 
 
AV327  5’ TTTTATATACCACAGCCA 3’ (HxB2: 8246-8263) 
 
AV328  5’ ATAATGATAGTAGGAGG 3’ (HxB2: 8270-8286) 
 
AV329  5’ GTCCCAGAAGTTCCACA 3’ (HxB2: 8557-8573) 
 
AV330  5’ GGARCCTGTGCCTCTTCA 3’ (HxB2:8496-8513) 
 
AV331  5’ TCTCATTCTTTCCCTTA 3’ (HxB2: 8833-8849) 
 
 
2. 12. Automatic sequencing 
 
The sequencing was performed in automatic ABI PRISM 3100-Avant Genetic Analyzer 
(Applied Biosystems). The PCR products, amplified previously by BigDye chemistry, 
were resuspended in 20 µl of formamide at RT. Before placing in the sequencer, the 96-
well plate with all PCR products was vortexed for 15 sec and centrifuged at 2000 g for 1 
min. 
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2. 13. Analysis of sequences 
 
The sequences were obtained from automatic sequencer ABI PRISM 3100 in a form of 
chromatograms. The chromatograms were analyzed, assembled with the reference se-
quence to form the full length fragment (contig) of desired product and edited by Ge-
neious Bioinformatics Software. 
 
2. 14. Genotypic prediction of HIV-1 coreceptor usage 
 
The nucleotide sequences corresponding to the region V3 of the HIV-1 gp120 were ana-
lyzed and utilized for genotypic prediction of HIV-1 tropism, that is determined by us-
age of coreceptors: either CCR5 (R5 tropic viruses) or CXCR4 (X4 tropic viruses), by 
using geno2pheno algorithm (www.geno2pheno.org) at the 5.75% false positive rate. 
 
2. 15. Production of recombinant viruses (See Chapter I. 2. 3.) 
 
2. 16. Infection in trans experiment with HIV-1 GP-pseudotyped retroviruses 
(See Chapter 1. 2. 5) 
 
 
3. RESULTS 
 
3. 1. Analysis of HIV-1 envelope sequences from clinical isolates 
 
The HIV-1 envelopes were obtained by RT-PCR, cloned and sequenced. The sequences 
of 30 HIV-1 envelopes (elite controllers–6, viremic controllers–8, patients with chronic 
infection–16) were analyzed by using Geneious Bioinformatics Software V6.1. The 
length and the number of N-glycosylation sites (PNGS) were determined in each vari-
able loop (VL) (Table 2 and Table 3). The length of V1 was 24-40 aa and the number of 
N-glycosylation sites was 3–6 PNGS (Fig. 51A). The length of V2 was 37-53 aa and the 
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number of PNGS was 1-5 PNGS (Fig. 51B). The total length of V1V2 varied significant-
ly in all envelopes and was in the range 61-83 aa and the number of PNGS was 4-9 
PNGS. The region of V3 is the most conserved in all envelopes since it is responsible 
for the interaction with the proper coreceptor on the host cell surface. The length of V3 
was 34-36 aa. The number of PNGS in all envelopes was 1 (Fig. 52A). The length of V4 
varied in 30 HIV-1 envelopes from 27 to 40 aa and the number of PNGS was 3-6 PNGS 
(Fig. 52B). The V5 region is the shortest VL of HIV-1 envelope. The length of V5 was 
10-18 aa and the number of PNGS was 0-3 PNGS (Fig. 52C). The total length of VL in 
30 HIV-1 envelopes was 139-164 aa and the number of PNGS was 9–16. The full gp160 
length was in range 843-874 aa and the number of PNGS was 26-36. The gp120 length 
was 498-524 aa and the number of PNGS was 22-32. The length of gp41 was in range 
344-353 aa. The number of N-glycans in gp41 was 4-7 PNGS (Table 2 and Table 3). 
 
 
3. 2. Genotypic prediction of HIV-1 clinical isolates coreceptor usage 
 
The tropism of each HIV-1 variant was predicted by geno2pheno statistical tool at the 
significance level of 2% and 5.75% that are optimized cut offs based on analysis of clin-
ical data from MOTIVATE clinical trial (McGovern et al., 2010). The significance level 
(false positives rate = FPR) is the probability of classifying an R5-virus falsely as X4. 
The evaluation of the results by geno2pheno is based on publically available data of 
1100 V3 sequences (769 R5, 210 X4, 131 R5X4) from 332 patients (mainly from the HIV 
sequence database in Los Alamos, but also from scientific publications that have not 
been included in the Los Alamos database so far). The classification of the tropism and 
the FPR value for each HIV-1 envelope was determined (Table 4). The analysis of V3 
region of gp120 in the group of patients showed that 28 out of 30 sequences were clas-
sified as R5 by geno2pheno tool. The envelope HIV-1 9-6 and 13-6 were predicted to be 
X4 tropic (FPR of 0.5% and 5.3% respectively). 
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 env V1 aa V1 N V2 aa V2 N V1V2 aa V1V2 N V3 aa V3 N V4 aa V4 N V5 aa V5 N 
1 3-1 27 3 53 5 79 8 35 1 34 6 14 1 
2 9-6 32 3 38 2 69 5 36 1 34 5 12 1 
3 12-2 26 3 40 2 65 5 35 1 33 5 11 1 
4 15-7 26 3 40 2 65 5 35 1 30 3 12 1 
5 19-10 40 6 42 2 81 8 35 1 30 4 13 2 
6 36-4 26 3 40 2 65 5 35 1 32 4 12 1 
7 37-2 25 3 40 1 64 4 35 1 28 4 12 0 
8 40-2 37 5 43 1 79 6 35 1 31 5 13 1 
9 88-1 30 4 46 2 75 6 35 1 30 4 11 2 
10 84-35* 27 4 41 3 67 7 35 1 32 5 11 2 
11 65-4* 32 4 40 2 61 6 35 1 36 5 10 1 
12 2-1* 31 4 40 2 70 6 34 1 29 4 17 2 
13 10-4* 26 3 46 3 71 6 35 1 33 4 14 2 
14 13-6* 24 3 39 2 62 5 35 1 27 5 13 1 
media  
Controllers 
29,2 3,6 42 2,2 69,5 5,8 35 1 31,4 4,5 12,5 1,3 
15 8-13 33 6 39 2 72 8 35 1 31 5 15 2 
16 16-4 26 3 48 3 73 6 35 1 28 5 13 1 
17 17-10 31 4 42 3 72 7 35 1 31 5 15 2 
18 18-4 35 4 49 3 83 7 35 1 33 4 13 2 
19 22-78 29 5 40 2 68 7 35 1 31 5 12 1 
20 22-52 28 4 39 2 66 6 35 1 33 5 13 2 
21 26-56 31 4 47 3 77 7 34 1 28 4 16 2 
22 26-88 25 4 42 2 66 6 35 1 29 3 14 2 
23 28-80 25 3 44 3 68 6 35 1 32 4 13 1 
24 29-01 29 6 42 1 70 7 35 1 29 3 14 2 
25 29-14 27 4 37 2 63 6 35 1 31 5 12 2 
26 26-87 26 3 40 2 65 5 35 1 31 5 17 2 
27 27-54 25 4 40 1 64 5 35 1 31 4 15 1 
28 28-46 32 6 45 3 76 9 35 1 33 5 18 3 
29 23-13 36 5 38 2 73 7 34 1 31 4 14 2 
30 20-41 26 3 47 3 72 6 35 1 40 4 12 2 
media IC 29 4,2 42,4 2,3 70,5 6,56 34,9 1 31,4 4,4 14,1 1,8 
 
 
Table 2. Comparison of the length and PNGS number in 30 HIV-1 clinical isolates (14 HIV-1 controllers 
and 16 chronically infected patients, IC). 
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 env 
HIV-1 
stage 
DC-SIGN 
ratio (J) 
DC-SIGN 
ratio (R) 
Tropism FPR (%) 
Net 
charge 
VL 
length 
VL 
PNGS 
gp120 
length 
gp120 
PNGS 
gp41 
length 
gp41 
PNGS 
gp160 
length 
gp160 
PNGS 
1 3-1 EC 8,57 21,62 R5 57,1 19,516 162 16 522 29 345 4 867 33 
2 9-6 VC 25,33 25,01 X4 0,5 23,516 151 12 514 25 345 7 859 32 
3 12-2 VC  53,83 R5 55,3 20,516 144 12 505 24 345 5 850 29 
4 15-7 EC 13,06 49,71 R5 30,1 17,516 142 10 503 22 345 5 848 27 
5 19-10 VC 8,99 5,61 R5 21 14,102 159 15 521 29 344 5 865 34 
6 36-4 EC 86,35 16,31 R5 24,7 23,516 144 11 505 22 345 5 850 27 
7 37-2 EC 21,58 38,33 R5 96,5 16,516 139 9 501 22 345 4 846 26 
8 40-2 EC 22,66 11,85 R5 12,1 15,102 158 13 521 25 345 5 866 30 
9 88-1 EC  46,45 R5 28,8 19,223 151 13 514 28 346 5 860 33 
10 84-35* VC  41,03 R5 78,8 16,516 145 15 507 28 346 5 853 33 
11 65-4* VC  39,61 R5 32,4 15,809 142 13 515 28 346 4 861 32 
12 2-1* VC 59,28 121,58 R5 14,8 25,102 150 13 514 26 345 5 859 31 
13 10-4* VC 56,29 56,92 R5 35,6 20,688 153 13 512 27 345 4 857 31 
14 13-6* VC 53,74 92,85 X4 5,3 18,516 139 12 498 24 345 5 843 29 
media EC+VC  32,84 45,49  35,21 19,01 148,50 12,64 510,86 25,64 345,14 4,86 856,00 30,50 
15 8-13 CI 20,84 26,23 R5 63,1 17,516 152 16 516 32 345 4 861 36 
16 16-4 CI 13,77 7,96 R5 35,3 16,688 149 13 510 26 346 4 855 30 
17 17-10 CI 25,41 13,32 R5 21,2 13,516 153 15 514 27 345 4 860 31 
18 18-4 CI 18,68 17,64 R5 79,5 17,809 164 15 524 28 345 4 869 32 
19 22-78 CI  22,20 R5 91,9 24,637 146 14 506 27 346 5 852 32 
20 22-52 CI  13,47 R5 29,5 19,223 147 14 508 25 353 5 861 30 
21 26-56 CI  33,50 R5 10,2 20,223 155 14 512 27 344 5 856 32 
22 26-88 CI  46,46 R5 8,1 19,102 144 12 505 23 345 5 850 28 
23 28-80 CI  27,72 R5 13 14,223 148 16 509 26 344 4 853 30 
24 29-01 CI  28,36 R5 48,9 16,102 148 13 507 28 346 5 853 33 
25 29-14 CI  5,32 R5 27,1 21,102 141 14 500 29 344 5 844 33 
26 26-87 CI  23,82 R5 30,1 19,809 148 13 507 25 345 5 852 30 
27 27-54 CI  14,82 R5 6 20,516 145 11 503 23 345 5 848 28 
28 28-46 CI  10,42 R5 34,6 19,102 162 18 522 30 345 4 867 34 
29 23-13 CI  9,60 R5 78,8 23,102 152 14 512 26 345 5 857 31 
30 20-41 CI  5,86 R5 12,5 17,102 159 16 522 24 346 4 868 28 
media IC  17,4 20,42  36,86 18,74 150,81 14,25 511,06 26,63 345,56 4,56 856,63 31,13 
Table 3. Characteristics of 30 HIV-1 clinical isolates including: patient information, sequence analysis and DC-SIGN-mediated trans-infection. 
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              A.                 B. 
                                   
Figure 51. Alignment of 30 HIV-1 envelopes representing: A. V1 loop. B. V2 loop. 
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A.                                             B.                                                C. 
                                  
 
Figure 52. Alignment of 30 HIV-1 envelopes representing: A. V3 loop. B. V4 loop. C. V5 loop. 
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  envelope subtype tropism FPR (%) 
1 3-1 B R5 57.1 
2 9-6 B X4 0.5 
3 12-2 B R5 55.3 
4 15-7 B R5 30.1 
5 19-10 B R5 21 
6 36-4 B R5 24.7 
7 37-2 B R5 96.5 
8 40-2 B R5 12.1 
9 88-1 B R5 28.8 
10 84-35* B R5 78.8 
11 65-4* B R5 32.4 
12 2-1* B R5 14.8 
13 10-4* B R5 35.6 
14 13-6* B X4 5.3 
15 8-13 B R5 63.1 
16 16-4 B R5 35.3 
17 17-10 B R5 21.2 
18 18-4 B R5 79.5 
19 22-78 B R5 91.9 
20 22-52 CRF_14-BG R5 29.5 
21 26-56 B R5 10.2 
22 26-88 B R5 8.1 
23 28-80 B R5 13 
24 29-01 B R5 48.9 
25 29-14 B R5 27.1 
26 26-87 B R5 30.1 
27 27-54 B R5 6 
28 28-46 B R5 34.6 
29 23-13 B R5 78.8 
30 20-41 B R5 12.5 
 
Table 4. Coreceptor usage and the tropism prediction for 30 HIV-1 clinical isolates. 
 
 
3. 3. Phenotypic prediction of HIV-1 clinical isolates coreceptor usage 
 
The phenotypic assay to confirm the coreceptor usage of HIV-1 clinical isolates was 
performed in U87-R5 and U87-X4 cells. Cells were challenged in the infection in cis as-
say with recombinant retroviruses pseudotyped with each HIV-1 envelope variant. The 
results of the phenotypic assay confirmed the results obtained by bioinformatics tool 
geno2pheno and showed the usage of CCR5 coreceptor in 29 out of 30 HIV-1 envelopes 
and the usage of CXCR4 in only one envelope 9-6. Although genotypic test predicted 
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the X4 tropism for HIV-1 envelope 13-6 (FPR=5.3%), the phenotypic assay clearly re-
vealed the usage of CCR5 receptor for this HIV-1 envelope (Fig. 53). 
 
 
 
Figure 53. Phenotypic assay of the coreceptor usage of 30 HIV-1 clinical isolates. The tropism of the virus 
was studied in the infection in cis experiment, where U87-R5 (blue bars) and U87-X4 (red bars) cells were 
challenged with HIV-1 pseudotyped retroviruses. 
 
 
 
3. 4. Trans-infection experiment with HIV-1 clinical isolates 
 
The trans-infection experiment with 30 HIV-1 envelopes was performed to study the 
differences in DC-SIGN-mediated infection (EC-6, VC-8 and CI-16). A substantial 
group of EC HIV-1 envelopes (10 out of 16) could not be tested in the trans-infection 
experiments. All of 10 HIV-1 envelopes were confirmed as not defective by sequencing, 
however in cellular assay 4 out of 10 were observed non-functional and 6 out of 10 
showed the infectivity continuously below dynamic range required for the infection 
experiments thus they were excluded from our analysis. 
 
Infection in trans was performed on Raji DC-SIGN+, which could capture and transmit 
HIV-1 pseudotyped retroviruses to susceptible cells. As a control, Raji cells, which did 
not express DC-SIGN on its surface, were used. The ratio between trans-infection Raji 
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DC-SIGN+ and Raji cells for 30 different HIV-1 envelopes was calculated as an average 
from at least 3-9 independent experiments. The results of the trans-infection ratio var-
ied significantly among all HIV-1 envelopes, being in the range 121.58-5.32 in the Raji 
system (Fig. 54). 
 
 
 
Figure 54. Trans-infection experiment in a group of EC (red), VC (blue) and patients with chronic HIV-1 
infection (green) using Raji DC-SIGN+/Raji cellular system. The bars on the graph represent mean of the 
ratio with SEM error bars of 3-9 independent experiments. 
 
 
3. 5. Analysis of trans-infection ratios in the groups of patients: Elite Controllers, Vi-
remic Controllers and patients with chronic HIV-1 infection 
 
The results of the trans-infection experiments were compared between different groups 
of patients to verify if the virological control might have any association with the ratio 
of trans-infection. The results obtained in the Raji DC-SIGN+/Raji system included 24 
results from 6 HIV-1 envelopes of elite controllers, 30 results from 8 HIV-1 envelopes of 
viremic controllers and 72 results from 16 HIV-1 envelopes of patients with chronic 
HIV-1 infection. The statistical analysis of differences between the groups of patients 
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was performed by using Mann-Whitney test (GraphPad Prism V4). The results ob-
tained in the analysis showed statistically significant differences between HIV-1 con-
trollers and patients with chronic HIV-1 infection with the mean controllers=45.49 vs 
CI=20.42 (<p=0.0001) (Fig. 55). 
 
 
 
Figure 55. Trans-infection ratios of HIV-1 controllers (red) and of patients with chronic HIV-1 infection 
(green) using Raji DC-SIGN+/Raji system. The statistical analysis was performed by using Mann-Whitney 
test. 
 
 
 
These differences were further verified separately between the subgroups of HIV-1 
controllers (elite and viremic controllers) to determine if the type of virological control 
could have influence DC-SIGN-mediated trans-infection result. The data obtained in 
this study clearly showed that the group of patients that was associated with higher 
DC-SIGN trans-infection was the subgroup of viremic controllers, patients at the limit 
of virological control. Significantly higher trans-infection ratio was observed in case of 
viremic controllers as compared with chronically infected patients (VC=56.6 vs 
CI=20.42, <p=0.0001) (Fig. 56). Interestingly, there was also a statistically significant dif-
ference in trans-infection ratio between VC and EC with the mean VC=56.6 vs EC=28.02 
(p=0.0007) (Fig. 56). When analysing EC and CI patients no statistically significant vari-
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ations were found, however there was a trend towards higher DC-SIGN-mediated 
trans-infection in EC individuals (EC=28.02 vs CI=20.42, p=0.1331) (Fig. 56).  
 
 
 
 
Figure 56. Trans-infection ratios of EC (red), VC (blue) and chronically infected patients (green) obtained 
in Raji DC-SIGN+/Raji system. The statistical analysis was performed by using Mann-Whitney test. 
 
 
 
3. 6. Analysis of differences in HIV-1 envelope sequence and trans-infection ratio 
between elite controllers, viremic controllers and patients with chronic HIV-1 infec-
tion 
 
For the identification of factors responsible for the differences in the ratio of trans-
infection, the length and PNGS in: gp160, gp120, gp40, V1-V5 were analyzed between 
EC, VC and CI (Table 2 and 3). No significant differences were found in V1-V4 regions 
with the exception of V5 (Fig. 57). The length of V5 was significantly shorter in the 
group of HIV-1 EC as compared with CI (EC=12.33 vs CI=14.13aa, p=0.0325). The group 
of VC also demonstrated a trend towards shorter V5 loop (VC=12.63 aa vs CI=14.13 aa, 
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p=0.0858). The number of PNGS in V5 was higher in the group of patients with chronic 
HIV-1 infection (EC=1 PNGS, VC=1.5 PNGS and CI=1.813, EC vs CI p=0.0072).  
 
A.                            
 
 
B.                
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*EC vs CI p=0.0072
 VC vs CI p=0.1958
 
 
 
Figure 57. Comparison of: A. Length of each VL; B. PNGS in each VL; in EC (red), VC (blue) and patients 
with chronic HIV-1 infection (green). The statistical analysis was performed by using Mann-Whitney test. 
 
 
Although the analysis of the HIV-1 envelope sequences between the patients showed 
statistically significant differences in V5 loop, there was no correlation found between 
the trans-infection ratio and the length of V5 (r=0.0925, p=0.6267) or the number of 
PNGS in V5 (r= -0.0895, p=0.6382) (Fig. 58).  
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Figure 58. Correlation analysis between DC-SIGN trans-infection and: A. Length of V5. B. PNGS in V5. p 
values, estimated by using two-tailed t test, are shown on each graph.  
 
 
 
4. DISCUSSION 
 
The receptor DC-SIGN was initially cloned and characterized as a receptor for the HIV 
envelope glycoprotein gp120. In fact, it was precisely shown that gp120 affinity for DC-
SIGN is even higher than for CD4 receptor, a classical HIV-1 entry receptor (Curtis et 
al., 1992). Years before the discovery of DC-SIGN, studies of Cameron et al. and Pope et 
al. showed that DC pulsed with HIV-1 endorsed infection of co-cultivated T cells 
(Cameron et al., 1992; Pope et al., 1994). Shortly after the identification of DC-SIGN, 
Geijtenbeek et al. defined this phenomenon as HIV-1 trans-infection (Geijtenbeek et al., 
2000b). It has been clearly shown that DC-SIGN binds carbohydrate structures, such as 
mannose-containing glycoconjugates, expressed on the surface of different pathogens 
(den Dunnen et al., 2010). The envelope of HIV-1 is one of the most highly glycosylated 
proteins in nature, containing 22-32 PNGS in gp120. Therefore, many different in vitro 
studies evidently have shown the high affinity of HIV-1 envelopes to cells expressing 
DC-SIGN receptor. DC-SIGN does not function as a direct HIV-1 receptor but it works 
efficiently in the viral transmission from periphery to secondary lymphoid tissues. It 
has been demonstrated that HIV-1 particles bound to DC-SIGN are remarkably stable 
and retain infective for prolonged periods (Geijtenbeek et al., 2000b). Despite of all 
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proposed roles of DC-SIGN based on in vitro models, the confirmation of the physio-
logical behaviour of DC-SIGN in vivo should be further clarified.  
 
The changes in the length and the number of N-glycosylation sites over the time of 
HIV-1 epidemic might be explained by the adaptation of HIV-1 envelopes to human 
immune response. During HIV-1 infection many antibodies are generated, however 
most of them are non-neutralizing (Weiss et al., 1985). The humoral immune response 
to HIV-1 infection is usually characterized by rather low levels of NAbs. It has been 
shown that several functionally conserved regions of HIV-1 envelope might serve as 
potential targets for NAbs, such as the CD4-binding site, coreceptor-binding site and 
the regions of gp120 and gp41 responsible for the fusion to target cells (Li et al., 2006; 
Migueles et al., 2000). However, the restricted accessibility of these conserved domains 
leads to difficulties in efficient eliciting of NAbs. It has been also shown that HIV-1 en-
velope uses many different mechanisms to escape from antibody neutralization, such 
as amino acid substitutions, insertions in the variable loops of gp120 (Bunnik et al., 
2008; Rong et al., 2007; Sagar et al., 2006) or increasing the number of glycans on its 
outer surface (Bunnik et al., 2008; Chackerian et al., 1997; Wei et al., 2003). It has been 
demonstrated that VLs of HIV-1 envelope tend to be shorter and contain fewer PNGS 
in viruses from early infection as compared to chronic isolates (Chohan et al., 2005; 
Frost et al., 2005). HIV-1-infected individuals develop neutralizing antibodies against 
HIV-1 envelope glycoprotein, which strongly drive the selection of antibody escape 
variants (Richman et al., 2003). Thus larger loops might mask epitopes recognized by 
those NAbs (Sagar et al., 2009). To date, several NAbs were described as having a 
broad potency to recognize and neutralize diverse HIV-1 isolates. Nevertheless, typi-
cally there is a long gap in the appearance of NAbs in the hosts. Over the time of infec-
tion escape mutants are selected mainly due to high levels of ongoing replication, thus 
by the time that NAbs are produced in the infected individuals, the newly produced 
viral particles are already resistant to neutralization (Richman et al., 2003; Wei et al., 
2003). NAbs are developed against earlier viral isolates and reveal very low neutraliz-
ing activity against contemporary viruses (Skrabal et al., 2005; Tremblay and 
Wainberg, 1990). It was claimed that antibody response for HIV-1 infection appears to 
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be going constantly after moving target (Montefiori et al., 1996). Although shorter VLs 
with fewer PNGS are characteristic for early viruses, the loss of some specific PNGS 
has been shown to be associated with chronic infection. Gnanakaran et al. demonstrat-
ed that glycans at positions N188, N362, N462, N392, N397 and N356 plays a role in 
early stages of HIV-1 infection and are lost over the course of disease (Gnanakaran et 
al., 2011). N188 is involved in the interactions with CD4 and CCR5 (Ly and Stamatatos, 
2000), N362 enhances fusogenicity at the moment of transmission (Sterjovski et al., 
2007), glycans N392, N397 and N356 were shown to be part of “silent face” of gp120 
responsible for binding to DC-SIGN enhancing therefore HIV-1 transmission 
(Geijtenbeek et al., 2000b; McCaffrey et al., 2004; Wyatt et al., 1998). N392 additionally 
was revealed to be to critical component of the epitope of the NAbs 2G12, thus the loss 
of this glycan site makes chronic isolates to be unrecognizable by this NAbs (Sanders et 
al., 2002). 
 
In addition to humoral response, the cellular immunity has been also demonstrated to 
play a role in HIV-1 infection. DCs are known as the most potent inducers of specific 
immune responses and essential for the initiation of primary antigen-specific immune 
reactions. DCs are able to activate antigen-specific T cell responses being thus crucial in 
adaptive immunity (Lu et al., 2004). The stimulation of CD8+ T lymphocytes and the 
formation of antigen-specific cytotoxic T cells depends on the peptide presentation to-
gether with MHC class I antigens. Cytotoxic T cells are able to recognize and eliminate 
virus-infected cells thus it was suggested that the initial HIV-specific CTL response 
contributes efficiently to better control of viremia during acute infection (Goonetilleke 
et al., 2009). CD8+ T cells recognize specific antigens in the context with HLA class I 
molecules on APC, while CD4+ T cells require the antigen presentation in the context 
with HLA class II molecules. The generation of HIV-specific immune response is de-
pendent on the individual HLA pattern, therefore APC might bind different HIV pep-
tides and activate CD8+ T cells in moderate way in each patient. The ability of DCs to 
activate T cells depends also on the presence of secretory cytokines, which might cause 
differentiation of CD4+ T cells into Th1 and Th2. CD4+ Th1 release IL-2 and INF-γ sup-
porting the effector functions of the immune system and CD4+ Th2 produce IL-4, IL-10, 
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IL-5 and IL-6 playing role in development of a humoral response (Clerici et al., 1992). 
The close contact between CD4+ T cells and APC, the presence of infectious virions on 
the surface of DCs and production of pro-inflammatory cytokines: IL-1, Il-6 or TNF-α, 
promotes the induction of viral replication in infected cells (Stacey et al., 2009). 
 
Although the majority of antiretroviral-untreated individuals develops immunodefi-
ciency of immune system and dies from AIDS-related complications in approximately 
10-year time after becoming infected, a very small percentage of untreated individuals 
remain clinically and/or immunologically stable for years (Cao et al., 1995; Munoz et 
al., 1995). The factors associated with HIV control in vivo have not been fully defined 
yet. It has been proposed that infection by attenuated or defective viruses might be re-
sponsible for virus control and/or immunologic non-progression (Alexander et al., 
2000; Hassaine et al., 2000; Kirchhoff et al., 1995; Lum et al., 2003; Wang et al., 1996; 
Yamada and Iwamoto, 2000). Less symptomatic primary infections were described 
more often in case of HIV controllers as compared with those destined to remain vire-
mic (Madec et al., 2005a). However, the most consistent host factor that might be asso-
ciated with virus control is the strong cellular response. The function of CD8+ T cells 
have been shown higher in controllers as compared with non-controllers (Migueles et 
al., 2002). The presence of several different HLA alleles in infected patients, which de-
tect and present HIV-1 antigens, have been described to be associated with effective 
HIV control, such as HLA-B57, HLA-B5801, HLA-B27, HLA-B14, HLA-A32 (Gao et al., 
2001; Geczy et al., 2000; Hendel et al., 1999; Kaslow et al., 1996; Keet et al., 1999; 
Magierowska et al., 1999; McNeil et al., 1996; Saah et al., 1998). Among protective HLA 
alleles, HLA-B57 allele was consistently shown to be associated with a delay onset to 
AIDS (Carrington and O'Brien, 2003; O'Brien et al., 2001). It seems clear that although a 
number of factors have been associated with control of HIV-1, none of these features 
alone might predict virus control (Deeks and Walker, 2007; Walker, 2007). 
 
In our study, we analyzed the sequences from 6 HIV-1 elite controllers, 8 HIV-1 vire-
mic controllers and 16 HIV-1 chronic infections for DC-SIGN-mediated trans-infection. 
Chapter 4: Discussion 
 
136 
 
The ratio of the trans-infection varied significantly among all HIV-1 envelopes showing 
correlation of DC-SIGN ratio with virological control in case of both cellular systems 
tested (Raji DC-SIGN+/Raji and Jurkat DC-SIGN+/Jurkat). The analysis of the results 
obtained from Raji DC-SIGN+/Raji system revealed overall significant difference in the 
ratio of DC-SIGN-mediated trans-infection between HIV-1 controllers and patients 
with chronic HIV-1 infection (Controllers=45.49 vs CI=20.42, p<0.0001) (Fig. 55). Inter-
estingly, the subgroup of HIV-1 viremic controllers demonstrated the highest DC-
SIGN-mediated trans-infection as compared with EC (VC=56.6 vs EC=28.02, p=0.0007) 
and CI (VC=56.6 vs CI=20.42, p<0.0001) (Fig. 56). EC showed a trend towards more effi-
cient trans-infection as compared with CI (p=0.1331), however much less efficient when 
compared with VC (Fig. 56). The overall result of the trans-infection experiment was 
subsequently confirmed by trans-infection experiment in Jurkat DC-SIGN+/Jurkat cellu-
lar system showing significantly higher DC-SIGN-mediated trans-infection as com-
pared with chronically HIV-1 infected patients (Controllers=32.84 vs CI=17.4, p=0.0233). 
The low association between EC and efficient DC-SIGN-mediated trans-infection might 
suggest that other factors, such as reduced viral fitness (Casado et al., 2013; Lassen et 
al., 2009; Miura et al., 2009) or extremely vigorous CD8+ T cell response (Goulder and 
Watkins, 2004; Migueles et al., 2002) account for virological control in this subgroup of 
patients. Our results have confirmed the frequent low fitness linked to EC envelopes. 
In our study, a considerable group of EC HIV-1 envelopes (10 out of 16) could not be 
tested in the trans-infection experiments. All of 10 HIV-1 envelopes were confirmed as 
not defective by sequencing, however in cellular assay 4 out of 10 were observed non-
funtional and 6 out of 10 had the infectivity continuously below dynamic range re-
quired for the infection experiments thus they were excluded from our analysis. Alt-
hough extremely strong CD8+ T cellular response has been frequently suggested as a 
factor associated with virological control in EC, other studies have demonstrated that 
the phenomenon of elevated CD8+ T cell activity in these patients was related to chron-
ic inflammation that eventually leads to progressive immunodeficiency. It was ob-
served that higher T cell activation was related to lower CD4+ T counts supporting the 
hypothesis that cellular response activation leads to disease progression independently 
of viral replication (Hunt et al., 2008). It was also suggested that sustained prolong very 
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low level of viral replication in EC individuals can be involved directly in endothelial 
damage (Torriani et al., 2008) as well as it can lead to continuous T cells and monocyte 
activation that can contribute to increased arterial inflammation (Pereyra et al., 2012). 
The higher atherosclerosis incidence in HIV-1 controllers was confirmed in study of 
Hsue et al., where EC in the absence of ART showed augmented chronic inflammation 
that accounted for atherosclerosis (Hsue et al., 2009). In the absence of ART, HIV-1 in-
fection has been associated with increased levels of IL-6, a pro-inflammatory cytokine 
that is strongly linked to cardiovascular problems and mortality in untreated HIV-1 
patients, including HIV-1 controllers (Kuller et al., 2008). Moreover, it has observed 
that EC were hospitalized significantly more frequently that treated individuals, most-
ly for pulmonary or cardiovascular causes  (Katsnelson, 2014). The first study of ART 
initiation in the group of HIV-1 controller was conducted by Hatano et al. to determine 
the virological and immunological effect of the treatment. This study revealed that con-
trollers had statistically decreased ultrasensitive plasma and rectal HIV RNA levels. 
Furthermore, the markers of T cell activation and T cell dysfunction in blood and gut 
mucosa were reduced substantially in EC on ART (Hatano et al., 2013). Virological con-
trol in the subgroup of HIV-1 viremic controllers is less well understood. It might be 
possible that this subgroup of patients have stronger innate immune response, which 
can influence virological control. VC have used DC-SIGN more efficiently as compared 
to other groups of patients, therefore it might be hypothesized that DC-SIGN in these 
patients play a potential role in antigen capture and further presentation for the proper 
immune system activation. 
 
To access the information about the basis of these differences in DC-SIGN-mediated 
trans-infection, the HIV-1 envelope length and PNGS number were compared between 
EC, VC and CI. Although it has been demonstrated that the envelope glycoprotein 
from HIV controllers is shorter and contains fewer PNGS (Bailey et al., 2006a), in our 
small study the virus sequences of HIV-1 controllers and patients with chronic infec-
tion were of similar length and containing comparable number of PNGS in most of 
gp160 regions with the only exception of V5 loop (Fig. 57). However, further analysis 
has shown that V5 length and V5 PNGS did not have any association with DC-SIGN 
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trans-infection ratio (Fig. 58). Thus it could be suggested that these changes occurred in 
the natural course of HIV-1 infection, possibly in the response to the pressure caused 
by NAbs. It has been previously shown that HIV-1 envelope length and glycan num-
bers have a tendency to increase over the course of HIV-1 epidemic (Bunnik et al., 2010; 
Bunnik et al., 2008). Our analysis of the data obtained from HIV Los Alamos Data base 
confirmed those studies showing the apparent evolution of the HIV-1 envelope glyco-
proteins towards longer and containing more PNGS (Supplementary material 1). 
Therefore the change in V5 towards longer loop containing more N-glycans and the 
increase in overall PNGS number in all variable loops could be explained by the HIV 
evolution pattern and did not have association with more efficient usage of DC-SIGN 
in the trans-infection experiment.  
 
The results of this study might contribute to better understanding of DC-SIGN receptor 
role in HIV-1 pathogenesis. We indicated the substantial usage of DC-SIGN receptor in 
the trans-infection experiment by HIV-1 controllers, especially in the subgroup of VC. 
Those results were verified in two cellular systems and both showed the association of 
higher trans-infection ratio with virological control. The HIV-1 envelopes of VC have 
used DC-SIGN more efficiently as compared with EC and patients with chronic HIV-1 
infection. It is possible that virological control in the group of EC results from reduced 
viral fitness or more effective adaptive cellular response rather than the role of DC-
SIGN in the first steps of virus infection. However, in the group of VC it might be pos-
sible that more robust involvement of this receptor is associated with antigen presenta-
tion and more effective immune system response rather than virus dissemination lead-
ing to better cellular control of the infection resulting in more efficient virological con-
trol. The HIV-1 virological control is characterized by maintaining low viral loads in 
the absence of antiretroviral therapy. Thus the low viral load and the lack of active rep-
lication determine that envelope sequences in HIV controllers have small loop and few 
number of N-glycans (Bailey et al., 2006a). Although DC-SIGN shows strong affinity 
for mannose-containing moieties, our study has confirmed that the number of PNGS is 
not the fundamental factor associated with stronger DC-SIGN bindings. The compari-
son of N-glycosylation pattern did not show any statistically significant differences be-
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tween the number of glycans in VC as compared with EC and CI, therefore higher DC-
SIGN-mediated trans-infection in the subgroup of VC could not be explained by the 
quantitative occurrence of N-glycosylation. It might be thus suggested that DC-SIGN 
binding involves complex pattern of specific N-glycosylation and not the amount of 
glycans on the envelope surface. Our data demonstrated that HIV-1 envelopes of con-
trollers although containing generally lower number of glycans on the virus surface, 
use DC-SIGN more effectively than HIV-1 chronic isolates. In this respect a viral evolu-
tion towards less use of DC-SIGN has been reported to occur during clinical follow up, 
specially between acute vs late-stage strains within the same individuals suggesting a 
negative DC-SIGN selection along the time of infection (Borggren et al., 2008).  
 
 
5. CONCLUSIONS 
 
1) The envelope glycoproteins of HIV-1 virological controllers use DC-SIGN more effi-
ciently in the trans-infection experiment as compared with patients with chronic HIV-1 
infection. 
 
2) DC-SIGN-mediated trans-infection is not associated with the amount of N-glycan 
residues in HIV-1 envelope glycoprotein. Probably a more complex pattern of specific 
N-glycosylation is responsible for this mechanism.  
 
3) In the group of VC, the observed significantly higher trans-infection could indicate 
that DC-SIGN participates in viral detection, presentation and immune control more 
than dissemination as in the case of observation of more efficient DC-SIGN-mediated 
trans-infection by Ebola Reston. 
 
4) The EC group did not show the same DC-SIGN trans-infection use as observed in 
VC. In this group of patients virological control could be more associated with factors 
such as viral fitness or vigorous CTL response. 
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VI. CONCLUSIONS 
 
1) The infection model based on cell lines expressing DC-SIGN is a consistent platform 
to study direct viral entry (Ebola virus) and the trans-infection phenomenon (Ebola vi-
rus and HIV) since the infection events depend almost exclusively on DC-SIGN-viral 
interaction. 
 
1) El modelo de infección basado en las líneas celulares que expresan DC- SIGN es una plataforma consis-
tente para estudiar la entrada viral directa (virus del Ébola) y el fenómeno de trans-infección (virus Ebola y 
VIH) debido a que la interacción virus-DC-SIGN en este sistema depende casi exclusivamente de la pre-
sencia DC–SIGN. 
 
 
2) The DC-SIGN infection model is a useful model of an antiviral screening platform to 
test carbohydrates strategies targeting DC-SIGN. 
 
2) El modelo de infección DC-SIGN es un modelo útil para estudiar estrategias antivirales dirigidas a DC-
SIGN. 
 
3) The inhibition of DC-SIGN-mediated infection by carbohydrate-based compounds 
depends strongly on the multivalency of glycan presentation. 
 
3) La inhibición de la infección mediada por DC-SIGN mediada por los compuestos basados en hidratos 
de carbono depende en gran medida de la multivalencia de presentación de los glicanos. 
 
4) The most potent antiviral activity was obtained by glycodendrinanoparticles show-
ing an effective antiviral activity in the picomolar to low nanomolar concentration 
range. Multivalency depends on the presentation of 1620 glycan moieties generating a 
large surface of interaction (30 nm in diameter). 
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4) La actividad antiviral más potente se obtuvo en caso de las glicodendrinanoparticulas que muestran 
una actividad antiviral eficaz en el rango de concentración picomolar -nanomolar. Multivalencia depende 
de la presentación de los 1620 glicanos generando una gran superficie de interacción (30 nm de diámetro). 
 
5) Despite the role of DC-SIGN in Ebola virus entry and potential initial dissemination, 
we found significantly higher DC-SIGN trans-infection by the non-pathogenic Ebola 
Reston strain. This finding could indicate that in Ebola virus infection DC-SIGN is in-
volved in a more efficient immune control. 
 
5) A pesar del papel del DC-SIGN en la entrada del virus del Ébola y la difusión inicial del virus, en nues-
tro estudio encontramos significativamente mayor uso de DC-SIGN por la cepa no patógena de Ébola Res-
ton. Este hallazgo podría indicar que DC-SIGN en caso de Ébola Reston está involucrado en un control 
inmunitario más eficiente. 
 
6) The envelope glycoproteins of HIV-1 virological controllers use DC-SIGN more effi-
ciently in the trans-infection experiment as compared with patients with chronic HIV-1 
infection. 
 
6) Las glicoproteínas de la envoltura del VIH- 1 de los controladores virológicos utilizan DC-SIGN más 
eficiente en el experimento de trans-infección en comparación con los pacientes con enfermedad crónica.  
 
7) DC-SIGN-mediated trans-infection is not associated with the amount of N-glycan 
residues in HIV-1 envelope glycoprotein. Probably a more complex pattern of specific 
N-glycosylation is responsible for this mechanism.  
 
7) La trans-infección mediada por DC-SIGN no está asociada con la cantidad de los N- glicanos en la glico-
proteína de la envuelta de VIH-1. Probablemente un patrón más complejo de N- glicosilación específica es 
responsable de este mecanismo. 
 
8) In the group of VC, the observed significantly higher trans-infection could indicate 
that DC-SIGN participates in viral detection, presentation and immune control more 
than dissemination as in the case of observation of more efficient DC-SIGN-mediated 
trans-infection by Ebola Reston. 
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8) En el grupo de VC, la significativamente mayor trans-infección observada podría indicar que DC-SIGN 
participa en la detección viral, presentación y control inmunológico más que en la difusión viral, como en 
el caso de trans-infección por Ébola Reston. 
 
9) The EC group did not show the same DC-SIGN trans-infection use as observed in 
VC. In this group of patients virological control could be more associated with factors 
such as viral fitness or vigorous CTL response. 
 
9) El grupo de EC no demostró la misma trans-infección que los VC. El control virológico en el grupo de 
los EC puede resultar de la reducción de la replicación viral o extremadamente vigorosa respuesta de las 
células T CD8+. 
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1. Introduction 
 
The mammalian immune system is composed of two types of immunity that are used 
to protect the host from infections: innate and adaptive immunity (Medzhitov and 
Janeway, 1999). The innate immune system is the first line of host defense against 
pathogens. It is immediate and genetically programmed to detect features of invading 
microbes. Adaptive immunity is highly specific and it is responsible for the elimination 
of pathogens in the late phase of infection and for the generation of immunological 
memory (Akira et al., 2006). The key role in translating innate information into adap-
tive immunity plays the members of the dendritic cell family (Reis e Sousa, 2001). Im-
mature DCs can express receptors that mediate adsorptive endocytosis, including C-
type lectin receptors and Toll-like receptors (TLRs). DC-SIGN is a type II C-type lectin, 
which belongs to the transmembrane PRR family. DC-SIGN plays a role in immune 
response through control of DC migration, T cell priming, antigen capture and presen-
tation. The receptor DC-SIGN was initially identified as an attachment factor for HIV, 
which binds to viral envelope and augments virus infection (Curtis et al., 1992; 
Geijtenbeek et al., 2000c). DC-SIGN contains a carbohydrate recognition domain 
(CRD), an extracellular stalk composed of seven complete and one partial tandem re-
peat, a transmembrane domain and a short cytoplasmic N-terminal domain with sev-
eral intracellular sorting motifs (Geijtenbeek et al., 2000c). The CRD of DC-SIGN shows 
high affinity for mannose and fucose residues (van Kooyk and Geijtenbeek, 2003). DC-
SIGN recognizes the glycoproteins that contain a relatively high number of N-linked 
carbohydrates present on the surface of different pathogens (Geijtenbeek and van 
Kooyk, 2003). DC-SIGN binds to HIV, Ebola virus, Cytomegalovirus, Hepatitis C virus, 
Dengue virus, Helicobacter pylori, Klebsiella pneumoniae, Mycobacterium tuberculosis, Can-
dida albicans, Leishmania, Schistosoma mansoni.  
 
DC-SIGN is not the main receptor for Ebola virus and many different cell lines lacking 
DC-SIGN has been earlier described as a target of viral infection (Wool-Lewis and 
Bates, 1998; Yang et al., 1998). It has been shown that the expression of DC-SIGN in-
creases the level of the infection with Ebola virus in susceptible cells. Moreover, DC-
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SIGN acts as a trans-receptor since Ebola particles might be captured by DC-SIGN-
expressing monocyte-derived DCs to be further transmitted to recipient cells (Alvarez 
et al., 2002). Although all predicted in vitro DC-SIGN functions have not been con-
firmed in in vivo studies, DC-SIGN was predicted to participate in the dissemination of 
the virus at the first moments of the infection. Therefore, over the years many different 
antiviral strategies based on carbohydrate compounds targeting DC-SIGN were used 
to block Ebola virus-DC-SIGN interaction. Ebola group of filoviruses comprises five 
subtypes: Zaire, Sudan, Reston, Cote dÍvoire, Bundibugyo, among which Ebola Zaire 
strain shows the highest mortality rate (50-90%), whereas Ebola Reston has never been 
associated with human disease (Usami et al., 2011). The phenomenon of Ebola Reston 
being non-fatal to humans has not been fully clarified yet. It has been speculated that 
envelope glycoproteins of both strains might be responsible for these differences in vi-
ral pathogenesis. This hypothesis was raised after a number of in vitro studies, which 
analyzed the possible role of immunosuppressive motifs (Becker, 1995; Volchkov et al., 
1992; Yaddanapudi et al., 2006), efficiency of cleavage by furin (Neumann et al., 2002; 
Neumann et al., 2007) or cytotoxicity (Alazard-Dany et al., 2006; Volchkov et al., 2001; 
Yang et al., 2000). However, these speculations have not been confirmed yet in a prop-
er in vivo model. 
 
The human immunodeficiency virus (HIV) is a lentivirus that belongs to the family of 
retroviruses. HIV is responsible for causing acquired immunodeficiency syndrome 
(AIDS) that is characterized by progressive failure of the immune system and appear-
ance of life-threatening opportunistic infections (Coffin, 1992; Coffin et al., 1997; Douek 
et al., 2009; Weiss, 1993). HIV infection is characterized by diminished counts of CD4+ T 
cells, an increase in CD8+ T cells and reduced mitogen-induced proliferative capacity of 
lymphocytes (Gottlieb et al., 1981; Masur et al., 1981). Most of HIV-1-infected patients 
show high plasma viral load and the loss of CD4+ T cells along the course of HIV-1 in-
fection in case of absence of antiretroviral therapy (Lassen et al., 2009). The majority of 
antiretroviral-untreated individuals eventually develops immunodeficiency of immune 
system and dies from AIDS-related complications in approximately 10-year time after 
becoming infected. However, a very small percentage of untreated individuals remain 
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clinically and/or immunologically stable for years (Cao et al., 1995; Munoz et al., 1995). 
The term of “long-term non-progressors (LTNP)” was used in case of people that were 
able to maintain normal CD4+ T cell counts for prolonged periods (>10 years). By viro-
logical criteria, a small subset of individuals (less than 1% of infected population) 
called “elite controllers (EC)” are able to maintain viral loads undetectable (<50 copies 
HIV RNA/ml) (Deeks and Walker, 2007). The International HIV Controller Consortium 
defined the second group of HIV controllers called viremic controllers (VC), individu-
als who maintain RNA levels below 2000 copies of viral RNA per ml in the absence of 
ART. The factors associated with HIV control in vivo have not been fully defined yet, in 
part due to the fact that HIV controllers form a very heterogeneous population (Lefrere 
et al., 1997). Individuals destined to become HIV controllers seem to have less symp-
tomatic primary infections as compared with those destined to remain viremic (Madec 
et al., 2005a), which suggest that complex virus and host interactions leading to pro-
longed control of viral replication play already an important role during the earliest 
phases of HIV disease (Altfeld et al., 2006). It has been suggested that infection with 
attenuated or defective virus may lead to no progression (Deacon et al., 1995). Several 
studies have shown that HIV envelopes derived from EC demonstrated reduced entry 
fitness (Casado et al., 2013; Lassen et al., 2009; Miura et al., 2009). Nevertheless, the 
most consistent factor responsible for virological control is a vigorous cellular re-
sponse. It has been shown that the function of cytotoxic CD8+ T cells is clearly higher in 
controllers as compared with non-controllers (Migueles et al., 2002). HLA molecules 
are involved in immune system recognition of virally infected cells and the presence of 
several different HLA alleles have been described to be associated with effective HIV 
control, such as HLA-B57, HLA-B5801, HLA-B27, HLA-B14, HLA-A32 (Gao et al., 2001; 
Geczy et al., 2000; Hendel et al., 1999; Kaslow et al., 1996; Keet et al., 1999; 
Magierowska et al., 1999; McNeil et al., 1996; Saah et al., 1998). Although, elite control 
of HIV infection has been associated with a number of factors, none of these features 
alone might predict elite control (Walker, 2007). 
 
DC-SIGN captures HIV-1 particles through its high-affinity interactions with HIV-1 
envelope glycoprotein. DCs are thought to facilitate viral dissemination through HIV-1 
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capture at mucosal site and transmission to secondary lymphoid tissues (Haase, 2005, 
2010; Pope et al., 1994; Shattock and Rosenberg, 2012; Steinman et al., 2003). The DC-
mediated HIV infection can occur through several distinct processes taking place con-
currently, including trans-infection through infectious synapse, trans-infection through 
exosomes or cis-infection following de novo production of viral particles in DCs (Wu 
and KewalRamani, 2006). Unprotected sexual intercourse is the most common global 
mode of HIV-1 transmission (Royce, 1997) therefore the development of HIV-1 preven-
tive strategies at mucosal site as a first line of contact with pathogens is the prior sub-
ject of interest. The attempts to develop an efficient vaccine against chronic viruses 
have failed so far, mainly due to the immunological escape mechanisms of these virus-
es or the lack of conserved epitopes of viruses involved in acute infections (Letvin, 
2006). Condom use and behavioral interventions have been only partially successful in 
slowing the spread of HIV-1 infection worldwide. There is an urgent need for addi-
tional interventions to prevent new infections, such as the development of female-
controlled topical formulations of anti HIV-1 compounds that could be used as a gel, 
cream, suppository before sexual intercourse (Elias and Coggins, 1996).  
 
2. Objectives 
 
The aim of our study was to standardize and evaluate a cellular model of viral infec-
tion mediated by DC-SIGN: (a) consistency of the infection model using different cell 
lines expressing the DC-SIGN receptor, (b) standardization of the DC-SIGN expression 
level and the infective titre of recombinant retroviruses for infection assays and (c) es-
tablish the proper conditions for the DC-SIGN mediated cis-infection and trans-
infection assays. We wanted to study the utility of the DC-SIGN infection model as a 
screening platform of antiviral strategies targeting DC-SIGN and analyze the potential 
antiviral effect of compounds such as glycodendritic structures, tetravalent dendrons, 
dendrimers-based compounds, glycofullerenes and glycodendrinanoparticles. We also 
evaluated the DC-SIGN-mediated trans-infection by the pathogenic and non-
pathogenic Zaire and Reston strains of Ebola virus as well as the implication of DC-
SIGN trans-infection in HIV-1 virological control. 
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3. Material and Methods 
 
3. 1. Cloning of HIV-1 envelopes 
The viral cDNA was synthesized by using SuperScriptIII System. The envelope sequence of 
HIV-1 was amplified by nested PCR using Expand High Fidelity PCR System and further 
cloned into pcDNA3.1/V5-His TOPO. Sequencing of HIV-1 envelopes was performed by using 
of BigDye Terminator v3.1 chemistry and the sequences were analyzed by Geneious Bioinfor-
matics Software. 
3. 2. Isolation of Peripheral Blood Mononuclear Cells (PBMCs) and generation of monocyte-
derived Dendritic Cells (DCs) 
PBMCs were isolated from buffy coats from healthy donors by Ficoll-Paque density-gradient 
centrifugation. The monocytes were then cultured in RPMI medium supplemented with cyto-
kines GM-CSF (200 ng/ml) and IL-4 (10 ng/ml). For the proper differentiation of immature 
monocyte-derived DCs, cells were incubated for 7 days and subsequently activated with cyto-
kines on a day 2 and 5. 
3. 3. Production of recombinant viruses 
Recombinant viruses were produced in 293 T cells by standard Calcium Chloride transfection 
protocol. The viral construction was pseudotyped with virus envelope (Ebola, HIV-1, VSV) and 
expressed luciferase as a reporter of the infection (Yang et al., 1999). 
3. 4. Infection in cis assay 
Infection in cis was performed on Jurkat cells expressing receptor DC-SIGN. Jurkat DC-SIGN+ 
(2.5–5 x 105) were incubated with carbohydrate compounds in 96-well suspension plates for 30 
min at RT and then challenged with 5000-10000 TCID of recombinant viruses for 48 h. 
3. 5. Infection in trans assay (Ebola virus) 
Jurkat DC-SIGN+ cells (2.5-5 x 105) were pre-incubated for 20 min at RT with carbohydrate com-
pounds. Then, the cells were challenged with 5000-10000 TCID of recombinant viruses for 2 h at 
RT with rotation. After pulsing with pseudoviruses, cells were intensively washed and co-
cultivated with adherent HeLa cells (105 cells/ well) for 48 h. 
3. 6. Infection in trans assay (HIV-1) 
Infection in trans was performed on Jurkat DC-SIGN+ or Raji DC-SIGN+ (5 x 105), which can cap-
ture and transmit HIV-1 virus to susceptible cells. Cells were pulsing with HIV-1 pseudoviruses 
for 3 h at 37º C. After challenging with recombinant viruses, cells were washed and co-
cultivated with susceptible U87-R5/X4 cells for 48 h. 
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3. 7. Carbohydrate-based compounds tested in the experiments of infection in cis and infec-
tion in transThe blocking effect of the following antivirals was studied: glycodendritic struc-
tures, tetravalent dendrons, dendrimers-based compounds, glycofullerenes and glycodendri-
nanoparticles. 
 
4. Results 
 
4. 1. DC-SIGN infection model 
The model of infection in cis, based on Jurkat DC-SIGN+/Jurkat cells, clearly showed 
dependence of the Ebola virus cell entry on DC-SIGN presence (ratio 2567.8). The cis-
infection of both cell lines by DC-SIGN independent VSV-G-pseudotyped retroviruses 
was at very similar level (ratio 0.96). The model of trans-infection confirmed the results 
obtained in the cis-infection experiment, revealing higher transmission of Ebola infec-
tion to susceptible cells by Jurkat DC-SIGN+ as compared with negative cells (ratio 
870.4). The trans-infection obtained with VSV-G-pseudotyped viruses was comparable 
between both cell lines. 
 
4. 2. DC-SIGN as a model of antiviral screening strategies 
The antiviral activity of carbohydrate compounds was tested using recombinant viral 
particles presenting Ebola virus GP. The possibility of blocking DC-SIGN receptor was 
examined in the experiments of cis-infection and trans-infection in the presence of car-
bohydrate-based compounds at different final concentrations. 
 
Glycodendritic structures 
The IC50 of compound RR114 was 3.6 µM and the IC50 for compound RR115 was 2.8 
µM. Although both compounds showed similar efficacy in the infection in cis, in the 
experiment of infection in trans compound RR115 was more potent than compound 
RR114 (IC50 of 7 µM vs IC50 of 52.4 µM). 
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Tetravalent dendrons 
The results obtained in the cis infection experiment revealed that the tetravalent sys-
tems presenting four copies of pseudomannotrioside (compound 14) showed a potency 
of 1 order of magnitude higher than the tetravalent systems presenting four copies of 
linear pseudomannobioside (compound 12). The IC50 of compound 14 was 106.5 nM 
and the IC50 of compound 12 was 1.4 µM. The results obtained in the trans-infection 
experiment were similar to the results from infection in cis. The tetravalent dendron 14 
with 4 copies of pseudomannotrioside showed an IC50 of 203 nM. The tetravalent den-
dron 12 with 4 copies of pseudomannobioside was 1 order of magnitude less potent 
with an IC50 of 1.22 µM. 
 
Dendrimer-based compounds 
Dendrimer-based compounds bearing 30-32 pseudomannotriosides (G3(pseudotri)32) 
or 30-32 pseudomannobiosides (G3(pseudodi)32) showed no difference in their potency 
of inhibition of EBOV GP pseudotyped particles cell entry. The IC50 value of compound 
G3(pseudotri)32 was 17.12 nM and the IC50 value of compound G3(pseudodi)32 was 
27.21 nM. The results obtained in the trans-infection experiment were similar to the re-
sults from infection in cis showing the IC50 values of the same order of magnitude. The 
IC50 of multivalent pseudomannobioside was 62 nM. The IC50 of multivalent pseudo-
mannotriose was 31.51 nM. 
 
Glycofullerenes 
Glycofullerene displaying with 12 mannoses showed the IC50 of 2 µM. The IC50 for the 
fullerene presenting 36 mannoses was 68 µM. The introduction of a longer spacer in 
glycofullerene with 36 mannoses had a very important effect on recovering the activity 
of this compound with the IC50 of 286.4 nM. Galactosyl fullerene, as expected, was not 
able to inhibit the infection process mediated by DC-SIGN. 
 
Glycodendrinanoparticles 
Compound Qβ was used in the experiment as a control of the impact of this new type 
of structures on the results in the infection in cis. The highest concentration of com-
Thesis summary (ENG) 
 
156 
 
pound Qβ (25 nM) used in the experiment could block infection in ~30-40%. The same 
concentration (25 nM) of compound Qβ-(Man3)180 could block infection in 50-60%. The 
concentration of 25 nM of compound Qβ-(Man9)180 could efficiently block infection in 
~90-100%. IC50s values were estimated with a 95% CI (7.7-24.3 nM for Qβ-(Man3)180 and 
404.2 pM–4.1 nM for Qβ-(Man9)180). Compounds Qβ and Qβ-(Man9)180 were tested at 
concentrations of 25 nM, 5 nM, 1 nM in the infection in cis experiment of DCs. Com-
pound Qβ-(Man9)180 displayed potent activity, inhibiting infection by >80% at 5 nM and 
>95% at 25 nM (estimated IC50~2 nM). 
 
4. 3.The role of DC-SIGN in Ebola pathogenesis 
 
The differences in DC-SIGN-mediated infection by Ebola Zaire and Ebola Reston were 
first studied in the trans-infection experiment in Jurkat DC-SIGN+/Jurkat cellular sys-
tem. The difference in the mean ratio in the trans-infection experiment between EBOZ 
and EBOR was statistically significant (p=0.0034). The differences between the infection 
levels of EBOZ and EBOR pseudoparticles were then studied in the DC-SIGN-
mediated trans-infection by primary DCs to HeLa cells. Results obtained in the experi-
ment revealed statistically significant differences between EBOZ and EBOR (p=0.0084). 
The cis-infection of immature DCs did not confirm results of both trans-infection exper-
iments (p=0.5479). 
 
4. 4. The role of DC-SIGN in HIV-1 pathogenesis 
 
Analysis of trans-infection ratios in the groups of patients: EC, VC and patients with 
chronic HIV-1 infection  
The results of the trans-infection experiments were compared between different groups 
of patients to verify if the virological control might have any association with the ratio 
of trans-infection. The results obtained in the analysis showed statistically significant 
differences between HIV-1 controllers and patients with chronic HIV-1 infection with 
the mean controllers=45.49 vs CI=20.42 (<p=0.0001). These differences were further veri-
fied separately between the subgroups of HIV-1 controllers (EC and VC) to determine 
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if the type of virological control could have influence DC-SIGN-mediated trans-
infection result. The data obtained in this study clearly showed that the group of pa-
tients that was associated with higher DC-SIGN trans-infection was the subgroup of 
VC. Significantly higher trans-infection ratio was observed in case of viremic control-
lers as compared with chronically infected patients (VC=56.6 vs CI=20.42, <p=0.0001). 
Interestingly, there was also a statistically significant difference in trans-infection ratio 
between VC and EC with the mean VC=56.6 vs EC=28.02 (p=0.0007). 
 
Analysis of differences in HIV-1 envelope sequence and trans-infection ratio be-
tween elite controllers, viremic controllers and patients with chronic HIV-1 infection 
For the identification of factors responsible for the differences in the ratio of trans-
infection, the length and PNGS in: gp160, gp120, gp40, V1-V5 were analyzed between 
EC, VC and CI. No significant differences were found in V1-V4 regions with the excep-
tion of V5 (Fig. 57). The length of V5 was significantly shorter in the group of HIV-1 EC 
as compared with CI (EC=12.33 vs CI=14.13aa, p=0.0325). The group of VC also demon-
strated a trend towards shorter V5 loop (VC=12.63 aa vs CI=14.13 aa, p=0.0858). The 
number of PNGS in V5 was higher in the group of patients with chronic HIV-1 infec-
tion (EC=1 PNGS, VC=1.5 PNGS and CI=1.813, EC vs CI p=0.0072). Although the analy-
sis of the HIV-1 envelope sequences between the patients showed statistically signifi-
cant differences in V5 loop, there was no correlation found between the trans-infection 
ratio and the length of V5 (r=0.0925, p=0.6267) or the number of PNGS in V5 (r= -0.0895, 
p=0.6382) 
 
5. Discussion 
 
5. 1. DC-SIGN as a model of antiviral screening strategies 
 
Although in vitro DC-SIGN models are not sufficient for understanding the physiologi-
cal role of DC-SIGN, the cellular model based on DC-SIGN+ cells might function as a 
useful model of antiviral screening platform. Infection by Ebola virus in cellular lines is 
dependent of the presence of DC-SIGN on the cell surface. The cellular model used in 
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this study for antiviral screening was based on Jurkat DC-SIGN+ cells, the human T cell 
lymphoblast-like cell line. Since Ebola virus does not infect T-lymphocytes, its entry to 
Jurkat cells is absolutely dependent on the interaction with DC-SIGN. 
 
The presented above cellular system might serve as an antiviral screening platform to 
test different carbohydrates strategies targeting DC-SIGN. This receptor recognizes 
mannosylated and fucosylated oligosaccharides presented in a multivalent manner on 
the surface of several pathogens. Therefore, the synthesis of multivalent carbohydrate 
systems is necessary for the efficient interaction with this receptor as well as for the ef-
fective competition with the natural ligands. The results obtained in the experiments 
performed within this thesis, could contribute in a very fast and effective way in the 
first studies of antiviral screening based on different strategies: tetravalent dendrons, 
dendrimer-based compounds, glycofullerenes and glycodendrinanoparticles. Tetrava-
lent dendrons and dendrimers-based compounds are the combination of new pseudo-
mannoside carbohydrate mimic and the potency of multivalent presentation. The im-
portance of the valency was evaluated by the presentation of the same pseudosaccha-
ride ligands on the tetravalent system presenting 4 copies of the ligand and on the mul-
tivalent scaffolds displaying 30-32 of selected ligands. The IC50 values obtained for the 
multivalent systems were around 20 nM, which showed that their inhibitory potency 
was between 1 to 2 orders of magnitude higher than that of corresponding tetravalent 
systems (Luczkowiak et al., 2011). The synthesis of glycofullerenes provided the 
achievement of even higher valency of 36 mannoses. These compounds were synthe-
sized by combining glycodendrons with a fullerene allowing thus globular presenta-
tion of carbohydrates. The results obtained in the infection in cis experiment highlight-
ed the importance of combination of an adequate scaffold to achieve the multivalency 
with the right ligand accessibility and flexibility. The inhibitory effect of glycofullerene 
presenting 36 mannoses was decreased as compared with glycofullerene displaying 12 
mannoses, however the subsequent introduction of longer spacer to this glycofullerene 
recovered inhibitory potency showing IC50 of 286.4 nM (10 times more potent than gly-
cofullerene with 12 mannoses and 340 times more potent than glycofullerene with 36 
mannoses containing short linker) (Luczkowiak et al., 2013). The highest valency con-
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structs were achieved in case of glycodendrinanoparticles. This design was based on 
the multivalent assembly of protein monomers (glycodendriproteins) carrying polyva-
lent glycan motifs (glycodendrons). In this way these constructs displayed many gly-
cans in a precise manner and created well-defined single entities of up to 32 nm in di-
ameter. Glycodendrinanoparticles showed antiviral activity in the low nanomolar to 
picomolar range (Ribeiro-Viana et al., 2012). 
 
5. 2. DC-SIGN in Ebola virus pathogenesis: DC-SIGN-mediated trans-infection in 
pathogenic and non-pathogenic strains of Ebola virus 
 
Ebola viruses cause a severe, often fatal disease consisting in a highly lethal hemor-
rhagic fever syndrome (Peters et al., 1996). Ebola virus strain Zaire is the virus variant 
with the highest mortality rate being in the range 50-90%. In contrast to the Zaire 
strain, Ebola Reston does not cause a disease in humans despite a number of docu-
mented infections during animal epizootics (Barrette et al., 2009; Miranda et al., 1999). 
The molecular basis for this difference in their pathogenesis remains unclear. Binding 
of Ebola virus GP to different cellular lectins has been previously shown to augment 
virus infection, both in cis and in trans (Alvarez et al., 2002). In our study, we have used 
recombinant particles expressing two Ebola virus envelope glycoproteins (EBOZ and 
EBOR) to study the potential role of DC-SIGN in the pathogenesis of both Ebola vari-
ants. The DC-SIGN-mediated infection was verified in the experiments of trans-
infection Jurkat DC-SIGN+/Jurkat, cis-infection of primary DCs and trans-infection 
DCs/HeLa cells. The first experiment of the trans-infection in cellular model Jurkat DC-
SIGN+/Jurkat revealed the significant differences in the mean ratio of the trans-infection 
experiment between Ebola Zaire and Ebola Reston (p=0.0034). The mean ratio of EBOR 
was about three times higher than the ratio of EBOZ (35.97 vs 99.64). The results ob-
tained in the trans-infection experiment based on human immune cells (DCs) have con-
firmed the results of trans-infection in the cell line system. The difference between the 
transmitted infection by Ebola Zaire and Ebola Reston pseudoparticles to susceptible 
HeLa cells was statistically significant (p=0.0084). Both of performed experiments 
demonstrated statistical significance of higher DC-SIGN-mediated trans-infection of 
Thesis summary (ENG) 
 
160 
 
EBOR as compared with EBOZ. Despite significant differences in EBOZ/EBOR usage of 
DC-SIGN in the trans-infection experiment, the direct infection of immature DCs did 
not give any significant result. Our results found the association between the Ebola 
Reston and a higher trans-infection ratio mediated by DC-SIGN. This finding might 
raise a hypothesis that although DC-SIGN receptor participates effectively in the cell 
entrance, in vivo it plays apparently more important role in the proper immune system 
activation. DC-SIGN may be responsible for virus capture, destruction and further 
presentation of its antigens to cells causing effective immunological control. DC-SIGN 
therefore, although able to capture effectively Ebola virus particles, might serve more 
as a host defence factor rather than pathogen escape receptor. Therefore the higher lev-
el of DC-SIGN-mediated entry of Ebola Reston might suggest that overall DC-SIGN 
might be more implicated in antiviral responses. The results obtained in performed ex-
periments somehow resemble the results from the Schaefer et al. study, in which mice 
expressing human DC-SIGN survived longer than wild-type mice after the infection 
with Mycobacterium tuberculosis (Schaefer et al., 2008). 
 
5. 3. DC-SIGN in HIV-1 pathogenesis: Implication of DC-SIGN-mediated trans-
infection in HIV-1 virological control 
 
The receptor DC-SIGN was initially cloned and characterized as a receptor for the HIV 
envelope glycoprotein gp120. In fact, it was precisely shown that gp120 affinity for DC-
SIGN is even higher than for CD4 receptor, a classical HIV-1 entry receptor (Curtis et 
al., 1992). Years before the discovery of DC-SIGN, studies of Cameron et al. and Pope et 
al. showed that DC pulsed with HIV-1 endorsed infection of co-cultivated T cells 
(Cameron et al., 1992; Pope et al., 1994). Shortly after the identification of DC-SIGN, 
Geijtenbeek et al. defined this phenomenon as HIV-1 trans-infection (Geijtenbeek et al., 
2000b). It has been clearly shown that DC-SIGN binds carbohydrate structures, such as 
mannose-containing glycoconjugates, expressed on the surface of different pathogens 
(den Dunnen et al., 2010). The envelope of HIV-1 is one of the most highly glycosylated 
proteins in nature, containing 18-32 PNGS in gp120. Therefore, many different in vitro 
studies evidently have shown the high affinity of HIV-1 envelopes to cells expressing 
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DC-SIGN receptor. DC-SIGN does not function as a direct HIV-1 receptor but it works 
efficiently in the viral transmission from periphery to secondary lymphoid tissues. It 
has been demonstrated that HIV-1 particles bound to DC-SIGN are remarkably stable 
and retain infective for prolonged periods (Geijtenbeek et al., 2000b). Despite of all 
proposed roles of DC-SIGN based on in vitro models, the confirmation of the physio-
logical behaviour of DC-SIGN in vivo should be further clarified. 
 
In our study, we analyzed the sequences from 6 HIV-1 elite controllers, 8 HIV-1 vire-
mic controllers and 16 HIV-1 chronic infections for DC-SIGN-mediated trans-infection. 
The ratio of the trans-infection varied significantly among all HIV-1 envelopes showing 
correlation of DC-SIGN ratio with virological control in case of both cellular systems 
tested (Raji DC-SIGN+/Raji and Jurkat DC-SIGN+/Jurkat). The analysis of the results 
obtained from Raji DC-SIGN+/Raji system revealed overall significant difference in the 
ratio of DC-SIGN-mediated trans-infection between HIV-1 controllers and patients 
with chronic HIV-1 infection (Controllers=45.49 vs CI=20.42, p<0.0001) (Fig. 55). Inter-
estingly, the subgroup of HIV-1 viremic controllers demonstrated the highest DC-
SIGN-mediated trans-infection as compared with EC (VC=56.6 vs EC=28.02, p=0.0007) 
and CI (VC=56.6 vs CI=20.42, p<0.0001) (Fig. 56). EC showed a trend towards more effi-
cient trans-infection as compared with CI (p=0.1331), however much less efficient when 
compared with VC (Fig. 56). The overall result of the trans-infection experiment was 
subsequently confirmed by trans-infection experiment in Jurkat DC-SIGN+/Jurkat cellu-
lar system showing significantly higher DC-SIGN-mediated trans-infection as com-
pared with chronically HIV-1 infected patients (Controllers=32.84 vs CI=17.4, p=0.0233). 
The low association between EC and efficient DC-SIGN-mediated trans-infection might 
suggest that other factors, such as reduced viral fitness (Casado et al., 2013; Lassen et 
al., 2009; Miura et al., 2009) or extremely vigorous CD8+ T cell response (Goulder and 
Watkins, 2004; Migueles et al., 2002) account for virological control in this subgroup of 
patients. Our results have confirmed the frequent low fitness linked to EC envelopes. 
In our study, a considerable group of EC HIV-1 envelopes (10 out of 16) could not be 
tested in the trans-infection experiments. All of 10 HIV-1 envelopes were confirmed as 
not defective by sequencing, however in cellular assay 4 out of 10 were observed non-
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funtional and 6 out of 10 had the infectivity continuously below dynamic range re-
quired for the infection experiments thus they were excluded from our analysis. Viro-
logical control in the subgroup of HIV-1 viremic controllers is less well understood. It 
might be possible that this subgroup of patients have stronger innate immune re-
sponse, which can influence virological control. VC have used DC-SIGN more efficient-
ly as compared to other groups of patients, therefore it might be hypothesized that DC-
SIGN in these patients play a potential role in antigen capture and further presentation 
for the proper immune system activation. 
 
To access the information about the basis of these differences in DC-SIGN-mediated 
trans-infection, the HIV-1 envelope length and PNGS number were compared between 
EC, VC and CI. Although it has been demonstrated that the envelope glycoprotein 
from HIV controllers is shorter and contains fewer PNGS (Bailey et al., 2006a), in our 
small study the virus sequences of HIV-1 controllers and patients with chronic infec-
tion were of similar length and containing comparable number of PNGS in most of 
gp160 regions with the only exception of V5 loop (Fig. 57). However, further analysis 
has shown that V5 length and V5 PNGS did not have any association with DC-SIGN 
trans-infection ratio (Fig. 58). Thus it could be suggested that these changes occurred in 
the natural course of HIV-1 infection, possibly in the response to the pressure caused 
by NAbs. It has been previously shown that HIV-1 envelope length and glycan num-
bers have a tendency to increase over the course of HIV-1 epidemic (Bunnik et al., 2010; 
Bunnik et al., 2008). Our analysis of the data obtained from HIV Los Alamos Data base 
confirmed those studies showing the apparent evolution of the HIV-1 envelope glyco-
proteins towards longer and containing more PNGS (Supplementary material 1). 
Therefore the change in V5 towards longer loop containing more N-glycans and the 
increase in overall PNGS number in all variable loops could be explained by the HIV 
evolution pattern and did not have association with more efficient usage of DC-SIGN 
in the trans-infection experiment.  
 
The results of this study might contribute to better understanding of DC-SIGN receptor 
role in HIV-1 pathogenesis. We indicated the substantial usage of DC-SIGN receptor in 
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the trans-infection experiment by HIV-1 controllers, especially in the subgroup of VC. 
Those results were verified in two cellular systems and both showed the association of 
higher trans-infection ratio with virological control. The HIV-1 envelopes of VC have 
used DC-SIGN more efficiently as compared with EC and patients with chronic HIV-1 
infection. It is possible that virological control in the group of EC results from reduced 
viral fitness or more effective adaptive cellular response rather than the role of DC-
SIGN in the first steps of virus infection. However, in the group of VC it might be pos-
sible that more robust involvement of this receptor is associated with antigen presenta-
tion and more effective immune system response rather than virus dissemination lead-
ing to better cellular control of the infection resulting in more efficient virological con-
trol. The HIV-1 virological control is characterized by maintaining low viral loads in 
the absence of antiretroviral therapy. Thus the low viral load and the lack of active rep-
lication determine that envelope sequences in HIV controllers have small loop and few 
number of N-glycans (Bailey et al., 2006a). Although DC-SIGN shows strong affinity 
for mannose-containing moieties, our study has confirmed that the number of PNGS is 
not the fundamental factor associated with stronger DC-SIGN bindings. The compari-
son of N-glycosylation pattern did not show any statistically significant differences be-
tween the number of glycans in VC as compared with EC and CI, therefore higher DC-
SIGN-mediated trans-infection in the subgroup of VC could not be explained by the 
quantitative occurrence of N-glycosylation. It might be thus suggested that DC-SIGN 
binding involves complex pattern of specific N-glycosylation and not the amount of 
glycans on the envelope surface. Our data demonstrated that HIV-1 envelopes of con-
trollers although containing generally lower number of glycans on the virus surface, 
use DC-SIGN more effectively than HIV-1 chronic isolates. In this respect a viral evolu-
tion towards less use of DC-SIGN has been reported to occur during clinical follow up, 
specially between acute vs late-stage strains within the same individuals suggesting a 
negative DC-SIGN selection along the time of infection (Borggren et al., 2008).  
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6. Conclusions 
 
1) The infection model based on cell lines expressing DC-SIGN is a consistent 
platform to study direct viral entry (Ebola virus) and the trans-infection phe-
nomenon (Ebola virus and HIV) since the infection events depend almost exclu-
sively on DC-SIGN-viral interaction. 
 
2) The DC-SIGN infection model is a useful model of an antiviral screening platform to 
test carbohydrates strategies targeting DC-SIGN. 
 
3) The inhibition of DC-SIGN-mediated infection by carbohydrate-based compounds 
depends strongly on the multivalency of glycan presentation. 
 
4) The most potent antiviral activity was obtained by glycodendrinanoparticles show-
ing an effective antiviral activity in the picomolar to low nanomolar concentration 
range. Multivalency depends on the presentation of 1620 glycan moieties generating a 
large surface of interaction (30 nm in diameter). 
 
5) Despite the role of DC-SIGN in Ebola virus entry and potential initial dissemination, 
we found significantly higher DC-SIGN trans-infection by the non-pathogenic Ebola 
Reston strain. This finding could indicate that in Ebola virus infection DC-SIGN is in-
volved in a more efficient immune control. 
 
6) The envelope glycoproteins of HIV-1 virological controllers use DC-SIGN more effi-
ciently in the trans-infection experiment as compared with patients with chronic HIV-1 
infection. 
 
7) DC-SIGN-mediated trans-infection is not associated with the amount of N-glycan 
residues in HIV-1 envelope glycoprotein. Probably a more complex pattern of specific 
N-glycosylation is responsible for this mechanism.  
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8) In the group of VC, the observed significantly higher trans-infection could indicate 
that DC-SIGN participates in viral detection, presentation and immune control more 
than dissemination as in the case of observation of more efficient DC-SIGN-mediated 
trans-infection by Ebola Reston. 
 
9) The EC group did not show the same DC-SIGN trans-infection use as observed in 
VC. In this group of patients virological control could be more associated with factors 
such as viral fitness or vigorous CTL response. 
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1. Introducción 
 
El sistema inmune de los mamíferos se compone de dos tipos de inmunidad que se uti-
lizan como protección ante las infecciones: inmunidad innata y adaptativa (Medzhitov 
and Janeway, 1999). La respuesta del sistema inmune innato es la primera línea de de-
fensa del organismo contra los patógenos, es inmediata y está genéticamente progra-
mada para detectar las características de los microorganismos invasores. Con respecto 
a la inmunidad adaptativa: esta es muy específica y es responsable de la eliminación de 
los agentes patógenos en la fase tardía de la infección así como de la generación de 
memoria inmunológica (Akira et al., 2006). Los miembros de la familia de las células 
dendríticas (DCs) tienen un papel crucial en la traducción de la información innata en 
inmunidad adaptativa (Reis e Sousa, 2001). Las DCs inmaduras expresan los receptores 
que median endocitosis de adsorción, incluyendo los receptores tipo Toll y las lectinas 
tipo C. DC-SIGN es un receptor tipo II de las lectinas tipo C, que pertenece a la familia 
de los receptores transmembrana. DC-SIGN juega un papel importante en la inmuni-
dad a través de regulación de la migración de las DCs, activación de las células T,  la 
captura y presentación de los antígenos (Geijtenbeek et al., 2000c). El receptor DC-
SIGN fue identificado inicialmente como factor de la unión del VIH-1, que capturaba la 
envoltura viral y facilitaba la infección (Curtis et al., 1992; Geijtenbeek et al., 2000c). 
DC-SIGN contiene un dominio de reconocimiento de carbohidratos (CRD), un tallo ex-
tracelular, un dominio transmembrana y un dominio N-terminal citoplasmático 
(Geijtenbeek et al., 2000c). El CRD del DC-SIGN muestra una alta afinidad por las mo-
léculas de manosa y fucosa (van Kooyk and Geijtenbeek, 2003). DC-SIGN reconoce las 
glicoproteínas que contienen un número relativamente alto de los N-carbohidratos 
presentes en la superficie de diferentes patógenos (Geijtenbeek and van Kooyk, 2003). 
DC-SIGN se une al VIH-1, virus del Ébola, citomegalovirus, virus de la hepatitis c, vi-
rus del dengue, Helicobacter pylori, Klebsiella pneumoniae, Mycobacterium tuberculosis, 
Candida albicans, Leishmania, Schistosoma mansoni.  
 
DC-SIGN no es el receptor principal del virus de Ébola porque se ha descrito anterior-
mente que muchas diferentes líneas celulares que carecen de DC-SIGN se pudieron 
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infectar con este virus (Wool-Lewis and Bates, 1998; Yang et al., 1998). Se ha demostra-
do que la expresión de DC-SIGN aumenta el nivel de la infección con el virus de Ébola 
en células susceptibles. Por otra parte, DC-SIGN actúa como un receptor en trans, un 
fenómeno que consiste que las partículas del  virus Ébola pueden ser capturadas por 
las DCs que expresan DC-SIGN y transmitidas a las células receptoras (Alvarez et al., 
2002). Los ensayos in vitro sugerían que DC-SIGN participa en la difusión del virus en 
los primeros momentos de la infección, por lo tanto, en los últimos años se diseñaron 
diferentes estrategias antivirales basados en compuestos de carbohidratos para blo-
quear la interacción del Ébola con DC-SIGN. Se ha descrito que el grupo de filovirus 
del Ébola comprende cinco subtipos: Zaire, Sudán, Reston, Costa de Marfil, Bundibu-
gyo, entre los cuales la cepa del Ébola Zaire muestra la tasa de mortalidad más alta (50-
90%), mientras que la del Ébola Reston nunca ha sido asociada con la enfermedad hu-
mana (Usami et al., 2011). El fenómeno de las diferencias en la patogénesis del EBOZ y 
EBOR no ha sido completamente aclarado todavía. Se ha especulado que las glicopro-
teínas de la envuelta de las dos cepas pueden ser responsables de estas diferencias en 
la patogénesis. Esta hipótesis surgió después de la realización de una serie de estudios 
in vitro, donde se investigó el posible papel de los elementos inmunosupresores 
(Becker, 1995; Volchkov et al., 1992; Yaddanapudi et al., 2006), la eficiencia de escisión 
por furina (Neumann et al., 2002; Neumann et al., 2007) y la citotoxicidad (Alazard-
Dany et al., 2006; Volchkov et al., 2001; Yang et al., 2000). Sin embargo, estas especula-
ciones no han sido confirmados aún en un modelo in vivo. 
 
El virus de la inmunodeficiencia humana (VIH) es un lentivirus que pertenece a la fa-
milia de los retrovirus. El VIH es responsable de la causa del síndrome de inmunodefi-
ciencia adquirida (SIDA) caracterizado por un fallo progresivo del sistema inmunitario 
que resulta en infecciones oportunistas y tumores (Coffin, 1992; Coffin et al., 1997; 
Douek et al., 2009; Weiss, 1993). El VIH fue descubierto por el grupo de Luc Montag-
nier y Françoise Barré-Sinoussi en 1983 (Barresinoussi et al., 1983), quienes en 2008 re-
cibieron el Premio Nobel de Medicina por este descubrimiento. La infección por VIH se 
caracteriza por la disminución de células T CD4+, un aumento en las células T CD8+ y 
una reducción de la capacidad proliferativa inducida por mitógenos de los linfocitos 
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(Gottlieb et al., 1981; Masur et al., 1981). La mayoría de los pacientes infectados por el 
VIH-1 muestran una alta carga viral en plasma y la pérdida de células T CD4+ a lo largo 
del curso de la infección por VIH-1 en caso de ausencia de la terapia antirretroviral 
(Lassen et al., 2009). Gran parte de los pacientes no tratados desarrollan la inmunodefi-
ciencia del sistema inmunológico y mueren a causa de las complicaciones relacionadas 
con el SIDA en un tiempo aproximado de 10 años tras haberse infectado. Sin embargo, 
un porcentaje muy pequeño de individuos no tratados permanecen clínicamente y/o 
inmunológicamente estables durante años (Cao et al., 1995; Munoz et al., 1995). El tér-
mino de no-progresadores a largo plazo (LTNP) se utiliza en el caso de las personas 
que fueron capaces de mantener el recuento de células T CD4+ normales por períodos 
prolongados (>10 años). Un pequeño subgrupo de los individuos (menos del 1% de la 
población infectada) denominados "controladores de élite (EC)" son capaces de mante-
ner una carga viral indetectable (<50 copias de ARN del VIH/ml) (Deeks and Walker, 
2007). El Consorcio Internacional de los Controladores del VIH definió el segundo 
grupo llamados “controladores virémicos (VC)”, que pueden mantener los niveles de 
ARN por debajo de 2000 copias de virus por ml en ausencia de ART. Los factores res-
ponsables del control virológico in vivo no han sido aún bien definidos. Los individuos 
destinados a ser controladores del VIH parecen tener infecciones primarias menos sin-
tomáticas en comparación con los pacientes destinados a padecer viremia (Madec et al., 
2005b), lo que sugiere que las interacciones complejas entre el virus y el organismo an-
fitrión juegan un importante papel ya durante las primeras fases de la enfermedad del 
VIH (Altfeld and Allen, 2006). Se ha sugerido que la infección por el virus atenuado o 
defectuoso puede estar asociado con la no progresión de la enfermedad (Deacon et al., 
1995). Varios estudios demostraron también el peor fitness de la entrada de las envuel-
tas del VIH-1 derivadas de los EC (Casado et al., 2013; Lassen et al., 2009; Miura et al., 
2009). El factor más consistente que podría estar asociado con el control del virus es 
una respuesta celular vigorosa. Se ha demostrado que la función de las células T ci-
totóxicas CD8+ es claramente superior en los controladores en comparación con los no-
controladores (Migueles et al., 2002). Las moléculas HLA están implicadas en el reco-
nocimiento del sistema inmune de las células infectadas por virus y la presencia de di-
ferentes alelos HLA se ha asociado con el control eficaz del VIH, tales como: HLA-B57, 
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HLA-B27, HLA-B5801, HLA-B14, HLA-A32 (Gao et al., 2001; Geczy et al., 2000; Hendel 
et al., 1999; Kaslow et al., 1996; Keet et al., 1999; Magierowska et al., 1999; McNeil et al., 
1996; Saah et al., 1998). Aunque, el control de élite de la infección por VIH-1 se ha aso-
ciado con una serie de diferentes factores, ninguna de estas características puede por sí 
sola predecir el control virológico (Walker, 2007). 
 
DC-SIGN captura las partículas del VIH-1 a través de sus interacciones de alta afinidad 
con la glicoproteína de la envoltura. Las DCs pueden facilitar la difusión de la infección 
viral mediante la captura del VIH-1 en la mucosa y la transmisión a los tejidos linfoides 
secundarios (Haase, 2005, 2010; Klenk and Garten, 1994; Pope et al., 1994; Shattock and 
Rosenberg, 2012; Steinman et al., 2003). La infección mediada por DCs puede producir-
se a través de varios procesos distintos que tienen lugar al mismo tiempo, incluyendo 
trans-infección a través de las sinapsis infecciosas, trans-infección por los exosomas o 
cis-infección mediante la producción de novo de las partículas virales por los DCs (Wu 
and KewalRamani, 2006). Tener relaciones sexuales sin protección es el modo más co-
mún de transmisión del VIH-1 (Royce, 1997). Por lo tanto el desarrollo de las estrate-
gias antivirales preventivas en los sitios de mucosa como la primera línea de contacto 
con los virus es la prioridad. Los intentos de desarrollar una vacuna eficaz contra los 
virus crónicos han fallado hasta ahora, debido principalmente a los mecanismos de es-
cape inmunológicos de estos virus o la falta de epítopos conservados de virus implica-
dos en las infecciones agudas (Letvin, 2006). El uso de preservativos y las intervencio-
nes conductuales han sido sólo un éxito parcial para frenar la propagación de la infec-
ción VIH-1 en todo el mundo. Existe una urgente necesidad de intervenciones adicio-
nales para prevenir nuevas infecciones, tales como el desarrollo de formulaciones tópi-
cas de compuestos anti-VIH-1 para las mujeres, que se podrían utilizar en formato de 
gel, crema o supositorio antes de la relación sexual (Elias and Coggins, 1996).  
 
2. Objetivos 
 
El objetivo de nuestro estudio fue estandarizar y evaluar el modelo celular de la infec-
ción por el virus mediada por DC-SIGN. Queríamos estudiar la utilidad del modelo de 
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infección mediada por DC-SIGN como una plataforma de monitorización de las estra-
tegias antivirales destinadas frente DC-SIGN: las estructuras glicodendríticas, los den-
drones tetravalentes, los compuestos basados en dendrímeros, los glicofullerenos y 
lasglicodendrinanoparticulas. Por otra parte, hemos tratado de evaluar la implicación 
del receptor DC-SIGN en la trans-infección por las cepas Zaire y Reston del virus de 
Ébola. Por último, hemos investigado el proceso de trans-infección del VIH-1 y su co-
rrelación con control virológico. 
 
3. Material y Métodos 
 
3. 1. Clonación de las envueltas del VIH-1 
El ADNc viral se sintetizó usando el Sistema SuperScriptIII. La secuencia de la envoltura com-
pleta del VIH-1 se amplificó por PCR usando el Expand High Fidelity PCR System y se clonó en 
pcDNA3.1/V5-His TOPO. La secuenciación de las envueltas del VIH-1 se realizó mediante el 
uso de BigDye Terminator Cycle Sequencing v3.1 y las secuencias fueron analizadas por el pro-
grama bioinformático Geneious. 
3. 2. Aislamiento de las células mononucleares de sangre periférica (PBMCs) y la generación 
de las células dendríticas derivadas de monocitos (DCs) 
PBMCs fueron aisladas de la capa leucocitaria de donantes sanos usando la centrifugación en 
gradiente de densidad Ficoll-Histopaque. Los monocitos se cultivaron en medio RPMI suple-
mentado con las citoquinas GM-CSF (200 ng/ml) y la IL-4 (10 ng/ml). Para la diferenciación co-
rrecta de las DCs inmaduras derivadas de monocitos, las células se incubaron durante 7 días y 
posteriormente se activaron con las citoquinas en los días 2 y 5. 
3. 3. Producción de virus recombinantes 
Los virus recombinantes se produjeron en las células 293T por el protocolo estándar de la trans-
fección de Cloruro de Calcio. La construcción viral fue pseudotipada con la envoltura del virus 
(Ébola, VIH-1 y VSV) y expresaba la luciferasa como un reportero de la infección (Yang et al., 
1999). 
3. 4. El ensayo de la infección en cis 
La infección en cis se realizó en las células Jurkat que expresaban el receptor DC-SIGN. Jurkat 
DC-SIGN+ (2.5-5x 105) se incubaron con compuestos de carbohidratos en placas de suspensión 
de 96 pocillos durante 30 min en temperatura ambiente (TA) y luego se infectaron con 5000-
10000 TCID de virus recombinantes durante 48 h. 
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3. 5. El ensayo de la infección en trans (Ébola) 
Las células (2.5-5x105) Jurkat DC-SIGN+ se pre-incubaron durante 20 min a TA con compuestos 
de carbohidratos. Posteriormente las células se infectaron con 5000-10000 TCID de virus recom-
binantes durante 2 h a TA con la rotación. Después de 2 h, las células se lavaron intensamente y 
co-cultivaron con las células HeLa (105 células/pocillo) durante 48 h. 
3. 6. El ensayo de la infección en trans (VIH-1) 
La infección en trans se realizó con Jurkat DC-SIGN+ o Raji DC-SIGN+ (5x105), debido a que 
pueden capturar y transmitir el virus VIH-1 a las células susceptibles. Las células fueron incu-
badas con las pseudopartículas del VIH-1 durante 3 h a 37ºC. Después, las células se lavaron y 
se co-cultivaron con las células U87-R5/X4 durante 48 h. 
 
4. Resultados 
 
4. 1. El modelo de infección mediada por DC-SIGN 
El modelo de infección en cis mediada por DC-SIGN en el sistema celular Jurkat DC-
SIGN+/Jurkat mostró claramente que la entrada del virus de Ébola a la célula es depen-
diente de la presencia de DC-SIGN (el ratio de trans-infección fue 2567.8). La infección 
en cis de las dos líneas celulares por las partículas recombinantes de un virus indepen-
diente de DC-SIGN (VSV-G) tuvo un nivel muy similar (el ratio de trans-infección fue 
0.96). El modelo de trans-infección confirmó los resultados obtenidos en el experimento 
de cis-infección, revelando una mayor transmisión de la infección por Ébola en las célu-
las susceptibles a través de las células Jurkat DC-SIGN+ en comparación con las células 
negativas (el ratio de trans-infección fue 870.4). La trans-infección con el virus recombi-
nante VSV-G fue equivalente entre las dos líneas celulares. 
 
4. 2. DC-SIGN como un modelo de estudiar diferentes estrategias antivirales 
La actividad antiviral de los compuestos basados en carbohidratos fue estudiada en los 
ensayos de inhibición de infección usando partículas virales pseudotipadas con la gli-
coproteína del virus de Ébola. La posibilidad de bloqueo del receptor DC-SIGN se 
examinó en los experimentos de cis y trans-infección en la presencia de compuestos ba-
sados en carbohidratos con diferentes concentraciones finales.  
 
Thesis summary (ES)/El Resumen de la Tesis 
 
175 
 
Estructuras glicodendríticas 
La IC50 del compuesto RR114 fue 3.6 µM y la IC50 para el compuesto RR115 fue de 2.8 
µM. Aunque ambos compuestos mostraron una eficacia similar en la infección en cis, el 
experimento de infección en trans mostró más potencia en el compuesto RR115 que el 
compuesto RR114 (IC50 de 7 µM vs IC50 de 52.4 µM). 
 
Dendrones tetravalentes 
Los resultados obtenidos en el experimento de la infección en cis revelaron que los sis-
temas tetravalentes que presentan cuatro copias de pseudomanotriosidas (compuesto 
14) mostraron una potencia de 1 orden de magnitud mayor que los sistemas tetravalen-
tes que presentan cuatro copias de pseudomanobiosidas lineales (compuesto 12). La 
IC50 del compuesto 14 fue 106.5 nM y la IC50 del compuesto 12 fue 1.4 µM. Los resulta-
dos obtenidos en el experimento de trans-infección fueron similares a los resultados de 
la infección en cis. El dendron tetravalente 14 con 4 copias de pseudomanotriosidas 
mostró una IC50 de 203 nM. El dendron tetravalente 12 con 4 copias de pseudo-
manobiosidas fue de 1 orden de magnitud menos potente con una IC50 de 1.22 µM. 
 
Compuestos basados en dendrímeros 
Los compuestos basados en dendrímeros que presentan 30-32 pseudomanotriosidas 
(G3(pseudotri)32) o 30-32 pseudomanobiosidas (G3(pseudodi)32) no mostraron diferen-
cias en su potencia de inhibición de la entrada de las partículas pseudotipadas con 
EBOV-GP a la célula. El valor de IC50 de compuesto G3(pseudotri)32 fue 17.12 nM y el 
valor de IC50 de compuesto G3(pseudodi)32G3 fue 27.21 nM. Los resultados obtenidos 
en el experimento de trans-infección fueron similares a los resultados de la infección en 
cis y mostraron valores de IC50 del mismo orden de magnitud. La IC50 de 
G3(pseudodi)32 fue de 62 nM y la IC50 de G3(pseudotri)32 fue 31.51 nM.  
 
Glicofullerenos 
El glicofullereno cubierto con 12 manosas mostró la IC50 de 2 µM.. La IC50 para el fulle-
reno que presentaba 36 manosas fue de 68 µM (34 veces menos activo que el fullereno 
presentando 12 manosas). La introducción de un espaciador más largo en el glicofulle-
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reno con 36 manosas tuvo un efecto muy importante en la recuperación de la actividad 
de este compuesto con una IC50 de 286.4 nM. El fullereno cubierto con galactosas no fue 
capaz de inhibir el proceso de infección mediada por DC-SIGN. 
 
Glicodendrinanopartículas 
El compuesto Qbeta se utilizó en el experimento como control de los efectos de este 
nuevo tipo de estructuras en los resultados de la infección en cis. La mayor concentra-
ción de compuesto Qbeta (25 nM) utilizada en el experimento fue capaz de bloquear la 
infección en ~ 30-40%. La misma concentración (25 nM) de compuesto Qbeta-(Man3)180 
pudo bloquear la infección en el 50-60%. La concentración de 25 nM de compuesto 
Qbeta-(Man9)180 fue capaz de bloquear en manera eficaz la infección en ~ 90-100%. Los 
valores de IC50 se calcularon con un CI del 95% (7.7 nM - 24,3 nM para Qβ-(Man3)180 y 
404.2 pM – 4.1 nM para Qβ-(Man9)180). Los compuestos Qbeta y Qbeta-(Man9)180 se es-
tudiaron en concentraciones de 25 nM, 5 nM, 1 nM en el experimento de la infección en 
cis de las DCs. El compuesto Qbeta-(Man9)180 mostró una potente actividad inhibiendo 
la infección por encima del 80% con una concentración de 5 nM, sobrepasando el 95% 
cuando la concentración era de 25 nM (IC50 estimada ~ 2 nM). 
 
 
4. 3. El papel de DC -SIGN en la patogénesis del virus del Ébola 
 
Las diferencias en la infección mediada por el DC-SIGN por las dos cepas del Ébola 
fueron estudiadas primero en el experimento de trans-infección en el sistema celular 
Jurkat DC-SIGN+/Jurkat. La diferencia en el ratio de trans-infección mediada por DC-
SIGN entre EBOZ y EBOR fue estadísticamente significativa (p=0.0034). La significa-
ción estadística de las diferencias entre los niveles de infección de EBOZ y EBOR se es-
tudió a continuación en la trans-infección mediada por las DCs primarias DCs a las cé-
lulas HeLa. Los resultados obtenidos en el experimento revelaron unas diferencias es-
tadísticamente significativas entre EBOZ y EBOR (p=0.0084). En cambio, la cis-infección 
de células dendríticas inmaduras no resultó en diferencias significativas (p=0.5479). 
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4. 4. El papel del receptor DC-SIGN en la patogénesis del VIH-1 
 
Análisis de los ratios de la trans-infección mediada del VIH-1 por DC-SIGN en gru-
pos de pacientes: EC, VC y los pacientes con infección crónica 
Los resultados de los experimentos de trans-infección se compararon entre diferentes 
grupos de pacientes para verificar si el control virológico podría tener alguna asocia-
ción con el ratio de trans-infección. Los resultados obtenidos en el análisis mostraron 
diferencias estadísticamente significativas entre ambos grupos de pacientes con la me-
dia EC+VC=45.49 vs CI=21.06 (p<0,0001). Estas diferencias se verificaron también en los 
subgrupos de los controladores: EC y VC para determinar si el tipo de control virológi-
co podría tener influencia en el resultado de trans-infección. Se observó que el ratio de 
trans-infección fue significativamente mayor en el subgrupo de los VC en comparación 
con las personas con infección crónica (VC=56.6 vs CI 20.42, p<0.0001). Curiosamente, 
también hubo una diferencia estadísticamente significativa en la trans-infección entre 
VC y EC (EC=56.6 vs EC=28.02, p=0.0007). 
 
 
El análisis de las secuencias de las envueltas y el ratio de trans-infección entre los 
EC, VC y los pacientes con infección crónica 
Para la identificación de los factores responsables de las diferencias en el ratio de trans-
infección se estudiaron las variable como la longitud y el número de PNGS en: gp160, 
gp120, gp41 y V1-V5 las envueltas del VIH-1 entre EC, VC y CI. No se encontraron di-
ferencias significativas a excepción de la región de V5. La longitud de la V5 fue signifi-
cativamente mayor en el grupo de pacientes con infección crónica en comparación con 
los EC y no con los VC (EC=12.33 aa vs CI=14.13aa, p=0.0325). El número de PNGS en 
la V5 mostró un tendencia hacía el mayor número de los glicanos en los aislados cróni-
cos del VIH-1 (EC= 1 PNGS, VC=1.5 PNGS y CI=1.813 PNGS, EC vs CI p=0.0072). El 
análisis posterior demostró que no había correlación entre el ratio de trans-infección y 
la longitud de V5 (r=0.0925, p=0.6267) o el número de PNGS en la V5 (r= -0.0895, 
p=0.6382). 
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5. Discusión 
 
5. 1. DC-SIGN como un modelo de estudiar las estrategias antivirales 
Aunque los modelos in vitro de la infección no son suficientes para comprender el pa-
pel fisiológico de DC-SIGN, el modelo celular basado en las células que expresan DC-
SIGN+ podría funcionar como un modelo de estudio eficaz de estrategias antivirales. La 
infección por el virus del Ébola en líneas celulares es dependiente de la presencia de 
DC-SIGN en la superficie celular. El modelo celular utilizado en este estudio para la 
investigación de los antivirales se basó en las células de la línea celular de linfocitos T 
CD4+ humanos, Jurkat DC-SIGN+. Dado que el virus del Ébola no infecta a los linfocitos 
T, su entrada a las células Jurkat es absolutamente dependiente de la interacción con 
DC-SIGN. 
 
El sistema celular Jurkat DC-SIGN+/Jurkat podría servir como una plataforma de moni-
torización de diferentes estrategias antivirales dirigidas a DC-SIGN. El receptor DC-
SIGN reconoce oligosacáridos fucosilados y manosilados, presentados de una manera 
multivalente en la superficie de varios agentes patógenos. Por lo tanto, la síntesis de los 
sistemas de carbohidratos multivalentes es necesaria para la interacción eficiente con 
este receptor, así como para la competición eficaz con los ligandos naturales. Los resul-
tados obtenidos en los experimentos realizados en esta tesis podrían contribuir de una 
manera muy rápida y eficaz en los primeros estudios de los antivirales basados en dife-
rentes estrategias: dendrones tetravalentes, compuestos basados en dendrímeros, glico-
fullerenos y glicodendrinanopartículas. Los dendrones tetravalentes y los compuestos 
basados en dendrímeros presentan en la manera multivalente los nuevos imitadores de 
carbohidratos denominados como pseudomanosidas. La importancia de la valencia se 
evaluó mediante la presentación de los mismos ligandos de pseudosacáridos en el sis-
tema tetravalente presentando 4 copias del ligando, y en los sistemas multivalentes que 
muestran de 30 a 32 ligandos seleccionados. Los valores de IC50 obtenidos para los sis-
temas multivalentes fueron alrededor de 20 nM, mostrando una potencia inhibidora de 
1 a 2 órdenes de magnitud superior que la de los sistemas de tetravalentes correspon-
dientes (Luczkowiak et al., 2011). La síntesis de glicofullerenos permitió alcanzar una 
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mayor valencia de 36 manosas. Estos compuestos se sintetizaron mediante la combina-
ción de glicodendrones con un fullereno que permite presentar los carbohidratos de un 
modo globular. Los resultados obtenidos en el experimento de infección en cis demos-
traron la importancia de la combinación de una estructura adecuada para lograr la 
multivalencia con la accesibilidad y flexibilidad del ligando. El efecto inhibidor del fu-
llereno con 36 manosas era menor en comparación con el glicofullereno que mostró 12 
manosas, sin embargo, la posterior introducción del espaciador más largo a este glico-
fullereno recuperó su potencia inhibidora y mostró una IC50 de 286.4 nM (10 veces más 
potente que el glicofullereno con 12 manosas y 340 veces más potente que el glicofulle-
reno con 36 manosas que contenía el espaciador corto) (Luczkowiak et al., 2013). La 
mayor valencia de presentación de los ligandos se generó en el caso de las glicodendri-
nanopartículas. Este diseño se basó en el conjunto multivalente de monómeros de pro-
teínas (glicodendriproteínas) que llevan componentes de glicanos polivalentes (glico-
dendrones). De esta manera, estas construcciones muestran un número elevado de gli-
canos de manera precisa y crean entidades individuales bien definidas de hasta 32 nm 
de diámetro. Las glicodendrinanopartículas mostraron una actividad antiviral en el 
rango de picomolar a bajo nanomolar (Ribeiro-Viana et al., 2012). 
 
5. 2. La función del DC- SIGN en la patogénesis del virus de Ébola: la trans-
infección mediada por DC-SIGN de diferentes cepas de virus del Ébola 
El virus del Ébola causa una enfermedad grave, a menudo fatal que consiste en un sín-
drome de fiebre hemorrágica altamente letal (Peters et al., 1996). La cepa Zaire es la va-
riante del virus con la mayor tasa de mortalidad en un intervalo del 50 al 90%. En con-
traste con la cepa Zaire, el Ébola Reston no causa enfermedad en los humanos a pesar 
de una serie de infecciones documentadas durante las epizootias animales (Barrette et 
al., 2009; Miranda et al., 1999). La base molecular de esta diferencia en su patogénesis 
no está bien definida. La unión del virus del Ébola GP a diferentes lectinas celulares ha 
sido demostrada previamente con el fin de aumentar la infección del virus, tanto en cis 
como en trans (Alvarez et al., 2002). En nuestro estudio, hemos utilizado partículas re-
combinantes que expresan dos glicoproteínas de la envoltura del virus del Ébola 
(EBOZ y EBOR) para estudiar el posible papel del DC -SIGN en la patogénesis de las 
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dos variantes del Ébola. La infección mediada por DC-SIGN de las dos cepas se verificó 
en los experimentos de trans-infección en el sistema Jurkat DC-SIGN+/Jurkat, cis-
infección de las DCs primarias y trans-infección DCs/HeLa. El primer experimento de 
trans-infección en el modelo celular Jurkat DC-SIGN+/Jurkat reveló diferencias signifi-
cativas en el ratio de trans-infección entre la cepa del Ébola Zaire y la cepa del Ébola 
Reston (p=0.0034). El ratio de trans-infeccion del EBOR era alrededor de tres veces su-
perior en comparación con el del EBOZ (35.97 vs 99.64). La relevancia de las diferencias 
en el uso del receptor DC-SIGN en el proceso de trans-infección también se verificó en 
el sistema inmunológico mediante el uso de las células dendríticas inmaduras. Las DCs 
inmaduras se incubaron con EBOZ/EBOR y tras la realización de dos lavados intensi-
vos, fueron co-cultivadas con las células susceptibles HeLa. Los resultados obtenidos 
en el experimento de trans-infección basado en las células inmunes humanas (DC) han 
confirmado los resultados de trans-infección en el sistema de línea celular. La diferen-
cia entre la infección transmitida por las pseudopartículas del Ébola Zaire y del Ébola 
Reston a las células HeLa fue estadísticamente significativa (p=0.0084). Ambos experi-
mentos realizados demostraron significación estadística de mayor uso de DC-SIGN en 
la trans-infección de EBOR en comparación con EBOZ. A pesar de las diferencias signi-
ficativas en el uso de DC–SIGN por EBOZ/EBOR en los experimentos de trans-
infección, la infección directa de las DCs inmaduras no ofreció ningún resultado signi-
ficativo. Nuestros resultados encontraron la asociación entre la cepa del Ébola Reston y 
un mayor ratio de trans-infección mediada por DC-SIGN. Este descubrimiento podría 
plantear la hipótesis de que a pesar de que DC-SIGN participa efectivamente en la en-
trada de virus a las células, in vivo este receptor juega aparentemente el papel más im-
portante en la activación adecuada del sistema inmune. DC-SIGN puede ser responsa-
ble de la captura del virus, su destrucción y de una presentación más eficaz de los antí-
genos de los patógenos a las células causando un buen rendimiento de control inmuno-
lógico. El DC-SIGN, por lo tanto, aunque es capaz de captar con eficacia las partículas 
del virus del Ébola, podría servir mejor como factor de defensa del organismo anfitrión 
en lugar de receptor de escape de patógenos. Por tanto, el nivel más alto del uso de 
DC-SIGN por el Ébola Reston podría sugerir que el DC-SIGN en general podría estar 
más implicado en las respuestas antivirales. Los resultados obtenidos en los experi-
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mentos realizados se pueden relacionar a los resultados de estudio de Schaefer et al., en 
el que los ratones que expresan el receptor humano DC-SIGN sobrevivieron más tiem-
po que los ratones de tipo salvaje después de la infección con Mycobacterium tubercu-
losis (Schaefer et al., 2008). 
 
5. 3. La función del DC- SIGN en la patogénesis del virus del VIH-1: implicación de 
la trans-infección mediada por DC-SIGN en el control virológico 
El receptor DC-SIGN se clonó y se clasificó inicialmente como un receptor para la gli-
coproteína de la envuelta del VIH-1 gp120. De hecho, precisamente se ha demostrado 
que la afinidad de la gp120 para DC-SIGN es incluso mayor que para el receptor CD4 
(Curtis et al., 1992). Años antes del descubrimiento de DC-SIGN, los estudios de Came-
ron et al. y Pope et al. mostraron que los DCs incubados con el VIH-1 causaron la infec-
ción de las células T co-cultivadas (Cameron et al., 1992; Pope et al., 1994). Poco des-
pués de la identificación del DC-SIGN, Geijtenbeek et al. definió este fenómeno como la 
trans-infección del VIH-1 (Geijtenbeek et al., 2000b). Se ha demostrado claramente que 
DC-SIGN se une a las estructuras de carbohidratos, tales como glicoconjugados que 
contienen manosa, expresadas en la superficie de diferentes patógenos (den Dunnen et 
al., 2010). La envuelta del VIH-1 es una de las proteínas más glicosiladas en la natura-
leza, que contiene de 18-32 PNGS en la gp120. Por lo tanto, numerosos estudios in vitro 
han demostrado la alta afinidad de la envuelta del VIH-1 a las células que expresan el 
receptor DC-SIGN. El receptor DC-SIGN no funciona como un receptor directo del 
VIH-1 pero transmite de manera eficiente el virus de la periferia a los tejidos linfoides 
secundarios. Se ha demostrado que las partículas del VIH-1 unidas a DC-SIGN son no-
tablemente más estables y retienen la infectividad durante períodos prolongados 
(Geijtenbeek et al., 2000b). A pesar de todas las funciones propuestas de DC-SIGN ba-
sado en modelos in vitro, la confirmación del comportamiento fisiológico de DC-SIGN 
in vivo debe seguir siendo estudiado. 
 
En nuestro estudio hemos analizado la glicoproteína de la envuelta de 30 aislamientos 
clínicos (6 de EC, 8 de VC y 16 de CI) en el ensayo de la trans-infección mediada por 
DC-SIGN. El experimento de trans-infección se realizó con 30 envueltas del VIH-1 para 
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estudiar la correlación del ratio la trans-infección y el control virológico en los dos sis-
temas celulares (Jurkat DC-SIGN+/Jurkat y Raji DC-SIGN+/Raji). El análisis de los resul-
tados obtenidos en el sistema Raji DC-SIGN+/Raji reveló diferencias significativas en la 
proporción del uso del DC-SIGN entre los controladores del VIH-1 y los pacientes cion 
infección crónica. Llamatívamente, el subgrupo de los VC demostró el ratio más alto de 
trans-infección en comparación con los EC (p=0.0007) y los CI (p<0.0001). Los EC mos-
traron una tendencia hacía una mayor eficiencia de trans-infección en comparación con 
los CI (p=0.1331), sin embargo mucho menos eficaz en comparación con los VC. El re-
sultado global fueron posteriormente confirmados por el experimento de trans-
infección con el sistema Jurkat DC-SIGN+/Jurkat (EC+VC=32.84 vs CI=17.4, p=0.0233). 
La baja asociación entre los EC y eficiente trans-infección mediada por DC-SIGN podría 
sugerir que otros factores, incluyendo el bajo fitness viral (Casado et al., 2013; Lassen et 
al., 2009; Miura et al., 2009) o la respuesta de las células T CD8+ extremadamente vigo-
rosa (Goulder and Watkins, 2004; Migueles et al., 2002), cuentan para el control viroló-
gico en este subgrupo de pacientes. Nuestros resultados han confirmado el bajo fitness 
de las envueltas derivadas de los EC. Una proporción considerable de las envueltas (10 
de las 16) no podría ser comprobada en los experimentos de la trans-infección. Todas 
las envueltas fueran secuenciadas y no mostraron ningún defecto en la secuencia.  Sin 
embargo, en los ensayos celulares 4 de ellas se mostraron no funcionales y 6 de ellas 
tenían la infectividad por debajo del rango dinámico requerido para los experimentos 
de infección. Control virológico en el subgrupo de los VC es menos conocido. Podría 
ser posible que en este subgrupo de pacientes, la respuesta inmune innata tuviese una 
mayor participación lo que puede influir el control virológico. Los VC utilizan DC-
SIGN en manera más eficiente en comparación con otros grupos de los pacientes, por 
lo tanto se podría proponer el hipótesis que el DC-SIGN en este subgrupo de indivi-
duos juega el papel importante en la captura de los antígenos virales y la presentación 
posterior para la activación adecuada del sistema inmune. 
 
Para acceder a la información sobre la base de estas diferencias, la longitud de la se-
cuencia y el número de PNGS en las glicoproteínas de la envoltura se compararon en-
tre ambos grupos de pacientes. Aunque se ha demostrado que la glicoproteína de la 
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envoltura de los controladores del VIH es más corta y contiene menos PNGS (Bailey et 
al., 2006a), en nuestro pequeño estudio las secuencias de los virus del VIH-1 de los con-
troladores y de los pacientes con infección crónica eran de longitud análoga y conte-
nían un número similar de PNGS en la mayoría de las regiones de la gp160 con la úni-
ca excepción de la región V5. Sin embargo, no se encontró ninguna correlación entre la 
longitud de la V5 o el número de PNGS en la V5 y el ratio de trans-infección. Se podría 
especular que estos cambios se produjeron en el curso natural de la infección por VIH-
1, posiblemente en la respuesta causada por los NAbs. Se ha demostrado previamente 
que el número de PNGS y la longitud de las envueltas del VIH-1 tienen una tendencia 
de aumentar en la epidemia del VIH-1 (Bunnik et al., 2010; Bunnik et al., 2008). Nuestro 
análisis de los datos de la Base de datos de VIH de Los Alamos confirmó estos estudios 
indicando la aparente evolución de la pandemia del VIH-1 hacía las glicoproteínas más 
largas y más glicosiladas. Por lo tanto el cambio en V5 y V1-V5 hacía el número más 
elevado de los PNGS podría ser explicado por el patrón la evolución del VIH-1 y no 
por la trans-infección más eficaz. Los resultados de este estudio podrían contribuir a 
una mejor comprensión de la función del receptor DC-SIGN en la patogénesis del VIH-
1. Este trabajo muestra el uso sustancial del receptor DC-SIGN en el experimento de 
trans-infección por los controladores del VIH-1, especialmente por los VC. Esos resul-
tados fueron verificados en dos sistemas celulares y ambos mostraron la asociación en-
tre un mayor ratio de trans-infección y el control virológico. Las envueltas del VIH-1 de 
los VC han utilizado DC-SIGN de forma más eficiente en comparación con los EC y los 
pacientes con infección crónica VIH-1. Es posible que el control virológico en el sub-
grupo de los EC resulte de la reducción de la replicación viral o respuesta celular adap-
tativa más eficaz. Sin embargo, en el grupo de los VC podría ser posible que la fuerte 
implicación de DC-SIGN estuviera más conectada con la presentación del antígeno y 
una respuesta más eficaz del sistema inmune, en lugar de la difusión del virus. El con-
trol virológico del VIH-1 se caracteriza por mantener cargas virales bajas en ausencia 
de terapia antirretroviral. Por lo tanto, la carga viral baja y la falta de replicación activa 
determinan que las secuencias de las envueltas en los controladores del VIH tengan las 
regiones variables más cortas y números más bajos de N-glicanos (Bailey et al., 2006a). 
Aunque el DC-SIGN muestra una fuerte afinidad por las moléculas que contienen ma-
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nosas, nuestro estudio ha confirmado que el número de PNGS no es un factor funda-
mental relacionado con uniones más fuertes al DC-SIGN. La comparación del patrón 
de N-glicosilación no mostró diferencias estadísticamente significativas entre los VC y  
los EC/CI, por lo tanto el mayor uso de DC-SIGN en la trans-infección por los VC no 
puede ser explicada por la presencia aumentada de los glicanos. Podría ser posible que 
la unión a DC-SIGN implique el patrón más complejo de N-glicosilación y no la canti-
dad de los glicanos en la superficie. Nuestros datos demuestran que las envueltas del 
VIH-1 de los controladores aunque contienen generalmente menor número de los gli-
canos en la superficie del virus, utilizan DC-SIGN más eficazmente que los aislados 
crónicos.  
 
6. Conclusiones 
 
1) El modelo de infección basado en las líneas celulares que expresan DC- SIGN es una 
plataforma consistente para estudiar la entrada viral directa (virus del Ébola) y el fe-
nómeno de trans-infección (virus Ebola y VIH) debido a que la interacción virus-DC-
SIGN en este sistema depende casi exclusivamente de la presencia DC–SIGN. 
 
2) El modelo de infección DC-SIGN es un modelo útil para estudiar estategias antivira-
les dirigidas a DC-SIGN. 
 
3) La inhibición de la infección mediada por DC-SIGN mediada por los compuestos 
basados en hidratos de carbono depende en gran medida de la multivalencia de pre-
sentación de los glicanos. 
 
4) La actividad antiviral más potente se obtuvo en caso de las glicodendrinanoparticu-
las que muestran una actividad antiviral eficaz en el rango de concentración picomolar 
-nanomolar. Multivalencia depende de la presentación de los 1620 glicanos generando 
una gran superficie de interacción (30 nm de diámetro). 
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5) A pesar del papel del DC-SIGN en la entrada del virus del Ébola y la difusión inicial 
del virus, en nuestro estudio encontramos significativamente mayor uso de DC-SIGN 
por la cepa no patógena de Ébola Reston. Este hallazgo podría indicar que DC-SIGN en 
caso de Ébola Reston está involucrado en un control inmunitario más eficiente. 
 
6) Las glicoproteínas de la envoltura del VIH- 1 de los controladores virológicos utili-
zan DC-SIGN más eficiente en el experimento de trans-infección en comparación con 
los pacientes con enfermedad crónica.  
 
7) La trans-infección mediada por DC-SIGN no está asociada con la cantidad de los N- 
glicanos en la glicoproteína de la envuelta de VIH-1. Probablemente un patrón más 
complejo de N- glicosilación específica es responsable de este mecanismo. 
 
8) En el grupo de VC, la significativamente mayor trans-infección observada podría 
indicar que DC-SIGN participa en la detección viral, presentación y control inmunoló-
gico más que en la difusión viral, como en el caso de trans-infección por Ébola Reston. 
 
9) El grupo de EC no demostró la misma trans-infección que los VC. El control viroló-
gico en el grupo de los EC puede resultar de la reducción de la replicación viral o ex-
tremadamente vigorosa respuesta de las células T CD8+. 
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IX. ABBREVIATIONS 
 
aa – amino acid 
Ab – antibody 
Ag – antigen  
AIDS – acquired immunodeficiency syndrome 
APC – antigen-presenting cell 
APOBEC3G – apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G 
ART – antiretroviral therapy 
ARV – AIDS-associated retrovirus 
ASGP-R – liver-specific asialoglycoprotein receptor 
BamHI – Bacillus amyloliquefaciens H 1 gene 
BCR – B-cell receptor 
BDCA-2 – blood DC antigen-2 
BG – Birbeck granule 
BGH – bovine growth factor 
BSA – bovine serum albumin 
CA – capsid 
CARD – caspase-recruitment domain 
CCR5 – C-C chemokine receptor type 5 
CD4 – cluster of differentiation 4 
CD8 – cluster of differentiation 8 
CD4Bs – CD4 binding site 
CDC – Centers for Disease Control and Prevention 
cDNA – complementary DNA 
Cl – chloride 
CMV – cytomegalovirus 
CoRBs – coreceptor-binding site 
CRD – carbohydrate recognition domain 
CTL – cytotoxic T cell 
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CXCR4 – C-X-C chemokine receptor type 4 
DAMPs – damage-associated molecular patterns 
DC – dendritic cell 
DCAL-1 – DC-associated lectin-1 
DCAR – DC immunoactivating receptor 
DCIR – DC immunoreceptor 
DC-SIGN – dendritic cell-specific intracellular adhesion molecule (ICAM)-3 grabbing 
non-integrin 
DEC-205 – lymphocyte antigen 75 
Dectin-1 – DC-associated C-type lectin-1 
DM – dual tropic 
DMEM – Dulbecco´s Modified Eagle´s Medium 
DMF –dimethylformamide 
DMSO – dimethyl sulfoxide 
DNGR-1/CLEC9A – DC, NK lectin group receptor 1 
dNTP –deoxynucleotide 
dsDNA – double-stranded DNA 
dsRNA – double-stranded RNA 
EBNA-1 – Epstein-Barr virus nuclear antigen 1 
EBV – Epstein-Barr virus 
EC – elite controller 
EcoRI – Escherichia coli R 1 gene 
EEE – tri-acidic clusters motif 
ELISA – enzyme-linked immunosorbent assay 
ER – endoplasmic reticulum 
Fab – fragment antigen-binding 
FACS – fluorescence-activated cell sorting 
Fc – fragment crystallisable region 
FDC – follicular dendritic cell 
FRα – folate receptor α  
Gal – galactose 
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GalNAc – N-acetyl-galactosamine 
GFP – green fluorescent protein 
Glc – glucose 
GlcNac - N-acetyl-glucosamine 
GM-CSF – granulocyte-macrophage colony-stimulating factor 
GP – glycoprotein 
gp120 – glycoprotein 120 
gp160 – glycoprotein 160 
gp41 – glycoprotein 41 
h – hour 
HAART – highly active antiretroviral therapy 
HBS – hepes buffer saline 
HEK 293T – human embryonic kidney 293 cell line 
HeLa – human cervical epithelial carcinoma cell line 
HindIII – Haemophilus influenzae Rd III gene 
HIV – human immunodeficiency virus 
HLA - human leukocyte antigen 
hMGL – human macrophage galactose lectin 
HPV18 – human papillomavirus 18 
HR – heptad region 
HTLV-I – human T-lymphotropic virus I 
HTLV-III – human T-lymphotropic virus III 
IAS – inner antisense 
ICAM-1 – intercellular adhesion molecule 1 
ICAM-2 – intercellular adhesion molecule 2 
ICAM-3 – intercellular adhesion molecule 3 
IgG – immunoglobulin G 
IL-1 – interleukin 1 
IL-4 – interleukin 4 
IL-6 – interleukin 6 
IL-10 – interleukin 10 
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IL-12 – interleukin 12 
IL-1R – interleukin 1 receptor 
IN – integrase 
INF – interferon 
IS – inner sense 
ITAM – immunoreceptor tyrosine-based activation motif 
ITIM – immune receptor tyrosine-based inhibition motif 
Langerin – Langerhans cell specific C-type lectin 
LAV – lymphadenopathy-associated virus 
LB – Luria-Bertani medium 
LC – Langerhans cell 
LGP2 – laboratory of genetics and physiology-2 
LL – di-leucine motif 
LRR – leucine-rich-repeat 
LSECtin –liver and lymph node sinusoidal endothelial cell C-type lectin 
L-SIGN – liver/lymph node intracellular adhesion molecule (ICAM-3) grabbing non-
integrin 
LTNP – long term non-progressor 
LTR – long terminal repeat 
M – molar 
MA – matrix 
Man – mannose 
MBL – mannose binding lectin 
MCS – multiple cloning site 
MDA5 - melanoma differentiation-associated gene 5 
MDCs – myeloid DCs 
MfeI – Mycoplasma fermentas I gene 
Mg – magnesium 
mg – milligram 
MHC – major histocompatibility complex 
MICL – myeloid inhibitory C-type lectin 
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min – minute 
Mincle – macrophage-inducible C-type lectin 
MIP-1β – macrophage inflammatory protein-1β 
ml – milliliter  
MLV – murine leukaemia virus 
mM – millimolar 
MMR – macrophage mannose receptor 
MR – mannose receptor 
mRNA – messenger RNA 
MTCT – mother-to-child transmission 
MW – molecular weight 
MyD88 – myeloid differentiation factor 
NAb – neutralizing antibody 
NaOAc – sodium acetate 
NBD – nucleotide-binding domain 
NC – nucleocapsid 
NF-kB – nuclear factor kB 
ng – nanogram 
NK – natural killer cell 
NLR – nucleotide oligomerization domain NOD-like receptor 
nM – nanomolar 
NOD – nucleotide oligomerization domain 
NotI – Nocardia otitidis-caviarum 1 gene 
OAS – outer antisense 
ORF – open reading frame 
OS – outer sense 
PAMPs –pathogen-associated molecular patterns 
PBMCs – Peripheral Blood Mononuclear Cells 
PBS – phosphate buffer saline 
PBS – primer-binding site 
PCP – Pneumocystis carinii pneumonia 
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PCR – polymerase chain reaction 
pDC – plasmacytoid dendritic cell 
pETF-b – transcription-elongation factor 
PGK-1 – phosphoglycerate kinase 1 
pol – polymerase 
pM – picomolar 
pmol – picomole 
PR – protease 
preGP – precursor GP 
PRRs- pattern recognition receptors 
RD – repressor domain 
RIG-I – retinoic acid inducible gene I 
RLR - retinoic acid inducible gene I (RIG-I) like receptors 
rpm – revolutions per minute 
RRE – rev response elements 
RT – room temperature 
RT – reverse transcriptase 
SA – sialic acid 
sec – second 
sGP – secreted glycoprotein 
ssGP – small soluble glycoprotein 
Siglecs – sialic-acid-binding Immunoglobulin-like lectins 
SIGNR1 – specific intracellular adhesion molecule-grabbing non-integrin receptor 1 
SIV – simian immunodeficiency virus 
SNP – single-nucleotide polymorphism 
ssDNA – single stranded DNA 
ssRNA – single stranded RNA 
SU – surface 
SV40 – simian virus 40 
T-20 – Tween 20 
TAR – transactivation-response element 
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TCID – tissue culture infectious dose 
TCR – T-cell receptor 
TEMED – tetramethylethylenediamine 
Th – T-helper cell 
TIR – Toll/IL-1R homology (TIR) domain 
TLR - Toll-like receptor 
TM – transmembrane 
TNF – tumor necrosis factor 
TRIM5α – tripartite motif protein isoform 5 alpha 
tRNA – transfer RNA 
TZM-bl – Human cervical epithelial carcinoma cell line expressing human CD4, CCR5, 
CXCR4 and containing HIV-1 Tat-regulated reporter genes for firefly lucifer-
ase and ß-galactosidase 
U87 – human gastroglioma cell line 
µg - microgram 
µl – microliter 
µM – micromolar 
V1 – variable loop 1 
V2 – variable loop 2 
V3 – variable loop 3 
V4 – variable loop 4 
V5 – variable loop 5 
VC – viremic controller 
VL – viral load 
VLs – variable loops 
VP – virion protein 
VSV – Vesicular Stomatitis virus 
WB –Western Blot 
wt – wild-type 
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XI. SUPPLEMENTARY MATERIAL 
 
1. Supplementary material 1: Analysis of subtype B HIV-1 envelopes from 
Los Alamos data base 
 
The molecular basis for the virus mutations in the envelope sequence, specifically 
PNGS, which might influence affinity to the lectin DC-SIGN, was also studied in gp160 
sequences from the Los Alamos database (http://www.hiv.lanl.gov/ components/ se-
quence/HIV/search/search.html). The HIV-1 gp160 sequences were obtained from sub-
type B HIV-1 variants fulfilling one of criteria: documented year of infection or docu-
mented time of collected sample from the beginning of the infection. 
 
The following number of gp160 HIV-1 sequences were collected from Los Alamos data 
base: 31 sequences obtained from patients infected in years 1983-1986, 65 sequences 
obtained from patients infected in years 2006-2009, 78 sequences from patients in acute 
infection period, 25 sequences obtained from patients in advance stage of disease, 14 
sequences obtained from the same 7 patients, first from acute infection period and se-
cond from chronic infection. The length of variable loops (VLs) in gp160 and the num-
ber of PNGS were analyzed in each group of patients. The statistical analysis to com-
pare different groups of patients was performed by implying Mann-Whitney test.  
 
A comparison of the length of VLs between the groups of patients with acute infection 
and between patients with chronic infection did not reveal any statistically significant 
difference in the length of each VL separately as well as in the length of total VLs or 
total gp160. Although no statistical significance was found in performed analysis, the 
mean length of V1 increased from 26.17 aa to 27.28 aa, the mean length of V1V2 in-
creased from 67.64 aa to 68.44 aa, the mean length of all VLs increased from 147.5 aa to 
149.52 aa and the mean length of gp160 increased from 854.28 aa to 856.84 aa in virus 
sequences from acute-chronic infection. The difference in the number of PNGS in both 
groups of patient was statistically significant in case of V1 and V3 (p=0.0814 and 
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p=0.0009, respectively). The mean number of PNGS in V1 decreased from 2.74 to 2.52 
PNGS and the mean number of PNGS in V3 decreased from 1.09 to 0.8 PNGS in virus 
from chronic infection as compared with acute. The number of PNGS in V2, V4, V5, all 
VLs and total gp160 did not show any significant difference (Fig. 59). 
 
A subsequent comparison of the length of VLs and the number of PNGS in VLs was 
performed between patients infected in years 1983-1986 and patients infected in years 
2006-2009. The length of VLs did not reveal any significant difference in both groups of 
patients. However, the number of PNGS varied considerably in V1, V1V2, V3, V5, all 
VLs and total gp160. The mean number of PNGS in V1 increased from 3.27 to 3.83 
PNGS, the mean number of PNGS in V3 increased from 0.92 to 1.06 PNGS, the mean 
number of PNGS in V5 increased from 1.27 to 1.59 PNGS, the mean number of PNGS 
in V1V2 increased from 5.61 to 6.22 PNGS, the mean number of PNGS in all VLs in-
creased from 12.47 to 13.22 PNGS and the mean number of PNGS in total gp160 in-
creased from 29.76 to 30.82 PNGS in patients infected in years 2006-2009. The number 
of PNGS in V2 and V4 did not show any statistical difference. Although the analysis of 
the HIV-1 envelopes length did not reveal any statistically significant difference, the 
mean length of V1 increased from 25.88 to 27.49 aa, the mean length of V1V2 increased 
from 67.83 to 69.53 and the mean length of gp160 increased from 854.57 to 857.43 aa in 
patients infected in years 2006-2009 (Fig. 60). 
 
The comparison of the length and the number of PNGS was also performed on the se-
quences obtained from Los Alamos data base from the same patient. Two HIV-1 enve-
lope sequences were obtained for each of 7 patients. The first sequence was obtained at 
the moment of acute infection of a patient and the second was obtained at the moment 
of AIDS stage of infection. The comparison of the length of VLs within the same patient 
at different stage of HIV-1 infection did not show any statistically significant differ-
ence. However, the mean length of V1 increased from 21 aa to 23 aa, the mean length of 
V2 increased from 42.71 aa to 43.43 aa, the mean length of V1V2 increased from 63.71 
aa to 66.43 aa, the mean length of all VL increased from 144.57 aa to 146.43 aa and the 
length of gp160 increased from 852.57 aa to 854.71 aa within the same patient over the 
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time of HIV-1 infection. The number of PNGS in VLs increased significantly over the 
course of disease (p=0.0368). The mean number of PNGS in V2 increased from 2 to 3.86 
PNGS (p=0.0032), the mean number of PNGS in V1V2 increased from 4.71 to 5.86 
PNGS (p=0.0728), the mean number of PNGS in all VLs increased from 11.43 to 13.57 
PNGS and the mean number of PNGS in gp160 increased from 28.71 to 31.57 PNGS 
(p=0.0450) in the same patients along the time of infection. The number of PNGS in V1, 
V3, V4 and V5 did not reveal any significant difference (Fig. 61). 
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Figure 59. Comparison of the length and the PNGS number in HIV-1 envelopes between patients with acute HIV-1 infection and patients with chronic HIV-1 infection. A. 
Length of V1. B. PNGS in V1. C. Length of V2. D. PNGS in V2. E. Length of V3. F. PNGS in V3. G. Length of V4. H. PNGS in V4. I. Length of V5. J. PNGS in V5. K. Length of 
VLs. L. PNGS in VLs. M. Length of gp160. N. PNGS in gp160. The p values, estimated by Mann-Whitney test, are shown above each graph.  
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Figure 60. The comparison of the VLs length and the PNGS number between patients infected in years 1983-1986 and patients infected in years 2006-2009. A. Length of V1. 
B. PNGS in V1. C. Length of V2. D. PNGS in V2. E. Length of V3. F. PNGS in V3. G. Length of V4. H. PNGS in V4. I. Length of V5. J. PNGS in V5. K. Length of VLs. L. 
PNGS in VLs. M. Length of gp160. N. PNGS in gp160. The p values, estimated by Mann-Whitney, test are shown above each graph.  
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Figure 61. Comparison of the length of VLs and the number of PNGS in the same patient over the time of HIV-1 infection. A. Length of V1. B. PNGS in V1. C. Length of V2. 
D. PNGS in V2. E. Length of V3. F. PNGS in V3. G. Length of V4. H. PNGS in V4. I. Length of V5. J. PNGS in V5. K. Length of VLs. L. PNGS in VLs. M. Length of gp160. N. 
PNGS in gp160. The p values, estimated by Mann-Whitney test, are shown above each graph.
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 stage of HIV-1 infection date of HIV-1 infection the same patient 
 acute vs chronic infection 1983-1986 vs 2006-2009 acute vs chronic infection 
V1 length 0.2614 0.1369 0.4382 
V1 PNGS 0.0814 0.0002 0.1525 
V2 length 0.7351 0.7492 0.7929 
V2 PNGS 0.5868 0.9593 0.0032 
V1V2 length 0.6004 0.3774 0.3363 
V1V2 PNGS 0.1917 0.0065 0.0728 
V3 length 0.1119 0.3669 0.5906 
V3 PNGS 0.0009 0.0132 0.9163 
V4 length 0.3364 0.1847 0.6996 
V4 PNGS 0.8553 0.3152 0.3104 
V5 length 0.9771 0.2114 0.9430 
V5 PNGS 0.8800 0.0008 0.6589 
V1-V5 length 0.2976 0.8832 0.5211 
V1-V5 PNGS 0.2480 0.0411 0.0368 
gp160 length 0.3527 0.7556 0.4783 
gp160 PNGS 0.6780 0.0107 0.0450 
 
 
 
Table 5. Statistical analysis of the length and the PNGS number in 3 groups of patients: 1) individuals with 
different stage of HIV-1 infection, 2) patients infected in years 1983-1986 or 2006-2009, 3) in the same pa-
tient on HIV-1 sequences obtained at different stages of HIV-1 infection. The p values were calculated by 
GraphPad Prism V4 applying Mann-Whitney test. 
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’ INTRODUCTION
Carbohydrates are involved in several biological processes
including cell-differentiation, migration, tumor progression and
metastasis, inflammation, pathogen infection, and so forth.1 Carbo-
hydrates participate in these events through complex and selective
recognition processes triggered by interaction with receptors.
One of the processes that initialize immune response to
pathogen invasion is the interaction of the pathogen surface glycans
with C-type lectin receptors expressed on the antigen-presenting
cells (APCs), such as dendritic cells (DCs). Although usually indi-
vidual carbohydrate unit binding to lectin is weak (KD in millimolar
range), the clustered organization of these receptors as well as high
glycosylation of their ligands create the conditions for more specific
multivalent interactions, and thus overcome low affinity prob-
lems.25 The use of scaffolds to prepare carbohydrate multivalent
systems is nowadays a very useful and common approach to develop
tools to understand and intervene in these biological processes
where carbohydrates play a key role.6,7
The lack of design in thesemultivalent systems is partly a result of
the often scarce information about the structural details of the
multivalent presentation of the corresponding receptors at the cell
surface. However, even if these details were known, topological
design of large, multivalent molecules would still not be straightfor-
ward and the valency and 3D structures required to achieve a strong
cluster effect on a given receptor cannot be estimated a priori. These
facts explain the huge number of examples illustrating different
strategies to target cellular receptors in a multivalent manner. In this
context, our research is focused on the development of glycoden-
drimers to block a C-type lectin, DC-SIGN, which recognizes
glycoconjugates present on the surfaces of several pathogens includ-
ing viruses (HIV, Ebola, Cytomegalovirus, Dengue, SARS), bacteria
(M. tuberculosis, S. pneumoniae) fungi (C. albicans, A. fumigatus), and
Received: January 21, 2011
Revised: March 31, 2011
ABSTRACT: The development of compounds with strong
affinity for the receptor DC-SIGN is a topic of remarkable
interest due to the role that this lectin plays in several pathogen
infection processes and in the modulation of the immune
response. DC-SIGN recognizes mannosylated and fucosylated
oligosaccharides in a multivalent manner. Therefore, multi-
valent carbohydrate systems are required to interact in an
efficient manner with this receptor and compete with the
natural ligands. We have previously demonstrated that linear
pseudodi- and pseudotrisaccharides are adequate ligands for
DC-SIGN. In this work, we show that multivalent presentations
of these glycomimetics based on polyester dendrons and
dendrimers lead to very potent inhibitors (in the nanomolar
range) of cell infection by Ebola pseudotyped viral particles by blocking DC-SIGN receptor. Furthermore, SPR model experiments
confirm that the described multivalent glycomimetic compounds compete in a very efficient manner with polymannosylated ligands
for binding to DC-SIGN.
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parasites (Leishmania, S. mansoni).814 It has been proven that this
lectin plays a key role in the early stages of the infection processes
caused by some of these pathogens. Therefore, DC-SIGN can be
selected as a new therapeutic target for the design of antiviral
drugs.1518 Previous results from our groups indicate that glyco-
dendrimers based on Boltorn-type structures bearing mannoses
exhibit a strong antiviral activity in a pseudotype Ebola viral particles
infection model both for in cis and in trans infection.1921 Addi-
tionally, we have demonstrated that carbohydrate mimics such as a
pseudomannobioside present an activity around 1 order of magni-
tude higher than mannose in such infection studies.22,23 These new
glycomimetics are more stable against enzymatic degradation than
the corresponding natural counterparts, and therefore, they are
more adequate compounds to be used in clinical applications.
In this study, we combined the improved binding properties of
these new pseudomannoside ligands with the potency of multi-
valent presentation on Boltorn scaffolds. Indeed, nanomolar
inhibition levels have been reached in a pseudotyped Ebola viral
particles infection model. Binding properties between these
compounds and their receptor, DC-SIGN, have been analyzed
at the molecular level using biosensors with surface plasmon
resonance (SPR) detection method. Altogether, this work opens
road to new compounds in antiviral strategy.
’MATERIALS AND METHODS
Reagents were purchased from Sigma-Aldrich, Senn Chemi-
cals, Flucka and were used without purification. Solvents were
dried by standard procedures. Reactions requiring anhydrous condi-
tions were performed under nitrogen. Synthetic compounds were
purified by flash chromatography using medium or fine silica gel or
by Sephadex (LH20, G25). Thin layer chromatography (TLC) was
carried out with precoated Merck F254 silica gel plates. Flash
chromatography (FC) was carried out with Macherey-Nagel silica
gel 60 (230400mesh). Reaction completionwas observed byTLC
using as development reagents phosphomolibdic acid, 10% sulfuric
acid in methanol or anisaldehyde. 1H and 13C spectra were recorded
at 400 MHz on Bruker Avance DPX 300, DRX 400, and DRX 500
MHz spectrometers. Chemical shifts (δ) for 1H and 13C spectra are
expressed in ppm relative to internal TMS (tetramethylsilane) using
manufacturer indirect referencing method. Signals were abbreviated
as s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; and m,
multiplet. Mass spectra were obtained with a Bruker ion-trap Esquire
3000 or 6000 apparatus (ESI ionization) and Microflex apparatus
(MALDI ionization) from Bruker. HRMS (FT-ICR, ESI) were
obtained with an Apex II instrument. Infrared spectra were recorded
with a Bruker Vector 22 FT-IR spectrometer. Elemental analyses
were obtained with a Leco CNHS instrument. All hydrogenation
reactions were carried out under H2 atmosphere at atmospheric
pressure.
Synthesis of Compounds. Compounds G1(Bn)4,
24 G1-
(OH)8,
25 1,26 2,27 3,28 6,29 11,23 13,22 and 141523 were prepared
as described previously in the literature.
Synthesis of G2(Bn)8. G1(OH)8 (100 mg, 0.17 mmol) and
DMAP (70 mg) were dissolved in dry pyridine (1 mL) and then
dilutedwithCH2Cl2 (2mL). Anhydride 1 (812mg, 2.04mmol) was
added and the reaction mixture was stirred at room temperature for
15 h. Then, the excess of anhydride 1 was quenched by stirring the
reaction mixture with 1 mL of pyridine/H2O (1:1) solution over-
night. The organic phase was diluted with CH2Cl2 (100 mL), and
washed with NaHSO4 1 M (2  40 mL), Na2CO3 (10%) (2 
40 mL), and NaCl sat. (40 mL). The organic phase was dried using
MgSO4 anh., and the solvent was evaporated under vacuum. The
residue was recrystallized from CH2Cl2/hexane to give G2(Bn)8
(370 mg, 97%) as white crystals. 1H NMR (300 MHz, CDCl3): δ
(ppm) 7.407.38 (m, 16 H, HAr), 7.327.26 (m, 30H, HAr), 5.36
(s, 8H, 8 CHBn), 4.53 (d, 16H, J = 11.7 Hz, CH2G2), 4.36 (d, 8H,
J = 11.4 Hz, CH2G1), 4.29 (d, 8H, J = 11.4 Hz, CH2G1), 3.89 (s, 8H,
CH2Pentaerythritol), 3.52 (d, 16H, J = 11.7 Hz, CH2G2), 1.15 (s, 12H,
CH3G1), 0.88 (s, 24H, CH3G1);
13C NMR (100 MHz, CDCl3) δ
(ppm) 175.9 (COOG2), 174.1 (COOG1), 140.2 (CPh), 131.2 (CPh),
130.4 (CHPh), 128.5 (CHPh), 104.0 (CHBn), 75.7, 75.7, 67.2, 63.6,
49.2, 44.8, 36.2, 20.0 (CH3G2), 19.9 (CH3 G1); ESI-MS for
C121H140O40; calcd 2232.9 [M]
þ; found 2256.7 [MþNa]þ and
1139.8 [Mþ2Na]2þ; Elemental analysis calcd (%) forC121H140O40:
C, 65.04%; H, 6.32%; found: C, 65.32%; H, 6.31%.
Synthesis of G2(OH)16. G2(Bn)8 (3.8 g, 1.70 mmol) was
dissolved in CH2Cl2 (50 mL) and diluted with MeOH (50 mL).
A catalytic amount of Pd(C) was added to the solution and the
reaction mixture was hydrogenated under vigorous stirring for 12 h.
Then, the reaction mixture was filtered over a pad of Celite. The
solvent was evaporated to giveG2(OH)16 (860mg, 95%) as a white
solid. 1HNMR(300MHz, CD3OD):δ (ppm) 4.39 (d, 8H, J= 11.1
Hz, CH2G1), 4.30 (d, 8H, J = 11.1 Hz, CH2G1), 4.29 (s, 8H,
CH2Pentaerythritol), 3.70 (d, 16H, J = 10.8 Hz, CH2G2), 3.61 (d, 16H,
J = 10.8 Hz, CH2G2), 1.35 (s, 12H, CH3G1), 1.17 (s, 24H, CH3G2);
13C NMR (75 MHz, CD3OD): δ (ppm) 176.0 (COOG2), 173.8
(COOG1), 66.1 (CH2Pentaerythritol), 65.9 (CH2G2), 63.6 (CG2), 51.8
(CH2G1), 44.3 (CG1), 18.3 (CH3G1), 17.4 (CH3G2); ESI-MS for
C65H108O40; calcd: 1528.6 [M]
þ; found: 1551.4 [MþNa]þ.
Synthesis of G3(Bn)16. G2)OH)16 (1.00 g, 0.654 mmol)
andDMAP (445mg) were dissolved in dry pyridine (20mL) and
then diluted with CH2Cl2 (40 mL). Anhydride 1 (6.02 g, 14.13
mmol) was added, and the reaction mixture was stirred at room
temperature for 15 h. Then, the excess of anhydride 1was quenched
by stirring the reaction mixture with 20 mL of pyridine/H2O (1:1)
solution overnight. The organic phase was diluted with CH2Cl2
(300 mL), and washed with NaHSO4 1M (2 150 mL), Na2CO3
(10%) (2 150 mL), and NaCl sat. (150 mL). The organic phase
was dried using MgSO4 anh., and the solvent was evaporated under
vacuum.The residuewas recrystallized fromCH2Cl2/MeOH to give
G3(Bn)16 (2.7 g, 97%) as white crystals.
1H NMR (500 MHz,
CDCl3):δ (ppm) 7.377.34 (m, 32H,CHPh), 7.277.21 (m, 48H,
CHPh), 5.32 (s, 16H, CHBn), 4.49 (d, 32H, CH2G3), 4.344.25 (m,
32H, 2  16 CH2G2), 4.12 (d, 8H, CH2G1), 4.11 (s, 8H,
CH2Pentaerythritol), 4.02 (d, 8H,CH2G1), 3.553.51 (m, 32H,CH2G3),
1.18 (s, 24H, CH3G2), 1.08 (s, 12H, CH3G1), 0.88 (s, 48H, CH3G3);
13C NMR (125 MHz, CDCl3): δ (ppm) 173.2 (COOG3), 171.9
(COOG2), 171.5 (COOG1), 138.0 (CPh), 128.8 (CHPh), 128.1
(CHPh), 126.2 (CHPh), 101.6 (CHBn), 73.4, 73.3, 64.9, 46.9, 46.6,
42.5 (CH2G3), 34.0, 25.0, 17.7 (CH3G2), 17.6 (CH3G3), 17.2
(CH3G1); ESI-MS for C257H300O88; calcd: 4793.9 [M]
þ; found:
2420.5 [Mþ2Na]2þ and 1621.8 [Mþ3Na]3þ; Elemental analysis
calcd (%) for C257H300O88: C, 64.34%;H, 6.30%; found: C, 64.07%;
H, 6.46%.
Synthesis of G3(OH)32. G3(Bn)16 (1.7 g, 0.354 mmol) was
dissolved in CH2Cl2 (30 mL) and diluted with MeOH (30 mL).
A catalytic amount of Pd(C) was added to the solution and the
reaction mixture was hydrogenated under vigorous stirring for 12 h.
Then, the reaction mixture was filtered over a pad of Celite. The
solvent was evaporated to give G3(OH)32 (1.14 g, 95%) as a white
solid. 1HNMR(500MHz,CD3OD):δ (ppm) 4.364.22 (m, 56H,
CH2PentaerythritolþCH2G1þCH2G2), 3.68 (m, 32H,CH2G3), 3.58 (d,
32H, J = 10.0 Hz, CH2G3), 3.39 (s, 32H, CH2OH), 1.34 (s, 12H,
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CH3G1), 1.30 (s, 24H,CH3G2), 1.12 (s, 48H,CH3G3);
13CNMR(75
MHz, CD3OD): δ (ppm) 176.0 (COOG2), 173.8 (COOG1), 66.1
(CH2Pentaerythritol), 65.9 (CH2G2), 63.6 (CG2), 51.8 (CH2G1), 44.3
(CG1), 18.3 (CH3G1), 17.8 (CH3G3), 17.4 (CH3G2); ESI-MS for
C65H108O40; calcd: 3385.4 [M]
þ; found: 1716.0 [Mþ2Na]2þ and
1151.0 [Mþ3Na]3þ.
Synthesis of G3(sucBn)32. (460 mg, 1.36 mmol), succinic
acid derivate 2 (1.086 g, 5.22 mmol) and DPTS (512 mg,
1.74 mmol) were disolved in CH2Cl2 (15 mL) under argon
atmosphere. DCC (1.433 g, 6.96 mmol) was added and the
reaction mixture was stirred for 24 h at room temperature.
Then, the reaction mixture was diluted with (6 mL), filtered
over a pad of Celite, and the solvent was evaporated. The residue
was purified by flash chromatography on silica gel (Hex-AcOEt,
1:1.2), to afford G3(sucBn)32 (1.10 g, 81%) as an oil.
1H NMR
(500 MHz, CDCl3): δ (ppm) 7.417.33 (m, 160H, CHAr), 5.13
(bs, 64H, CH2Bn), 4.504.21 (m, 120H, CH2dendrimer), 2.63 (bs,
128H, CH2suc), 1.39 (bs, 12H, CH3G1), 1.31 (bs, 24H, CH3G2),
1.23 (bs, 48H, CH3G3);
13C NMR (125 MHz, CDCl3) δ (ppm)
171.9 (COOG3), 171.7 (COOG2), 171.6 (COOG1), 135.9 (CArBn),
128.5 (CHArBn), 128.4 (CHArBn), 128.2 (CHArBn), 66.4 (CH2Bn),
65.1, 64.9 (CH2dendrimer), 46.7 (CG1), 46.6 (CG2), 46.3 (CG3),
28.9 (CH2suc), 28.8 (CH2suc), 17.7 (CH3G3), 17.6 (CH3G2), 17.4
(CH3G1); ESI-MS for C497H556O184; calcd: 9467.4 [M]
þ;
found: 4758.5 [Mþ2Na]2þ and 3185.3 [Mþ3Na]3þ; Elemental
analysis calcd (%) for C497H556O184: C, 63.01%; H, 5.92%;
found: C, 62.54%; H, 6.00%.
Synthesis of G3(suc)32. G3(sucBn)32 (87 mg, 9.19  103
mmol) was dissolved in CH2Cl2 (3 mL) and diluted withMeOH
(6 mL). A catalytic amount of Pd(C) was added to the solution and
the reactionmixture was hydrogenated under vigorous stirring for 12
h. Then, the reaction mixture was filtered over a pad of Celite. The
solvent was evaporated to giveG3(suc)32 (79mg, quant.) as a white
solid. 1H NMR (300 MHz, D2O): δ (ppm) 4.504.20 (m, 120,
60 CH2OCO), 2.70257 (m, 128H, 64 CH2suc), 1.42 (s, 12H,
4 CH3G1), 1.35 (s, 32H, 8 CH3G2), 1.28 (s, 52H, 16 CH3G3);
13C NMR (125 MHz, CD3CN): δ (ppm) 174.2 (COO), 173.0
(COO), 172.9 (COO), 66.3 (CH2O), 47.4 (C), 29.1 (CH2suc), 17.9
(CH3).
G3(pseudodi)32. To a solution of G3(suc)32 (3.5 mg, 5.31
104 mmol, 1 equiv) in dry DMA (100 μL) under nitrogen
atmosphere, HATU (13 mg, 0.034 mmol, 64 equiv) and DIPEA
(12μL, 0.068mmol, 128 equiv) were added. After 15min a solution
of 13 (16.0 mg, 0.037 mmol, 69 equiv) in dry DMA (170 μL) was
added. The reaction was stirred at room temperature for 1 day.
MALDI mass analysis of a sample of the reaction mixture showed
the completion of the reaction. The reaction mixture was diluted in
methanol and charged directly onto a Sephadex LH-20 column in
methanol. Slow elution led to the purification of the product
G3(pseudodi)32 that was isolated in good yield (9.2 mg, 88%).
1HNMR(400MHz,D2O):δ (ppm) 5.00 (s,H1M), 4.434.14 (m,
CH2OG1 þ CH2OG2 þ CH2OG3), 4.023.95 (m, HD2 þ H2M),
3.92 (s,H2M), 3.86 (d, J = 11.2 Hz,H6MB), 3.81 (dd, J = 3.2 and 8.8
Hz,H3M), 3.783.56 (m,H6MAþHD1þH4MþH5MþH7), 3.69
(s, COOCH3), 3.69 (s, COOCH3), 3.423.32 (m,H8), 2.972.81
(m, HD4 þ HD5), 2.722.61 (m, CH2COO), 2.612.49 (m,
CH2CONH), 2.162.03 (m, HD6eq þ HD3eq), 1.891.71 (m,
HD6axþ HD3ax), 1.391.18 (m, CH3G1þ CH3G2þ CH3G3); 13C
NMR (100 MHz, D2O): 177.1, 176.8, 173.4 (COOCH3,
COOCH2, CONH), 98.7 (C1M), 73.9 (CD1), 73.6 (C4M), 71.1
(CD2), 70.6 (C2Mþ C3M), 67.1 (C7), 66.9 (C5M), 65.5 (CH2OG1
þCH2OG2þCH2OG3), 61.1 (C6M), 52.5 (CH3O), 46.5 (CquatG1
þ CquatG2 þ CquatG3), 39.5 (C8), 39.1 (CD4, CD5), 30.2
(CH2CONH), 29.3 (CH2COO), 27.3, 26.9 (CD6, CD3), 17.3
(CH3G1 þ CH3G2 þ CH3G3); MALDI-ToF MS (matrix, SA):
distribution centered on 31 sugar loaded, for 31 sugars [MþNa]þ
calculated: 19614.8, found: 19689.5.
G3(pseudotri)32. To a solution ofG3(suc)32 (7.6 mg, 1.15
103 mmol, 1 equiv) in 100 μL of dry DMA under nitrogen
atmosphere, HATU (28.1 mg, 0.074 mmol, 64 equiv) and DIPEA
(26μL, 0.148mmol, 128 equiv) were added. After 15min, a solution
of 15 (35.7 mg, 0.06 mmol, 52 equiv) in dry DMA (230 μL) was
added. The reaction was stirred at room temperature for 2 days.
MALDImass analysis of a sample of the reactionmixture showed the
completion of the reaction. The reaction mixture was diluted in
methanol and charged directly onto a Sephadex LH-20 column in
methanol. Slow elution led to the purification of the product
G3(pseudotri)32 that was isolated in good yield (25.5 mg, 88%
yield). 1H NMR (400 MHz, D2O): δ (ppm) 5.00 (s, H1M0 ), 4.84
(s, H1M), 4.404.10 (m, CH2OG1 þ CH2OG2 þ CH2OG3), 4.04
(s, HD2), 3.97 (bs, H2M0 ), 3.92 (s, H2M), 3.893.53 (m, H3M0 þ
H6M0 BþH6MBþHD1þH6M0 AþH6MAþH3MþH4MþH4M0 þ
H7 þ H5M þ H5M0 ), 3.69 (s, COOCH3), 3.68 (s, COOCH3),
3.493.34 (m, H8), 3.002.85 (m, HD4 þ HD5), 2.732.59 (m,
CH2COO), 2.592.46 (m, CH2CONH), 2.272.03 (m, HD6eqþ
HD3eq), 1.891.71 (m, HD6ax þ HD3ax), 1.401.15 (m, CH3G1 þ
CH3G2 þ CH3G3); 13C NMR (100 MHz, D2O): δ (ppm) 177.3,
177.0, 173.5, 173.0 (COOCH3, COOCH2, CONH), 99.9 (C1M),
98.7 (C1M0 ), 74.7 (CD1), 73.5, 72.2 (C4M þ C4M0 ), 71.0 (CD2),
70.9, 70.7, 70.6 (C2M0 þ C3M þ C3M0 ), 70.2 (C2M), 68.2 (C6M),
67.1, 66.9 (C5Mþ C5M0 ), 66.2 (C7), 65.4 (CH2OG1þ CH2OG2þ
CH2OG3); 61.1 (C6M0 ), 52.6 (CH3O), 46.4 (CquatG1þ CquatG2þ
CquatG3), 39.1, (CD4, CD5), 39.0 (C8), 30.1 (CH2CONH), 29.2
(CH2COO), 27.2, 26.9 (CD6, CD3), 17.3 (CH3G1 þ CH3G2 þ
CH3G3). MALDI-ToF MS (matrix: SA): distribution centered
on 31 sugar loaded, for 31 sugar [C1041H1612N32O664Na]
þ
calcd: 25222.75, found: 25227.9.
2-Azidoethyl Isopropylidene-2,2-bis(oxymethyl)propio-
nate (4). 2-Bromoethanol (1.2 mL, 17.0 mmol) and DMAP
(0.325 g, 2.6 mmol) were dissolved in pyridine (25 mL), followed
by the addition of CH2Cl2 (70 mL). The anhydride of isopropyli-
dene-2,2-bis(oxymethyl)propionic acid 6 (7.4 g, 22.4 mmol) was
added slowly.The solutionwas stirred at room temperature overnight
and then was quenched with water (1 mL) under vigorous stirring,
followed by dilution with of CH2Cl2 (200mL), and the solution was
washed with 10% of NaHSO4 (3 40 mL), 10% of Na2CO3 (3
40 mL), and brine (20 mL). The organic phase was dried with
MgSO4, filtered, and concentrated. The crude product was purified
by flash chromatography on silica gel, eluting with hexane (100 mL)
and gradually increasing the polarity to EtOAc/hexane (9:1; 6:1) to
give 2-bromoethyl isopropylidene-2,2-bis(oxymethyl)propionate as
colorless oil (4.9 g, 86%). This bromo derivative (4.9 g, 14.6 mmol)
and NaN3 (2.6 g, 40.0 mmol) were dissolved in dry DMF (50 mL)
and the reactionmixturewas stirred at 50 Cfor 15h.The solventwas
removed under high vacuum and AcOEt was added to the residue.
The NaN3 on excess was taken off by filtration, and the solvent was
removed to obtain 4 as colorless oil (3.53 g, 99%). 1H NMR (300
MHz, CDCl3) δ: 4.30 (t, 2H, J = 5.1 Hz, CH2CH2N3), 4.18 (d, 2H,
J =11.9Hz,CH2OCO), 3.64 (d, 2H, J =11.9Hz,CH2OCO), 3.67 (t,
2H, J = 5.1 Hz, CH2CH2N3), 1.41 (s, 3H, CH3), 1.36 (s, 3H, CH3),
1.19 (s, 6H, 2  CH3); 13C NMR (100 MHz, CDCl3) δ: 173.8
(COO), 98.0 (Cipr), 65.8 (CH2OCO), 63.5 (CH2CH2N3), 49.7
(CH2CH2N3), 41.9 (C), 24.8, 22.2 (CH3), 17.7 (CH3); ESI-MS for
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C9H15N3O4; calcd: 243.1, [M]
þ; found 266.1 [MþNa]þ. IR
(υ, cm1): 3448 (bs), 2992, 2940, 2105, 1734, 1638.
2-Azidoethyl 2,2-Bis(hydroxymethyl)propionate (5). Azi-
do derivative 4 (11.0 g, 45.2 mmol) was dissolved in MeOH
(50 mL). One teaspoon of a Dowex, Hþ resin was added, and the
reaction mixture was stirred at 40 C until complete disappearance
of starting material. When the reaction was complete, the Dowex
Hþ resin was filtered off in a glass filter and carefully washed with
methanol. The methanol was evaporated to give 5 as colorless oil
(9.0 g, 98%). 1H NMR (CDCl3, 300 MHz) δ: 4.34 (t, 2H, J = 5.1
Hz,CH2CH2N3), 3.92 (d, 2H, J = 11.2Hz,CH2OCO), 3.74 (d, 2H,
J = 11.2 Hz, CH2OCO), 3.52 (t, 2H, J = 5.1 Hz, CH2CH2N3), 3.02
(bs, 2H,OH), 1.12 (s, 3H,CH3);
13CNMR (CDCl3, 100MHz) δ:
175.3 (COO), 67.8 (CH2OCO), 63.5 (CH2CH2N3), 49.8
(CH2CH2N3), 49.4 (C), 17.0 (CH3); ESI-MS for C7H13N3O4;
calcd: 203.1 [M]þ; found: 226.0 [MþNa]þ. IR (υ, cm1): 3405
(bs), 2945, 2885, 2105, 1729, 1660, 1459. Elemental analysis calcd.
(%) for C7H13N3O4: C, 41.38%, H, 6.45%; N, 20.68%; found: C,
41.83%; H, 6.79%; N, 20.50%.
Compound 7. Azido derivative 5 (2.4 g, 11.8 mmol) and
DMAP (0.43 g, 3.54 mmol) were dissolved in pyridine (6 mL),
followed by the addition of CH2Cl2 (12 mL). The anhydride of
isopropylidene-2,2-bis(hydroxymethyl)propionic acid 6 (9.3 g,
30.7 mmol) was added slowly. The solution was stirred at room
temperature until completion. The reaction was quenched with
water (1 mL) under vigorous stirring, followed by dilution with
CH2Cl2 (50 mL), and the solution was washed with 10% of
NaHSO4 (3  20 mL), 10% of Na2CO3 (3  20 mL), and brine
(10 mL). The organic phase was dried with MgSO4, filtered, and
concentrated. The crude product was purified by flash chromatog-
raphy on silica, eluting with hexane (100 mL) and gradually
increasing the polarity to EtOAc/hexane (1:3) to give 7 as colorless
oil (4.4 g, 73%). 1HNMR(CDCl3, 300MHz)δ: 1.17 (s, 6H,CH3),
1.34 (s, 3H, CH3), 1.38 (s, 6H, CH3), 1.43 (s, 6H, CH3), 3.51 (t, J =
5.1 Hz, 2H, CH2CH2N3), 3.64 (d, J = 11.9 Hz, 4H, CH2OCO),
4.17 (d, J = 11.8 Hz, 4H, CH2OCO), 4.344.28 (t, J = 5.1 Hz, 2H,
CH2CH2N3), 4.36 (s, 4H, CH2OCO);
13C NMR (CDCl3, 75.5
MHz) δ: 173.5, 172.3 (COO), 98.1 (Cipr), 66.0, 66.0, 65.3
(CH2OCO), 63.9 (CH2CH2N3), 49.6 (CH2CH2N3), 46.9, 42.1
(C), 25.3, 22.0 (CH3
ipr), 18.0, 17.0 (CH3); ESI-EM calc for
C23H37N3O10(m/z): 515.2; found 538.2 [MþNa]þ. IR
(υ, cm1): 3453 (bs), 2991, 2940, 2876, 2106, 1738, 1643, 1455.
Compound 8. Azido derivative 7 (4.3 g, 8.4 mmol) was
dissolved in MeOH (20 mL). One teaspoon of a Dowex Hþ
resin was added, and the reaction mixture was stirred at 40 C until
complete disappearance of starting material by TLC. When the
reaction was complete, the Dowex Hþ resin was filtered off in a
glass filter and carefully washed with methanol. The methanol was
evaporated to give 8 as colorless oil (3.5 g, 97%). 1HNMR (CDCl3,
300 MHz) δ: 4.46 (d, J = 11.1 Hz, 2H, CH2OCO), 4.364.26 (m,
4H, CH2OCO, CH2CH2N3), 3.903.78 (m, 4H, CH2OCO),
3.763.67 (m, 4H, CH2OCO), 3.51 (t, J = 5.1 Hz, 2H,
CH2CH2N3), 3.192.87 (bs, 4H), 1.36 (s, 3H, CH3), 1.08 (s,
6H, CH3);
13C NMR (CDCl3, 75.5 MHz) δ: 175.0, 175.0, 172.8
(COO), 67.3, 67.2, 67.2, 64.8 (CH2OCO), 64.0 (CH2CH2N3),
49.8 (CH2CH2N3), 49.8, 49.6 (C), 18.0, 17.0 (CH3); ESI-EM calcd
for C17H29N3O10 (m/z): 435.2; found 458.2 [MþNa]þ. IR
(υ, cm1): 3405 (bs), 2943, 2886, 2108, 1731, 1469.
Compound 10. 4-Oxo-4-(2-(trimethylsilyl)ethoxy)butanoic
acid (9) (1.43 g, 6.57 mmol), tetraol 8 (0.50 g, 1.09 mmol), and
DPTS (0.65 g, 2.18 mmol) were mixed in CH2Cl2 anhydrous
(10 mL). Then, the reaction flask was flushed with argon and
DCC (1.35 g, 6.57 mmol) was added. Stirring at 40 C was
continued for 15 h under argon atmosphere. Once the reaction
was complete, the formed urea was filtered off on a glass filter and
washed with a small volume of CH2Cl2. The crude product was
purified by liquid chromatography Sephadex LH20 (CH2Cl2/
MeOH; 1:1) to give 10 as colorless viscous oil (1.11 g, 81%). 1H
NMR (CDCl3, 300 MHz) δ: 4.433.97 (m, 14H, 4 CH2G1, 8
CH2G2, 2 CH2CH2N3, 8 CH2CH2COCH2), 3.533.43 (t, J = 5.1
Hz, 2H, CH2CH2N3), 2.652.47 (m, 16H, CH2suc), 1.26 (s, 3H,
CH3 G1), 1.20 (s, 6H, CH3 G2), 1.000.88 (t, J = 8.5 Hz, 8H, CH2-
TMS), 0.00 (s, 36H,CH3TMS);
13CNMR(CDCl3, 75.5MHz) δ:
172.1, 171.9, 171.9, 171.7 (COO), 65.6, 65.3, 64.0, 62.9 (CH2OCO,
CH2CH2N3, CH2CH2COCH2), 49.6 (CH2CH2N3), 46.7, 46.4
(CCH2O), 29.1, 28.8 (CH2suc), 17.7, 17.4 (CH2-TMS,CH3), 17.2,
1.5,1.9 (CH3TMS); ESI-HRMS calcd for C53H93N3O22Si4Na
(m/z): 1258.5291; found: 1258.5226. IR (υ, cm1): 2955, 2898,
2104, 1730, 1471.
Compound 11. TFA (5 mL) was added to a solution of 10
(142 mg, 0.115 mmol) in CH2Cl2 (5 mL). The mixture was
stirred at room temperature for 2 h. After complete conversion, the
solventwas evaporated and dried in high vacuum to afford 11 as pale
yellow syrup (96 mg, 100%). The compound was used in the next
step without purification. 1H NMR (MeOH-d4, 400 MHz) δ: 4.30
(m, 28H, 4CH2 G1 8CH2 G2, 2CH2CH2N3), 3.57 (t, J = 5.1Hz, 2H,
CH2CH2N3), 2.62 (m, 16H, CH2CONH, CH2COO), 1.34 (s, 3H,
CH3G10), 1.27 (s, 6H, CH3G20);
13C NMR (CDCl3, 100 MHz) δ:
174.4, 172.2, 172.2, 172.0 (COO), 65.5, 65.3, 65.2, 64.0 (CH2OCO,
CH2CH2N3, CH2CH2COCH2), 49.4 (CH2CH2N3), 46.9, 46.5,
46.3 (CCH2O), 28.6, 28.5, 28.3, 28.2 (CH2CONH, CH2COO),
16.7, 16.5 (CH3); ESI-HRMS calcd for [MþNa] C33H45N3O22Na
(m/z): 858.2392; found: 858.2435.
Compound 12. To a solution of the scaffold dendron 11 (6.0
mg, 0.00718 mmol, 1 equiv) in 150 μL of dry DMA under
nitrogen atmosphere, HATU (22 mg, 0.0575 mmol, 8 equiv) and
DIPEA (20 μL, 0.1157mmol, 16 equiv) were added. After 15min, a
solution of 13 (23.4 mg, 0.05349 mmol, 8 equiv) in dry DMA
(210 μL) was added. The reaction was stirred at room temperature
for 3 days. MALDI mass analysis of a sample of the reaction mixture
showed the completion of the reaction. The reaction mixture was
diluted in methanol and charged directly onto a Sephadex LH-20
column (methanol). Slow elution led to the purification of the
product 12 that was isolated in good yield (16.9mg, 94%). 1HNMR
(400 MHz, D2O): δ (ppm) 4.93 (s, 4H, H1), 4.27 (bs, 6H,
OCH2CH2N3, CH2OG1), 4.18 (bs, 8H, CH2OG2), 3.91 (bs, 8H,
D2, H2), 3.78 (d, 4H, H6B, J = 12 Hz), 3.763.71 (m, 4H, H3),
3.693.59 (m, 8H,H6A,HD1), 3.63 (s, 24H,OCH3), 3.593.49 (m,
18H, H4, H5, H7, CH2N3), 3.30 (bt, 8H, H8), 2.912.72 (m, 8H,
HD4, HD5), 2.652.56 (m, 8H, CH2COO), 2.542.45 (m, 8H,
CH2CONH), 2.101.99 (m, 8H, HD6eq, HD3eq), 1.811.64 (m,
8H, HD6ax, HD3ax), 1.26 (s, 3H, CH3G10 ), 1.19 (s, 6H, CH3G20 );
13C
NMR (100 MHz, D2O): 177.4, 177.2, 174.1, 174.0, 173.8, 173.7
(COOCH3, COOCH2, CONH), 98.6 (C1M), 73.8 (CD1), 73.5
(C4M), 71.0, 70.5 (CD2, C2M, C3M), 66.9 (C7), 66.8 (C5M), 65.9
(OCH2G1, OCH2G2), 64.8 (OCH2CH2N3), 61.0 (C6M); 52.6
(CH3O); 49.4 (CH2N3); 46.6, 46.4 (Cquat G1, G2); 39.4 (C8);
39.0 (CD4, CD5); 30.1 (CH2CONH); 29.3 (CH2COO); 27.0,
26.7 (CD6, CD3); 16.9 (CH3G1,G2); ESI-MS calcd for [C105H161-
N7O62Na2]
þ2 1279.7, found: 1279.2; MALDI-ToF MS (matrix
DHB) [C105H161N7O62Na]
þ calcd: 2536.4, found: 2537.2.
Production of Recombinant Viruses. Recombinant viruses
were produced in 293 T cells. The viral construction was pseudo-
typed with Ebola virus envelope glycoprotein (EboGP) and
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expressed luciferase as a reporter of the infection. The infection of
Jurkat cells (a CDþT-lymphocyte cell line) by EboGP is absolutely
dependent on virus envelope interaction with DC-SIGN. As a
control of DC-SIGN independent infection, we produced recom-
binant viruses pseudotyped with vesicular stomatitis virus envelope
glycoprotein (VSV-G).
One day (1824 h) before transfection, 6  106 293 T cells
were seeded onto 10 cm plates. Cells were cultured in DMEM
medium supplemented with 10% heat-inactivated FBS, 25 mg
Gentamicin, and 2 mM L-glutamine. Few minutes before transfec-
tion, the medium on transfection plates was changed to 9 mL
DMEM and 25 μM chloroquine. Transfection reaction with all
reagents at room temperature (r.t.) was prepared in 15 mL tubes:
183 μL of 2 M CaCl2, 450 ng of Ebola virus envelope, 21 μg of
pNL43 luc, and 1200 μL of H2O. Next, 1.5 mL of 2HBS
(Hepes Buffer Saline) pH 7.00 was added quickly to the tubes and
bubbled for 30 s. HBS/DNA solution was dropwise added onto
medium. After 8 h of incubation at 37 Cwith 5%CO2, medium on
transfection plates was changed to 10 mL DMEM and once again
one day after transfection to 7 mL DMEM. Transfection super-
natants were harvested after 48 h, centrifuged at 1200 rpm for 10
min at r.t. to remove cell debris, and stored frozen at 80 C.
Infection Assay. Infection in cis. Infection was performed on
Jurkat cells expressing DC-SIGN. Since Ebola virus does not
infect T-lymphocytes, its entry into Jurkat cells is absolutely
dependent on the interaction with DC-SIGN.30
DC-SIGNþ Jurkat cells (2.5  105) were incubated with
carbohydrate multivalent compounds on 24-well suspension
plates for 30 min at r.t. and then challenged with 10 000 tissue
culture infective dose (TCID) of recombinant viruses. After 48 h
of incubation, cells were washed twice with PBS and lysed with
100 μL of 1 Lysis Buffer for luciferase assay (Promega).
Infection control experiment was performed with VSV-G
pseudoviruses under the same conditions.
Infection in trans. DC-SIGNþ Jurkat cells (2.5  105) were
preincubated for 20 min at r.t. with carbohydrate multivalent
compounds. Then, they were challenged with 10 000 TCID of
recombinant viruses and incubated for 2 h at r.t. with rotation. After
2 h, cells were centrifuged at 1000 rpm for 5 min and washed twice
with 1 mL of PBS supplemented with 0.5% bovine serum albumin
(BSA) and 1mMCaCl2.DC-SIGN
þ Jurkat cells were resuspended
in 500 μL of RPMI medium and co-cultivated with adherent HeLa
cells (105 cells/well) on 24-well plate. After 48 h, supernatant was
removed and monolayer of HeLa was washed twice with 1 mL of
PBS and lysed with 100 μL of 1 Lysis Buffer for luciferase assay.
As control experiment, trans-infection test with VSV-G pseu-
doviruses was performed.
Surface Plasmon Resonance. Extracellular domain (ECD)
of DC-SIGN protein (residue 66404) has been overexpressed
and purified as described previously.31 All experiments were
performed on a Biacore 3000 using functionalized CM4 sensor
chips and the corresponding reagents from BIAcore. Two flow
Scheme 1. Synthesis of Compound G3(suc)32 from Pentaerythritol
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cells were activated as previously described.32 Flow cell one was
then blocked with 30 μL of 1 M ethanolamine and used as a
control surface. The second one was treated with BSA-ManR1
3[ManR16]Man (BSA-Mannotriose, Dextra) (60 μg/mL) in
10 mM acetate buffer, pH 4. Remaining activated groups were
blocked with 30 μL of 1 M ethanolamine. The final density
immobilized on the surface of the second flow cell was 1200 RU.
The BSA-Mannotriose used to functionalize CM4 chip harbors
12 glycosylation sites according to manufacturer. The affinity of
the various sugars and mimics was then estimated through a DC-
SIGN ECD binding inhibition assay. The ECD of DC-SIGN was
injected onto the BSA-Mannotriose surface, at 20 μM alone or in
presence of an increasing concentration of the sugar derivatives.
Injections were performed at 20 μL/min using 25 mMTris-HCl,
pH 8, 150 mMNaCl, 4 mMCaCl2, and 0.005% of P20 surfactant
as running buffer. The original sensorgrams are reported as
Supporting Information.
To determine IC50 values for sugar derivatives, the steady state
binding responses of DC-SIGN ECD to BSA-Mannotriose sur-
face were obtained from sensorgrams and converted to relative
residual activity values. Relative IC50 values were determined
from the plots of sugar derivative concentration vs relative
residual DC-SIGNECD activity by fitting four-parameter logistic
model (see eq 1 in SI) to the experimental data.
’RESULTS
In previous works, we have demonstrated that the commer-
cially available and very cheap third generation of a Boltorn
Scheme 2. Synthesis of Tetravalent Compounds 12 and 14
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dendritic polymer was a very convenient platform for a multi-
valent presentation of carbohydrates.19 This polydisperse den-
dritic polymer, bearing 32 copies of mannose, exhibited a high
antiviral activity (IC50 = 0.3 μM) in an Ebola infection model.
20
The polydispersity of the commercial Boltorn scaffold is a major
drawback of this strategy. On the basis of these preliminary
results, we decided to prepare a Boltorn-type polyester dendri-
mer in a completely monodisperse manner. To approach this
synthesis, we used a divergent strategy based on the anhydride 1
as a building block monomer and pentaerythritol as a central
core, a strategy previously used to prepare polyester dendrons.26
A sequential set of two reactions was employed as described in
Scheme 1. A coupling reaction with anhydride 1 to grow to the
next generation, followed by hydrogenolysis using palladium on
carbon as catalyst to remove the benzylidene protecting groups,
yielded the first (G1(OH)8), second (G2(OH)16), and third
(G3(OH)32) generations of the polyester dendrimers in a very
efficient way and with complete monodispersity, as shown by mass
spectrometry. These dendrimers were prepared in multigram-scale
and purified by recrystallization in a very straightforward way.
Carboxylic acids were introduced as functional groups at the
surface of the third-generation dendrimer G3(OH)32 to allow
coupling with conveniently functionalized ligands by the formation
of amide bonds. In contrast to our previous experience, where the
carboxylic acids were introduced by reaction of G3(OH)32 with a
large excess of succinic anhydride, succinic acidmonobenzyl ester and
DCC were used for the coupling reaction (Scheme 1). Using this
strategy, the resulting compoundG3(sucBn)32was soluble in organic
solvents and very easy to purify by flash chromatography on silica gel.
Again, a complete analysis of the compound, especially by MS,
confirmed themonodispersity of the molecule. After a simple step of
benzyl ester deprotection by hydrogenolysis at atmospheric pressure
using Pd(C) (10%) at room temperature, the dendrimer G3(suc)32
with 32 carboxylic acids was obtained almost quantitatively.
To evaluate the importance of the valency, a tetravalent system
also based on 2,20-bis(hydroxymethyl) propionic acid (bis-MPA)
(Scheme 2) was considered as a scaffold for presentation of four
copies of selected ligands.
Starting from the isopropylidene-2,2-bis(methoxy)propionic
acid (3) prepared as reported in the literature28 and following the
experimental procedure described in Scheme 2, we obtained 4 in
good yields with adequate functionalization. As a protecting group of
the carboxylic acid, the azidoethanol was used. This terminal azide
has been used in our laboratory in a convergent strategy to create
higher valency compounds applying a click chemistry Cu catalyzed
cycloaddition (unpublished results). Compound 4 was prepared in
good yields by reaction of 3 with 2-bromoethanol in the presence of
DCCand4-(dimethylamino)pyridinum4-toluenesulfonate (DPTS)
followed by treatment with sodium azide in DMF at 40 C. After
deprotectionof the hydroxyl groups using an acidic resin inmethanol,
the tetraol 8 was prepared using a two-step synthetic sequence
reported in the literature to prepare similar polyester dendrons.28,29,33
This synthetic sequence begun coupling 5 with 2 equiv of anhydride
6 which, in turn, was prepared in one step from acid 3 using DCC,29
in pyridine and dimethylaminopyridine as catalyst. The second step
was the deprotection of the isopropylidene acetals of 7 using Dowex
Hþ. Tetraol 8 was obtained in good yield after chromatographic
purification. The introduction of the carboxylic acid linkers on 8 was
performed using the trimethylsilylethanol monosuccinate 9 prepared
by ring-opening of succinic anhydride by trimethylsilylethanol as
described in the literature.34 In thisway, the silyl protected compound
was prepared in good yields and easily purified. After deprotection
using trifluoroacetic acid at room temperature, the tetraacid 11 was
obtained in very good yield andwas used in the next stepwithout any
further purification.
Our previous studies have demonstrated that compounds 13
and 15, linear glycomimetics of the disaccharide ManR1,2Man
and of the trisaccharideManR1,2ManR1,6Man, respectively, were
Scheme 3. Coupling of Glycomimetics 13 and 15 on G3(suc)32
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very adequate ligands for DC-SIGN providing better stability
against enzymatic degradation than the corresponding natural
counterparts. The synthesis of these glycomimetics has been
previously described.22,23
Conjugation of 13 and 15 on the tetra- and multivalent
scaffolds was performed using HATU as an activating reagent in
the presence of DIPEA at room temperature and afforded the
correspondingmultivalent systemswith high yields after purification
by size exclusion chromatography as described in Schemes 2 and 3.
The tetravalent compoundswere fully characterized byNMR, IR,
and MS analysis. MALDI-MS of the compounds G3(pseudodi)32
and G3(pseudotri)32 using sinapinic acid (SA) as matrix allowed to
observe a complex signal centered on the molecular weight
corresponding to the 31-loaded dendrimer both for pseudodi-
and pseudotrimultivalent systems (see SI for MS spectra). This
is consistent with the number of 3032 ligands which could be
estimated based on the integration of significant signals in the
1H NMR spectrum (see SI). Although the MS spectra were not
conclusive, we concluded that almost all the reactive sites of the
scaffold were conjugated with ligands to obtain a high load
narrowly disperse system.
Infection Studies. The antiviral activity of these tetra- and
multivalent systems was tested using pseudotyped viral particles
presenting the EboGP and Jurkat cell line expressing DC-SIGN
on the surface. Two kinds of experiments were set up: a cis-
infection assay of DC-SIGNþ Jurkat cells with this artificial
Ebola virus, and a trans-infection experiment of HeLa cells using
DC-SIGNþ Jurkat cells as viral particle transporters.
We have used these infection models previously to test the
activity of mannosylated Boltorn-type hyperbranched dendritic
polymers.20 The DC-SIGN blocking efficiency has been evaluated
as dependence of multivalency and of the different pseudomanno-
side ligands used in the compounds synthesized. The infection
inhibition analysis has been done as a function of compound
concentration. All compounds were used in at least 3 independent
experiments. The results of the infection assays are represented as a
percentage of infection inhibition compared with DC-SIGNþ
Jurkat cells infected by pseudoviruses without addition of any
compound (blank experiment). The IC50 values were calculated
with the 95% confidence intervals. Control experiment with VSV-G
pseudoviruses was performed with final concentrations of 10 nM
and 10 μM (negative control).
The results obtained in the cis infection experiments indicate
that the tetravalent systems presenting four copies of the pseudo-
mannotrioside, 14, show an IC50 1 order of magnitude lower than
the system with four pseudomannobiosides, 12 (Figure 1). In a
previous publication, we have shown that the tetravalent system 14
bearing four copies of linear pseudomannotrioside 15 was an
effective inhibitor of T-cell trans infection by HIV.23
Multivalent systems with an average of 3032 copies of
glycomimetic ligands were tested. In this case, no significant
differences were found as a function of the pseudosaccharide
presented. The IC50 values found for the multivalent systems
were around 20 nM (around 0.5 μM, based on ligand con-
centration), which shows that their inhibitory potency is between
Figure 1. Infection results of the cis-experiments using 12, 14, G3(pseudodi)32, and G3(pseudotri)32 compounds as inhibitors. Concentrations are
expressed based on ligand concentration.
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1 to 2 orders of magnitude higher than that of the corresponding
tetravalent systems.
Similar results were obtained in the trans infection experi-
ments (Figure 2). The IC50 of 32-valent systems bearing
pseudomannobioside 13 or pseudomannotrioside 15 were
62 nM and 31.5 nM, respectively (2 and 1 μM, based on ligand
concentration, respectively). The tetravalent dendron 14 with
four copies of pseudomannotrioside showed an IC50 of 203 nM
(0.8 μM, based on ligand concentration), and the tetravalent
dendron 12with four copies of pseudomannobioside was 1 order
of magnitude less potent with an IC50 of 1.22 μM(4.9 μM, based
on ligand concentration) (Figure 2).
SPR Studies. Competition experiments using Biacore SPR
were performed to analyze the interaction of these glycomimetic
tetra- and multivalent systems with the receptor DC-SIGN and
to characterize the interaction at the molecular level.
For this aim, Biacore CM4 sensor chip was functionalized
as described in the experimental section with BSA-Mannotriose.
A fixed amount of DC-SIGN ECD was injected over the
sensor chip flow cells in the presence or absence of different
concentrations of the glycodendritic compounds to be evaluated.
Analysis of the sensorgrams (see Supporting Information)
allowed estimating IC50 for the monovalent, tetravalent,
and multivalent compounds. At the monovalent level, strong
differences were found (almost 1 order of magnitude) between
the IC50 of monovalent pseudodi- and pseudotrisaccharides
(IC50 1.19 mM for the pseudodisaccharide 13 and 0.16 mM for the
pseudotrisaccharide15).However, these differences decrease notably
when the ligands are presented on the tetravalent scaffold (IC50
227 μM for the tetravalent pseudodi 12 and 120 μM for the
tetravalent pseudotri 14) and are very similar when a dendrimer
of third generation is used as multivalent platform (IC50 2 μM for
the multivalent pseudodi G3(pseudodi)32 and 1.25 μM for the
multivalent pseudotri G3(pseudotri)32. (Figure 3)
These data show that tetravalent presentation of the pseudo-
disaccharide 13 on dendron 12 affords a very modest (1.3 per
pseudosugar), if any, polyvalency effect (β), which improves
significantly (18 per pseudosugar) in the full dendrimer G3-
(pseudodi)32. Strikingly, the tetravalent presentation of the
pseudotrisaccharide 15 on dendron 14 does not afford any
affinity increase (β = 0.3 per pseudosugar) and only a modest
improvement (4 per pseudosugar) is observed for the full
dendrimer G3(pseudotri)32.
’DISCUSSION
DC-SIGN is considered a very interesting therapeutic target for
the design of new antiviral drugs. In addition, the ability of DC-SIGN
to trigger signaling pathways that lead to a specific immune response
has attracted attention on this lectin.3542 The development of
specific tools to interact with and to understand the role and function
of this lectin is of great interest. Furthermore, specific ligands designed
to block the carbohydrate recognition domain of this lectin could be
good candidates to be tested as antimicrobial agents.
Figure 2. Infection results of the trans experiments using 12, 14, G3(pseudodi)32, and G3(pseudotri)32 compounds as inhibitors. Concentrations are
expressed based on ligand concentration.
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In this context, we have selected two linear pseudosaccharides
13 and 15 with good affinity for this receptor. The affinity has been
remarkably enhanced via amultivalent presentation of these ligands.
Tetra- andmultivalent scaffolds based on bis-MPA as building block
have been prepared with adequate functionalization on the surface
for attachment of the selected ligands. The corresponding glyco-
conjugates with 4 and 32 copies of these ligands were prepared in
good yields and were characterized using typical spectroscopic
methods. MS analysis demonstrated the monodispersity of the
tetravalent systems (compounds 12 and 14). Higher valency
systems obtained from monodisperse G3 Boltorn-type dendrimer
G3(OH)32 did not give good MS spectra and by analysis of the
NMR spectra could only be described as systems with 3032
ligands as an average loading; therefore, themonodispersity of these
systems was not confirmed.
These tetra- and multivalent systems were tested in vitro as
antiviral compounds in a well-established infection model based
on pseudotyped viral particles with the Ebola virus envelope
glycoprotein GP1. This infection system is a very efficient and
“clean” model where the infection is exclusively dependent on
DC-SIGN.20 Cells that do not express the receptor and viruses
able to infect the cells independently of DC-SIGN have been
used as controls in these experiments. The results obtained have
clearly demonstrated inhibition of the infection through blockage
of the DC-SIGN receptor. The tetravalent systems 12 and 14
were very active in the lowmicromolar range, and themultivalent
systems G3(pseudosugar)32 showed a very strong inhibition
effect with IC50 in the nanomolar range. These systems could
be considered as very potent inhibitors to be tested in further
experiments. On the other hand, relatively small differences were
observed between the two selected monovalent ligands the
pseudodi 13 and the pseudotrisaccharide 15.
In order to analyze this in more detail and to have additional
molecular-level data on the interaction of these compounds with
DC-SIGN, competition experiments using a biosensor with SPR
detection were performed. A chip functionalized with mannosy-
lated BSA was used to compete with our ligands for DC-SIGN.
Analysis of the results obtained in these competition experiments
demonstrates that the pseudosugars are good ligands for DC-
SIGN, and that the pseudotrisaccharide 15 is 1 order of
magnitude better than the pseudodisaccharide 13 when used as
monovalent units. Surprisingly, this trend was not observed when
the ligands are used in multivalent presentations: they both
present a similar affinity when are exposed on the multivalent
scaffolds. A plausible explanation for these facts could be the loss
of different binding modes of the ligands when they are linked to
a scaffold. In the particular case of DC-SIGN, it has been
experimentally determined by X-ray43 and also by NMR44 that
different binding modes are possible for carbohydrate ligands.
These binding modes were observed for free ligands, but once
they are conjugated to scaffolds, some or all of these alternative
binding modes could become inaccessible; consequently, this
could notably influence binding affinity. As a consequence,
despite the improved affinity of the pseudomannotrioside at
the monovalent level, our data suggest that the pseudomanno-
bioside is the effective lead compound to use for further
improvement of our multivalent pseudosaccharide compounds.
More structural experiments are currently being carried out
in our laboratory at the monovalent level to obtain more detailed
information and to investigate the factors that govern this
phenomenon.
In summary, we present in this work the preparation of
carbohydrate mimics on a tetra- and multivalent presentations
and the analysis of their antiviral activity using a pseudotyped
Ebola virus infection model. A strong inhibitory activity was
found for the higher valency compounds with IC50 in the
nanomolar range. Competition experiments using SPR have also
demonstrated the ability of these compounds to interact with
DC-SIGN and compete for this receptor. Our results confirm
pseudoglycosylated multivalent systems as very promising anti-
viral drugs with strong activities and encourage us to pursuemore
in vitro and in vivo studies concerning the potential biomedical
applications.
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ABSTRACT: Water-soluble glycofullerenes based on a hexakis-adduct of
[60]fullerene with an octahedral addition pattern are very attractive
compounds providing a spherical presentation of carbohydrates. These
tools have been recently described and they have been used to interact
with lectins in a multivalent manner. Here, we present the use of these
glycofullerenes, including new members with 36 mannoses, as compounds
able to inhibit a DC-SIGN-dependent cell infection by pseudotyped viral
particles. The results obtained in these experiments demonstrate for the
first time that these glycoconjugates are adequate to inhibit efficiently an
infection process, and therefore, they can be considered as very promising
and interesting tools to interfere in biological events where lectins such as
DC-SIGN are involved.
■ INTRODUCTION
Carbohydrate−protein interactions govern many biological
processes including inflammation, embryogenesis, tumor
progression and metastasis, pathogen infection, and so on.1−3
These interactions are characterized by a high selectivity, metal
ion dependence, and a low affinity compensated in nature by
multivalency.4,5 The search for adequate systems to achieve a
multivalent presentation of sugars is a topic of extensive
research.6−9 The lack of information about the adequate
orientation of ligands required to obtain the strongest
interaction has induced chemists to try any possible and
accessible scaffold. Calixarenes,10 gold-nanoparticles,11 poly-
mers,12 liposomes,13,14 and dendrimers15 are among the most
studied and frequent structures used for constructing multi-
valent glycoconjugates.
Since its discovery in 1985,16 biochemical and biomedical
applications of fullerenes, and specially C60, have attracted
much attention. Biological properties of fullerenes have been
tested in different areas such as DNA photocleavage, neuro-
protection, antibacterial and antiviral activity, antioxidation, and
drug delivery.17−22
Carbohydrate derivatives of fullerenes, glycofullerenes, had
been previously studied due to the combination of interesting
biological properties.23−31 However, most of these derivatives
showed an amphiphilic character with the fullerene being the
lipophilic part of the structures. Recently, we have shown that
this amphiphilic character of sugar-fullerene conjugates can be
avoided by obtaining hexakis-adducts of [60]fullerene in which
the C60 sphere is completely surrounded by sugar moieties in a
T-symmetrical octahedral addition pattern.32 In fact, some of
the advantages of fullerenes in comparison to other carbon
nanostructures are related to its 3D structure and the possibility
to functionalize different positions of the C60 cage in a
controlled fashion.33 In this sense, fullerenes can be considered
very attractive spherical scaffolds for a multivalent presentation
of ligands in a globular shape.
By employing a Cu(I)-catalyzed azide−alkyne cycloaddition
(CuAAC) methodology to click sugar residues to alkyne-
substituted Bingel-Hirsch hexakis-adducts, we have obtained
glycofullerenes with up to 24 sugar moieties on the periphery of
C60.
34 These compounds are water soluble and interact with
Concanavalin A in a multivalent manner, demonstrating the
accessibility of these sugars on the fullerene surface to be
recognized by a lectin. Moreover, the compounds show a good
stability and low toxicity which confirm the appropriate features
to be used in cellular assays. This kind of fullerene glycoclusters
have recently been investigated as inhibitors of various
glycosidases,35 FimH, a bacterial adhesin,36 PA-IL, a bacterial
lectin from Pseudomonas aeruginosa,37 and WaaC, a glycosyl-
transferase.38 Many of these enzymes play key roles in the
infection processes caused by several pathogens and are,
therefore, therapeutic targets for the search for new drugs.
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We have proved that dendritic molecules decorated with
carbohydrates (mannoses or fucoses) can be considered as
good ligands to interact with and block the receptor DC-
SIGN.39−45 DC-SIGN is a C-type lectin able to interact with
glycoconjugates present on the surface of several pathogens,
including viruses like HIV or Ebola. Due to the important role
of this lectin in infection processes, the discovery of new
compounds with an adequate affinity for this receptor is of
great interest. We have envisaged that the globular presentation
of carbohydrates provided by the fullerene as scaffold could
afford interesting glycomimetics to achieve this goal. This rigid
spherical scaffold permitted reaching a distance between two
ligands on this multivalent presentation (at least 1 nm of
diameter for the fullerene plus the distance provided by the
dendritic moiety), increasing the chances to get an efficient
multivalent interaction. Additionally, the 3D presentation of
these ligands on 360° could better mimic the surface of
pathogens such as HIV having more possibilities for
encountering a receptor due to the symmetry of the multivalent
system.
In this work, we would like to present the preparation of
globular glycofullerenes with higher valency by a convergent
strategy combining trimannosylated glycodendrons with a
Bingel-Hirsch hexakis-adduct [60]fullerene to obtain glycoden-
drofullerenes with 36 mannoses and two different spacers. Also,
we introduce for the first time the biological activity of these
compounds in a cellular infection model providing important
information about the potential use of these new glycomimetics
as antiviral agents.
■ MATERIALS AND METHODS
Reagents were purchased from Sigma-Aldrich, Senn Chemicals, and
Flucka and were used without purification. Solvents were dried by
standard procedures. Reactions requiring anhydrous conditions were
performed under argon. Synthetic compounds were purified by flash
chromatography using medium or fine silica gel or by sephadex
(LH20, G25). Thin layer chromatography (TLC) was carried out with
precoated Merck F254 silica gel plates. Flash chromatography (FC) was
carried out with Macherey-Nagel silica gel 60 (230−400 mesh).
Reaction completion was observed by TLC using as development
reagents phosphomolibdic acid, 10% sulfuric acid in methanol or
anisaldehyde. 1H, and 13C spectra were recorded on Bruker Avance
DPX 300, DRX 400, DRX 500, and AVIII 700 MHz spectrometers.
Chemical shifts (δ) for 1H and 13C spectra are expressed in ppm
relative to the residual solvent signal using manufacturer indirect
referencing method. Signals were abbreviated as s, singlet; bs, broad
singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Mass spectra
were obtained with a Bruker ion-trap Esquire 6000 apparatus (ESI)
and a Bruker ULTRAFLEX III (MALDI-ToF) from Bruker Daltonics;
HRMS were obtained with an Apex II instrument (FT-ICR, ESI) and
with a Micromass Autospec-Q (FAB).
Synthesis. Compounds 3−8 have been previously reported.32,45
Glycofullerene 1. Alkyne-functionalized hexakis-adduct 5 (7.4 mg,
3.5 × 10−3 mmol) was dissolved in 2 mL of DMSO under an argon
atmosphere, and sugar-dendron 6 (70 mg, 0.063 mmol), CuBr·S-
(CH3)2 (4 mg, 0.018 mmol), and a piece of Cu metal wire were added.
The mixture was vigorously stirred over a period of 72 h. The green
crude was purified using a short chromatographic column with
QuadraSil Mercaptopropyl (2 g) in DMSO as solvent, obtaining a red
solution. The product was isolated by precipitation and centrifugation
with AcOEt (15−20 mL) as a red solid (47 mg, 87%).
1H NMR (DMSO-d6, 700 MHz): δ 8.02 (s, 36H), 7.82 (s, 12H),
5.12 (m, H), 5.01 (m, H), 4.76−4.59 (m, H), 4.27 (m, H), 3.95 (m,
H), 3.89 (m, H), 3.78 (m, H), 3.62−3.55 (m, H), 3.18−3.04 (m, H),
2(s, H). 13C NMR (DMSO-d6, 175 MHz): δ 162.79, 147.71, 145.60,
145.42, 141.15, 124.49, 122.74, 102.25, 100.26, 75.94, 74.55, 73.13,
71.27, 70.53, 69.25, 69.06, 67.19 65.35, 64.59, 61.58, 60.24, 55.39,
49.70, 49.07, 45.39, 28.17, 21.25. IR (neat): 3308, 3137, 2881, 2821,
1742, 1607, 1427, 1354, 1223, 1136, 1093, 1059, 878, 814, 777, 674,
520, 477 cm−1. MS (MALDI-TOF) Calcd for [M]+ C606H936N144O300,
15450.147; found, 15450 [M]+.
Glycofullerene 2. Alkyne-functionalized hexakis-adduct 5 (11.8 mg,
5.5 × 10−3 mmol) was dissolved in 2 mL of DMSO under an argon
atmosphere, and sugar-dendron 10 (120 mg, 0.1 mmol), CuBr·S-
(CH3)2 (5 mg, 0.020 mmol), sodium ascorbate (12 mg, 0.06 mmol),
and a piece of Cu metal wire were added. The mixture was vigorously
stirred over a period of 72 h. After this time, the green crude was
purified using a short chromatographic column with QuadraSil
Mercaptopropyl (2 g) in DMSO as solvent, obtaining a red solution.
The product was isolated by precipitation and centrifugation with
AcOEt (15−20 mL) as a red sticky solid (71 mg, 78%).
1H NMR (DMSO-d6, 700 MHz): δ 8.16 (s, 36H), 7.75 (s, 12H),
5.19−4.97 (m, H), 4.76−4.59 (m, H), 4.31−4.21 (m, H), 3.90−3.70
(m, H), 3.65−3.54 (m, H), 3.18−3.04 (m, H), 2.07−1.98 (m, H). 13C
NMR (DMSO-d6, 175 MHz): δ 169.8, 161.0, 147.7, 146.2, 144.9,
141.3, 131.4, 131.1, 128.5, 125.6, 122.7, 102.0, 101.6, 100.2, 75.9, 75.3,
74.5, 73.1, 71.1, 70.5, 69.2, 69.0, 67.2, 66.6, 65.3, 65.0, 64.6, 64.2, 63.4,
61.5, 60.3, 54.6, 49.7, 49.1, 46.7, 36.1, 31.2, 28.2, 21.2, 20.9. IR (KBr):
3311, 3177, 3099, 2881, 2864, 1731, 1620, 1503, 1431, 1378, 1223,
1207, 1136, 1081, 1059, 878, 817, 757, 672, 526, 504, 458 cm−1. MS
(MALDI-TOF) Calcd for [M]+ C690H1032N144O324, 16506.776; found,
16506 [M]+.
Glycodendron 9. 2-Azidoethyl-α-D-mannopyranoside 8 (50 mg, 0.2
mmol), [2-[2-(2-chloroethoxy)ethoxy]ethoxy]ethoxymethyl trikis(2-
propyniloxymethyl)methane 7 (27 mg. 0.06 mmol), CuSO4·5H2O
(1.5 mg, 0.006 mmol), TBTA (6.5 mg, 0.01 mmol), and sodium
ascorbate (4.8 mg, 0.024 mmol) were dissolved in 1 mL of THF/H2O
(1:1). The solution was heated at 60 °C in a microwave oven for 25
min. A metal scavenger resin, QuadrasilMP, was added to the reaction
solution and stirred for 5 min. After that, the mixture was filtered and
the resulting solution was purified by size-exclusion chromatography
(Sephadex LH-20 MeOH 100%), furnishing the glycodendron 9 as a
white foam (61 mg, 85%).
1H NMR (D2O, 400 MHz): δ 8.07 (s, 3H, Htriazol), 4.83−4.75 (m,
3H, H1‑man), 4.72−4.62 (m, 6H, NCH2CH2O), 4.59 (s, 6H,
OCH2Ctriazol), 4.15−4.05 (m, 3H, NCH2CH2O), 3.98−3.90 (m, 3H,
NCH2CH2O), 3.90−3.54 (m, 31H, H2‑man, H3‑man, H5‑man, H6‑man,
OCH2CH2O, OCH2CH2O, CH2CH2Cl, CH2CH2Cl), 3.47 (s, 6H,
CH2Opentaerythritol), 3.42 (s, 2H, CH2Opentaerythritol), 3.14−3.06 (m, 3H,
H4‑man).
13C NMR (D2O, 400 MHz): δ 145.0 (Ctriazol), 125.3
(CHtriazol), 99.5 (C1‑man), 72.7 (C4‑man), 70.7 (CH2O), 70.5 (C3‑man),
70.4 (CH2O), 69.8 (C2‑man), 69.6 (CH2O, CH2O), 69.5 (CH2O), 69.4
(CH2Opentaerythritol), 68.3 (CH2Opentaerythritol), 66.3 (C5‑man), 65.4
(OCH2CH2N), 63.5 (OCH2Ctr iazo l), 60.6 (C6 ‑man), 50.0
(OCH2CH2N), 44.7 (Cpentaerythritol), 43.1 (CH2CH2Cl). MS (ESI)
Calcd for [M]+ C46H78ClN9O25, 1191.5; found, 1214.1 [M + Na]
+.
HRMS (CI) Calcd for C46H78ClN9O25Na: 1214.4659. Found:
1214.4695 [M + Na]+.
Glycodendron 10. Glycodendron 9 (99 mg, 0.083 mmol) and
sodium azide (54 mg, 0.83 mmol) were dissolved in DMF (2 mL).
The mixture was stirred at 60 °C for 4 days. After consumption of the
starting material, the solvent was concentrated and the crude was
purified by size-exclusion chromatography (Sephadex G-25 H2O/
MeOH 9:1), furnishing glycondendron 10 (86 mg, 86%) of as a white
foam.
1H NMR (D2O, 400 MHz): δ 8.04 (s, 3H, Htriazol), 4.84−4.76 (m,
3H, H1‑man), 4.73−4.64 (m, 6H, NCH2CH2O), 4.56 (s, 6H,
OCH2Ctriazol), 4.13−4.05 (m, 3H, NCH2CH2O), 3.95−3.87 (m, 3H,
NCH2CH2O), 3.86−3.83 (m, 3H, H2‑man), 3.76−3.56 (m, 28H, H3‑man,
H5‑man, H6‑man, OCH2CH2O, OCH2CH2O, CH2CH2N3, CH2CH2N3),
3.43 (m, 6H, CH2Opentaerythritol), 3.39 (s, 2H, CH2Opentaerythritol), 3.1−
3.04 (m, 3H, H4‑man).
13C NMR (D2O, 400 MHz): δ 144.2 (Ctriazol),
125.4 (CHtriazol), 99.5 (C1‑man), 72.7 (C4‑man), 70.5 (CH2CH2N3), 70.4
(C3‑man), 69.8 (C2‑man), 69.6 (CH2O, CH2O), 69.5 (CH2O, CH2O),
69.2 (CH2Opentaerythritol), 69.0 (CH2O), 68.2 (CH2Opentaerythritol), 66.3
(C5‑man), 65.4 (OCH2CH2N), 63.5 (OCH2triazol), 60.6 (C6‑man), 50.1
Biomacromolecules Article
dx.doi.org/10.1021/bm3016658 | Biomacromolecules 2013, 14, 431−437432
(CH2CH2N3), 50.0 (OCH2CH2N), 44.7 (Cpentaerythritol). MS (ESI)
Calcd for [M]+ C46H78N12O25, 1198.5; found, 1221.4 [M + Na]
+.
HRMS (CI) Calcd for C46H78N12O25Na: 1221.5115; found, 1221.5099
[M + Na]+.
Production of Recombinant Viruses. Recombinant viruses were
produced in 293T cells. The viral construction was pseudotyped with
EboGP or VSV-G and expressed luciferase as a reporter of the
infection.46 One day (18−24 h) before transfection, 5 × 106 293T
were seeded onto 10 cm plates. Cells were cultured in DMEM
medium supplemented with 10% heat-inactivated FBS, 25 μg/mL
gentamycin, and 2 mM L-glutamine. Few minutes before transfection,
the medium on transfection plates was changed to 9 mL DMEM and
chloroquine was added to 25 μM final concentration. Transfection
reaction with all reagents at room temperature (RT) was prepared in
15 mL tubes: 500 ng of Ebola virus envelope plasmid, 21 μg of pNL4−
3Luc,47 183 μL of 2 M CaCl2, 1300 μL of H2O, and 1.5 mL of 2 ×
HBS (Hepes buffer saline) pH 7.00. HBS/DNA solution was bubbled
for 30 s and gently dropped onto the plates. After 8 h of incubation at
37 °C with 5% CO2, medium on transfection plates was changed to 10
mL of DMEM and once again 1 day after transfection to 7 mL of
DMEM. Transfection supernatants were harvested after 48 h,
centrifuged at 1200 rpm for 10 min at RT to remove cell debris,
and stored frozen at −80 °C.40,48
Infection in cis Experiment. Infection was performed on Jurkat
cells (A CD4+ T-lymphocyte cell line) expressing the receptor DC-
SIGN on its surface.49 Because the Ebola virus does not infect T-
lymphocytes, Ebola virus entry is absolutely dependent on DC-SIGN
for infection of Jurkat cells.39,49 On a day of infection assay, 5 × 104 of
Jurkat DC-SIGN cells were plated into each well of 96-well plate. Cells
were incubated at RT for 20 min with the carbohydrate-based
compounds and then challenged with 5000 TCID of recombinant
viruses. After 48 h of incubation, cells were washed twice with PBS,
lysed, and assayed for luciferase activity. VSV-G-pseudotyped viruses
were used as controls, of DC-SIGN independent infection under the
same conditions. The values of inhibition of infection presented in
Figure 2 correspond to the mean of six experiments performed in two
independent assays. Error bars correspond to the standard errors of
the mean. The IC50 values were estimated using GraphPad Prism v6.0
with a 95% confidence interval and settings to normalize dose−
response curves.
■ RESULTS AND DISCUSSION
Glycofullerenes endowed with 12 (3) and 24 copies of
mannoses have previously been prepared in our laboratory
using a straightforward strategy based on a Cu(I)-catalyzed
azide−alkyne cycloaddition (CuAAC), so named click chem-
istry, for the conjugation of sugars onto a Bingel-Hirsch
hexakis-adduct [60]fullerene.32,34 This strategy affords com-
pounds very efficiently in few steps with good yields. Also, a
[60]fullerene with 12 copies of galactose (4) has been prepared
as negative control for experiments involving DC-SIGN as
target molecule, since this lectin is not able to recognize
galactose. (Figure 1) Due to the success of this synthetic
approach, we decided to address the preparation of
glycofullerenes with higher valency. Two [60]fullerenes bearing
36 copies of mannoses (1 and 2) have been prepared based on
a convergent strategy using small mannosylated glycodendrons
(6 or 10) and the hexakis-adduct 5 depicted in Scheme 1.
Glycodendron 6, which presents a short linker at the focal
position had been previously prepared in large scale using a
conveniently functionalized mannose with an azido group and
it is a suitable building block to create highly multivalent
species.45
For the preparation of glycodendrofullerene 1, the
conjugation of this key glycodendron 6 with the hexakis-
adduct 5 was performed using CuBr·SMe2 and Cu(0) as copper
source in DMSO affording the glycodendrofullerene with 36
mannoses 1 in good yield (Scheme 1). The compound was
precipitated and washed extensively. To remove all traces of
copper metal, a commercially available resin (QuadraSil
Mercaptopropyl) was used. We have observed that considerable
amounts of copper can be retained into the glycodendrofuller-
ene inducing high cellular toxicity (data not shown). In fact, cell
death has been detected in experiments using glycodendro-
fullerene without the resin treatment. Consequently, this
removal of copper was always done previous to the use of
these fullerenes in biological assays. ICP analysis allowed
determining the amount of copper present into the samples
(copper concentration below 0.1%). The use of QuadraSil
Mercaptopropyl resin prevents the presence of copper and
reduces completely the toxicity of these fullerene derivatives.
Compound 1 was completely characterized by using standard
spectroscopic and analytical techniques (see Supporting
Information). In particular, analysis of the IR data evidence
the absence of the signals corresponding to the C−H stretching
band of terminal alkyne and the CC band (3289 and 2117
cm−1, respectively) present in compound 5. This experimental
finding unambiguously indicates that all alkyne moieties have
Figure 1. Structures of mannose (3) and galactose (4) glycofullerenes.
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reacted. 1H NMR spectrum showed the characteristic signals
for the triazole protons at δ ∼ 8.02 and 7.82 in a 3:1
proportion, attending to the chemical structure of glycofuller-
ene 1. 13C NMR is particularly useful for demonstrating both
the full functionalization of the alkyne moieties and the T
symmetry of the structure. Thus, the signals corresponding to
the alkyne in the precursor 5 (at around 69.0 and 83.3 ppm)
are not observed for the final compound 1, and only two signals
appear for the sp2 carbons of the C60 cage (at around 145 and
147 ppm), together with the signal at δ ∼ 69 for the two sp3
carbons of the C60 core. In the
13C NMR spectrum, we can also
observe one signal for the 12 carbonyl groups at δ ∼ 162.8. The
C atoms of the triazole rings are observed at δ ∼ 141.1 and
124.5 for the peripheral triazole rings and at δ ∼ 147.1 and
122.7 for the 12 inner triazole rings. The anomeric carbon of
the sugar moieties is observed at δ ∼ 100.2.
Using the same strategy, we have synthesized the
glycodendrofullerene 2 (Scheme 1). This compound contains
Scheme 1. Synthesis of Glycofullerenes 1 and 2a
aReagents and conditions: CuBr·SMe2, Cu(0), DMSO, 72 h, rt, 88%.
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a larger spacer between the carbohydrate ligands and the
fullerene scaffold. The aim of this tetraethylenglycol based
linker is the increment of the flexibility of the carbohydrate
ligands on the fullerene surface allowing a better accessibility
and availability of ligands to be recognized by the receptor. For
this aim, a trivalent mannosylated dendron 10 was prepared in
two steps using the previously described trivalent scaffold 744,45
and the conveniently functionalized mannose derivative 8
(Scheme 2). Trialkynylated dendron 7 has been conjugated
with three copies of mannose using a click chemistry reaction.
In particular, we employed CuSO4 as copper salt, sodium
ascorbate to reduce in situ Cu(II) to Cu(I) and TBTA as
additive to stabilize Cu(I). Under these conditions, the
glycodendron 9 was obtained in good yield after sephadex
and QuadraSil Mercaptopropyl purification. In a second step,
the chlorine atom was substituted by an azido group using
sodium azide in DMF at 60 °C to afford the glycodendron 10
conveniently functionalized to be conjugated with the hexakis-
adduct 5.
Glycodendrofullerene 2 was prepared using the same
conditions as those used for glycofullerene 1. After QuadraSil
Mercaptopropyl purification compound 2 was obtained in 78%
yield. The characterization of this compound was performed by
NMR, IR, and MS. The same parameters described above for
glycodendrofullerene 1 were used to confirm the structure of
glycodendrofullerene 2.
Initial binding studies with glycofullerenes using Concana-
valin A and isothermal titration calorimetry (ITC) demon-
strated that mannoses on the surface of these glycofullerene
systems were recognized by this lectin in a multivalent
manner.34 These studies were a proof of the adequate
presentation of carbohydrates on the spherical platform. With
the aim to know the efficiency of these mannosylated systems
in cellular experiments we addressed an infection study assay
using Ebola virus glycoprotein (EboGP) pseudotyped viral
particles as infectious agents. This is a very robust and clean
infection assay to test the capability of molecules to interfere
with lectin-mediated viral infection since the Ebola pseudovirus,
in this experimental model, is absolutely dependent on
interaction with DC-SIGN for viral entry and infection.49
This infection assay has been previously used to test the
antiviral activity of glycodendritic structures prepared in our
laboratory.39,40,50 Therefore, these experiments will allow the
comparison of the results with those previously obtained. In
this way the relevance of the globular presentation of
carbohydrates in the fullerene scaffold could be analyzed.
Briefly, infection was performed on Jurkat cells expressing
DC-SIGN. Because Ebola virus does not infect T-lymphocytes,
Ebola virus entry is absolutely dependent on DC-SIGN for
infection of Jurkat cells. Infection by Vesicular Stomatitis Virus
Glycoprotein (VSV-G) pseudoviruses was performed in the
same conditions as the negative control because infection with
VSV-G is independent of the presence of DC-SIGN receptor.
Also, Jurkat cells not expressing DC-SIGN were used as
negative control of infectivity. Cells were incubated at RT for
20 min with the carbohydrate-based compounds and then
challenged with recombinant viruses. After 48 h of incubation
the inhibition of infection was evaluated for each compound.
The results obtained in these experiments show the
dependence of the inhibition effect on the mannoses (Figure
2). Galactosyl fullerene 4 was not able to inhibit the infection
process mediated by DC-SIGN, as expected. The comparison
of the mannosylated compounds 1 and 3 with different valency
(12 and 36) showed an important decrease of activity with the
increase of valency. Glycofullerene 3 with 12 mannoses showed
an IC50 of 2 μM, which is very promising; however, an
unexpected result was obtained for the activity of the
glycodendrofullerene 1 with 36 mannoses. The IC50 found
for this compound was 68 μM, or in other words, 34-fold less
activity than the fullerene with 12 mannoses. In this case, the
increase of the valency produced a decrease in the activity. The
introduction of a longer spacer in glycodendrofullerene 2 has a
very important effect, recovering the activity of this compound
with an IC50 around 0.3 μM, (more than 200-fold increase in
comparison with glycodendrofullerene 1, which is present in
the same valency). This value was basically the same to the
previously obtained with a glycodendrimer based on a polyester
Scheme 2. Synthesis of Glycodendron 10
Figure 2. Inhibition of infection by pseudotyped Ebola virus infection
of Jurkat DC-SIGN+ cells using mannosylated glycofullerenes 1, 2, 3,
and negative control 4.
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scaffold of similar valency in the same infection assay.39 In this
case, a clear multivalent effect was observed and this new
glycodendrofullerene can be considered as a very active
inhibitor of the DC-SIGN-dependent infection process.
■ CONCLUSIONS
We have prepared mannosylated fullerenes containing several
copies of carbohydrates in a globular presentation. These
multivalent systems have a good solubility in aqueous media
and a low cytotoxicity against several cell lines. Preliminary
binding studies using the model lectin Concanavalin A
demonstrated the potency of these glycodendrofullerenes to
interact with lectins in a multivalent manner.
In this work, we have shown for the first time the potential
application of glycodendrofullerenes as antiviral agents. The
antiviral activity of these compounds in an Ebola pseudotyped
infection model were in the low micromolar range for fullerenes
with 12 mannoses, a very promising data. Interestingly, the
increase of valency in glycofullerene 1 induced a loss of antiviral
effect. This could be probably related to steric congestion of
sugars at the surface of the fullerene. One important factor to
achieve high affinity in binding processes is not only the spatial
presentation of the ligand but also the adequate accessibility of
these ligands to interact with the corresponding receptor. Using
the glycodendrofullerene 2 showing the same valency as
compound 1 but including a longer spacer, we have increased
remarkably the inhibitory activity of these compounds with
IC50 in the nanomolar range, probably due to a more efficient
interaction with DC-SIGN. This result highlights the
importance to combine an adequate scaffold to achieve the
multivalency (the spherical fullerene) with the right ligand
accessibility and flexibility. The valency of the compound is an
important factor to obtain good affinities in a carbohydrate−
lectin interaction, but as it has been shown in these
experiments, it is not the only factor to be taken into account.
Based on these results, we can consider fullerenes as very
attractive scaffolds for a globular multivalent presentation of
sugars. These promising results prompt us to search new
approaches addressing the preparation of glycodendritic key
building blocks to conjugate on fullerenes avoiding steric
hindrance with the aim to achieve better antiviral activities.
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Virus-like glycodendrinanoparticles displaying
quasi-equivalent nested polyvalency upon
glycoprotein platforms potently block viral infection
Renato Ribeiro-Viana1,2, Macarena Sa´nchez-Navarro1, Joanna Luczkowiak3, Julia R. Koeppe1,
Rafael Delgado3, Javier Rojo2 & Benjamin G. Davis1
Ligand polyvalency is a powerful modulator of protein–receptor interactions. Host–pathogen
infection interactions are often mediated by glycan ligand–protein interactions, yet its
interrogation with very high copy number ligands has been limited to heterogenous systems.
Here we report that through the use of nested layers of multivalency we are able to assemble
the most highly valent glycodendrimeric constructs yet seen (bearing up to 1,620 glycans).
These constructs are pure and well-defined single entities that at diameters of up to 32 nm
are capable of mimicking pathogens both in size and in their highly glycosylated surfaces.
Through this mimicry these glyco-dendri-protein-nano-particles are capable of blocking (at
picomolar concentrations) a model of the infection of T-lymphocytes and human dendritic
cells by Ebola virus. The high associated polyvalency effects (b4106, b/N B102–103) dis-
played on an unprecedented surface area by precise clusters suggest a general strategy for
modulation of such interactions.
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T
he initial stages of an infectious process are crucial for
subsequent immune response and elimination of patho-
gens1. The innate immune system comprises mechanisms
and specialized cells responsible for first contact with external
biological agents2. Detection of invaders via pathogen recognition
receptors and subsequent activation of antimicrobial defences
triggers specific antigen responses3. DC-SIGN (dendritic cell-
specific intercellular adhesion molecule-3-grabbing nonintegrin)
receptor is one of the most important pathogen recognition
receptor. It is expressed mainly on the surface of dendritic
cells (DCs), and some subtypes of macrophages4. DC-SIGN
recognizes in a multivalent manner mannose and fucose
containing glycoproteins5, such as ICAM-3 (intercellular
adhesion molecule 3) present in T cells, and envelope
glycoproteins found on pathogens6. By using DC-SIGN as an
entry point some viruses are capable of escaping from the
processing and degradation events carried out by the immune
defence machinery at antigen-presenting cells7. Therefore,
the inhibition of pathogen entry through the blockade of this
receptor at early stages of infection is one strategy for new
antiviral agents.
Several studies have been directed towards the preparation of
synthetic carbohydrate systems able to block or stimulate DC-
SIGN8–21. Despite their elegant design, one of the problems that
these artificial systems face is achieving adequate size and
multivalency to sufficiently mimic natural systems such as viruses
or other pathogens while maintaining full control of shape and
structure16. Indeed, ligand valencies beyond 32 (refs 9,18) have not
been possible before with full control (Indeed, valencies 4100 are
rare in any glycodendrimeric structure. See the following references
Andre´ et al.22 and Camponovo et al.23 for examples of 128-mer
lactoside and 243-mer xyloside display, respectively.)22,23.
We have previously demonstrated that symmetrically multi-
valent glycan ligands mounted on protein platforms (glycoden-
driproteins) are useful tools to study carbohydrate–protein
interactions and are able to control or modulate a desired
response24–27. Other dendrimeric displays on proteins have also
been explored subsequently28–30. However, to date, this approach
has provided only limited carbohydrate valency levels on single
protein platforms. We envisaged that a controlled design for a
highly polyvalent protein display of sugars might be achieved
through a novel strategy of ‘nested polyvalency’ (polyvalent
display of polyvalency) (Fig. 1a).
We describe here the realization of this approach through the
multivalent assembly of protein monomers themselves carrying
polyvalent glycan display motifs (glycodendrons). The resulting
glycodendriprotein homomultimers display many glycans in a
precise manner. Consistent with associated guiding physical
principles31–33, these constructs therefore display symmetry and
pseudosymmetry at both the level of protein assembly and
glycodendron. These synthetic glycoprotein assemblies display
the highest known number of glycans (n¼ 1,620) yet presented in
a homogeneous manner. We have applied this idea (Fig. 1) here
to the inhibitory immunomodulation of a DC-SIGN-pathogen
glycoprotein interaction (Fig. 1b).
Results
Construction of glyco-dendri-protein-nano-particles. We rea-
soned that assembly of an entity with similar dimensions (in the
form of a self-assembled protein sphere-like icosahedron Qb34,
B28 nm in diameter) might mimic the display in target
pathogens (Ebola pseudotyped virus particles have B90 nm in
diameter). Using a tag-and-modify27 strategy, we chose to
selectively introduce a non-natural amino acid (tag) on the
protein that could be used for the attachment (modify) of the
selected glycodendrons appropriately functionalized at the focal
position. As a stringent test of this approach we chose to mimic the
highly glycosylated pathogen envelopes of Ebola virus. We selected
a monomer Qb34,35 protein as carrier, which assembles into a 180-
copy multimer. Qb multimer has been used by us and others to
display glycans for other purposes but in these prior experiments
only partial levels of nonspecific modification were achieved (see
Supplementary Discussion). The result of these prior incomplete
reactions was a formation of mixtures and not the desired
homogeneous and (pseudo)symmetrical display required for this
study36,37. This proteic platform provided the necessary viral mimic
scaffold (core diameter, B28nm)34 to construct the desired
multivalent systems.
The designed glycodendrons were prepared in a straightforward
manner by the Cu(I)-catalysed modification38,39 of the Huisgen
cycloaddition as depicted in Fig. 2. a-D-Mannose was chosen to be
introduced onto the dendritic scaffolds as a relevant ligand that is
recognized by DC-SIGN5. Synthesis of glycodendron 4 was
accomplished using a modular strategy that advantageously
avoided the need for carbohydrate protection. First, unprotected
azidoethyl mannoside 3 (see Supplementary Methods)8 was
coupled to the trialkynyl pentaerythritol core 2 using CuSO4 and
sodium ascorbate in a 1:1 mixture of water:THF (tetrahydrofuran)
at room temperature (RT)40. The focal azido group required for
subsequent site-specific conjugation to the protein tag, was
introduced by reaction with sodium azide to give 5. The designed
modular strategy also allowed use of 5 in the construction of higher
generation glycodendron 8. Thus, coupling of 5 with the trialkynyl
core 6 gave 7 (Fig. 2), which was similarly converted to an azide 8
for protein modification.
Unnatural alkyne-containing amino acid L-homopro-
pargylglycine (Hpg) was site-specifically introduced into the
protein that would make up the proteic scaffold (Qb) to serve as
an alkyne ‘tag’ through the expression of corresponding gene
sequences in an auxotrophic strain of E. coli (B834(DE3))41. Gene
sequences were designed to create a protein displaying alkyne at a
site on the outer surface of the eventual icosahedral platform
(Hpg16) for which the position could simply be controlled by the
‘Met’ triplet codon ATG. Replacement of wildtype methionine
(Met) residues, with near-isosteric amino acid isoleucine allows
reassignment of the codons in the gene sequence to allow
incorporation instead of Hpg as a ‘tag’ (see Supplementary
Methods for full details). The resulting Qb-(Hpg16)180 was
characterized, including by mass spectrometry and dynamic light
scattering (Fig. 3 and see Supplementary Methods and
Supplementary Fig. S1), demonstrating the introduction of the
Hpg amino acid into the sequence. On the basis of previous
results42,43, Qb-(Hpg16)180 was modified using a reaction mixture
of Cu(I)Br complexed by tris[(1-ethylacetate-1H-1,2,3-triazol-4-yl)
methyl]amine in acetonitrile (Fig. 3a). It should be noted that the
presence of Hpg on the protein results in slower Huisgen
cycloaddition reaction rates in comparison with those obtained
when azide in the form of azidohomoalanine (Aha) is present in the
protein42,43. Optimization of the reaction conditions by varying
catalyst loading and stepwise addition, afforded the desired
glycodendron-bearing virus-like particles. Thus, reaction of Qb-
(Hpg16)180 with trivalent glycodendron 5 afforded Qb-(Man3)180
bearing 540 terminal mannosyl residues and reaction with second-
generation nonavalent glycodendron 8 gave Qb -(Man9)180. Both
reactions proceeded with495% conversion; consistent with greater
bulk a longer reaction time (up to 7.5 h) was required for reaction
of 8 to form 1,620-mer Qb- (Man9)180. Increasing particle diameter
was observed, Qb (27.6 nm)-Qb-(Man3)180 (29.8)-Qb-
(Man9)180 (32.0), consistent with the controlled introduction of
‘shells’ of glycosylation B1.1 nm thick (Fig. 3b and see
Supplementary Table S1 for rough estimate of dendron length)
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for each dendron generation. To the best of our knowledge,
this is the first synthesis reported of such highly functionalized
monodisperse glycodendriproteins (bearing up to 1,620 terminal
sugar moieties) using a convergent approach.
Inhibition of DC-SIGN in vitro and on T lymphocytes. The
inhibitory function of these glycodendriprotein particles was
tested in several ways. Competition ELISA assay (See
Supplementary Methods and Supplementary Figs S2 and S3)
revealed that Qb-(Man3)180 could completely inhibit the binding
of DC-SIGN (as an Fc chimera) to a synthetically mannosylated
glycoprotein (albumin bearing Mana1–3(Mana1–6)Man) with an
estimated IC50 B35–40 nM. A complete lack of inhibition by
control, non-glycosylated Qb confirmed dependence of this
promisingly potent inhibition upon glycan.
Next, an Ebola viral infection model44, was explored using
mammalian T-lymphocyte (Jurkat) cells displaying DC-SIGN.
Recombinant viruses were produced in HEK 293 T cells; the viral
construction was pseudotyped with Ebola virus envelope GP
(EboGP) or the vesicular stomatitis virus envelope glycoprotein
(VSV-G) and expressed luciferase as a reporter of the infection45.
The inhibition of DC-SIGN-dependent infection of T-lymphocyte
Jurkat cells (examined in at least three independent experiments)
demonstrated that unglycosylated Qb reduced infection minimally
(Fig. 4a). In contrast, Qb-(Man3)180 and Qb-(Man9)180 showed
strong dose-dependent inhibition of the infection process (Fig. 4a–
c). Indeed, Qb-(Man9)180 presented a notable antiviral activity,
inhibiting infection byB80% at 5 nM; estimated IC50s¼ 9.62 nM
for b-(Man3)180 and¼ 910 pM for Qb-(Man9)180.
VSV-G is able to infect T-lymphocyte Jurkat cells
independently of DC-SIGN44 and provided a positive control in
infection experiments; consistent with the proposed model of
inhibition (Fig. 1) this glycan-independent pathway for VSV-G
was completely uninhibited (Fig. 4b,c). In this model, the Ebola
infection process is absolutely dependent on the presence of DC-
SIGN on the cell surface. Jurkat cells not expressing DC-SIGN
were used as a negative control in the infection studies and
showed no infection by Ebola pseudovirus (See Supplementary
Fig. S4). The ratio of infection in cis between Jurkat DC-SIGNþ
and Jurkat cells wasB2,600 for Ebola virus infection and 0.96 for
VSV infection.
Blocking of DC infection by pseudotyped Ebola. Having shown
such potent inhibition of infection of a stable cell line that dis-
plays DC-SIGN, we next evaluated inhibition in the perhaps more
relevant and more demanding context of inhibition of primary
cells. DCs are a primary target of Ebola infection; these display
multiple C-type lectins that could provide a different or modu-
lated route for infection with potentially higher affinty for virus.
Accordingly, DCs were generated from isolated human peripheral
blood mononuclear cells (PBMCs) and tested. We were pleased to
find that as for the stable Jurkat cell line presenting DC-SIGN
alone, Qb-(Man9)180 displayed potent activity (Fig. 4d), inhibiting
infection by480% at 5 nM and495% at 25 nM (estimated IC50
B2 nM for Qb-(Man9)180). Excitingly, these data indicate that the
mode of inhibition of these synthetic glycodendrinanoparticles
translates into cellular contexts relevant to human infection and
are consistent with the mode of action suggested in Fig. 1.
Discussion
Although the evaluation of the number of monomer units
interacting during these inhibitory processes is complicated by
quasi-equivalence32, the data obtained indicate that these systems
afford a clear polyvalency effect (b)46 when compared with the
O +
n n
m
m
m
n
m
n
m
n
n
m
O
O
O
n = 1 or 3 n = 1 or 3
m = 180
O
O
O
O
O
O
O
O
O
O n
m
O
OO
O O
OO
O
Figure 1 | Schematic representation of the nested polyvalency strategy. (a) Nested symmetrical assembly of virus-like glycodendrinanoparticles using a
tag-and-modify strategy. Glycodendrons are created through iterative multivalent assembly and then attached to multiple tags, each in a monomer protein.
(b) Ebola (shown in red) infection model and its competitive inhibition with virus-like glycodendrinanoparticles.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2302 ARTICLE
NATURE COMMUNICATIONS | 3:1303 | DOI: 10.1038/ncomms2302 | www.nature.com/naturecommunications 3
& 2012 Macmillan Publishers Limited. All rights reserved.
O O
O
O
O
4, R = Cl
5, R = N3
2
7, R = Cl
8, R = N3
NaN3,
DMF 80 %.
6
O
OH
HO
HO
HO
O
N3
O O
O
O
N
N
N
NN
N
O
OH
HO
HO
HO
O
O
OH
HO
HO
HO
O
N
N
N
O
OH
HO
HO
HO
O
O
3
O
O
O
O
Cl
4
O
O
O
OH
1
N
N
N
O
O
O
O
N
NN
N
N
N
O
OHHOHO
HO
O
O
OHHOHO
HO
O
N
N
N
O
OHHOHO
HO
O
O
O
O
O
O
R
4NN
NO O O
O
N
N
N
NN
N
O
OH
HO
HO
HO
O
O
OH
HO
HO
HO
O
N
N
N
O
OH
HO
HO
HO
O
O
N
NN
O
O
O
O
NN
N
N
N
N
OHO
HO
HO
HO
O
OHO
HO
HO
HO
O
NN
NOHO
HO
HO
HO
O
O
Cl
R
CuSO4.5H2O
sodium ascorbate
TBTA,
75 %
Bis(2-chloroethyl) ether
Bu4NHSO4
 NaOH 50% (w:v)
75 %
Bis(2-(2-chloroethoxy)ethyl)ether
Bu4NHSO4
NaOH 50 % (w:v)
70 %
CuSO4.5H2O
sodium ascorbate
TBTA 86 %
NaN3, DMF
95 %
O
O
O
3
O
O
O
Figure 2 | Creation of polyvalent mannose-terminated glycodendrons. Synthesis of the glycondendron reagents 5 and 8 used in the assembly of virus-like
glycodendri-nano-particles (see Fig. 3). TBTA, tribenzyl(tris)triazoylamine; DMF, N,N-dimethylformamide.
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monomer methyl a-D-mannopyranoside) (see Supplementary
Table S2). The inhibitory properties of each mannoside monomer
unit can therefore be considered46 to be B250-fold and B860-
fold (as judged by b/N, see Supplementary Table S2) more potent
when displayed in Qb(Man3)180 and Qb-(Man9)180, respectively,
than when displayed alone. The efficiency of this system therefore
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Figure 3 | Controlled assembly and characterization of virus-like glycodendri-nano-particles. (a) A tag-and-modify strategy allowed the generation of
the second nested layer of multivalency from Qb-(Hpg16)180 using glycondendron reagents 5 and 8. R¼ corresponding glycodendron. (b) Dynamic light
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relies upon a vital combination of not only a high number of
displayed ligands but also display size and geometry. To date, no
homogeneous polyvalent systems have been described that can
generate such a large surface area (solvent-accessible surface area
B725,000Å247) as the systems we have described here. The
system we describe here is based on an icosahedral scaffold
(T¼ 3, triakis iscosahedral) that generates several underlying
quasi-symmetry elements including those that relate the
displayed glycodendrons in a two-fold, three-fold and six-fold
manner (see Supplementary Movie 1). It is tempting to speculate
that this, in turn, allows the simultaneous display of many distinct
putative global glycan clusters where the glycan ‘tips’ are also
quasi-equivalent (for example, 6-fold-related faces displaying a
resultant 54-mer in Qb-(Man9)180 or a 3-fold-related 9-mer in
Qb-(Man3)180, see Supplementary Movie 1). In this way, the
nested glycan polyvalency that we have developed here may allow
many subtly varying polyvalent combinations to be displayed,
each of which (or even a combination of which) might give rise to
optimal biological function (here inhibition of Ebola binding).
These constructs are therefore not ‘balls of sugar’ but
homogenous constructs that array varying faces with different
polyvalent glycan arrangements. Thus, their most relevant
structural features may well not be simply their average glycan-
to-glycan distance (as estimated, say, from Ca-to-Ca residue
distances of B28–40Å for 2-fold up to 6-fold quasi-symmetry)
but instead the specific topology of glycan display and how that
relates to both the inter-domain distances in the DC-SIGN
tetramer48 as well as its organization on cell surfaces.49 Moreover,
initial inspection of other viral surfaces suggests that such
topologies might effectively out-compete not only Ebola but also
other human pathogens. The striking b values that we have
discovered here may well arise from such specific ‘optimal’ faces
(see Supplementary Movie 1 for illustrative examples of these
quasi-symmetrical faces). Indeed, although direct comparison
with non-viral systems is not possible, non-viral particles
displaying multiple mannosyl residues in a less ordered manner
are notably less potent and show much lower multivalency effects
(br20, see Supplementary Table S2).
In summary, a novel nested polyvalency approach combined
with tag-and-modify site-selective protein synthesis has allowed
the creation of homogeneous protein platforms bearing glyco-
dendrons. These well-defined polyvalent glycoprotein assemblies
present on their surface up to 1,620 copies of glycan, a remarkably
high valency never obtained before using a fully controlled
strategy. These glycodendriprotein particles show exciting anti-
viral activity, preventing mammalian cell infection by Ebola
pseudotyped virus through competitive blockade of the DC-SIGN
receptor in the nanomolar to picomolar range. These results
clearly indicate the efficiency of these systems to interact with this
pattern recognition receptor and to compete with pathogens
during their entry into target cells. Their in vivo activity remains
to be tested and it is possible that such constructs, if used in this
context, could elicit humoral responses that might potentially
neutralize some of the interactions studied here. The high activity
and fascinating (quasi)symmetric, high surface area morphology
of these new glycoconjugates provides promising candidates for
the development of both new antiviral agents as well as probes of
larger-scale biological events.
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Figure 4 | Inhibition of viral infection of mammalian cells. (a) Comparison of infection rates of T-lymphocyte (Jurkat) cells displaying DC-SIGN by EboGP
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psuedovirus (VSV-G) in the infection (% infection)of T-lymphocyte (Jurkat) cells displaying DC-SIGN; (c) as for (b) using Qb-(Man9)180. Values correspond
to means of three experiments with s.e.m. shown; the IC50s were estimated using Graphpad Prism v4.0 at 95% with a 95% confidence interval (4.43–
20.9nM for Qb-(Man3)180 and 651 pM–1.3 nM for Qb-(Man9)180) and settings for normalized dose-response curves. See the Supplementary Fig. S5 for
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blocks DC-SIGN. Immature DCs were generated from isolated human PBMCs. Blockade with anti-DC-sign antibody was used as a positive control.
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Methods
Synthesis of glycodendrons. Glycodendron 4: 2-Azidoethyl a-D-mannopyrano-
side (306mg, 1.2mmol), 2-(2-chloroethoxy)ethoxymethyl trikis(2-propynylox-
ymethyl)methane (128mg. 0.37mmol), CuSO4  5H2O (9mg, 0.04mmol),
tribenzyl(tris)triazoylamine (39mg, 0.07mmol) and sodium ascorbate (29mg,
0.15mmol) were dissolved in 2ml of THF/H2O (1:1). After consumption of the
starting material (3 h), the solvent was evaporated and the crude was purified by
size-exclusion chromatography (Sephadex LH-20 MeOH 100%), furnishing the
glycondendron 4 as a white foam (347mg, 86%).
Glycodendron 5: Glycodendron 4 (80mg, 0.07mmol) and sodium azide (47mg,
0.7mmol) were dissolved in N,N-dimethylformamide (2ml). The mixture was stirred
at 60 1C for 4 days. After consumption of the starting material, the solvent was
concentrated and the crude was purified by size-exclusion chromatography (Sephadex
G-25 H2O/MeOH 9:1), furnishing glycondendron 5 (76mg, 95%) as a white foam.
Glycodendron 7: Glycodendron 5 (30mg, 0.03mmol), [2-[2-(2-chloroethox-
y)ethoxy]ethoxy]ethoxymethyl tris(2-propynyloxymethyl)methane (3.6mg,
0.008mmol), CuSO4  5H2O (0.5mg, 0.002mmol), tribenzyl(tris)triazoylamine
(1.7mg, 0.003mmol) and sodium ascorbate (1.3mg, 0.006mmol) were dissolved in
THF/H2O (1:1, 1ml). After consumption of the starting material, the solvent was
evaporated and the crude was purified by size-exclusion chromatography (Sephadex
LH-20 MeOH 100%), furnishing glycondendron 7 (22mg, 75%) as a white foam.
Glycodendron 8: Glycodendron 7 (25mg, 0.007mmol) and sodium azide (4mg,
0.07mmol) were dissolved in N,N-dimethylformamide (1ml). The mixture was
stirred at 60 1C for 4 days. After that, the solvent was concentrated and the crude was
purified by size-exclusion chromatography (Sephadex G-25 H2O/MeOH 9:1), fur-
nishing glycondendron 8 (20mg, 80%) as a white foam.
Synthesis of virus-like glycodendrinanoparticles. Glycoprotein Qb-(Man3)180:
Glycodendron 5 (2.84mg, 0.002mmol) was dissolved in sodium phosphate buffer
(50mM, pH¼ 8, 200ml). Protein solution (180 mg, 100ml) was added to the above
solution and mixed thoroughly. A freshly prepared solution of copper (I) bromide
(99.999%) in acetonitrile (32.6 ml of 10mgml 1) was premixed with an acetonitrile
solution of tris[(1-ethylacetate-1H-1,2,3- triazol-4-yl)methyl] amine (12.6 ml of
100mgml 1). The preformed Cu-complex solution (25 ml) was added to the
mixture and the reaction was agitated on a rotator for at RT. After 4 h, 150 ml of
buffer and 50ml of fresh Cu-complex solution were added to the mixture again and
the reaction was agitated for a further 1.5 h. The resulting mixture was purified in
PD-MiniTrap (G-25) twice and concentrated on a vivaspin membrane con-
centrator (30 KDa molecular weight cut off) to 400 ml. To a virus-like particle
aliquot (20ml) was added 1 ml of TCEP (1M) to allow the protein to denature
before analysis by liquid chromatography–mass spectrometry. Electrospray Ioni-
zation Mass Spectrometry (TOF ESþ ) (m/z): calc. 15,215; found 15,216.
Glycoprotein Qb-(Man9)180: Glycodendron 8 (4.8mg, 0.001mmol) was dissolved
in sodium phosphate buffer (50mM, pH¼ 8, 50ml). Protein solution (90mg, 50ml)
was added to the above solution and mixed thoroughly. A freshly prepared solution
of copper (I) bromide (99.999%) in acetonitrile (32.6 ml of 10mgml 1) was pre-
mixed with an acetonitrile solution tris[(1-ethylacetate-1H-1,2,3- triazol-4-yl)me-
thyl] amine, (12.6 ml of 100mgml 1). The preformed Cu-complex solution (25ml)
was added to the mixture and the reaction was agitated on a rotator at RT. After 3
and 6 h, 50 ml of buffer and 12.5 ml of fresh Cu-complex solution were added to the
mixture again (each time) and the reaction was agitated for further 1.5 h. The
resulting mixture was purified in PD-MiniTrap (G-25) twice and concentrated on a
vivaspin membrane concentrator (30KDa molecular weight cut off) to 400 ml. To a
virus-like particle aliquot (20ml) was added 1 ml of TCEP (1M) to allow the protein
to denature before analysis by liquid chromatography–mass spectrometry. ESI-MS
(TOF ESþ ) (m/z): calc. 17,889; found 17,893.
Production of recombinant viruses. Recombinant viruses were produced in 293T
cells. The viral construction was pseudotyped with EboGP or VSV-G and expressed
luciferase as a reporter of the infection45. One day (18–24h) before transfection,
6 106 293T were seeded onto 10 cm plates. Cells were cultured in DMEM medium
supplemented with 10% heat-inactivated FBS, 25mg gentamycin, 2mM L-glutamine.
A few minutes before transfection, the medium on transfection plates was changed to
9ml DMEM and chloroquine was added to 25mM final concentration. Transfection
reaction with all reagents at RT was prepared in 15ml tubes: 183ml of 2M CaCl2,
450 ng of Ebola virus envelope, 21mg of pNL4-3 luc50, 1,300ml of water. Next, 1.5ml
of 2xHBS (hepes buffer saline) pH 7.0 was added quickly to the tubes and bubbled
for 30 s. HBS/DNA solution was gently dropped onto medium. After 8 h of
incubation at 37 1C with 5% CO2, medium on transfection plates was changed to
10ml DMEM and once again 1 day after transfection to 7ml DMEM. Transfection
supernatants were collected after 48 h, centrifuged at 1,200 rpm for 10min at RT to
remove cell debris, and stored frozen at  80 1C (ref. 51).
Infection of Jurkat cells displaying DC-SIGN in cis. Infection was performed on
Jurkat cells (T-lymphocyte cell line) expressing receptor DC-SIGN on their surface.
One day before infection, 5 104 of Jurkat DC-SIGN cells were plated into each
well of 96-well plate. Cells were incubated at RT for 20min with the carbohydrate-
based compounds and then challenged with 5000 Tissue Culture Infective Dose of
recombinant viruses. After 48 h of incubation cells were washed twice with PBS and
lysed for luciferase assay. The range of concentrations tested for compounds Qb
and Qb-(Man3)180 was 100 pM–50 nM and for compound Qb-(Man9)180 was
50 pM–50 nM. As a control, an experiment of infection with VSV-G pseudoviruses
was performed under the same conditions. Infection with VSV-G is independent of
the presence of DC-SIGN receptor.
Generation of monocyte-derived DCs (DCs). PBMCs were isolated from buffy
coats from healthy human donors (Hospital 12 de Octubre, Madrid, Spain) by
Ficoll-Paque (Pharmacia, Uppsala, Sweden) density-gradient centrifugation. Fol-
lowing the centrifugation of 40ml of whole blood samples on Ficoll-Paque at
2,000 rpm for 30min, the cells from interface were collected and washed five times
with PBS at 1,500 rpm for 5min at RT. PBMCs were then resuspended in RPMI
medium supplemented with 10% heat-inactivated FBS, 25mg gentamycin, 2mM
L-glutamine at concentration 2 106 cells per ml and placed onto 24-well plate for
1 h at 37 1C with 5% CO2. The adherent monolayer of monocytes were then
washed twice with PBS and resuspended in RPMI medium supplemented with
cytokines granulocyte–macrophage colony-stimulating factor (200 ngml 1) and
IL-4 (10 ngml 1). For the differentiation of immature monocyte-derived DCs,
cells were incubated at 37 1C with 5% CO2 for 7 days and subsequently activated
with cytokines on day 2 and 5 (refs 44,52,53).
Infection of immature monocyte-derived DCs in cis. Immature monocyte-
derived DCs were incubated at RT for 20min with the carbohydrate-based com-
pounds and then challenged with 5000 TCID of EBOV-GP recombinant
pseudoviruses. After 48 h of incubation cells were washed twice with PBS and lysed for
luciferase assay. The range of concentrations tested for Qb-(Man9)180 was 1, 5
and 25nM. As a control, experiment of inhibition of infection of EBOV-GP was
performed in the presence of antibody anti-DC-SIGN and mannan at concentration
of 25mgml 1.
Statistical methods. Dynamic light scattering: Dynamic light scattering values
represent the average of 10 independent measurements, where 10 individual
acquisitions were taken per measurement the results analysed using OmniSIZE
software.
Infection assays: Statistical analysis was performed using GraphPad Prism v6.0.
Infection of mammalian Jurkat cells displaying DC-SIGN by EboV-GP pseudo-
typed viruses: The values of percentage of infection presented on the graph cor-
respond to the mean of six independent experiments with error bars corresponding
to the s.e.m. The IC50 values were estimated using GraphPad Prism v6.0 with a 95%
confidence interval and settings to normalize dose-response curves.
Infection of primary monocyte-derived DC by EboV-GP pseudotyped viruses: The
values of percentage of infection correspond to the mean of two independent
experiments (error bars describe the range between the two values obtained).
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